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The main objective of the emerging field of metabolomics is the analysis of all small molecule 
metabolites present in a particular living system in order to provide better understanding of dynamic 
processes occurring in living systems. This type of studies is of interest in various fields including 
systems biology, medicine and drug discovery. The main requirements for sample preparation 
methods used in global metabolomic studies are lack of selectivity, incorporation of a metabolism 
quenching step and good reproducibility. The efficiency of metabolism quenching and stability of 
analytes in selected biofluid or tissue dictate how accurately the analytical results represent true 
metabolome composition at the time of sampling. However, complete quenching of metabolism is not 
easily accomplished, so sample preparation can significantly affect metabolome's composition and the 
quality of acquired metabolomics data. In this research, the feasibility of the use of solid-phase 
microextraction (SPME) in direct extraction mode for global metabolomic studies of biological fluids 
based on liquid chromatography-mass spectrometry (LC-MS) was investigated for the first time.  
Initial research presented in this thesis focused on resolving several outstanding issues regarding the 
use of SPME for the analysis of biological fluids. SPME was not simultaneously capable to provide 
high-sample throughput and high degree of automation when coupled to LC-MS. This was 
successfully addressed through the development and evaluation of a new robotic station based on a 
96-well plate format and an array of 96 SPME fibres. The parallel format of extraction and desorption 
allowed increased sample throughput of >1000 samples/day which represents the highest throughput 
of any SPME technique to date. This exceeds sample throughput requirements for a typical 
metabolomics study whereby ~100 samples/day are processed.   
SPME can also be used for direct in vivo sampling of flowing blood of an animal without the need to 
isolate a defined sample volume. This format of SPME is particularly attractive for metabolomic 
studies as it decreases the overall number of steps and also eliminates the need for metabolism 
quenching step because only small molecular weight species are extracted by the device, whereas 
large biological macromolecules such as proteins are not extracted by the coating. In current work, in 
vivo SPME sampling was successfully applied for sampling of mice for the first time. The proposed 
sampling procedure was fully validated against traditional terminal and serial sampling approaches 
for a pharmacokinetic study of carbamazepine and its metabolite. Excellent agreement of 
pharmacokinetic parameters such as systemic clearance, steady-state volume of distribution and 
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terminal half-life  was found for all three methods, with no statistically significant differences 
(p>0.05). The performance of new prototype commercial SPME devices based on hypodermic needle 
was also evaluated within the context of the study. The availability of such single-use devices with 
excellent inter-fibre reproducibility (<10% RSD) presents an important step forward in order to gain 
wider acceptance of in vivo SPME sampling. 
Finally, existing SPME coatings were not suitable for the simultaneous direct extraction of both 
hydrophilic and hydrophobic species, which is one of the requirements for a successful global 
metabolomics study. To address this issue, a systematic study of 40 types of commercially available 
sorbents was carried out using a metabolite standard test mixture spanning a wide molecular weight 
(80-777 Da)  and polarity range (log P range of -5 to 7.4). The best performance for balanced 
extraction of species of varying polarity was achieved by (i) mixed-mode coating containing 
octadecyl or octyl group and benzenesulfonic acid ion exchange group, (ii) polar-enhanced 
polystyrene-divinylbenzene polymeric coatings and (iii) phenylboronic acid coatings.  
The second aspect of the research focused on the evaluation of SPME for a global metabolomics 
study of human plasma using two complementary LC-MS methods developed on benchtop Orbitrap 
MS system: reverse-phase method using pentafluorophenyl LC stationary phase and HILIC method 
using underivatized silica stationary phase.  The parameters influencing overall method sensitivity 
such as voltages, mass ranges and ion inject times into C-trap were optimized to ensure best 
instrument performance for global metabolomic studies. Orbitrap system provided a powerful 
platform for metabolomics because of its high resolution and mass accuracy, thus helping to 
distinguish between metabolites with same nominal mass. The acquisition speed of the instrument at 
the highest resolution setting was insufficient for use with ultrahigh performance liquid 
chromatography (UHPLC), so all methods were developed using conventional LC. However, overall 
metabolite coverage achieved in current study compared well or even exceeded metabolite coverage 
reported in literature on different LC-MS or UHPLC-MS platforms including time-of-flight, 
quadrupole time-of-flight and hybrid Orbitrap instruments.  
The performance of SPME was fully compared versus traditional methods for global metabolomics 
(plasma protein precipitation and ultrafiltration). The main findings of this systematic study show that 
SPME provides improved coverage of hydrophobic metabolites versus ultrafiltration and reduces 
ionization suppression effects observed with both plasma protein precipitation and ultrafiltration 
methods.  Using SPME, <5% and <20% of peaks showed significant matrix effects in reverse phase 
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and HILIC methods, respectively and the observed effects were mostly correlated to elution within 
retention time window of anticoagulant for the majority of metabolites showing this effect. This 
improves overall quality of collected metabolomics data and can also improve metabolite coverage. 
For example, the highest number of metabolite features  (3320 features) was observed using SPME in 
combination with negative ESI reverse-phase LC method, while in positive ESI mode plasma protein 
precipitation with methanol/ethanol mixture provided the most comprehensive  metabolite coverage 
(3245 features versus 1821 features observed for SPME). Method precision of SPME method was 
excellent as evaluated using median RSD (11-18% RSD) of all metabolites detected. A proof-of-
concept in vivo SPME study was also performed on mice to study the effects of carbamazepine 
administration and shows that SPME can be used as successful sample preparation method for global 
metabolomic studies in combination with unsupervised statistical data analysis techniques.  This 
study highlights important advantages of in vivo sampling approaches including the ability to capture 
short-lived and/or unstable metabolites, to achieve truer representation of the metabolome at the time 
of sampling than achievable by blood withdrawal methods and the ability to use smaller animal 
cohorts while obtaining highly-relevant data sets. The experimental results provide new and useful 
insight into the effects of different sample preparation methods on the collected metabolomics data, 
and establish both in vitro and in vivo SPME as a new tool for global LC-MS metabolomics analysis 
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1.1 Metabolomics, metabonomics and biomarkers 
Metabolomics can be defined as the comprehensive analytical approach to study all low molecular 
weight species present in a given biological system under study. Metabolome is the collection of all 
these small molecular weight species (typically defined as <1000 Da or <1500 Da).
1
  The data 
obtained in metabolomics is complementary to data obtained by other “omics” approaches: genomics, 
transcriptomics and proteomics. The integration of all these types of biological data provides a 
holistic picture of a living organism as shown in Figure 1.1 and is invaluable within the discipline of 
systems biology. From historical perspective, metabolomics is both an old and a new field. Chinese 
doctors used ants for disease diagnosis based on the properties of patient’s urine in 1500-2000 BC, 
and similar approaches were employed in ancient Egypt and Greece.
2
 The modern term of 
metabolomics was only coined in late 1990’s by Fiehn
3
 but first metabolite profiling studies were 
carried out much earlier (1960-1970s) using gas chromatography-mass spectrometry (GC-MS) and 
can be classified as metabolomic studies under current terminology.
2, 4, 5
 For instance, Williams 
discussed the utility of multicomponent analyses as early as 1950s
6
, while the major strides in 
carrying out such studies experimentally were made by Horning and Horning who even introduced 
the term “metabolic profiles” for the first time
7, 8
. Jellum  proposed the idea of finding biomarkers for 
all possible diseases and conditions once a full inventory of all constituents and their concentrations 
in biofluids and tissues can be established.
9
 Finally, Pauling described the concept of personalized 
medicine which is currently accepted as one of the driving forces behind “omics” studies.
10
 Thus, 
conceptually the field of metabolomics was born much earlier than given credit for, but the 
limitations of analytical methods employed could not fulfill the full promise of this novel concept 
back in 1960 and 1970s. More recently, technological advancements in instrumentation have sparked 
a flurry of research activity in this area because increased analytical capability enables much more 
complete global (untargeted) metabolomics  studies with the objective of simultaneous analysis of as 
many metabolites as possible using a particular analytical platform.   
Metabolomics approach appears to be particularly promising because metabolites represent 
endpoints of the molecular pathways perturbed by other “omes”. Thus metabolome defines the 
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individual phenotype, whereas transcriptomic and proteomic information alone does not reveal 
individual phenotypes.
4, 11, 12
 For example, observed increases in mRNA may not always result in 
increases in protein expression, and an over-expressed protein may or may not be enzymatically 
active. The level of each metabolite is dependent not only on the concentration of proteins present 
within the system but also on  processes such as  transcription and translation, allosteric regulation of 
enzymes and the degree and type of protein-protein interactions. Most metabolites also participate in 
several metabolic pathways, which convolves biological interpretation and makes recent global 
approaches very attractive. For example, genome-scale models, show that <30% of metabolites are 
involved in only two reactions while ~12% participate in >10 reactions.
13
 Most reactions involve 
more than one product and substrate, resulting in very tightly connected metabolic networks, which 
can be sensitive to even small perturbations in proteome.
14
 In addition to genetic factors and health  
 
Figure 1.1 Interaction of the different -omes in a cell. Each -ome (except the genome) is a 
complex function of the other -omes, and the amount of integration increases from the bottom 
to the top of the Figure. Thus, the metabolome and the fluxome represent integrative functions 
of the other -omes, and, at the same time, they are closely connected. Exchange with the 
environment occurs primarily via the metabolome (i.e. between the endometabolome and the 
exometabolome).  Figure reprinted from reference with permission of publisher.
13
 
status, other factors also contribute to the observed metabolome of an individual and include 
environment, age, sex, dietary intake and gut microflora thus complicating interpretation of 
metabolomics data even further.
15
 However, recent study of human urine over three-year period 
supports the idea of unique metabolic phenotype as it was possible to accurately classify urinary 





 This indicates that genetic factors play important role in an individual’s 
metabolomic phenotype, and that metabolic phenotypes are not extremely variable on the timescale of 
years for an individual. Of course, additional large-scale longitudinal studies are needed to further 
elucidate the contributions of various factors to metabolic phenotypes and the stability of metabolic 
phenotype over an individual’s lifetime. In another interesting study, Minami et al. successfully used 
global metabolomics of blood, to accurately predict internal body time in mice.
17
 This study provides 
important resource regarding the number and identity of metabolites which exhibit known circadian 
rhythms, and shows that the combination of these metabolites can be used to pinpoint exact internal 
body time due to the presence of highly reproducible oscillating time profiles. The prediction was 
robust in terms of different strains of mice, sex, age, and feeding conditions and could even detect jet-
lag. 
The overall workflow of a global metabolomics study is shown in Figure 1.2. The first step of this 
type of global metabolomics study typically involves differential comparison of several subject or 
treatment groups (for example: normal versus treated, healthy versus disease) without a priori 
identification of all metabolites detected. After sample collection, data is processed using appropriate 
statistical techniques (for example, principal component analysis) in order to isolate a smaller number 
of potentially relevant metabolites that are believed to differentiate the groups (potential biomarkers). 
According to National Institute of Health definition, biomarker is a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention.
18
 The main uses of biomarkers in medicine are 
diagnosis of human disease, assessment of drug efficacy and/or safety and selection of patients with 
highest  probability of benefiting from a particular treatment. After the first step of isolation of 
potential biomarkers, subsequent experiments focus on their identification and the development of 
quantitative analytical methods for selected potential biomarkers.  In final stage, the utility of 
biomarker is further investigated/confirmed using large-scale studies on a large number of subjects 
and the biological explanation for the observed change in biomarker is also researched.  
Majority of global metabolomic studies to date deal with the first stage of the process where the 
goal is to simply isolate potential metabolites of interest (“differentiating metabolites”) and/or 
improve the analytical methodology employed.
19
 The outcomes of such studies cannot be viewed as 
potential biomarkers as these differentiating species may not be related to the disease of interest, but 




Figure 1.2 Typical workflow of a global metabolomics study.  
studies where glycerophosphatidylcholines are reported as differentiating metabolites in various 
diseases, but clearly these species are not specific biomarkers of a particular disease, which 
minimizes their utility in clinical diagnosis.
19
 In other words, a clinically useful biomarker must 
distinguish not only between a healthy and diseased individual, it must also be able to distinguish 
between the individuals with one particular disease versus other diseases. Overall, the difficulties in 
the initial stage of metabolomic studies have prevented rapid progress in biomarker validation stage 
with a notable exception of a recent study reporting sarcosine as potential biomarker of prostate 
cancer.
20
 In this study, after isolation of sarcosine as putative biomarker of prostate cancer in urine 
and confirmation of its elevated levels using targeted GC-MS method in an independent sample set, 
the authors also show that both the addition of sarcosine and genetic knock-down of enzyme 
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enzyme that produces sarcosine limits prostate cancer invasion. These biological assays provide 
additional evidence of a mechanistic link between this metabolite and prostate cancer progression, 
and can also potentially lead to new drugs that target this pathway. This example application shows 
the potential of global metabolomic studies using liquid chromatography-mass spectrometry (LC-
MS). It is generally believed that the use of several biomarkers can provide better predictive value 
than the use of single biomarker, and it is hoped that the use of global metabolomics approaches can 
enable the recognition of relevant patterns for sets of biomarkers.  However, the discovery of 
clinically relevant biomarkers is only one type of application of the field of metabolomics.
1, 19
 Other 
applications include understanding of disease
21, 21-23
 and other biological processes (growth, aging, 
stress, etc.); toxicology
24
; effect of nutrition on health
15, 25
; understanding the mechanisms of drug 
action, metabolism or toxicity
23, 26, 27





; and plant metabolism and breeding
4, 29
.  
The main difference between the terms metabolomics and metabonomics is that the goal of 
metabolomics is quantitative and qualitative analysis of metabolites in a given biological system, 
whereas the goal of metabonomics is the comparison of metabolite levels in a given system in 
response to a particular stimulus or treatment.
30, 31
 Thus, by definition, the evaluation of normal levels 
of metabolites in urine, for example, would fall under the category of metabolomics study, while the 
comparison of metabolome of healthy versus diabetic mice would fall under the category of 
metabonomics study. In more recent literature, the distinction between the two terms is slowly 
disappearing, with both terms used interchangeably. In this dissertation, the term metabolomics will 
be used throughout. 
1.2 Analytical approaches for global metabolomic studies 
The analytical approaches used in global metabolomic studies are  not yet as well-defined as in other 
“omics” studies and are currently an active area of research. Considering the large number of possible 
metabolites, their chemical diversity and large range of possible concentrations (estimated 7-9 orders 
of magnitude
14
),  there is no single analytical platform that can claim to achieve full coverage of the 
entire metabolome. As such, a variety of techniques is employed, with nuclear magnetic resonance 
(NMR) and mass spectrometry (MS) being the most dominant. NMR is a non-destructive analytical 
method and also provides the advantages of absolute quantification and identification, good 
reproducibility, easy sample preparation and high sample throughput. It can be employed both in the 
solution state and for solid samples such as tissues using high-resolution magic angle spinning. 
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However, sensitivity of NMR is relatively low, so typical metabolomic studies by NMR are able to 
accurately determine about 25-100 of most abundant metabolites even when hyphenated with liquid 
chromatography to reduce sample complexity and improve metabolite coverage.
21, 22, 32
 A typical 
biological fluid sample is expected to contain >1000 metabolites even by most conservative 
accounts
33, 34
, while Human metabolome project estimates the number of endogenous metabolites in 
humans to be ~3000
35
. As a result, MS has been employed extensively to increase metabolite 
coverage and is starting to overtake NMR as the analytical platform of choice for metabolomic 
studies.   
Direct infusion MS (DIMS) has been successfully used for classification and identification of 
microorganisms
11, 36
 and in plant metabolomics
29
. Its advantages are high-throughput with typical 
analysis times 1-5 min.
14, 37
 However, competitive ionization of metabolites can lead to low sensitivity 
and low metabolite coverage as well as reproducibility issues. Furthermore, structural isomers cannot 
be differentiated, and data interpretation is complicated due to the presence of multiple ions from the 
same metabolite species (adducts, fragments or multimers).
37-39
 One of the reasons DIMS has been 
successful in cell and plant metabolomics, but not in other areas, is because cells and plants can be 
grown with isotopically labelled media (for example 
13
C by growing plant using 
13
CO2 in the growth 
chamber). The fully isotopically-labelled biological material is then used as complex internal or 
external standard, and offers several advantages including (i) ability to differentiate ions of  biological 
origin versus background and contaminant ions (ii) improved relative quantitation for observed 
metabolites, as the labelled metabolite can be used to reduce effects of ionization suppression from 
the data and (iii) improved identification capability because
13
C labelling provides number of C atoms 
thus reducing number of potential chemical formulas for a given unknown metabolite.
39
 High-
throughput metabolic profiling strategy using matrix-assisted laser desorption ionization (MALDI) 
MS has also been proposed.
40, 41
 The main advantages of this approach are the use of very small 
sample volumes (1 µL), better tolerance for the presence of salts within the sample and very rapid 
analysis time (1.5 min). The formation of multiple adducts such as encountered in electrospray 
ionization (ESI) is avoided, resulting in easier interpretation of mass spectra. However, only negative 
ionization mode is feasible due to the limited availability of appropriate matrices for the analysis of 
small molecular weight compounds without the interference of matrix background and no data on 
analytical reproducibility is provided, although typical RSDs of >30% can be expected in typical 
MALDI analysis according to literature.
37
 Recently, the utility of the combination of ion mobility and 





Due to the complexity of biological samples, however, best results are obtained if mass 
spectrometry is preceded by an appropriate separation step, such as gas chromatography (GC), liquid 
chromatography (LC) or capillary electrophoresis (CE). The choice of separation technique is 
primarily dictated by analyte properties, with GC-MS  most-suitable for volatile and semi-volatile 
analytes, LC-MS most suitable for polar and non-volatile analytes and CE most suitable for charged 
analytes. In a recent study investigating potential biomarkers of nephrotoxicity, comparison of GC-
MS and LC-MS methods resulted in 547 metabolites detected in kidney tissue and 657 metabolites in 
urine samples.
43
 Among these 30% and 46% respectively were detected by GC-MS, and the 
remaining were detected by LC-MS. In a similar study on human plasma, approximately 60% of 
metabolites were detected by LC-MS and 40% by GC-MS, with about 10-15% overlap between the 
two platforms.
44
 A recent systematic study compared several GC, LC and CE-MS platforms (two 
complementary methods/platform) using a defined mixture of 91 metabolites covering central carbon 
metabolism, redox metabolism, amino acids and nucleotides.
45
 For the analyses on a single platform, 
LC-MS provided the most comprehensive metabolite coverage with 65 out of total of 75 non-
isomeric species detected, whereas CE-MS and GC-MS platforms detected 64 and 42 species, 
respectively. About 23-33 compounds could be detected using all three platforms depending on the 
complexity of sample matrix. CE-MS was found the least suitable platform for metabolomics because 
of poor robustness observed for the analysis of real biological samples.  
In comparison to GC-MS, LC-MS does not require derivatization step and can be coupled  to 
fraction collector for further metabolite characterization. One major disadvantage of LC-MS versus 
GC-MS is the lack of LC-MS libraries which makes compound identification very challenging.  The 
main reason for the lack of libraries, is the variability of ESI which can result in the variation in 
relative ion abundances due to adduct formation and in-source fragmentation.
37
 Due to the variability 
inherent in both chromatographic and MS steps, LC-MS data are much less robust than NMR data, 
and comparison between the data acquired on different instruments and even on different days can be 
very difficult, if not impossible.
23
 In order to facilitate comparisons between different data sets 
collected by different groups, an initiative to standardize the information reported for any 
metabolomic study has been proposed.
46
  These guidelines address all aspects of metabolomics 
workflow including sample collection, preparation, analysis and data processing to ensure sufficient 
detail is provided to enable more successful subsequent data interpretation. In terms of sample 
preparation, the draft guidelines recommend the documentation of addition of buffers and/or internal 
standards, storage conditions, detailed extraction protocol, any derivatization strategies, description of 
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all sample containers used during sample handling, and details of any robotics equipment used, as all 
of these can impact the collected metabolomics data. 
1.3 Sample preparation methods for global metabolomic studies by LC-MS 
The choice of sample preparation method plays an extremely important role in metabolomic studies 
because it affects both the metabolite content and data quality.
12, 34, 47
 Despite its importance, sample 
preparation is often an overlooked aspect of metabolomics workflow.
34
 An ideal sample preparation 
method for the metabolomic analysis of biofluids by LC-MS should (i) be non-selective (ii) be simple 
and fast to prevent metabolite loss and/or degradation during preparation procedure and enable high-
throughput (iii) be reproducible and (iv) incorporate metabolism quenching step.
31
 Metabolism 
quenching step aims to stop metabolic processes through the use of low temperatures (cold solvent 
addition, freezing in liquid nitrogen), addition of acid or fast heating.
14, 41, 45, 48, 49
 However, metabolic 
processes are very fast with timescales <1 s, so the quenching step must be extremely rapid to be fully 
effective, and can be very difficult to implement for biological samples within appropriate time 
scale.
14
 Quenching step is typically included in most studies on microorganisms, but similar studies 
on biofluids typically do not employ any quenching step and the analytical data in support of 
omission of quenching step for biofluids is currently lacking. As such, it is not clear how well the 
analyzed metabolome reflects the true metabolome at the time of sampling and further research is 
clearly needed. Furthermore, even when a quenching step is applied, the application of this step can 
cause inadvertent degradation or loss of some metabolites. Freezing can result in loss of metabolites, 
while the use of acidic treatments can cause severe degradation of some metabolites, poor overall 
metabolite coverage and poor compatibility with MS methods.
22
 The following sections provide a 
brief overview of the most common methods employed for metabolomics analysis of biofluids, 
tissues and microorganisms, while section 7.1 provides a more in-depth discussion of the sample 
preparation methods employed to date, specifically for the analysis of human plasma. 
1.3.1 Sample preparation methods for biofluids  
The most commonly employed method for global metabolomic studies of biofluids by LC-MS is 
protein precipitation with organic solvent (methanol, acetonitrile, ethanol, acetone or combination 
thereof), and for urine “dilute-and-shoot” strategy is also often employed.
31
 These methods 
predominate in the field of metabolomics because they are the most unselective, thus providing high 
metabolite coverage. However, the main issues that are often overlooked or inadequately discussed in 
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reported precipitation methods are ionization suppression which can occur due to the competitive 
nature of ESI process and the issues of metabolite loss due to co-precipitation with proteins
50
 and/or 
poor solubility of metabolites in selected solvent. Furthermore, the use of such methods with poor 
sample clean-up can significantly reduce column lifetime and cause contamination of ion source, thus 
requiring frequent MS cleaning. In fact, several publications to date advocate metabolomics sample 
runs of no more than 100 samples to ensure good data quality, with source cleaning between each 
data set.
51, 52
 This is not surprising when the complexity of a typical biological fluid is considered. For 
example, total protein concentration of blood serum or plasma is 6-8 g/dL, while concentration in 
urine is significantly less, but still considerable, with approximate concentrations of 50-100 mg/dL.
50
 
More recently, few reports of successful use of ultrafiltration
32, 53-55
 and solid-phase extraction 
methods
24, 26, 51, 56
 were published. Ultrafiltration is a simple sample preparation procedure where a 
sample is filtered through a special filter which only allows molecules of certain molecular weight to 
pass through, and the filtration is achieved through application of pressure or via centrifugation. 
Filters with molecular weight cutoffs of 3000 Da, 10000 Da and 30000 Da are commonly available. 
The use of 3000 Da filter can physically separate small molecular weight species from proteins or 
other macromolecules present in a given sample, and is thus useful for metabolomics. Solid-phase 
extraction (SPE) uses large amount of sorbent, typically housed in cartridge format, to exhaustively 
extract an analyte from a given sample. The analyte is subsequently removed from the sorbent using 
solvent elution. Depending on the sample volume applied on the cartridge and volume of elution 
solvent used, significant analyte pre-concentration can be achieved using this method. Furthermore, 
prior to the elution process, cartridge can be washed to remove various interferences which are less 
strongly bound to the sorbent than the analyte of interest, thus providing better sample clean-up than 
achievable by simple plasma protein precipitation methods.   The main driving force for exploring the 
use of SPE in LC-MS metabolomics applications is to try and address matrix effects and increase 
column lifetime and overall method robustness by injecting much cleaner samples. The main 
disadvantage is that the selection of the sorbent material increases the selectivity of the preparation 
procedure which can reduce metabolite coverage. For metabolomics applications, the use of C18 
sorbent
51
, the combination of C18 and polystyrene-divinylbenzene sorbents
56
 and the use of 
divinylbenzene/n-vinylpyrrolidone co-polymer
24, 26
 has been proposed. In a recent plant metabolomics 
study, the combination of strong cation-exchange and anion-exchange sorbent was also successfully 





One emerging technique in the field of bioanalysis and metabolomics is the dried blood spot 
sampling.
1
 In this approach, small drop of whole blood is placed on filter paper and allowed to dry.  
This spot is subsequently extracted in solvent prior to analysis. The use of this sampling strategy has 
proven very successful for neonatal screening using targeted metabolite approach. However, limited 
data to date exists on the stability of analytes within dried blood spots, and the effect of long-term 
storage on observed metabolite profile for untargeted studies.
1
  
In addition to the choice of sample preparation method, all steps from sample collection to the 
injection of the sample into LC-MS system can influence the observed metabolite profile. These 
include choice of anticoagulant, sample processing times and temperatures, degree of hemolysis in 
the sample, sample storage parameters, clotting times (for serum), age of the sample and the number 
of freeze-thaw cycles.
47, 57
 For example, the choice of anticoagulant used during blood collection was 
found to influence observed metabolic profiles in a recent study.
58
 Another study by NMR found 
differences in energy metabolites depending on clotting time used for human serum.
47
 They 
recommend the use of clotting times up to 35 min on ice, to ensure no compositional changes occur, 
and immediate centrifugation post-clotting is necessary. For both plasma and serum, exact time to 
centrifugation is important to eliminate bias in order to minimize metabolism and transport of 
metabolites between different compartments. Remaining enzymatic activity was found in rat plasma 
stored refrigerated for prolonged periods, and resulted in increased levels of choline, glycerol, 
tyrosine and phenylalanine.
59
 In another study of the factors influencing the stability of metabolites in 
cerebrospinal fluid, the authors found that rapid centrifugation and snap-freezing immediately after 
collection were important to preserve accurate metabolite levels.
60
  After delayed storage of 30 and 
120 min, numerous metabolites showed significantly elevated levels including glucose and ten amino 
acids (Thr, Glu, Gly, His, Ser, Ala, Phe, Tyr, Ile and Asn) due to unquenched enzymatic activity. The 
storage of plasma or urine at ambient conditions can also cause the depletion of easily oxidizable 
species such as ascorbic acid, adrenaline, noradrenaline and dopamine.
61
  Enzymatic conversion of 
various species can also occur rapidly after sample collection, for example conversion of cytidine into 
uridine or adenosine into inosine.
61
 Another study investigating optimum storage conditions for 
peptides found clear dependence of peptide recovery for hydrophobic peptides on storage container.
62
 
Surely, similar results can be expected for some of the more hydrophobic metabolites and this 
deserves further investigation. These examples show various possible sources of systematic bias 
which can affect the results of metabolomics analysis especially during statistical analysis of data, and 





The recommendations based on systematic investigation of bacterial overgrowth in urine included 
urine centrifugation immediately upon collection, immediate refrigeration and addition of appropriate 
preservatives such as boric acid or sodium azide prior to long-term storage in freezer.
63
 Although this 
study was performed from proteomics perspective, the presence of bacterial contamination would be 
expected to have adverse effects on metabolite profiles as well, although this effect has not yet been 
examined in detail. For the analysis of urine samples, storage at even -80°C was found to impact 
metabolite levels and pH, with some authors advocating storage for a minimum of 1 week to achieve 
consistent degradation of urinary components across the cohort.
64
 Although such approach can 
facilitate comparison across samples, it is clear that the analyzed metabolome is not entirely reflective 
of true metabolome, as the potential metabolites of interest may not be present at the time of analysis 
while peaks due to degradation may be misidentified as possible features of interest.  
In fact, processes occurring prior to sample collection also impact the composition of biofluids 
collected. For example, dietary intake was found to affect observed profiles in human and animal 
biofluids.
65, 66
 These effects could be minimized in urine by the consumption of standardized diet by 
subjects on the day prior to the sample collection, but such standardized diet approach did not reduce 
variability of plasma and salivary metabolomics profiles.
15, 2523, 23
 Gut flora was also found to have 
significant impact on metabolomics data, both in human and animal studies, with up to 15-fold 
differences in some metabolites observed.
23, 25
 Obviously, this factor cannot be standardized in human 
studies, but improved understanding of contributions of gut flora can aid in data interpretation. 
More similar studies for collection of specimens for metabolomic studies are needed in order to 
eliminate bias caused by sampling procedures and to enable comparison of various data sets. For 
metabolomics analysis, the choice of plasma versus serum could also play an important role since the 
clotting process needed to obtain serum is carried out at room temperature for 30-60 min, but no 
relevant studies have been reported to date on how the clotting step impacts the composition of the 
metabolome.  
The need for the standardization of sample collection and storage procedures has been well-
recognized in proteomics community because of its documented impact on analytical outcome.
57
 This 
idea is also slowly becoming more accepted in the field of metabolomics. Standardized collection, 
storage and handling protocols, and ensuring all the samples are treated exactly the same can help 
alleviate some of these problems, so that truly differential metabolites rather than artifacts are 
detected during unsupervised statistical analysis. When such proper care is taken, analytical variation 
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was shown to be smaller than biological variation using both NMR and LC-MS studies.
47, 67
 However, 
the standardization merely ensures that all of the samples are treated exactly the same, thus 
minimizing the differences between samples due to handling. It does not address how well the 
composition of the metabolome at the time of the analysis matches the metabolome composition in 
the living system at the time of sampling. Thus, additional research into best practices to ensure that 
the analyzed metabolome reflects well the true metabolome is also needed. 
1.3.2 Sample preparation methods for tissues 
A recent comparison of methods for the extraction of selected target metabolites from muscle tissue 
found the best performance for boiling water extraction, while boiling ethanol and perchloric acid 
showed the poorest overall performance.
48
 Methods that can simultaneously extract both hydrophilic 
and lipophilic species, such as chloroform/methanol extraction are also popular but the use of 
chloroform is problematic in LC-MS necessitating further sample manipulation prior to injection.
22
 
Sun et al. proposed methanol/chloroform/water extraction protocol for the analysis of mouse heart 
tissue in order to extract both lipophilic and hydrophilic species, and eliminate ionization suppression 
effects inherent when perchloric acid extraction was used for the same analysis.
41
 Williams et al. 
successfully used similar extraction approach for brain samples.
68
 
1.3.3 Sample preparation methods for microorganisms 
The choice of sample preparation methods for the analysis of cells is also complicated and depends 
on the type of cells and whether the analysis of intra- or extra-cellular metabolites is of interest.
11, 49
 
For the analysis of extra-cellular metabolites, the possibility of inadvertent leakage of intracellular 
metabolites must be examined, while for the analysis of intra-cellular species effective methods of 
disruption of cell membrane are necessary. Canelas et al. compared the efficiency of five commonly 
used methods for intracellular metabolite extraction (quantitative analysis of 44 metabolites) from 
yeast cells: hot water extraction, boiling ethanol extraction, chloroform-methanol extraction, acidic 
acetonitrile-methanol extraction and freezing-thawing cycles in methanol.
69
 All of these methods are 
well-established for extraction of intracellular metabolites, with the first two available since 1950’s 
and the rest of methods introduced as milder alternatives in 1990’s. The results show the best 
performance of boiling ethanol extraction and chloroform-methanol extraction for the majority of 
metabolites tested (38 out of 44), indicating that these methods meet most of the criteria of ideal 
metabolomics method for yeast. On the other hand, the results for acidic acetonitrile-methanol and for 
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freezing-thawing cycles in methanol methods  show poorer precision, and significant changes in 
recovery of phosphorylated metabolites attributed to metabolite loss (solubility issues and accidental 
co-precipitation) or metabolite conversion during extraction procedure (due to incomplete metabolism 
quenching). The latter result is particularly interesting as the literature prior to this study reported 
freezing-thawing method in methanol as the best choice for yeast metabolomics. Hot water extraction 
generally performed well but evidence of protein degradation was observed which resulted in increase 
in the levels of relevant amino acids. Although not specifically focused on the development of sample 
preparation methods, another study reports the potential losses of oxaloacetate, oxalate and 
glyceraldehyde during sample preparation process and attributes these losses to the incorporation of a 
drying step within the procedure.
45
 
Bolten et al. showed that the choice of best sample preparation protocol is organism-dependent and 
should be properly validated prior to start of any metabolomics study.
49
 The common quenching 
method of cold methanol followed by centrifugation was found to lead to drastic loss of metabolites 
(>60%) resulting in large errors in determined in vivo intracellular levels of metabolites in prokaryotic 
organisms, while fast filtration worked well for metabolites with low turnover rates, but is not 
sufficiently rapid for metabolites with high turnover rates. Among the various methods tested, no 
single method appeared sufficiently universal, and the authors strongly recommend further research 
into improvement and design of sampling protocols in order to improve the quality of metabolomics 
data collected. Currently, the one species with commonly accepted sample preparation protocol is 
yeast and involves cold methanol quenching and boiling ethanol extraction.
45
 Energy charge ratio 
([ATP]+0.5[ADP])/([ATP]+[ADP]+[AMP]) is frequently used to evaluate sample preparation 
methods.
49, 70
 These phosphate species have very fast turnover rates in cells with half lives less than 
0.1 seconds, so they can be used to evaluate the efficiency of metabolism quenching step in cell 
metabolomic studies.
28
 The ratio of 0.80-0.95 is expected for a growing cell, but  an examination of 
sample preparation methods reported in literature showed ratios far from expected physiological 
range (0.16-0.66) indicating that the metabolism was not sufficiently quenched.
49
 Although this is just 
an example of a small subset of metabolites, similarly erroneous results can be expected for other 
metabolites with high turnover ratios. 
1.3.4 Importance of sample preparation method selection 
It is clear from above discussion that the choice of sampling, sample collection and sample 
preparation strategy plays an important role in the quality of metabolomics data. Clearly, the success 
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of metabolomics requires further research in this important area in order to provide better 
understanding of which method should be employed for which type of sample and analysis, and to 
better understand the shortcomings of the methods employed and thus limitations of the data 
collected. Without such fundamental studies, the field of LC-MS-based metabolomics can continue to 
suffer from isolation of “biomarkers” which are subsequently discovered to be artifacts of the 
analytical procedure. This point was well-illustrated by Canelas et al. who showed that even the 
relative levels of metabolites (up- or down-regulation when comparing two conditions) could be 
distorted on the basis of sample preparation method selection leading to erroneous conclusions,
69
.  
In contrast, for the analysis of human hepatocytes, the source of hepatocytes was the most 
significant contributor to the variation observed in regulation processes and collected metabolomic 
data.
71
 This is in line with majority of other well-designed studies where technical variability 
(evaluated by preparation of technical replicates of the same sample) is significantly lower than 
biological variability. For example, another study used ANOVA to characterize analytical, sample 
preparation and biological variability within collected data sets, and found analytical < sample 
preparation < biological regardless of analytical platform employed (GC-MS versus LC-MS).
72
 
These examples collectively show that increased validation and understanding of existing sample 
preparation methods as well as the emergence of new sample preparation techniques for 
metabolomics is necessary before the potential of metabolomics can be fully exploited. Once these 
technical aspects are adequately addressed, metabolomic studies can start to generate accurate 
quantitative data and build appropriate databases which will allow subsequent integration with other 




Given the variety of problems described above, in vivo sample preparation and/or analysis becomes 
an attractive option for its capability to provide a true(r) representation of the metabolome without 
some of the issues inherent in multi-step sample handling procedures and taking the sample out of its 
biological milieu.
4
 In fact in vivo dynamics, for example metabolite fluxes, can only be revealed in 






1.4 Introduction to solid-phase microextraction (SPME) 
Solid-phase microextraction (SPME) is a non-exhaustive sample preparation method which permits 
integration of sampling and sample preparation steps. The technique was originally introduced for the 
extraction of organic species followed by GC analysis
74, 75
, but over the past twenty years the 
technique has matured with numerous applications spanning environmental, food, pharmaceutical, 
forensic and clinical fields.
76-78
 
The most common format of SPME is fibre geometry, in which a small amount of extracting phase 
is immobilized on a solid support as shown schematically in Figure 1.3. Other formats of SPME such 
as thin film, coated stir-bar and coated capillary are also available, and the format of the device can be 
modified depending on the application requirements. The main steps of SPME procedure are (i) 
extraction of the analyte by SPME coating from the sample solution and (ii) desorption of the 
extracted analytes from the coating. The extraction process can be carried out by exposing fibre to the 
headspace above sample solution (headspace extraction) or by direct contact of the fibre with the 
sample solution (direct immersion). The former is applicable to volatile and semi-volatile species, 
while the latter extraction mode can be applied regardless of analyte volatility, and is illustrated in 
Figure 1.3 (a). The desorption of the analytes from the coating can be carried out (i) thermally by 
direct insertion of fibre into GC injector or (ii) using appropriate solvent as shown in Figure 1.3 (b). 
The work described in this thesis deals with the analysis of polar and/or non-volatile species from 
biological fluids, so direct extraction mode and solvent desorption were utilized throughout this work. 
The amount of analyte extracted by SPME depends on the time of contact between sample and 
extraction phase. If the time of contact is sufficiently long, equilibrium between extraction phase and 
sample is established. In this case, the amount of analyte extracted is given by Equation 1.1, 
         Equation 1.1 
 
where n is the number of moles of analyte extracted, C0 is the initial analyte concentration in the 
sample, Vs is the volume of  the sample, Vf is the volume of fibre coating, and Kfs is the distribution 
constant between SPME coating and sample matrix defined as the ratio of analyte concentration in the 
coating 𝐶𝑓
∞  to the analyte concentration in the sample at equilibrium 𝐶𝑠
∞  according to Equation 1.2 












Figure 1.3 Schematic of SPME procedure using direct extraction mode. (a) Fibre is exposed 
directly to the sample solution, and analyte of interest is extracted into the coating. (b) Fibre is 
now exposed to desorption solvent, and the analyte is desorbed from the coating into the solvent 
solution. Small arrows indicate the direction of mass transfer. 
The magnitude of Kfs depends on the nature of analyte and coating selected for the analysis, but is 
also impacted by the exact properties of sample matrix such as temperature, pH, addition of organic 
solvent and ionic strength, so it is important to keep these factors constant during sample analysis. 
Microextraction process is considered complete when equilibrium is reached between sample and 
coating, and increasing the extraction time beyond the time required to reach equilibrium does not 
result in any further increases in the amount extracted within experimental error. Thus, 
microextraction methods are considerably different from traditional exhaustive methods of sample 
preparation such as SPE, because complete extraction of analyte from the sample is not achieved. 
Only a small portion of analyte is extracted from the sample because the employed volume of 
extraction phase is typically much smaller than the sample volume. This is in contrast to SPE, where 
large volume of sorbent is used to ensure exhaustive removal of analyte from the sample.   
Equation 1.1 is applicable to absorptive coatings, such as polydimethylsiloxane (PDMS) where 
analyte can diffuse within the entire coating volume within the time scale of the experiment. In 
contrast, solid adsorptive coatings such as polypyrrole have limited number of surface sites, and the 
diffusion coefficient of analyte within the sorbent is too small, so the analytes can only be extracted 
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by the surface of the coating and not diffuse within the entire volume of the coating. In this case the 
amount of analyte extracted at equilibrium can be calculated using Equation 1.3, 
 
 
where Cf max is the maximum concentration of active sites on the coating, 𝐶𝑓
∞  is the equilibrium 
concentration of analyte on the fibre, and KAfs is the analyte’s adsorption equilibrium constant rather 
than partitioning constant described in Equation 1.1. From Equation 1.3, it can be seen that for low 
analyte concentrations on the fibre (if 𝐶𝑓
∞  << Cf max), when the number of occupied sites is low, the 
amount of analyte extracted is linearly proportional to initial sample concentration. However, if 
analyte concentrations are sufficiently high, saturation of the surface can occur, which results in 
nonlinear adsorption isotherms. Furthermore, one analyte can be competitively displaced from the 
coating by other analytes or other competing interferences present in the sample. The likelihood of 
this occurrence depends on the magnitude of K values of competing interferences as well as their 
concentration in the matrix. 
Furthermore, Equation 1.1 assumes that sample matrix is homogenous and that no headspace is 
present in the system. For multi-phase systems and heterogeneous samples, this equation can be 
















       Equation 1.4 
where 
 siis CCK  is the distribution constant of the analyte between the i
th
 phase and the matrix 
of interest, and the rest of the terms are the same as defined previously. For example, i
th
 phase can be 
headspace, and contribution of this phase should be taken into account for volatile analytes. In 
complex matrices, i
th
 phase can be binding matrix such as proteins present in blood samples. Equation 
1.4 has two very important consequences: it shows that the amount of analyte extracted is 
proportional to unbound analyte concentration and that the exact composition of sample matrix can 
impact the amount extracted by SPME when dealing with complex heterogeneous samples. The 
former is an important advantage of SPME over traditional methods, as it enables the use of SPME to 
determine free (unbound) or total (bound + unbound) concentration of analyte in given sample by 




















without (for free concentration) presence of binding matrix. However, from calibration perspective, 
Equation 1.4 shows that strict control is necessary to ensure calibration samples exactly match the 
composition of real samples, and that small variations in matrix composition can have adverse effects 
on method performance.  
From theoretical perspective, time required to reach equilibrium is infinite. From practical 
viewpoint, it is useful to define equilibrium time as the time required to extract 95% of analyte and 













where Ds is the diffusion coefficient of the analyte in the sample matrix,  (b-a) is the coating thickness 
and δ is the thickness of boundary layer. The time required to reach equilibrium depends on factors 
such as agitation conditions, physicochemical properties of analytes and the dimensions of sample 
matrix and fibre coating. Thus, for best sample throughput, it is recommended to use thin coatings 
and employ efficient agitation conditions. 
The extraction process can be interrupted before equilibrium is reached, and in this case the amount 
of analyte extracted is based on the timed accumulation of the analyte in the extraction phase and can 
be calculated using Equation 1.6 proposed by Ai
79
: 
           Equation 1.6 
where t is the extraction time and  a is time constant whose magnitude depends on factors such as 
mass transfer coefficients, distribution constant, sample volume, and volume and surface area of 
extraction phase. When equilibrium is reached, Equation 1.6 reduces to Equation 1.1. Clearly, the 
amount of analyte extracted is the highest at equilibrium, so if highest analytical sensitivity is needed 
for a particular application, extraction should be performed at equilibrium. However, if analytical 
sensitivity achievable with short extraction times is sufficient for a given application, pre-equilibrium 
SPME can be used to increase sample throughput.  
Both equations 1.1 and 1.6 show that the amount of analyte extracted is linearly proportional to 
initial sample concentration, thus enabling quantitative analysis. However, for this linear relationship 
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remain constant. In contrast, the amount of analyte extracted is independent of agitation conditions at 
equilibrium.   
One interesting feature of SPME is that under the conditions of negligible depletion, when Vs >> 
VfKfs, Equation 1.1 reduces to Equation 1.7, and the amount of analyte extracted by SPME becomes 
approximately  independent of sample volume.  
          Equation 1.7  
 
This equation is very important from the perspective of integrating sampling and sample 
preparation, as it indicates that defined sample volume is not necessary for quantitative analysis. This 
means that sampling can be performed directly on-site (for example, direct on-site sampling of river 
or lake) or directly within a living system (for example, direct sampling of circulating blood of an 
animal).  This capability of direct in vivo sampling makes SPME very attractive from the perspective 
of the field of metabolomics, as it should enable the capture of true metabolome at the time of 
sampling. 
For in vivo SPME applications where temporal resolution is important, such as pharmacokinetic 
studies, it is not feasible to wait to establish equilibrium between the analyte and extraction phase. In 
this case, SPME can still be used for quantitative analysis to accurately determine the initial analyte 
concentration in the living system, but appropriate pre-equilibrium calibration methods need to be 
employed.
80-83
 One such calibration method is called kinetic on-fibre standardization method.
84, 85
 
This calibration method uses the process of desorption of calibrant from the fibre coating in order to 
calibrate the process of the extraction of the analyte into the coating. These two processes are 
symmetric provided the calibrant employed has the same time constant as the analyte of interest. To 
fulfill this requirement, deuterated analogue of analyte is often employed
86-88
, although other studies 
have demonstrated that other compounds with similar diffusion properties can also be successfully 
used.
89
 The simultaneous processes of analyte extraction and calibrant desorption are governed by the 
following equation which is derived from Equation 1.6: 
         Equation 1.8 
where n and ne are the same as described previously, Q is the standard remaining on the fibre at time 












However from equation 1.1 we know that the amount of analyte extracted at equilibrium using 
SPME is a function of distribution coefficient, fibre volume and sample volume. Thus, if these two 
equations are combined, the initial concentration of analyte in in vivo sample is given by following 










      Equation 1.9 
Equation 1.9 shows that it is necessary to determine the product of Kfs•Vf in order to determine initial 
analyte concentrations in the system under study. This must be accomplished at equilibrium, by 
performing SPME using a set of calibration standards of known analyte concentration prepared in an 
appropriate matrix.  
Finally, on-fibre standardization method also compensates well for unknown agitation within a 
living system, such as the unknown or changing blood flow rate over the course of the entire in vivo 
experiment. Such uncontrolled agitation conditions cannot be well replicated and compensated using 
simple in vitro calibration methods.  
1.4.1 SPME and metabolomics: an overview    
In vitro and in vivo headspace SPME in combination with GC-MS analysis was previously 
successfully used for clinical metabolomic studies of volatile and semi-volatile species. The main 
types of applications reported to date include analysis of (i) disease biomarkers in human breath (ii) 
human skin emissions and (iii) analysis of cell lines. Soini et al. developed a very rapid sampling 
methodology using commercially available Twister PDMS stir bar for high-throughput metabolomic 
studies of human skin emissions.
90-92
 This device was rolled on 10 cm
2
 area of human skin for 10-12 
seconds. Rich metabolite profiles and good sampling reproducibility (both intra- and inter-day) were 
achieved. Two internal standards (7-tridecanone and 
13
C-benzyl alcohol) were preloaded in the 
PDMS devices prior to sampling in order to compensate for small variations in sampling and 
instrumental responses over time. Long-term reproducibility of 14.3% and 14.7% RSD was achieved 
for the two internal standards obtained during analysis of  total of 960 in vivo samples over 3-month 
period.
90
 Riazanskaia et al. investigated the use of thin PDMS film geometry for sampling of 
carcinoma lesions and other skin disorders.
93
 Very rich volatile profiles containing >300 peaks were 
obtained after thermal desorption of the PDMS thin films by GC-MS, and precision of repeated in 
vivo sampling was satisfactory with RSD <20% for selected representative metabolites. In another 
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study, the use of headspace in vivo SPME with specially designed sampling chamber resulted in 
profiles with >100 peaks.
94
  Gallagher et al. compared the performance of in vivo SPME versus 
hexane extraction for the analysis of human skin emissions.
95
 They tentatively identified a total of 92 
compounds: 58 were found using in vivo SPME while 49 were found in hexane extracts, indicating 
that the two techniques are complementary in nature. Higher molecular weight compounds 
predominated in hexane extracts, while SPME was more suitable for collection of lower molecular 
weight aldehydes and ketones. SPME was useful to extract five compounds that varied significantly 
according to age, among which the authors propose dimethylsulphone, benzothiazole and nonanal as 
biomarkers of aging.  In another example, Zimmermann et al. were able to identify for the first time 
methyl dodecanoate, decan-1-ol, heptan-1-ol, 3-methylbutan-1-ol, pentadecan-2-one, nonan-2-one 




Although the above-mentioned studies were able to propose some tentative biomarkers, the data 
should still be interpreted with caution as it typically relied on small data sets (with the exception of 
Soini et al . study) and requires further biomarker validation. For example, the tentative lung cancer 
biomarkers proposed by Gaspar et al. may not be specific for lung cancer, as they were previously 
also correlated to breast cancer, indicating that these compounds may be good general markers of 
oxidative stress rather than specific disease.
97
 In another example, Xue et al. investigated volatile 
biomarkers in liver cancer blood using in vitro SPME, and suggested hexanal, octane and 1-octen-3-
ol as possible biomarkers of liver cancer. However, elevated levels of hexanal were reported in other 
types of cancer such as lung cancer, leukemia, bone cancer and lymphoma.
102
 These examples 
illustrate that biological interpretation of metabolomics data can be very difficult and requires multi-
disciplinary collaboration to interpret and deconvolve observed trends. 
In addition to metabolomic studies by GC-MS, the potential of SPME to characterize short-lived 
and/or unstable species or reaction intermediates has also been demonstrated. For example, SPME 
was successfully used to elucidate biotransformation pathways of explosives and natural products, 
biotransformation routes of hydrocarbons such as benzene and biodesulfurization pathway of 
dibenzothiophene.
103-105, 105-108
 For example, SPME was used to propose stepwise desulfurization 
metabolism of dibenzothiophene (DBT) though formation of DBT-sulfoxide, DBT-sulfone, DBT -
sultine, DBT-sultone to the final product of 2-hydroxybiphenyl.
106
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to monitor yeast metabolism during fermentation processes in order to determine optimum 
fermentation time
109
 and to differentiate between toxigenic strains of mycotoxin-producing Fusarium 
fungi.
110
 In another study, SPME was used to isolate lilac aldehydes and alcohols for the first time as 
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metabolic byproducts of fungal biotransformation of linalool.
108
 Furthermore, in vivo SPME has been 
extensively applied for study of insect emissions such as semiochemicals and defense chemicals.
111-119
 
These studies were performed using headspace SPME or direct contact between the fibre and the 
insect, followed by GC analysis. For example, undecane was isolated as recruitment pheromone in 
ants which enables long-range intra-species communication when a good supply of food is 
discovered.
111
 In another study, SPME was used to identify for the first time sex pheromone (blend of 
tetradecanal and pentadecanal) in praying mantid.
115
 Prior to the availability of SPME for this type of 
application, insect sacrifice followed by solvent extraction was employed, and did not permit 
monitoring of dynamic changes in emissions of semiochemicals over time or changes in emissions 
upon interactions with other individuals, exposure to environmental stimuli or when limited number 
of colonies are available. Another interesting study comparing the results of hexane extraction and 
SPME subsequently showed that the results obtained for hexane extraction were incorrect, and the 
observed peaks were contaminants rather than true representation of cuticular hydrocarbon 
secretions.
120
 In contrast, the results of SPME were correct. This study effectively illustrates that 
increased number of steps often involved in traditional sample preparation methods can sometimes 
lead to inadvertent contamination and erroneous results/conclusions. Finally, metabolomics 
applications of in vivo SPME are not confined to sampling of animals and microorganisms, but SPME 
has also been successfully applied in plant metabolomics for isolation and monitoring of scent 
development, wound response, infestation, etc.
121-123
 For instance, in a targeted metabolomics study of 
scent development over time and corresponding circadian rhythms, the performance of in vivo and in 
vitro sampling was compared. Using in vitro sampling (freezing with liquid N2 to stop the 
metabolism), additional peaks attributed to lipid peroxidation were observed indicating the effects of 
sample preparation method on observed metabolome.
122
 
1.5 Research objectives 
The main research objective of this thesis is to demonstrate for the first time the suitability of  SPME 
in direct extraction format for global metabolomic studies using LC-MS.  
The main requirements for a sample preparation method of biofluids were discussed in detail in 1.3 
and include (i) speed and simplicity, (ii) high throughput and automation, (iii) efficient extraction of 
diverse range of metabolites and (iv) the need to quench metabolism. However, SPME methodology 
required further development in terms of automation and selectivity of extraction before it could be 
successfully applied to metabolomic studies. Thus, Chapter 2 describes initial work regarding 
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automation of SPME in 96-well plate format to enable higher sample throughput. Chapters 3 and 4 
describe the commercial development of in vivo SPME sampling device in collaboration with Supelco 
Inc. and optimization of in vivo SPME procedures including the first application of in vivo SPME to 
mice. The extension of in vivo SPME sampling to small rodents such as mice was deemed particularly 
important from metabolomics perspective, as the advantages of elimination of the need of blood 
withdrawal are particularly important for such animals where very limited amount of blood is 
available (<2 mL total blood volume). Mice are often utilized in metabolomic studies of disease 
models and pharmaceutical discovery
23, 124
 and recently it was recommended that all control strains 
used to generate transgenic or knock-out mice should be used as controls in metabolomic studies on 
the basis of significant influence of strain on metabolomics data.
21
 Such recommendations for 
increased animal use or the need for longitudinal studies of same animals to monitor metabolic 
trajectories such as return to healthy metabolic profile after particular treatment or to monitor 
progress of disease
23, 125
 make blood-free approaches such as in vivo SPME even more attractive. 
Chapter 5 discusses the development of SPME coatings suitable for direct extraction of diverse range 
of metabolites which make up the metabolome, as suitable coatings for this type of application were 
not previously reported in literature. 
Chapter 6 describes the development of the basic SPME methodology suitable for use in 
metabolomic studies and describes in detail the optimization of LC-MS methods. The latter 
optimization was very important in order to ensure adequate metabolite coverage, as SPME extracts 
only small portion of metabolite, so good instrumental sensitivity is of paramount importance. 
Chapter 7 summarizes the results of  a full in vitro metabolomics study on human plasma and also 
compares the performance of SPME to traditional methods of plasma protein precipitation and 
ultrafiltration. This comparison was useful to place SPME within the context of commonly employed 
methods and to evaluate whether the developed methodology was sufficient for application during in 
vivo studies in terms of analytical parameters such as sensitivity, precision and metabolite coverage. 
Chapter 8 describes the successful application of in vivo SPME to mice to study the effects of 
carbamazepine administration in a preliminary proof-of-concept study. Clear advantages of in vivo 
sampling approach versus the methods relying on blood withdrawal are demonstrated. Finally, 
Chapter 9 summarizes the main research findings of current work and proposes future directions and 





Automation of SPME in 96-well plate format for high-throughput 
analysis of biological fluids 
2.1 Preamble and introduction 
2.1.1 Preamble 
This chapter has been published as a paper: Vuckovic, D., Cudjoe, E., Hein, D. & Pawliszyn, J. 
Automation of solid-phase microextraction in high-throughput format and applications to drug 
analysis. Anal. Chem. 80, 6870-6880 (2008). Tables and figures are reprinted from this publication 
with permission from American Chemical Society (Copyright 2008 American Chemical Society). 
The full procedure for automated SPME developed in this original work was also described in step-
by-step fashion for future users in Vuckovic, D., Cudjoe, E., Musteata, F. M. & Pawliszyn, J. 
Automated solid-phase microextraction and thin-film microextraction for high-throughput 
bioanalytical applications and ligand-receptor binding studies. Nat. Protocols 5, 140-161 (2010).  
Table 2.7 and Figures 2.8 and 2.19 are reprinted from this work with permission from Nature 
Publishing Group according to Nature Publishing Group policy whereby the ownership of the 
copyright remains with the authors and permission “to reproduce the Contribution in whole or in part 
in any printed volume (book or thesis) of which they are the author(s)” is automatically granted. The 
application of automated system to ligand-binding studies is beyond scope of this research thesis, so 
this material is not included in the chapter. On this basis, the permission of Marcel Florin Musteata 
who developed the theory of ligand-receptor binding by SPME regardless of the degree of depletion 
is considered to not be required. 
The contribution of co-author, Erasmus Cudjoe to the work described within this chapter was in the 
development of 96-SPME device (the design of the device described in section 2.2.4) and the 
improvement of prototype PAS Concept 96 autosampler including programming of Concept software. 
Dietmar Hein designed and built PAS Concept 96 autosampler which was used to perform the 
experimental work described herein.  




I, Dietmar Hein, authorize Dajana Vuckovic, to use the material for her thesis. 
 
2.1.2 Introduction 
SPME is easily coupled to gas chromatography due to its solvent-free nature and syringe device 
format both of which permit direct introduction of device into GC injector. Commercial autosamplers 
capable of performing all steps of SPME extraction and introduction into GC system have been 
available since 1990s and permit application of SPME for unattended analysis of large number of 
samples with sample throughput compatible with GC analysis times.
126
 The first coupling of SPME to 
LC was reported in 1995
127
 and involved manual introduction of SPME device into the path of mobile 
phase using a simple desorption chamber. All of the extracted analytes are swept onto the analytical 
column, so high analytical sensitivity can be achieved, and the process is analogous to thermal 
desorption used successfully in GC. This strategy was subsequently commercialized by Supelco, but 
all steps of the process are performed manually, and this format has not been successfully automated 
to date. Furthermore, high pressures typically encountered during LC analysis can cause inadvertent 
leaks at the interface and thus accidental loss of sample during the desorption step. Existing 
commercially available coatings for HPLC also swell considerably using aqueous solvent mixtures 
typically employed as mobile phases in LC. For example, commonly used commercial coating 
Carbowax/template resin (CW/TPR) was found to swell 36-40% after 15-min exposure to 
water/methanol or water/acetonitrile mixtures. 
128
 Such swelling significantly increases overall 
diameter of the device, so the coating can be accidentally stripped during removal from the interface 
due to the increase in dimensions. A second strategy for coupling of SPME to LC is called in-tube 
SPME because this strategy relies on the use of coated capillary rather than the more common fibre 
geometry. This strategy has been fully automated, and the main principle involves the placement of 
this coated capillary within the path of LC system, for example in lieu of sample injection loop or 
transfer tube. The sample is then drawn into and ejected from this capillary using appropriate 
software program that can be written for any commercial HPLC autosampler. During each draw 
cycle, analyte can partition into the extraction phase, and the process of drawing/ejecting provides 
agitation in the system in order to enhance mass transfer.  Once extraction is completed, mobile phase 
is directed through the capillary and the analytes are desorbed and swept onto the analytical column 
for LC separation and analysis. The main advantages of this approach are full automation and high 
sensitivity because all of the analyte extracted is introduced onto the analytical column. However, the 
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use of capillary geometry means that sample pre-treatment such as filtration, centrifugation or 
dilution, is necessary to remove any particulate matter in order to avoid clogging of the capillary. 
Furthermore, sample throughput is relatively low, because samples are processed serially, and each 
extraction and desorption step can be time consuming due to slow mass transfer kinetics in liquid 
phase. One way to achieve high sample throughput when coupling SPME is to perform offline 
solvent desorption of many samples in parallel using regular HPLC vials, vial inserts or 96-well 
plates. In addition to lack of automation, the main disadvantage of this approach is decrease in 
sensitivity as all of the extracted analyte is not introduced into analytical system. For example, 
minimum desorption volume of 100 µL is typically used to ensure complete immersion of the coating 
within the solvent, although volumes as low as 40-50 µL have also been reported.
129
 Thus, to date, 
none of the three main desorption strategies used in combination with LC, was capable of 
simultaneously providing both high sample throughput and high desorption efficiency.  
The main goal of research described in this section was to evaluate and improve new autosampler 
designed to fully automate SPME in 96-well plate format using offline solvent desorption. The initial 
idea for a device consisting of 96 fibres which fit into the centres of a commercial 96-well plate was 
described in 2005
126
, and a simple semi-automated proof-of-concept study using an array of eight 
commercial PDMS-DVB fibres was carried out to investigate the feasibility of SPME in bioanalysis 
by comparison against accepted automated 96-well plate liquid-liquid extraction (LLE) method.
130
 
Good performance of SPME was reported with following figures of merit for a candidate drug 
molecule: linear range of 1-500 ng/mL for both methods, accuracy of 95.2-103.7% for SPME versus 
98.0-101.8% for LLE, and method precision of 0.5-6.9% for SPME versus 0.8-3.3% for LLE. 
However, due to the high cost of a single commercial SPME fibre building a 96-fibre array with such 
commercial devices was very cost-prohibitive, so alternative configurations were explored by 
Hutchinson et al.
131
 This work proposed the use of pins found in commercial 96-pin-tool replicator 
device as the metal support for immobilization of SPME coating. Hollow PDMS tubing (medical 
grade) was found to work well for the extraction of semi-volatile polyaromatic hydrocarbons. Among 
different agitation methods, orbital agitation while fibres are kept stationary was found to provide 
more uniform agitation than sonication or magnetic stirring. Based on the results of this study, 
Dietmar Hein and PAS technology designed and built prototype SPME autosampler, named Concept 
96, which consisted of two orbital agitators, one arm capable of  positioning 96-pin-tool replicator 
device, syringe arm (to dispense desorption solvent, internal standard) and a 96-well plate nitrogen 
blowdown device to permit incorporation of evaporation/reconstitution step for applications requiring 
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additional sensitivity. The availability of such system was deemed important for both bioanalytical 
and metabolomics applications of SPME as it would enable for the first time the use of SPME in 
laboratories needing to process large number of samples.   
For the evaluation of Concept 96 autosampler, several benzodiazepines shown in Figure 2.1 were 
selected as target analytes because of their widespread use as tranquilizers, hypnotics, muscle 
relaxants, and anticonvulsants and their amenability to analysis by electrospray LC-MS. PDMS 
coating proposed by Hutchinson et al.
131
 was found unsuitable for drug analysis due to very slow 
kinetics and poor intra-fibre reproducibility, so an alternative simple and reproducible fibre 
preparation procedure based on SPE-type sorbents was investigated and optimized for multi-fibre 
SPME.
132
 The performance of the system was evaluated with respect to following parameters: 
selection of coating, carryover of analyte in the extraction phase, well cross-talk, fibre robustness, 
selection of optimal calibration method, uniformity of agitation in all wells, suitability for pre-
equilibrium SPME, and fibre-to-fibre reproducibility. After full optimization, multi-fibre SPME-LC-
MS/MS method was fully validated for high-throughput analysis of benzodiazepines in whole blood 
to show an example application in a complex heterogeneous matrix.   
 





2.2.1 Chemicals and materials  
Diazepam, nordiazepam, oxazepam, and diazepam-d5 were purchased from Cerilliant (Round Rock, 
TX, USA) as 1 mg/mL methanolic solutions, while lorazepam was purchased as a 1 mg/mL solution 
in acetonitrile. Acetonitrile (HPLC grade), methanol (HPLC grade), and glacial acetic acid were 
purchased from Fisher Scientific (Ottawa, Canada). Sodium chloride, potassium chloride, and 
potassium phosphate were purchased from EMD Chemicals (Gibbstown, NJ, USA). Sodium 
phosphate and human serum albumin were purchased from Sigma-Aldrich (Oakville, Canada). 
Polypropylene 96 deep multi-well plates and BD K2 EDTA 18 mg Plus Vacutainer blood collection 
tubes were purchased from VWR International (Mississauga, Canada). Nanopure water ( ≥18.0 MΩ)  
was obtained from water purification system (Barnstead, Thermo Fisher, San Jose, CA, USA). 
2.2.2 Preparation of buffers and standard solutions 
Instrument calibration was performed using a set of calibration standards prepared in desorption 
solvent (acetonitrile/water, 1/1, v/v). These standards were injected in duplicate at the beginning and 
end of each sample run, and one quality control (QC) standard was also injected periodically 
throughout the run to ensure suitable instrument performance. These standards were stored 
refrigerated, and fresh standards were prepared monthly. 
Phosphate-buffered saline (PBS) solution pH 7.4 was prepared by dissolving 8.0 g of sodium 
chloride, 0.2 g of potassium chloride, 0.2 g of potassium phosphate, and 1.44 g of sodium phosphate 
in 1 L of purified water and adjusting the pH to 7.4, if necessary. For all SPME optimization and 
evaluation experiments, standard solutions were prepared at appropriate concentration (typically 100 
ng/mL unless otherwise indicated in text) in PBS buffer is such a way to keep the organic solvent 
concentration at exactly 1% (v/v) methanol. Fresh standards were prepared in PBS daily. 
For the application of optimized method to whole blood samples, calibration standards and 
validation samples were prepared by spiking an appropriate amount of each drug standard in whole 
blood (final concentration range from 1 ng/mL to 1000 ng/mL) in such a way as to keep the organic 
solvent concentration at exactly 1% methanol. After spiking, samples were left standing for a 
minimum of 1 hr to ensure sufficient time for drug-protein binding to take place prior to extraction. 
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2.2.3 Preparation of 96-SPME device using pin-tool replicator and PDMS coating 
The initial design of the device was based on the work described by Hutchinson et al. who used a 
commercially available pin-tool replicator as the support to immobilize SPME coatings.
131
 Pin-tool 
replicator (model AFIX96FP3) and floating pins (FP8, 0.356 mm diameter) were purchased from 
V&P Scientific (San Diego, CA, USA).The coating used for this device was HelixMark 
polydimethylsiloxane-based hollow tubing with 0.31 mm ID and 0.64 mm OD and was made from 
PDMS and proprietary filler (Helix Medical, Carpinteria, CA, USA). This tubing was cut into 2 mm 
pieces and placed directly over floating replicator pins. The thickness of the extraction phase for these 
fibres was 165 μm, as determined by the thickness of the tubing. Pin-tool replicator was directly 
attached to PAS autosampler arm using appropriate screws.   
2.2.4 Preparation of 96-SPME device using 1.55 mm diameter stainless steel wire and 
coated silica particles 
Based on the results of the coating optimization procedure (discussed in Section 2.3.1.9), thick 1.55 
mm solid supports were found to perform better than thin solid supports. In order to house these new 
solid supports in a 96-SPME device, a simple prototype device was designed and built by Machine 
Shop at the University of Waterloo. This device consisted of top and bottom plates. Bottom plate was 
drilled with holes to fit 1.55 mm solid support. The spacing of the holes was chosen to match the 
centre of each well of commercial 96-well plates.  The two plates were held together with screws in 
the four corners. 96-plate Silicone PCR-Mat was purchased from Ultident Scientific (St. Laurent, 
Canada) and placed between the two plates to ensure that the solid supports are sufficiently 
immobilized. The device is shown in Figure 2.2 (a). The attachment of the device to PAS autosampler 
is shown in Figure 2.2 (b) and was designed by E. Cudjoe and D. Hein. 
To prepare thin SPME coatings on 1.55 mm support (stainless steel wire, type 316, Small Parts Inc. 
Miami Lakes, FL, USA), the procedure reported by Mullett and Pawliszyn was used.
132
 This 
procedure involves the immobilization of coated silica particles using strong adhesive, and was 
previously shown to be suitable for solvent desorption. In current work, the procedure was further 
optimized to improve inter-fibre reproducibility. The overview of optimized procedure is shown in 
Figure 2.3. The main changes included optimization of the solid support diameter and an increase in 




Figure 2.2 (a) Custom-made multi-fibre SPME device constructed using 1.55 mm stainless steel 
wires and RPA extraction phase. (b) Photo showing the details of SPME multi-fibre device, 96 
multi-well plate and agitator employed in PAS robotic system. 
Briefly, stainless steel wire was cut into 10 cm pieces using special metal cutter from Small Parts 
Inc. to obtain clean cut. The ends of wires were then sanded using aluminum oxide sand paper, 
followed by 20 min sonication in acetone and 2 hr sonication in 6M nitric acid. The wires were rinsed 
thoroughly with purified water and then methanol, and then allowed to air dry. A thin layer of Loctite 
349 glue (modified methacrylate ester adhesive, R.S. Hughes Company, Plymouth, MI, USA) was 
placed on the wires by filling 2 mL HPLC vial with glue, capping it and passing the wire through the 
septum. The fibres were then rolled in 5-10 µm coated silica particles (C18 or C16 amide particles 
obtained as research samples from Supelco, Bellefonte, PA, USA) to obtain good surface coverage. 
Coating length was 1.5 cm. Coated fibres were then cured under an ultraviolet lamp for 1 hour. 
During UV curing, fibres were rotated every 10 min to ensure all sides were cured. 
Before initial use, the fibres were conditioned by overnight exposure to a methanol/water (1/1, v/v) 
solution using 850 rpm agitation, followed by a 30 min exposure to purified water and a 30-min 
exposure to acetonitrile/water (1/1, v/v) mixture. The long overnight conditioning with agitation was 
found important to remove any loosely bound particles from the surface. For subsequent uses, the 




Figure 2.3 Overview of optimized coating procedure using 5-µm coated silica particles.  
2.2.5 Description of PAS autosampler for automated SPME 
The automated SPME system was designed and obtained from PAS (Magdala, Germany) as research 
prototype. The unit was designed to automate all sample preparation steps of SPME procedure, 
including the addition of an internal standard, multi-fibre SPME extraction and desorption for a preset 
amount of time with controlled agitation, evaporation of the solvent, reconstitution, and injection of 
the final sample solution from individual wells into the HPLC injection port.  To achieve this, the unit 
consisted of a three-arm robotic autosampler, HPLC injection port and two orbital agitators. It was 
fully controlled with Concept software.  One XYZ arm of the autosampler was used to hold, 
transport, and position the 96-fibre SPME device for the extraction and desorption steps of SPME. 
The second arm was equipped with a N2 blow-down device in order to perform solvent evaporation 
and analyte pre-concentration steps if enhanced sensitivity was required. This feature was not used in 
current work and it was evaluated in separate research by E. Cudjoe. The third arm consisted of an 
XYZ arm equipped with a 250 µL syringe and was designed to dispense preset volumes of 
reconstitution/desorption solvents or internal standard solutions into the individual wells of the 96-
well plate, as well as to perform sample injection into the HPLC port of the analytical system. The 
desorption volume used in current work was 800–1000 µL, which exceeded the syringe capacity. 
Thus, the desorption solvent was either dispensed manually using an air displacement Fisherbrand 
200–1000 µL pipette or using  an automated 96/384-well microplate reagent dispenser (Ultraspense 
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Figure 2.4 Photo showing PAS Concept 96 robotic system. A and B are orbital agitators used 
for extraction and desorption, C is system controller, D is the arm used to manipulate SPME 
multi-fibre device, E depicts SPME multi-fibre device, F is syringe arm and G is the arm used 
for simultaneous nitrogen evaporation from all wells.  
2.2.6 LC-MS/MS analysis  
Benzodiazepines were analyzed using a LC-MS/MS system consisting of CTC-HTS PAL 
autosampler with cooled sample tray, Shimadzu 10AVP LC with dual pumps (Shimadzu LC10ADvp) 
and system controller (SCL10Avp) and API3000 triple quadrupole mass spectrometer equipped with 
TurboIonspray source (Applied Biosystems/MDS Sciex, Concord, Canada). The flow of column 
effluent was diverted to waste for the first 1.0 min of chromatographic run time using bypass pump 
and a Waters switching valve. Analyst software version 1.4.1 was used for data acquisition and 
processing. Analytes were separated using Symmetry Shield RP18 column with dimensions of 2.1 x 
50 mm and 5 µm particles (Waters, Millford, MA, US) using chromatographic conditions previously 
developed by Lord et al.
133
 Samples (20 µl) were injected in duplicate and kept at 5 °C on the 
autosampler while waiting for analysis. Mass spectrometric conditions used were: nebulizer gas = 6, 
curtain gas = 10, CAD gas =12, ionspray voltage 5300 V, and source temperature set to 400°C. The 
analysis was performed using positive ESI in multiple reaction monitoring (MRM) mode using 
instrument settings described in Table 2.1. These parameters were obtained by direct infusion of 1 













each parameter until maximum signal was obtained. Dwell time of 200 msec was used for monitoring 
of each ion. 
Table 2.1 Summary of MS/MS parameters for the analysis of benzodiazepines. 
2.2.7 SPME procedure during optimization/evaluation experiments 
SPME was performed using 1000 µL aliquots of appropriate benzodiazepine standard prepared in 
PBS buffer, pH 7.4. Extraction time was varied depending on the experiment as stated in text. 
Extraction and desorption were performed using 850 rpm agitation. The desorption was performed 
using 1000 µL of desorption solvent (acetonitrile/water, 1/1, v/v) for stated amount of time (60 min 
for PDMS coating and 30 min for C18 and RPA coatings). The carryover was evaluated by performing 
a second desorption using fresh portion of desorption solvent. These extracts were then analyzed 
directly using LC-MS/MS. 
2.2.8 SPME procedure for high-throughput analysis of benzodiazepines in whole 
blood 
Whole blood was collected from a healthy volunteer using BD K2 EDTA 18 mg Plus Vacutainer 
tubes and kept on ice until use. Whole blood was processed within 24 hr from collection, and stored 
refrigerated when not in use. The internal standard (diazepam-d5) dissolved in methanol was added to 
all samples and standards at the final concentration of 400 ng/mL. SPME procedure was performed 
using PAS autosampler and following extraction conditions: 800 µL sample volume, 30 min 
extraction, 850 rpm agitation. Immediately after extraction, fibres were rinsed manually for 30 
seconds using purified water in order to eliminate any blood droplets or red blood cells from the fibre 
surface. Initial design of PAS autosampler did not incorporate the possibility of wash step, but based 
on the results of this work, subsequent improved design of the unit incorporated a wash station where 























Diazepam 285.0 153.9 92 120 7.5 39 10 
Lorazepam 321.1 275.1 101 360 10 31 20 
Oxazepam 287.1 241.1 61 160 10 31 18 
Nordiazepam 271.1 140.0 66 170 10 39 10 
Diazepam-d5 290.2 154.1 92 120 7.5 39 10 
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water. The desorption was performed using 800 µL of desorption solvent (acetonitrile/water, 1/1, v/v) 
for 30 min at 850 rpm. These extracts were then analyzed directly using LC-MS/MS.  
2.2.9 Data analysis and calculations 
Calibration was performed using 1/y weighted linear regression in SigmaPlot 2004 for Windows 
version 9.0 software. Weighted regression was found to perform better than simple linear regression 
by improving the accuracy of low concentration standards. Extraction efficiency (or absolute 
recovery) was calculated by dividing the amount of analyte extracted by the coating (in ng) with the 
total amount of analyte originally present in the spiked sample (in ng), and multiplying this result by 
100% to convert it to percentage. The amount of analyte extracted was determined using instrument 
calibration curve for each analyte prepared directly in desorption solvent (single standard per 
concentration level, minimum of 6 levels to cover the entire linear range of the instrument). Relative 
recovery (or accuracy) was calculated by dividing experimentally determined sample concentration 
(in ng/mL, determined using calibration curve prepared in whole blood) by true sample concentration 
(in ng/mL), and multiplying this result by 100% to convert it to percentage. Whole blood calibration 
was performed by SPME of each standard in duplicate, and a minimum of six concentration levels 
across the entire linear range were used as described in Section 2.2.2.  
2.3  Results and discussion 
2.3.1 Optimization and evaluation of automated 96-SPME system and PAS 
autosampler 
Research prototype PAS autosampler was designed on the basis of the concept initially proposed by 
O’Reilly et al.
126
 and further supported by the results of a proof-of-concept study
131
. In this study, 
orbital agitation while fibres are held stationary was found to provide the best results when compared 
to sonication and magnetic stirring.
131
 The authors also found that commercially available pin-tool 
replicator could successfully be used to immobilize an array of 96 SPME fibres. In this study, 
polyaromatic hydrocarbons were used as analytes and the analysis was performed using gas 
chromatography after solvent desorption.  
The first objective of current research was to build on the study performed by Hutchinson et al. and 
evaluate the performance of new PAS Concept 96 autosampler for drug analysis with respect to 
factors such as (i) selection of the best fibre coating, (ii) optimization of the fibre coating procedure 
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(iii) selection of the best stainless steel support, (iv) examination of the need for fibre pre-
conditioning and/or rinsing, (v) selection of the optimal calibration method, (vi) evaluation of fibre 
carryover, (vii) evaluation of well cross-talk and (vi) confirmation of uniform agitation in all wells. 
Additional factors such as agitation speed, optimization of extraction phase geometry and the 




PDMS coating, recommended by Hutchinson et al., was initially evaluated for use with PAS 
autosampler.
131
 However, the performance of this coating for drug analysis was found to be 
inadequate as described in detail subsequent sections, so new coatings based on C18- and RPA-coated 
silica particles were also incorporated into this evaluation in order to improve the overall performance 
of the system.  
2.3.1.1 Optimization of desorption conditions for PDMS coating  
Optimization of solvent desorption conditions during SPME method development involves testing of 
different solvent compositions and desorption times in order to achieve efficient desorption of the 
analyte while minimizing or eliminating carryover. Carryover is defined as the amount of analyte 
remaining in the coating after first desorption. It is determined experimentally by performing a second 
desorption using fresh portion of desorption solvent, and can be calculated using Equation 2.1. 
% 𝑐𝑎𝑟𝑟𝑦𝑜𝑣𝑒𝑟 =
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑎𝑛𝑎𝑙𝑦𝑡𝑒 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 𝑖𝑛 𝑑𝑒𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛 2
𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑎𝑛𝑎𝑙𝑦𝑡𝑒 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 𝑖𝑛 𝑑𝑒𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛𝑠 1 𝑎𝑛𝑑 2
 ×  100% 
In current study, polar solvents such as methanol or acetonitrile were tested for their ability to 
desorb the analytes from the fibre.  Non-polar solvents are not suitable for desorption since they swell 
or dissolve the PDMS extraction phase.
  
The results obtained are shown in Figure 2.5. Two desorption 
solvent compositions were found to remove ≥99% of analyte from the coating when 60-min 
desorption time with agitation speed of 850 rpm was used:  acetonitrile/water (1/1, v/v) mixture and 
pure acetonitrile. Under these conditions, the carryover was found to be less than 1%. In addition to 
desorption efficiency, two other factors play a role when selecting the most appropriate desorption 
solvent for this automated SPME system. These are desorption solvent compatibility for direct 
injection into LC-MS and potential for solvent evaporation duirng the desorption step. According to 
this criteria, acetonitrile/water (1/1, v/v) solution was chosen as the desorption solvent for all 




gradient reverse-phase LC-MS method for the analysis of benzodiazepines and less susceptible to 
evaporative losses during desorption step than pure acetonitrile. 
 
Figure 2.5 Optimization of desorption conditions for diazepam using PDMS coating (n=3). 
Extraction was performed from 100 ng/mL diazepam standard in PBS buffer pH 7.4 for 60 min 
using agitation of 850 rpm. 
2.3.1.2 Determination of extraction time profile for PDMS coating  
An extraction time profile was determined experimentally by measuring the amount of analyte 
extracted by the fibre as a function of time and is shown in Figure 2.6 (a). The equilibrium for 
diazepam was reached after 1200 min. As discussed in Section 1.4, the equilibration time is defined 
as the time after which the amount of analyte extracted remains constant within experimental error. 
The equilibration time is affected by coating thickness, sample temperature, agitation conditions and 
distribution constant, and the long equilibration time observed in current study was attributed to the 
thickness of extraction phase which is approximately 165 μm. However, the coating thickness could 
not be further reduced using this method of constructing an array of 96-SPME devices, because this 
was the thinnest tubing commercially available with the appropriate dimensions. Such long extraction 
times are not suitable for high-throughput applications, and high sample throughput was the primary 
goal of this research. Therefore, in the next step, the suitability of Concept 96 system for pre-
equilibrium SPME was examined.  
























































































































For pre-equilibrium SPME methods, accurate timing of extraction step is very important in order to 
achieve good method precision because the amount of analyte extracted depends on the exact length 
 
Figure 2.6 (a) Representative extraction time profiles for the extraction of diazepam from 100 
ng/mL standard solution for 6 different fibres and well positions (data for all 96 fibres was 
collected as discussed in text, but is shown for only 6 fibres for clarity) (b) Dependence of % 
RSD for the amount extracted of diazepam (n=96 fibres) on the extraction time. 
of extraction time as shown previously in Equation 1.6. Therefore, to examine the performance of 
Concept 96 robotic station for pre-equilibrium SPME, extraction was performed using all 96 fibres 
and the extraction time was varied from 15 min to 1800 min. The results of this experiment are shown 
in Figure 2.6 (b).  Excellent method precision with RSD of 8-12% was found for all extraction times 
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observed at pre-equilibrium times (60-960 min) versus equilibrium extraction times (1200 -1800 
min). The main reason such good precision was observed at pre-equilibrium extraction times is that 
the extraction is performed in parallel for all samples and accurate timing and fibre positioning is 
achieved using software control via Concept software. However, using very short extraction time of 
15 min, very poor method precision was observed with RSD of almost 30%. Possible reasons for this 
finding include that some time is required to establish uniform agitation in all of the wells and/or 
eliminate any air bubbles within the wells. Overall, the results show suitability of Concept 96 for pre-
equilibrium SPME, but the use of short extraction times ≤ 15 min should be avoided to ensure 
uniform agitation can be established in all wells. 
2.3.1.3 Evaluation of inter-fibre and intra-fibre reproducibility of PDMS fibres 
Most SPME analyses rely on the use of a single fibre for extraction of all samples and standards in a 
given batch, rendering the issue of inter-fibre reproducibility not important for this type of analysis, as 
long as fibre is not damaged during the analysis. However, in current research, extraction of samples 
and standards is performed by an array of 96 fibres, so it is crucial for the reproducibility between the 
amount of analyte extracted by different fibres to be very good to ensure reliable quantitative 
analysis. To obtain good inter-fibre reproducibility of the amount extracted, it is important for the 
volume of the coating to be the same for all fibres. For hollow-tubing PDMS coating, the fibre-to-
fibre reproducibility is thus limited by the uniformity of the tubing thickness and the ability to cut the 
tubing into pieces of equal length. The inter-fibre reproducibility of resulting PDMS coatings for the 
array of 96 fibres was evaluated using the extraction of diazepam from 100 ng/mL standard solution. 
Using equilibrium extraction and optimized desorption conditions, inter-fibre reproducibility (n=96 
fibres) was found to be 10 and 11% RSD for each of two independent experiments as shown in Table 
2.2. The results from a representative extraction are also shown in Figure 2.7 by plotting well position 
versus amount extracted. These plots were collected for several days and examined for any apparent 
trends. For example, a fibre with significantly lower volume of coating would be expected to extract 
smaller amounts of analyte on each day tested. However, no such trends in data were observed  and 
no outlier fibres were detected, indicating that this coating could be made with satisfactory inter-fibre 
reproducibility.  
It was previously reported that rinsing of the fibres between extraction and desorption steps can 
help further improve method precision by removing any small droplets from the surface of the 
fibres.
133




Figure 2.7 Amount of diazepam extracted from 1 mL of 100 ng/mL diazepam standard solution 
using automated multi-fibre SPME (n=96 fibres). 
obtained are included in Table 2.2 and show that rinsing did not affect the amount of analyte 
extracted nor improve method precision. Therefore, the rinsing step could be omitted or added 
depending on the complexity of sample matrix. For example, in subsequent studies using whole blood 
(Section 2.3.2), presence of small blood droplets and/or red blood cells was found on the surface of 
the fibre after extraction, and addition of 30-second wash step helped eliminate these possible 
interferences prior to desorption resulting in clear particulate-free extracts.
 
Table 2.2 The effect of fibre rinsing on the amount of diazepam extracted and inter-fibre 
reproducibility using multi-fibre SPME with PDMS coating. 
Rinse 
Mean amount of diazepam extracted 
(ng) 
(n=96) 
% RSD of 
extraction 
(n=96) 
No 26.5 10 
No 26.0 11 
Yes 26.6 12 
Yes 25.4 10 
Overall Mean (n=4): 26.1 NA 
% RSD (n=4): 2.1 NA 
 
The intra-fibre reproducibility is defined as the reproducibility of the amount extracted when a 
single fibre is used to carry out repeated extractions. This parameter was evaluated using the data 
from five independent extractions of diazepam standard solution of known concentration (100 
ng/mL). The average amount extracted by each fibre (n=5 extractions) and RSD were calculated 
individually for each of 96 fibres. The results for this evaluation are shown as histogram in Figure 




























2.8. The mean % RSD for the entire experiment was 9% (average RSD for all 96 fibres studied) 
which is acceptable for quantitative analysis by electrospray LC-MS. However, Figure 2.8 also shows 
that a significant number of fibres had unacceptably high RSDs ranging from 10-23%. Possible 
causes for the observed spread of RSD values were further investigated with the goal to further 











Figure 2.8 Evaluation of intra-fibre reproducibility using PDMS coating. The distribution of 
fibres with given RSD  for n=5 independent extractions using the same fibre is shown. The 
performance of fibres with % RSD exceeding 10 was deemed unacceptable for quantitative 
analysis. All of the extractions were performed using 100 ng/mL standard solution of diazepam 
in PBS and optimized SPME conditions. 
2.3.1.4 Investigation of carryover using PDMS coatings 
Although carryover was evaluated during the optimization of desorption conditions (Section 2.3.1.1), 
this evaluation was performed using only n=3 fibres. Furthermore, the initial carryover test was 
performed using only 60-min extraction time, so it was possible that carryover after equilibrium 
extraction is more significant, because higher amount of analyte is extracted at equilibrium. 
Furthermore, if the amount of carryover is not the same for all fibres, it could possibly cause poor 
intra-fibre reproducibility. This possibility was investigated by determining the carryover for all 96 
fibres after 20 hr equilibrium extraction. The average carryover was found to be 0.3% using optimum 
desorption conditions (range observed was from none detected to 0.7%), thus confirming previous 
results. This indicated that carryover is not a significant contributing factor to poor intra-fibre 
reproducibility observed for some fibres. 
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2.3.1.5 Investigation of the uniformity of agitation using orbital shaking and PDMS coatings 
A second possible explanation for poor reproducibility of repeated extractions using some fibres was 
that the agitation in all of 96 wells is not uniform. This possibility was examined by plotting the 
residual plots of the amount extracted versus well position over eight independent extractions using 
n=96 fibres and equilibrium extraction conditions. Figure 2.9 shows two example plots obtained in 
this study, and illustrates that no apparent trends were observed. It was also examined whether the 
amount of analyte extracted by the wells in the centre of the plate was significantly different than the 
amounts extracted by the wells on the outside edges of the plate, due to differences in agitation. No 
such trends were observed. However, these plots were powerful enough to detect that the leveling of 
the system was not adequate after the movement of the unit from one lab to another. In this case, the 
residual plots showed consistently high positive residuals for rows A and B, indicating they were 
extracting higher amounts. During subsequent troubleshooting, improper leveling of the agitator was 
discovered and fixed. The subsequent residual plots became random in appearance. These 
experiments indicate that the use of residual plots is useful to evaluate the system performance and 
detect changes in agitation. More importantly, the results also indicate that the agitation within all 
wells is uniform and not likely cause of poor intra-fibre reproducibility observed for some fibres. 
In a final set of experiments, the uniformity of agitation within wells was further confirmed by 
constructing extraction time profiles for all 96 fibres. The main hypothesis for performing these 
experiments was that any significant differences in agitation among the wells should result in longer 
extraction times for the equilibrium to be reached in some of the wells. Figure 2.6 (a) showed the 
results for six representative fibres, and the result for remaining 90 fibres were consistent with this, 
indicating no apparent differences in uniformity of agitation among the wells within the experimental 
error. Based on this study, agitation of 850 rpm using orbital shaking was found to be uniform and no 






Figure 2.9 Dependence of the amount extracted on well position in two typical experiments. The 
residual plots for the amount of diazepam extracted by each well of a 96-well plate are shown.  
Both figures are plotted using the same scale, and 0 position represents the overall mean 
amount of diazepam extracted (n=96) for the given extraction. 
2.3.1.6 Investigation of well cross-talk using PDMS coatings 
The cross-talk between wells is another important factor to examine during the evaluation of 
automated systems based on multi-well plate technology.
135
 This issue was found particularly 
problematic for LLE methods based on multi-well plates as sealing of the plates during the mixing 
step may not be sufficient, and monitoring the performance with two or more contamination tracers is 
usually recommended to ensure good data quality.
50
 In order to evaluate if there is any well cross-
contamination for proposed SPME set-up, a blank  buffer solution was placed in random well 
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high concentration of diazepam standard (300 ng/mL). After extraction and desorption, this plate was 
analyzed for the presence of any trace quantities of diazepam in the chromatograms obtained for the 
wells containing blank solution. No diazepam was found in these blank solutions confirming that the 
cross-contamination across the wells does not occur using optimum agitation conditions and sample 
volumes. If the agitation speed is further increased (for example >1000 rpm), this resulted in spilling 
and possible cross-contamination, indicating very high agitation speeds should be avoided. 
Furthermore, if the fibres are not properly centered within the wells, this was also found to cause 
inadvertent spilling and cross-contamination. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A S S B S S B S S B S B S 
B S B S S B S S B S S S S 
C B S B S S B S S S B S B 
D S S S S B S S B S S S S 
E S B S B S S B S S S B S 
F B S S S S S B S B S S S 
G S S S B S B S S S S S B 
H B S S S S S S B S S S S 
Figure 2.10 Plate map indicating well selection for cross-talk experiment. B denotes placement 
of blank PBS solution in the well and S denotes placement of 300 ng/mL diazepam standard 
solution in the well. 
2.3.1.7 Summary of overall performance of PDMS coatings 
According to the results presented above, PDMS coating was found to perform well for drug analysis 
using Concept 96 system in terms of extraction efficiency, carryover, and inter-fibre reproducibility. 
The array of fibres was easy to prepare and affordable. The same set of fibres was used for all of the 
experiments described here indicating good coating reusability (> 50 times with no loss of extraction 
efficiency). However, two main issues were encountered with this coating: (i) very long extraction 
times and (ii) large range of RSD values observed during evaluation of intra-fibre reproducibility. The 
former impacts the analytical sensitivity, while the latter adversely affects quantitative analysis which 
is especially problematic for subsequent application development. Possible causes for poor intra-fibre 
reproducibility were investigated in detail, but no satisfactory explanation for the observed results 
was found after the examination of carryover, well cross-talk and uniformity of agitation.  One 
possible explanation is that long extraction times result in slight and unpredictable variations in room 
temperature (for example, laboratory temperature during the day versus night), which affect the 
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magnitude of distribution constant and the amount of analyte extracted. The addition of internal 
standard (lorazepam) before extraction did not improve the observed results, so further use of this 
coating was discontinued and research efforts focused on finding a more suitable coating for this 
automated multi-fibre SPME system. 
2.3.1.8 SPME coatings based on coated silica particles: influence of particle type on coating 
properties  
The new coating needed to satisfy four main criteria: (i) good extraction efficiency for drugs (ii) low 
cost of preparation (iii) thin to facilitate mass transfer of analytes and (iv) good intra- and inter-fibre 
reproducibility. Polypyrrole coatings were previously found to meet the first three criteria, but 
exhibited poor inter-fibre reproducibility (>30% RSD) despite extensive efforts to optimize the 
coating preparation procedure.
136
  Materials that are typically used as stationary phases in reverse-
phase liquid chromatography such as octadecyl (C18) porous silica particles were previously shown to 
perform well as SPME extraction phases due to their good extraction capacity and reasonable 
extraction kinetics for more polar analytes such as drugs and metabolites.
86, 87, 132, 137-139
 The 
optimization of coating procedure based on coated silica particles was also attractive for future work 
in metabolomics, as the properties of the coating could be modified by changing the type of particles 
employed in the coating procedure.  Thus, based on good potential of these coatings for both 
bioanalytical and metabolomics applications, their suitability for use with the automated multi-fibre 
SPME system was investigated. 
Previous work within our research group recommended a simple coating procedure on the basis of 
the attachment of the coated silica particles to the stainless steel surface using a strong adhesive 
(Loctite commercially-available UV-curing adhesive based on methacrylate ester) with good 
chemical resistance.
132
 However, no extensive data regarding inter-fibre reproducibility of this 
coating existed, so the first step of coating development focused on the evaluation of this parameter 
using benzodiazepines as model analytes. First experiment compared the performance of five 
different types of coated silica particles for coating preparation. Two main types of coated particles 
were considered: (i) C18 and (ii) C16 with an embedded amide group (reverse phase amide or RPA). 
The comparison focused on three main parameters: inter-fibre reproducibility, extraction efficiency 
and adhesion of the coating upon repeated use. Figure 2.11 shows the results of this comparison for 
diazepam, but the results for lorazepam, oxazepam, and nordiazepam showed similar trends. Two 
consecutive extractions were performed using 12 fibres of each coating type. Among different C18 
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particles tested, C18 silica particles of 10 µm diameter had the highest extraction efficiency for 
benzodiazepines. However, the results for the second extraction using this coating show noticeable 
decrease in the amount extracted and significant deterioration of inter-fibre reproducibility.  This  
indicates significant loss of coating upon repeated use. In contrast, SPME coatings based on 5 µm 
particles showed improved adhesion and the results for two consecutive extractions show excellent 
agreement.  Among these coatings, Ascentis® RPA coating had the best inter-fibre reproducibility, so 
this particle type was selected for all further experiments. 
 
Figure 2.11 Evaluation of different coated silica particles for use as SPME extraction phases. 
The amount shown is the mean amount extracted by 12 fibres tested. The error bars show one 
standard deviation from the mean. The results for two consecutive extractions are shown as an 
indication of coating adhesion. 
2.3.1.9 Evaluation of inter-fibre and intra-fibre reproducibility for C18 and RPA coatings 
Considering the poor intra-fibre reproducibility observed with PDMS coating, the next step of the 
evaluation focused on this parameter prior to proceeding any further with the coating development. A 
total of 14 experiments was performed on three consecutive days using 15 fibres with RPA 5 µm 
particle coating in order to evaluate both intra-day and inter-day reproducibility of the amount 
extracted by each individual fibre. The results obtained are summarized in Table 2.3. Mean %RSD 
ranged from 9-19% for intra-day reproducibility experiments, and 11-18% for all 14 experiments. 
Furthermore, the use of lorazepam as internal standard improved intra-fibre reproducibility  
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Table 2.3 Summary of intra-fibre reproducibility results for 15 fibres coated with RPA 5 µm 
extraction phase and using 0.81 mm stainless steel support. The results are shown as intra-day 
and inter-day reproducibility. The effect of the use of lorazepam as internal standard to 
improve reproducibility is also shown. 
NA = not applicable since lorazepam was used as internal standard 
 
Figure 2.12 Diagram showing reusability of RPA 5 µm coatings over 14 extractions. The 
amount extracted of diazepam and oxazepam is shown over time for three representative fibres. 
Data points for lorazepam and nordiazepam are omitted for clarity. 































Fibre 1 - Diazepam Fibre 2 - Diazepam Fibre 3 - Diazepam
Fibre 1 - Oxazepam Fibre 2 - Oxazepam Fibre 3 - Oxazepam
 Mean % RSD 
Diazepam 
Mean % RSD 
Oxazepam 
Mean % RSD 
Nordiazepam 
Mean % RSD 
Lorazepam 
INTRA-DAY REPRODUCIBILITY - no internal standard 
Day 1 ( n=6 experiments) 9 15 10 15 
Day 2 (n=3 experiments) 14 15 12 19 
Day 3 (n=5 experiments) 12 16 12 12 
INTRA-DAY REPRODUCIBILITY - using lorazepam as internal standard 
Day 1 ( n=6 experiments) 7 5 5 NA 
Day 2 (n=3 experiments) 11 8 8 NA 
Day 3 (n=5 experiments) 4 6 3 NA 
INTER-DAY REPRODUCIBILITY – no internal standard 
All data (n=14 experiments) 11 17 11 18 
INTER-DAY REPRODUCIBILITY – using lorazepam as internal standard 
All data (n=14 experiments) 7 10 8 NA 
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considerably with all intra- and inter-day mean %RSD ≤11%. This showed that all of the factors 
during extraction could be well-controlled and that this coating was a good candidate for further 
development. Figure 2.12 shows the results for repeated extraction of diazepam and oxazepam for 
three representative fibres. The results show good reusability of coating and no loss of coating upon 
repeated use, indicating strong adhesion of the coating to the metal support. 
Although the fibres based on coated silica particles showed acceptable intra- and inter-fibre 
reproducibility, further optimization of coating procedure was performed to investigate if the 
performance of the fibres could be further improved.  The results of the experiment comparing the 
performance of stainless steel wires of different dimensions are shown in Figure 2.13 in order to 
determine the most suitable dimensions for use with automation. As predicted by SPME theory, the 
extraction efficiency of the fibres increased as the surface area of the solid support increased. Further 
increases in diameter beyond 0.061-inch (or 1.55 mm) were not considered because of the limitations 
of well dimensions in order to prevent scratching of the coatings by contact with the sides of the well 
during agitation. Increasing solid support diameter also resulted in improved inter-fibre 
reproducibility as indicated by lowest RSD in Figure 2.13 (b) for the thickest stainless steel wires. 
This indicates it was easier to achieve more uniform surface coverage with thicker fibre cores. 
Finally, increasing the diameter of stainless steel support was found beneficial to improve the 
mechanical robustness of the fibres and their compatibility with Concept 96 system. For PDMS 
coatings, the use of thin pins as solid support occasionally resulted in accidental bending of some 
fibres during the positioning step, but this problem was completely eliminated with the use of 
proposed 1.55 mm solid support. A custom-made multi-fibre SPME device was built to hold these 
1.55-mm fibres as described in Experimental section with the help of the University of Waterloo 
machine shop. This new device was used for all subsequent experiments. 
After the selection of optimum solid support, inter-fibre reproducibility was examined for all 96 
fibres as shown in Table 2.4. The results showed that the fibres could be coated reproducibly with 
RSD values ranging from 13-17%, which is quite good for a lab-made coating. In agreement with 
previous results, internal standard was able to compensate well for variations in extraction efficiency 





Figure 2.13 (a) Evaluation of the effect of the diameter of stainless steel support on extraction 
efficiency for diazepam. The bars show the mean amount extracted by batch of 12 fibres, and 
the error bars show one standard deviation of results (b) Comparison of inter-fibre 
reproducibility (% RSD for the amount extracted) of batches of 12 fibres prepared using 
different dimensions of stainless steel support. 
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Table 2.4 Summary of inter-fibre reproducibility results for 96 fibres coated with RPA 5 µm 
extraction phase and using 1.55 mm stainless steel support. The effect of the use of lorazepam as 
internal standard to improve reproducibility is also shown. 
Analytical Parameter Diazepam Nordiazepam Oxazepam 
Mean amount extracted, n=96 fibres, no 
internal standard (ng) 
35.9 28.2 9.8 
% RSD, no internal standard, n=96 fibres 15 13 17 
Mean amount extracted, n=96 fibres, with 
internal standard (ng) 
37.9 28.7 9.8 
% RSD, with internal standard, n=96 fibres 9 6 6 
2.3.1.10 Optimization of acid etching time 
During coating preparation, acid etching step helps to improve adhesion of the coating to stainless 
steel wire. The effect of varying acid etching time on inter-fibre reproducibility was examined. Figure 
2.14 shows that increasing acid etching time to 2 hr significantly improved coating procedure.   
 
Figure 2.14 Optimization of nitric acid etching time. Batches of 15 fibres (1.55 mm diameter) 
were prepared using coating procedure described in Experimental except acid etching time was 
increased from 20 min to 2 hr. The extraction was performed from 100 ng/mL benzodiazepine 
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2.3.1.11 Examination of coating surface using scanning electron microscopy (SEM) 
The surface of the optimized coatings was examined using scanning electron microscope (LEO 1530 
field emission SEM, Carl Zeiss NTS GmbH, Oberkochen, Germany).  SEM images were acquired by 
trained operator Francois Breton using an acceleration voltage of 15 kV and are shown in Figure 2.15. 
Carbon conductive tape and specimen mounts (Ted Pella, Redding, CA, USA) were used to hold the 
samples. Prior to analysis, fibres were cut into 1-mm pieces, dried for 1 hr in oven at 140°C, and then 
sputtered with ~10 nm of gold. The images show that very uniform coverage of particles was 
achieved, with tight packing of spherical silica particles. Furthermore, a portion of the surface was 
removed on purpose to estimate the coating thickness. The coating consisted of a single layer of 
particles and estimated coating thickness was 5.7 µm which is in line with particle dimensions of 5 
µm. It is interesting to note in the 600x magnification image that the particle size is not uniform. This 
large variability in particle size is expected to be an important contributing factor to observed inter-
fibre variability in extraction efficiency. In future, this factor could possibly be explored to further 
improve inter-fibre reproducibility by finding a supply of more uniformly sized coated silica particles 
or to extend the procedure to the use of nanoparticles. 
 
Figure 2.15 SEM images of 1.55 mm SPME fibre coated with 5 µm RPA particles and prepared 
according to procedure described in Experimental. (a) surface morphology using 300x 
magnification  (b) estimation of coating thickness using 600x magnification.  
2.3.1.12 Optimization of automated SPME method for benzodiazepines 
Using optimized fibres, the extraction time profiles were constructed for all four benzodiazepines 
using extraction times ranging from 1 to 120 min.  The equilibrium was reached in 30 min for all 
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benzodiazepines tested, as shown in Figure 2.16. This confirms that the kinetics of the extraction for 
these SPME fibres are much faster than those for PDMS-based fibres due primarily to significant 
reduction in coating thickness (165 µm versus 5 µm). The optimized desorption conditions were 
determined to be acetonitrile/water (1/1, v/v), with 30 min desorption time using 850 rpm agitation. 
These desorption conditions resulted in the carryover of 1-2% for the four benzodiazepines. However, 
the presence of carryover did not affect subsequent analysis, because the observed carryover was 
completely eliminated during pre-conditioning step. Therefore, the 30- min preconditioning step in 
methanol/water (1/1, v/v)  served a dual purpose of :  (i) wetting the fibre surface in preparation for 
the extraction and  (ii) eliminating any carryover of analyte remaining in the extraction phase from a 
previous extraction.  
 
Figure 2.16 Extraction time profile for diazepam, nordiazepam, oxazepam and lorazepam using 
RPA coating. Extraction conditions: 100 ng/mL benzodiazepine standard in PBS pH 7.4, 850 
rpm agitation. 
2.3.1.13 Summary of coating evaluation results: comparison of PDMS versus RPA coating 
The summary of results obtained during evaluation of PDMS and RPA types of coatings is shown in 
Table 2.5. The experimental results clearly indicate better overall performance of thin RPA coating, 
with particular improvements observed in time required to reach equilibrium and improved intra-fibre 
reproducibility. Both coatings also had similar extraction efficiency for benzodiazepines tested, but 
lower carryover was observed with PDMS coating. However, the latter issue was successfully 
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resolved for RPA coating during preconditioning step, where any carryover is fully removed prior to 
next extraction as long as fresh portion of solvent is used each time precondition step is carried out. 
Therefore, RPA coating was selected for all subsequent experiments and evaluated in applications 
using more complex biological matrix as discussed in Section 2.3.2. 
Table 2.5 Comparison of performance of PDMS and RPA coatings for the extraction of 
diazepam. 
Analytical parameter PDMS RPA 
Extraction efficiency for diazepam 30% 30% 
Carryover 0.3% 1-2% 
Intra-fibre reproducibility (n=5 extractions, mean of 96 fibres) 9% RSD 7% RSD 
Intra-fibre reproducibility (n=5 extractions, RSD range for 96 fibres) 1-23% RSD 6-10% RSD 
Inter-fibre reproducibility (n=96 fibres, no internal std) 10% RSD 12% RSD 
Inter-fibre reproducibility (n=96 fibres, with internal std) 15% RSD 7 % RSD 
Equilibration time 20 hr 30 min 
2.3.1.14 Comparison of method precision for manual versus automated dispensing of 
desorption solvent 
The only step of the sample preparation procedure which was not automated with the proposed 
SPME-LC-MS/MS system was the placement of samples and desorption solution into wells. 
Although the original prototype unit of Concept 96 included a syringe arm for desorption solvent 
dispensing, the arm could only be used to dispense volumes of up to 250 µL which was not sufficient 
in current work. Furthermore, the dispensing step was time consuming due to serial nature of 
dispensing. To address this issue, an automated multi-well plate dispensing unit (for example, 
Ultraspense 2000) can be used to dispense solutions into the wells instead of manual pipetting. The 
dispensing is performed in parallel for a row of wells, so the entire plate can be filled within 1 min. 
The effect of the use of automated 96/384 well microplate reagent dispenser (Ultraspense 2000) on 
overall method precision was examined (Table 2.6). Both methods of dispensing offered equivalent 
accuracy and precision, but the use of automated dispensing enhanced automation and reduced the 




Table 2.6 Comparison of method precision (n=96 fibres) of  manual pipetting versus automated 
dispensing. For manual pipetting, standard solution and desorption solvent were placed into 
wells using air displacement Fisherbrand 100-1000 µL pipette. For automated dispensing 
experiment, standard solution and desorption solvent were placed into wells using 
Ultraspense2000.  
Analyte Analytical parameter Manual pipetting Automated dispensing 
Diazepam 




















2.3.1.15 Comparison of calibration methods 
The use of lorazepam as internal standard was found to improve overall method precision 
significantly as previously shown in Tables 2.3, 2.4 and 2.5. A more detailed study was then 
conducted to evaluate whether the use of deuterated internal standard provides additional 
improvements, and whether other calibration approaches such as fibre constant calibration and on-
fibre standardization can also be employed when developing automated multi-fibre SPME methods.  
Briefly, using the on-fibre standardization calibration approach (see also Section 1.4), a known 
amount of calibrant (usually a deuterated analogue) is preloaded into the extraction phase prior to 
performing an extraction.
84, 85, 140, 141
 The process of desorption of calibrant from the extraction phase 
into the system can be used to calibrate the simultaneous and symmetric process of analyte extraction 
into the coating. This calibration approach is particularly useful for calibration of pre-equilibrium 
SPME methods because it successfully corrects for non-uniform agitation conditions. For automated 
SPME methods with Concept 96, this means that sample throughput could be further improved by 
using very short pre-equilibrium extraction times. Fibre constant calibration is a simple method where 
the magnitude of KfsVf product is determined for each fibre for a given analyte using a standard 
solution of known analyte concentration and the relationship shown in Equation 1.1. The magnitude 
of Kfs is constant for a given analyte and extraction conditions, so the variations in magnitude of KfsVf 
product are reflective of small variations in the amount of coating deposited on each fibre. This 
correction factor derived for each individual fibre can then be applied to all subsequent extractions 
and used to eliminate inter-fibre variability from the data. 
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Figure 2.17 (a) shows the effect on method precision obtained using each of five calibration 
methods tested: (i) external calibration (ii) lorazepam as internal standard (iii) diazepam-d5 as internal 
standard (iv) on-fibre standardization and (v) calibration using fibre constant. The comparison was 
performed using the same set of 12 randomly selected fibres for the extraction of diazepam. The 
results shown for external calibration correspond to the true variability of the 12 fibres used for the 
experiment, as no correction to compensate for variation in Vf has been applied. The best results were 
obtained with internal standard calibration or the calibration using fibre constants. Among these two 
calibration methods, internal standard calibration is simpler and less time-consuming because it does 
not require any additional experiments. Both lorazepam and deuterated diazepam were found to 
perform equally well when used as internal standards for the quantitation of diazepam. More 
surprisingly, on-fibre standardization did not improve overall method precision when compared to the 
results obtained using external calibration.  One possible explanation for the observed result is the 
compounding of experimental uncertainty because multiple parameters must be determined 
experimentally in order to apply on-fibre standardization. Both the amount of analyte extracted and 
the amount of calibrant remaining in the extraction phase must be determined experimentally. The 
performance of on-fibre standardization was further examined by investigating whether it can be used 
to correct for intra-fibre reproducibility for repeated extractions using the same fibre. This test was 
performed using a subset of five fibres and the results were compared to internal standard calibration 
as shown in Figure 2.17 (b). The results show equivalent performance of both methods. These results 
show that on-fibre standardization is suitable to use to correct for variation in extraction conditions 
and can improve inter-fibre reproducibility. Poor performance for the correction of inter-fibre 
reproducibility can possibly be caused by insufficient optimization of calibrant loading procedure. In 
other experiments described in Section 3.3.9, preloading of standard from methanol/water was found 
to provide improved performance. However, such approach for 96-array of fibres would be cost-
prohibitive because it would consume large quantity of calibrant. Based on the results obtained, the 
internal standard calibration method was selected as the best and simplest calibration method for 





Figure 2.17 (a) Comparison of external standard, internal standard and on-fibre 
standardization (standard-on-the fibre) calibration methods for the use with automated multi-
fibre SPME. The dependence of % RSD (n=12 fibres) of the amount extracted on the choice of 
calibration method is shown. All extractions were performed from 100 ng/mL diazepam 
standard solution in PBS buffer pH 7.4 using optimal SPME conditions. (b) Comparison of 
standard-on-fibre versus internal standard calibration for improving intra-fibre 
reproducibility. The dependence of % RSD (n=5 extractions using each fibre) on the choice of 
calibration method is shown. 
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2.3.1.16 SPME method development using Concept 96: general considerations  
In conclusion, the performance of Concept 96 autosampler was found satisfactory, and the use of this 
robotic station provides high sample throughput with high degree of automation. Figure 2.18 shows 
an overview of the parameters that can be optimized during method development of such automated 
SPME methods. The main parameters whose optimization is mandatory is the type of coating and 
corresponding optimum preconditioning procedure, optimization of wash procedure to ensure no loss 
of analyte occurs between extraction and desorption step and the optimization of desorption 
conditions. Depending on the nature of analyte, sample matrix and overall analytical sensitivity 
required for a particular application, optimization of additional parameters such as pH, ionic strength, 
sample volume and addition of evaporation/reconstitution step can also be considered. Finally, the 
overall workflow of an automated SPME procedure using Concept 96 is shown in Figure 2.19 to 
show the recommended sequence of steps. Based on the results of this research, the prototype design 
of initial Concept 96 system was changed by PAS Technology to incorporate three orbital agitators: 
one for preconditioning, one for extraction and one for desorption. Furthermore, a wash station was 
added to the design to enable automation of the wash step. No agitator is used for this step to prevent 
any inadvertent desorption of the analyte(s). The option of temperature control during agitation was 
also added to enable temperature-controlled ligand-receptor binding studies. Finally, Concept 
software was revised to enable simple user-programming of all steps described in Figure 2.19. 
 
Figure 2.18 Overview of parameters which may require optimization during method 




Figure 2.19 Overview of automated SPME procedure using Concept 96 robotic station 
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2.3.2 Example application of PAS autosampler: high-throughput analysis of 
benzodiazepines in whole blood  
Once the performance of Concept 96 was found satisfactory, full validation of the optimized SPME-
LC-MS/MS method for the high-throughput analysis of benzodiazepines in whole blood was carried 
out according to Food and Drug Administration (FDA) guidelines for the method validation of 
bioanalytical methods.
142
 These guidelines are used extensively in pharmaceutical industry, and any 
useful sample preparation method in regulated bioanalysis must be able to meet these stringent 
regulatory guidelines. The main aspects of validation included selectivity, linearity, limit of  
quantitation (LOQ), stability, matrix effects, method precision and accuracy. The latter two 
parameters require validation over minimum of three concentration levels and over minimum of three 
days, to establish both intra-day and inter-day method performance. 
 The selectivity of the method was evaluated by analyzing two lots of blank whole blood samples 
and no interferences at the retention time of analytes (2.0-2.5 min) were detected in any of the 
chromatograms. Example extracted ion chromatograms (XIC) of blank whole blood and 50 ng/ml 
benzodiazepine standard in whole blood are shown in Figure 2.20.  Post-preparative stability of 
samples was demonstrated up to 72 hours when stored in refrigerated autosampler by re-analysis 
against the freshly acquired calibration curve. Longer times were not evaluated as the analysis of all 
samples was expected to be completed within this time window. 
2.3.2.1 Evaluation of matrix effects 
The widespread use of LC-MS/MS in bioanalysis is mainly due to the excellent sensitivity and 
selectivity achievable by this method of analysis when dealing with complex mixtures such as 
biological fluids.  However, one of the issues that complicates accurate and precise analysis in LC-
MS methods is the susceptibility of ESI to matrix effects. These matrix effects can be defined as the 
change in the signal of the analyte in the presence of matrix components due to competition for 
ionization, and can result in signal increase (ionization enhancement) or signal decrease (ionization 
suppression). As such, regulatory guidelines recommend the determination of matrix effects using 
various lots of biological fluids in order to evaluate how robust method is to such effects.
142
 The main 
approaches to minimize/eliminate matrix effects are to develop sample preparation methods with 
efficient clean-up in order to remove as many matrix components as possible and to ensure good 
chromatographic retention and chromatographic resolution of analytes whenever possible.
143
 Among 
sample preparation methods, plasma protein precipitation methods provide the poorest sample clean-
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up and can result in largest degree of ionization suppression. Solid-phase extraction and liquid-liquid 
extraction generally provide much improved sample clean-up. Due to equilibrium extraction nature of 
SPME, it can provide even better sample clean-up than SPE because only a limited amount of sorbent 
is used and the amount of extraction is governed by the magnitude of distribution coefficient for both 
analytes of interest and other sample components.  
 
Figure 2.20 Example extracted ion chromatograms (XIC) of diazepam, nordiazepam, oxazepam 
and lorazepam in (a) blank whole blood sample and (b) 50 ng/mL benzodiazepine standard in 
whole blood. 
Therefore, as part of method validation, proposed SPME-LC-MS/MS method was evaluated in 
terms of absolute matrix effects. This test is performed by comparing signal intensity of blank 
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biological fluid sample spiked post-extraction with analytes  versus signal intensity for neat standard 
prepared directly in desorption solvent at the same concentration level. In absence of any matrix 
effects, the two standard solutions should result in the same signal intensity within experimental error, 
and differences of ± 20% are generally acceptable. The results for this experiment are shown in Table 
2.7. A set of duplicate standard solutions was prepared at concentration level of 1 µg/mL and directly 
infused into mass spectrometer. The results show that no matrix effects were observed for lorazepam, 
while the remaining analytes showed significant degree of ionization suppression. This example 
highlights the importance of incorporating an LC separation step in overall workflow. Once entire 
LC-MS/MS method was evaluated, no matrix effects were observed for any of the analytes as 
indicated by the relative signal response ranging from 95-102%. Acceptable range is considered 80-
120% which takes into account typical precision of electrospray LC-MS/MS methods. 
Table 2.7 Results of the evaluation of absolute matrix effects for the analysis of benzodiazepines 
in whole blood. % signal represents the ratio of the signal of blank whole blood extract spiked 
post-extraction versus neat standard prepared directly in desorption solvent at the same 
concentration level. 
Analyte 
Direct infusion into MS (1 µg/mL) 
% Signal post-extraction spike 
versus neat standard 
LC-MS/MS (20 ng/mL) 
% Signal post-extraction spike 
versus neat standard 
Lorazepam 97 95 
Oxazepam 79 101 
Nordiazepam 46 100 
Diazepam 49 102 
Diazepam d5 (IS) 45 102 
2.3.2.2 Linearity, limit of detection (LOD) and limit of quantitation (LOQ) 
The limit of detection (LOD) for the proposed method was determined according to 3x signal-to-
noise criteria and was found to range from 0.8 ng/mL for oxazepam to 3 ng/mL for diazepam. Limit 
of quantitation (LOQ) for the proposed method was determined according to FDA guidelines.
142
 In 
this definition, LOQ is the lowest concentration of the analyte in given matrix which meets the 
following acceptance criteria: (i) accuracy of ± 20% from the nominal concentration and (ii) precision 
≤ 20% RSD for five replicate determinations. The lowest concentration tested (4 ng/mL) of all four 
benzodiazepines met this criteria, and the results are presented in Table 2.8. This sensitivity was 
sufficient for assaying clinically relevant concentrations of benzodiazepines. For example, expected 
therapeutic range of diazepam and nordiazepam is 0.15-0.8 µg/mL
144
, whereas the therapeutic 
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concentration of more potent lorazepam is about 0.03 µg/mL.
145
 Therefore, the strategies for further 
improving LOQ, such as addition of evaporation/reconstitution step were not further explored. 
The method was linear in the range of 4-1000 ng/mL for diazepam and nordiazepam and in the 
range of 4-500 ng/mL for oxazepam and lorazepam, making it amenable for therapeutic drug 
monitoring of these drugs. Linearity was evaluated by constructing six independent calibration curves 
using independent sets of fibres, to investigate if calibration curves acquired using single point per 
calibration standard were sufficient for quantitative analysis. The results showed excellent agreement. 
For instance, the average slope of six calibration curves in two different lots of whole blood was 
found to be 0.00243±0.00005 for diazepam, while the linear regression coefficients (r
2
) ranged from 
0.997-0.999. This linearity data further confirms the ability of internal standard to compensate 
properly for inter-fibre variation, and good overall performance of SPME method. It should be noted 
that the upper limit of linear dynamic range reported in Table 2.8 is limited by the linear dynamic 
range of the instrument due to detector saturation or ESI droplet surface saturation
146, 50
, and not by 
SPME procedure itself. This means that samples exceeding the upper limit can still be successfully 
analyzed after appropriate dilution. 
Table 2.8 Automated SPME-LC-MS/MS method validation results: LOQ and linear range. 
Analytical parameter Diazepam Oxazepam Nordiazepam Lorazepam 
LOQ (ng/mL) 4 4 4 4 
Mean % accuracy (n=5): 102 111 105 102 
% RSD (n=5) 11 17 9 14 
Signal-to-Noise Ratio 5 19 16 16 
Dynamic Linear Range (ng/mL) 4-1000 4-500 4-1000 4-500 
 
2.3.2.3 Method accuracy and precision: intra- and inter-day results 
The accuracy and intra-day precision of the proposed method was evaluated at four concentration 
levels (10, 25, 100 and 500 ng/mL) using five replicate samples at each level (Table 2.9).  For all 
compounds and all levels, the precision of the results does not exceed acceptance criteria of 15% RSD 
(range 2-14% RSD). Mean accuracy of 87-109%, also meets requirements of 85-115%. One 
suspected outlier (recovery of 121%) for oxazepam was detected in the results presented in Table 2.9 
and is marked with asterisk (*). More robust statistics, median and median absolute difference were 
used for this concentration level as recommended by Analytical Methods Committee when dealing 
with small data sets containing a suspected outlier.
147
 The significant difference observed between  
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Table 2.9 Automated SPME-LC-MS/MS method validation results: summary of intra-day 















116 93 86 98 
103 81 89 88 
105 114 106 123 
120 94 117 115 
100 82 94 101 
Mean (n=5): 109 93 98 105 
% RSD (n=5): 8 14 13 13 
25 ng/mL 
84 75 103 84 
102 79 99 113 
96 92 102 94 
99 87 113 93 
87 121* 114 100 
Mean (n=5): 94 87* 106 97 
% RSD (n=5): 8 9* 6 11 
100 ng/mL 
102 108 97 99 
103 98 99 109 
109 94 100 105 
108 104 108 116 
92 86 95 99 
Mean (n=5): 103 98 100 106 
% RSD (n=5): 6 9 5 7 
500 ng/mL 
97 87 106 83 
101 102 96 102 
97 96 96 94 
100 100 92 110 
101 87 99 100 
Mean (n=5): 99 94 98 98 
% RSD (n=5): 2 8 5 10 
 
mean-based and median-based statistics (20% RSD versus 9% RSD) supports the presence of outlier 
in this data set. This is further supported by the results collected for the evaluation of inter-day 
method accuracy and precision and shown in Table 2.10. This experiment was performed using five 
independent extractions of the same spiked whole blood standard solution at four different 
concentration levels. Five fibres were used at each level to submit the method to even more stringent 
evaluation than required by the regulatory guidance (five independent extractions for n=1 fibre at n=3 
concentration levels is sufficient according to the guidance). Method accuracy ranged from 89-115%, 
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while intra-day method precision ranged from 1-12% RSD, both of which meet acceptance criteria for 
quantitative bioanalysis. 
Table 2.10 Automated SPME-LC-MS/MS method validation results: summary of accuracy and 




















115 (1) 99 (8) 89 (6) 94 (11) 
102 (2) 89 (10) 91 (6) 85 (12) 
115 (1) 112 (7) 115 (4) 115 (10) 
104 (2) 101 (8) 108 (5) 109 (10) 
99 (2) 90 (10) 96 (6) 96 (11) 
25 ng/mL 
113 (3) 97 (8) 100 (4) 99 (7) 
97 (3) 98 (8) 93 (1) 87 (9) 
102 (4) 107 (8) 106 (4) 103 (8) 
96 (4) 101(8) 104 (4) 107 (10) 
100 (3) 96 (7) 95 (4) 96 (8) 
100 ng/mL 
112 (5) 115 (10) 101 (4) 109 (12) 
104 (6) 96 (10) 100 (3) 100 (11) 
97 (5) 106 (10) 101 (4) 115 (11) 
101 (5) 113 (10) 101 (4) 91 (11) 
113 (5) 101 (10) 107 (3) 115 (9) 
500 ng/mL 
105 (6) 104 (12) 103 (4) 103 (10) 
97 (5) 95 (10) 92 (2) 94 (8) 
102 (3) 103 (11) 94 (4) 106 (10) 
99 (5) 104 (10) 90 (3) 97 (10) 
95 (5) 91 (12) 96 (3) 104 (8) 
2.3.2.4 Summary of method performance 
The performance of proposed SPME-LC-MS/MS method was found satisfactory for the analysis of 
benzodiazepines in whole blood, and the method meets all regulatory requirements. The proposed 
sample preparation procedure is simple, automated and applicable to the extraction of whole blood 
samples without any sample pretreatment steps required. The validated method requires about 100 
minutes (30 min preconditioning, 30 minute extraction, 30 minute desorption, ~10 min for dispensing 
of samples/wash solvent/desorption solvent) for the preparation of 96 samples. This translates into 
sample throughput of >1000 samples/day in labs where robotic plate feeder and liquid dispensing 
station is available to permit completely unattended operation, and represents highest SPME 
throughput reported to date. Table 2.11 gives an overview of various SPME method reported for the 
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analysis of diazepam in blood, plasma or serum. The results show that LOQ (4 ng/mL) achieved in 
current work is similar or better than obtained for other SPME methods, while the achieved sample 
throughput is considerably improved due to parallel nature of extraction. Furthermore, through the 
optimization of coating and the geometry of the extraction phase (by increasing fibre diameter), the 
disadvantages of offline desorption with no evaporation/reconstitution step could be successfully 
overcome (only 20 µL out of 800 µL was injected in current study), so that analytical sensitivity in 
current work is comparable to that achieved by in tube SPME, thermal or manual desorption methods 
where all of the extracted analyte is introduced onto analytical column. 
Table 2.11 Summary of SPME methods reported for analysis of diazepam in plasma, serum or 
whole blood. 
Method type LC-UV LC-MS GC-MS LC-MS LC-MS/MS LC-MS/MS 











and in vivo 












Precision 5.0% NR 6-15% 12% NR NR 
LOD (ng/mL) 24 1 0.3 20 7 1.7 
Linear Range 
(ng/mL) 






















NR = not reported, 
a
 Linear range reported in the manuscript was 1-1000 ng/mL, but this 
contradicts LOD of 7 ng/mL also stated in the manuscript. Based on the data provided it is not clear 
which figure of merit is correct. 
2.4 Conclusions and future directions  
The optimized automated SPME system (Concept 96) was found to perform very well for the analysis 
of biological fluids and provided highest sample throughput reported to date with typical sample 
preparation times of ≤ 1 min/sample for the applications developed to date.
151, 152
 Furthermore, 
parallel extraction format allows very accurate timing of extraction and desorption steps and 
reproducible computer-controlled positioning of fibres within the wells. These characteristics allow 
the use of pre-equilibrium extraction times with no sacrifice in method precision. SPME sample 
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throughput is now for the first time comparable to sample throughput achievable by automated SPE 
and LLE methods in 96-well plate format and is better than online SPE methods. Furthermore, in 
comparison to traditional methods employed for bioanalytical sample preparation, several features of 
SPME make it particularly attractive for analysis of biological fluids using LC-MS. First of all, 
SPME can provide improved sample clean-up, which can minimize/eliminate the occurrence of 
ionization suppression effects. This is achieved mainly through the use of small volume of extraction 
phase, which leads to the extraction of smaller amounts of analytes and potential interferences. This 
reduces potential for competitive ionization effects, which can be concentration-dependent, although 
the underlying mechanisms are not well-understood.
146
 Secondly, SPME is fully compatible with the 
extraction of heterogeneous samples such as whole blood or tissue homogenates without the need for 
any sample pretreatment (filtration, centrifugation). This minimizes the overall number of sample 
handling steps, increases overall sample throughput and eliminates potential sample losses due to 
sample transfer between various devices (for example, adsorption to centrifuge tube walls or filter 
materials). The analysis of whole blood is also attractive for the determination of drug partitioning 
into red blood cells, and such experiments can easily be carried out using SPME (refer to Chapter 4 
for an example using carbamazepine). Finally, SPME allows the determination of  both unbound and 
total drug concentrations using a single sample by employing two different calibration strategies 
(matrix-free for unbound concentration  and matrix-matched for total concentration). Traditional 
methods do not offer such flexibility, so the sample needs to be re-prepared using a different sample 
preparation method if both pieces of information are required, thus increasing the overall cost of 
analysis and adversely impacting sample throughput. 
One of the limitations of proposed SPME automated system is that it is applicable only to non-
volatile analytes because the wells are not sealed during extraction and desorption processes. Some 
data exists on using the system with semi-volatile polyaromatic hydrocarbons, however even with the 
use of appropriate internal standard to help correct for any evaporative losses, method precision 
worsens considerably as the volatility of analyte increases (RSD 14-40% depending on the analyte 
volatility).
131
 A second limitation of proposed system is that the amount of analyte extracted by 
SPME is typically very small, especially when using biological fluids with high amount of protein 
(such as plasma, serum or whole blood) and/or when dealing with analytes with high-degree of 
protein binding (for example, >90% binding of diazepam). Thus, absolute recoveries for SPME in 
such cases are typically 1-2%, so highly sensitive analytical instrumentation is necessary to ensure 
adequate LOD/LOQ for a given application. This limitation has largely been addressed over the last 
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few years with the development of highly sensitive MS instrumentation. The MS instrument used in 
current work (API3000) already provided sufficient analytical sensitivity for therapeutic drug 
monitoring without need for further preconcentration through addition of evaporation/reconstitution 
step. Newer triple quadrupole instruments currently available (such as API5500 from Applied 
Biosystems or TSQ Vantage from Thermo) provide additional 10- to 100-fold improvement in 
sensitivity, thus enabling easy implementation of microextraction methods for a variety of clinically 
relevant applications. Finally, for the best method performance using any type of microextraction 
method, it is important to keep extraction conditions exactly the same for both standards and samples, 
so careful attention should be paid to extraction parameters such as pH, ionic strength, temperature 
and exact matrix composition as discussed in Section 1.4. 
Beyond the work described in this chapter, Erasmus Cudjoe further developed Concept 96 robotic 
system by modifying the geometry of SPME device from fibre geometry described herein to thin-film 
geometry.
134
 The main advantages of the thin-film geometry are improvement in extraction efficiency 
due to increased surface area, improved agitation as the new device acts like a stirring blade, and 
improvement in the extraction rate when using very short pre-equilibrium extraction times because 
analyte uptake by the coating in this linear portion of extraction time curve is directly proportional to 
the surface area of the device. Based on these improvements (up to 2-fold improvement in analytical 
sensitivity and extraction rate), commercial SPME device of Concept 96 incorporates thin film 
geometry. Currently, further modifications of Concept 96 are underway in order to enable the use of 
this system for parallel, automated desorption of in vivo SPME samplers thus increasing throughput 
of in vivo SPME methods such as described in Chapter 4.  
2.5 Addendum 
The text of this chapter was rewritten in comparison to published research article. The author 
expresses sincere gratitude to Francois Breton for the acquisition of SEM images. The loan of 





In vitro evaluation of in vivo SPME devices 
3.1 Preamble and introduction 
3.1.1 Preamble 
This chapter has been published as a paper: Vuckovic D., Shirey B., Chen Y., Sidisky L., Aurand C., 
Stenerson K., & Pawliszyn J., In vitro evaluation of new biocompatible coatings for solid-phase 
microextraction: implications for drug analysis and in vivo sampling applications. Anal. Chim. Acta 
638, 175-185 (2009). The figures and tables are reprinted from this manuscript with the permission of 
Elsevier (Copyright Elsevier 2009). 
The contributions of co-authors Bob Shirey, Yong Chen, Len Sidisky, Craig Aurand and Katherine 
Stenerson, were the production and coating development of all prototype SPME devices used in this 
work. Furthermore, Bob Shirey performed the experimental work to evaluate the degree of swelling 
of these new coatings on exposure to common solvents. 
I, Bob Shirey, authorize Dajana Vuckovic to use the material for her thesis. 
 
I, Yong Chen, authorize Dajana Vuckovic to use the material for her thesis. 
 
I, Len Sidisky, authorize Dajana Vuckovic to use the material for her thesis. 
 
I, Craig Aurand, authorize Dajana Vuckovic to use the material for her thesis. 
 
I, Katherine Stenerson, authorize Dajana Vuckovic to use the material for her thesis. 
 
3.1.2 Introduction 
Presently, applications of SPME in combination with GC predominate in literature over SPME-LC 
applications. Two main reasons behind this trend are: (i) the lack of automation of SPME-LC 
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methods (addressed in Chapter 2) and (ii) the availability of a limited number of extraction phases 
suitable for use with LC applications.
153, 154
 Figure 3.1 gives an overview of properties desired for LC 
applications with particular focus on the analysis of biological fluids including in vivo SPME 
sampling applications. Currently, only four coatings are available commercially: 
polydimethylsiloxane (PDMS), polydimethylsiloxane/divinylbenzene (PDMS/DVB), polyacrylate 
(PA) and Carbowax-templated resin (CW-TPR).  These coatings do not possess sufficient mechanical 
robustness for use with in vivo applications. Furthermore, they exhibit poor extraction efficiency 
towards polar analytes and are expensive (>$100 per fibre) which makes the use of multiple fibres 
during an animal study cost-prohibitive. As these coatings are meant for multiple uses, the issue of 
inter-fibre reproducibility has not been adequately documented for these fibres. Finally some of these 
coatings are not biocompatible. Although PDMS is generally considered biocompatible, it is not the 
first choice for use in medical devices that will be exposed directly in vivo. 
 Recent research efforts into the development of improved SPME coatings resulted in reports of 
monolithic silica coatings
155, 156
 and polymer monolithic coatings
157, 158
 which improve extraction 
kinetics and/or extraction of polar compounds by incorporation of appropriate functional groups. 
Various tailor-made sol-gel coatings have also been reported in literature as the means of improving 
chemical and mechanical stability and extraction efficiency, but these have predominantly been used 
in GC applications.
159
 Finally, different types of coatings have been proposed in literature to address 
the biocompatibility requirement for in vivo SPME applications and include polypyrrole coatings
133, 
136, 160-162
, coatings based on restricted access materials
132, 139, 163, 164
, and coatings based on mixtures of 
SPE sorbents (coated silica particles) with biocompatible polymers
86, 137, 138
. Among these, the latter 
type was recently selected by Supelco for commercialization and further development. 
 


















The main objective of this work was to evaluate in vitro the performance of a new line of 
biocompatible coatings produced by Supelco for the extraction of drugs from biological fluids. The 
model drugs evaluated in this work were diazepam, carbamazepine, ranitidine, pseudoephedrine and 
propranolol. Their structures are shown in Figure 3.2  and an overview of their properties is given in 
Table 3.1. The performance of these coatings with other classes of compounds commonly analyzed in 
biological fluids by LC such as riboflavin (water-soluble vitamin), adenosine (nucleoside) and 
hydrocortisone and progesterone (hormones) is also briefly reported. The proposed coatings were 
immobilized on a 200 µm metal fibre core and consisted of a mixture of proprietary biocompatible 
binder and various types of porous coated silica (octadecyl, polar embedded RP-Amide and cyano) 
particles whose structures are shown in Figure 3.3. 
    
 
Figure 3.2 Chemical structures of model drugs used in the evaluation of biocompatible coatings 
(a) carbamazepine, (b) propranolol (c) pseudoephedrine (d) diazepam (e) ranitidine. 
3.2 Experimental 
3.2.1 Chemicals and materials  
All drug standards were purchased as solids of highest purity from Sigma-Aldrich (Oakville, ON, 
Canada), except diazepam (Cerilliant, Round Rock, TX, USA) and carbamazepine-d10 (CBZ-d10,  
Alltech, Deerfield, IL, USA) which were purchased as 1 mg/mL and 100 µg/mL methanolic solutions 
respectively. Acetonitrile (HPLC grade), methanol (HPLC grade), and glacial acetic acid were 
purchased from Fisher Scientific (Ottawa, ON, Canada), while human plasma with EDTA as anti-




coagulant was purchased from Cedarlane Laboratories Limited (Burlington, ON, Canada).  Drug-free 
human urine was collected in sterile collection flasks from healthy volunteer and stored frozen at -
20°C until use. All commercial (Carbowax-templated resin, CW-TPR, 50 µm thickness)  and 
prototype SPME coatings were obtained as research samples from Supelco (Bellefonte, PA, USA).   
Research prototype biocompatible SPME coatings for HPLC use  included (i) Discovery™ C18 15 µm 
thickness (ii)  Discovery™ C18 30 µm thickness (iii) Discovery™ C18 45 µm thickness (iv) 
Discovery™ C18 60 µm thickness (v) Ascentis™ RP-Amide (RPA) 45 µm thickness and (vi) 
Discovery™ Cyano 45µm thickness. Chemical structure of coatings is shown in Figure 3.3. 
Discovery
TM
  silica has 180 A pore size and 200 m
2
/g surface area, while Ascentis
TM
 silica has 100 A 
pore size and 450 m
2
/g surface area. The length of coating was 15 mm for all prototypes. The 
coatings were prepared by mixing appropriate coated porous silica particles of 5 µm size with 
proprietary biocompatible binder, followed by immobilization on an inert, flexible metal alloy wire 
(200 µm diameter). Prototype fibres were housed inside in vivo SPME assembly based on 22-gauge 
hypodermic needle as shown in Figure 3.4. This design of in vivo SPME device is based on work by 
Musteata et al.
88
, but was modified as appropriate to accommodate the fibres immobilized on 200 µm 
flexible wire in current work.  
(a)      (b)      (c)  
 
Figure 3.3 Chemical structures of coatings evaluated in this chapter (a) octadecyl (C18) (b) C16 
with an embedded amide group (reverse-phase amide, RPA) and (c) cyanopropyl coating. 
3.2.2 Preparation of standard solutions 
Instrument calibration was performed daily before and after each sample set using a set of standard 
solutions prepared with known drug concentrations (0.5 - 250 ng/mL, minimum of n=6 standards) in 
desorption solvent. These standard solutions were prepared by serial dilution of stock standard 
solution prepared in methanol at the concentration of 10 µg/mL. Phosphate-buffered saline (PBS) 
solution pH 7.4 was prepared as described previously (Section 2.2.2). Spiked biological standards 
were prepared in three different matrices: PBS pH 7.4, human urine and human plasma at the 
concentrations ranging from 1 to 1000 ng/mL depending on the experiment. Organic content of all 
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spiked standards used for extraction was kept constant at 1% v/v methanol. Spiked analytes in 
biological fluids (urine and plasma) were pre-incubated for 60 min prior to the extraction to allow for 
drug-protein binding to occur. For carbamazepine, this incubation time was found insufficient as 




Figure 3.4 Prototype in vivo SPME probe obtained from Supelco Inc. (A) SPME fibre is housed 
inside commercial hypodermic syringe for protection and for piercing living system or septum 
of sampling device. (B) Pushing on the plunger exposes SPME coating during extraction and 
desorption steps.  
3.2.3 SPME procedure 
Prior to each use, fibres were preconditioned for minimum of 30 min in methanol/water (1/1, v/v) at 
1000 rpm agitation. Extraction was performed at room temperature (24 ± 2°C) from 1.5 mL sample 
solution contained within 2 mL amber HPLC vial, except for sample volume experiments where 
extraction was performed from 0.25 mL sample contained within 0.3 mL amber polypropylene vial. 
For pre-equilibrium experiments, extraction times of 2 min (PBS buffer and urine) and 5 min 
(plasma) were used, unless otherwise stated in text. No agitation was employed during extraction, 
unless otherwise specified in text.  Fibres were desorbed for 5 min using 2400 rpm vortex agitation 
using 100 µL of desorption solvent (acetonitrile/water, 1/1, v/v) spiked with 100 ng/mL 
carbamazepine d10. Desorption was carried out in 0.15 mL capacity tapered polypropylene HPLC 
inserts (Supelco) and using multi-tube vortexer with foam insert of 50-vial capacity  (model DVX-





standard primarily to correct for slight variations in the injection volume during LC-MS analysis. For 
ranitidine and pseudoephedrine, the use of weaker desorption solvent (water/acetonitrile, 9/1, v/v) 
ensured solvent strength was suitable for direct injection into LC-MS/MS system.  
3.2.4 LC-MS/MS analysis  
LC-MS/MS analysis was performed using instrument consisting of 500 ion trap MS, 430 
autosampler, 212 LC pumps and MS Workstation Version 6.6 software (Varian, Walnut Creek, CA, 
USA).  Injection volume for all experiments was 20 µl. Analytes were separated using Varian Pursuit 
5 µm C18, 50 x 2.0 mm column. Mobile phase A consisted of acetonitrile/water/acetic acid 
(10/89.9/0.1) and mobile phase B of acetonitrile/water/acetic acid (90/9.9/0.1). Analytes were eluted 
using 300 µL/min flow rate and simple gradient program which included a short hold at 100% A for 
0.5 min, followed by linear increase to 90% B over 4.5 min, and short hold of 0.5 min at 100% B. 
Total run time per sample was 8.0 min, including column re-equilibration time of 2.5 min. Higher 
flow rates were explored but could not be used successfully due to insufficient desolvation at flow 
rates > 300 µL/min based on the limitations of the design of this ion source.  
MS parameters were optimized using direct infusion of 1 µg/mL of individual analyte standard 
solutions prepared in acetonitrile/water. Analytes were ionized using positive ESI, with ion source 
temperature set to 400 °C.Chromatographic run time was divided into two MS timed events. During 
the first event (0-3.0 min), pseudoephedrine and ranitidine were monitored, and needle voltage of 
3300V was used. Second timed event (3.0-8.0 min) was used to monitor diazepam, propranolol, 
carbamazepine and carbamazepine d10, and needle voltage of 5600 V was employed. The rest of 
MS/MS parameters are summarized in Table 3.1. 

























Diazepam 3.4 2.82 4.9 285.0 257.0 76 79 1.31 




0.27 0.8 315.0 176.0 51 85 1.20 
Propranolol 9.42 3.48 3.7 260.1 183.0 66 77 0.70 
Carbamazepine 7 2.45 4.1 237.0 194.0 65 71 1.20 
Carbamazepine 
d10 
NA NA 4.1 247.0 204.0 65 71 1.05 
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3.2.5 Data analysis and calculations 
Extraction efficiency and relative recovery were calculated according to procedures previously 
described in detail in section 2.2.9. In current study, calibration curves in PBS, urine and plasma were 
acquired. Each point of each calibration curve in each matrix was acquired using a different fibre, and 
a minimum of six concentration levels were used in all experiments.   
3.2.6 SEM procedure  
In preparation for SEM, the coatings were cut into 2-3 mm pieces, dried for 1 hr at 140°C, and 
sputtered with ~10 nm of gold. SEM images of the coating (mounted using carbon conductive tape 
and specimen mounts Ted Pella, Redding, CA, USA) were acquired using LEO 1530 field emission 
SEM (Carl Zeiss NTS GmbH, Oberkochen, Germany) and an acceleration voltage of 15 kV. The 
images were collected by trained SEM operator, Francois Breton.  
3.3 Results and discussion 
The goal of this study was to evaluate the performance of a new line of biocompatible coatings 
prepared by Supelco using appropriate in vitro experiments. Any suitable coatings evaluated using 
this procedure could then be further evaluated in vivo, and the results of such experiments are 
described in Chapter 4. Commercial availability of single-use fibres with biocompatible coating 
would be advantageous for in vivo SPME studies, and the use of well-controlled commercial 
production process was expected to improve inter-fibre reproducibility for such devices.  The 
coatings were prepared using a semi-automated batch manufacturing procedure by depositing 
multiple layers of a mixture of proprietary biocompatible polymer and coated porous silica particles 
typically used as stationary phases in LC or as SPE sorbents. The biocompatible nature of polymer 
was important to eliminate any adverse/toxic in vivo reactions such as clot formation as well as to 
reduce adsorption of proteins to the surface in order to avoid problems with analyte uptake into the 
coating. Three types of coatings were included in this comparison: C18, RPA and cyano. Example 
SEM image with 300× magnification shows the surface of the RPA biocompatible fibre (Figure 3.5), 
and shows the coverage of particles with a layer of biocompatible polymer. The surface of the coating 
is also smoother than previously reported for lab-made coatings which can help minimize interactions 






Figure 3.5 Example SEM image acquired using 300x magnification of the surface of 
biocompatible RPA coating (3 µm particle size). Upper portion of coating was removed on 
purpose to facilitate the determination of coating thickness as shown in the image (41.4 µm). 
The selection of the experiments to carry out for this evaluation was based on the primary end-use 
of these coatings, which was in vivo SPME sampling. The main parameters investigated included 
mechanical robustness, extraction efficiency, carryover, extent of sample clean-up and inter-fibre 
reproducibility. In addition, the performance of coatings upon exposure to solvent was investigated by 
Supelco as reported elsewhere.
128
 The new coatings were found not to swell upon the exposure to 
common LC solvents such as acetonitrile, methanol and aqueous combinations of these solvents. This 
presents an advantage over existing commercial coatings such as Carbowax TPR (CW-TPR) which 
swelled 36-40% upon 15-min exposure to common desorption solvents such as methanol/water or 
acetonitrile/water (1/1, v/v). Such high degree of swelling is highly problematic as it can cause 
inadvertent stripping of coating (and corresponding loss of sample) when retracted into SPME device 
and/or accidental stripping of coating within manual SPME-LC interface.
129, 168
 The fibres were aimed 
for single-use so long-term reusability of coatings after exposure to biofluids was not investigated. 
Matrix modifications which can be used to improve extraction efficiency during in vitro experiments, 
such as pH adjustment and addition of salt, were not examined because they are not applicable to in 
vivo sampling of living systems. Many of the evaluation experiments were performed in PBS buffer 
because it is a good and simple alternative to use for in vitro SPME optimization experiments in order 
to avoid unnecessary exposure to human biological fluids and avoid lot-to-lot differences in the 
composition and pH of urine or plasma during SPME method development experiments. In addition, 
it does not contain any binding matrix so it is often used to perform matrix-free calibration in order to 
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determine free (unbound) analyte concentration in bioanalytical SPME methods.
86
 More complex 
matrices such as urine and plasma were investigated when necessary to evaluate the fibre 
performance for complex matrices. 
3.3.1 Evaluation of extraction efficiency and comparison to commercial CW-TPR 
coating 
The extraction efficiency of new cyano, C18 and RPA coatings was compared to that of the most 
commonly used existing commercial coating (CW-TPR). The experiment was performed using 
extraction of drug standard prepared in PBS buffer and short extraction time of 2-min was employed 
to mimic a typical in vivo sampling situation. The performance of C18 and RPA coatings was found to 
be better than cyano coatings for the model drugs tested, and similar to the performance of 
commercial CW-TPR fibre as shown in Figure 3.6. The only exception to this trend was diazepam, 
where the commercial fibre extracted significantly higher amounts of diazepam in comparison to the 
new proposed coatings. Overall, some dependence of extraction efficiency on analyte log P values 
(Table 3.1) was observed, with more polar compounds (ranitidine and pseudoephedrine) exhibiting 
lower extraction efficiencies than more hydrophobic analytes.  
To enable direct comparison of CW-TPR coating and the new biocompatible coatings such as 
shown in  Figure 3.6 and Table 3.2, different dimensions of the two coating types needed to be taken 
into account. Commercial CW-TPR fibre was available only with the coating dimensions of 1 cm 
coating length, 160 µm diameter of fibre core and 50 µm coating thickness, while the dimensions of 
biocompatible coatings tested herein were 1.5 cm coating length, 200 µm diameter of fibre core and 
45 µm thickness. Direct comparison is further complicated by the fact that the new coatings use 
coated porous spherical silica particles as the sorbent, so it is difficult to estimate exact volume of the 
coating. If both types of coatings are treated simply as cylinders and it is assumed the entire volume 
of immobilized phase could act as sorbent, an estimated correction factor of 1.6 can be applied to 
CW-TPR data to correct for the differences in coating volume. This correction factor was calculated 
by treating fibres as cylinders.  According to this approach, the volume of two cylinders can be 
calculated: (i) the volume of fibre core cylinder only (radius = core diameter/2) and (ii) the volume of 
entire fibre (radius = fibre core diameter/2 + coating thickness). The volume of the coating is then 
determined by the subtraction of fibre core volume (i) from the total volume of entire fibre (ii). Full 
calculation is shown in Table 5.3. This comparison is only an approximation because it is expected to 
overestimate coating volume for biocompatible coatings because the biocompatible binder and the 
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core of silica particles which are present within the coating do not act as a sorbent. Despite of this, the 
approximation is useful to give an estimate of how the performance of new coatings compares to 
existing coatings. 
CW-TPR coatings were previously found to perform poorly for the extraction of very polar 
analytes, but this was not reflected in the data collected using model drugs within this experiment. 
Therefore, the performance of the coatings was further tested by increasing the polarity range of 
analytes to include some even more polar species such as adenosine and riboflavin. The results 
obtained are shown in Table 3.2 for an equilibrium extraction from 5 µg/mL standard solution 
prepared in PBS pH 7.4 buffer. In general, the results confirm that the new RPA and C18 coatings 
have better extraction efficiency for more hydrophilic compounds such as riboflavin and 
hydrocortisone than CW-TPR. However, this is general trend only and extraction efficiency is very 
analyte dependent, so for adenosine all coatings had similar extraction efficiencies, and no 
improvement was observed for new coatings. For more hydrophobic analyte such as progesterone, the 
extraction efficiency of proposed biocompatible coatings is approximately the same as that of CW-
TPR. As expected, the RPA coating had improved extraction efficiency than C18 coating towards 
more polar compounds because its structure incorporates a polar embedded functional group. 
However, the observed improvement was <2-fold even at equilibrium, and no noticeable differences 
could be observed within experimental error for short extraction times of 2-min. 
Table 3.2 Comparison of extraction efficiency at equilibrium of proposed biocompatible 












riboflavin -1.46 0.02 0.18 2.3 1.3 
adenosine -1.05 0.20 0.16 0.27 0.18 
hydrocortisone 1.61 1.34 0.85 19 20 
progesterone 3.87 24 12 30 30 
* Correction factor of 1.6 was applied to CW-TPR % extracted data in order to account for different 






Figure 3.6 (a) Comparison of the extraction efficiency of RPA, C18 and cyano coatings  (45 µm 
thickness, n = 10 fibres of each type) for the extraction of various drugs. Extraction conditions: 
2 min without agitation from 100 ng/mL drug standard in PBS buffer pH 7.4.  Correction 
factor of 1.6 was applied to CW-TPR data in order to account for different thickness and 
dimensions of CW-TPR fibre as discussed in text. (b) Effect of sample volume (1.8 mL versus 
0.25 mL) on the amount of drug extracted from plasma using 45 µm C18 SPME coating (n=3 
fibres per sample volume). Extraction conditions: equilibrium extraction from human plasma 
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Equation 1.1 shows that at equilibrium, the amount extracted by SPME exhibits non-linear 
dependence on sample volume. This distinguishes SPME from traditional exhaustive techniques 
where linear dependence is encountered, and a reduction in sample volume results in linear decrease 
in analytical sensitivity. For SPME as shown in Figure 3.6 (b), the use of smaller sample volume 
(0.25 mL) versus 1.8 mL resulted in an approximately 2-fold decrease in the amount extracted. This 
feature makes SPME particularly attractive for analyses where limited amount of biofluids is 
available, for example in neonatal screening or rodent studies.  The exact magnitude of the effect of 
sample volume depends on the magnitude of Kfs, so more hydrophilic analytes with lower Kfs values 
(ranitidine and pseudoephedrine) were not affected at all by the 7.2-fold reduction in sample volume, 
indicating the extraction takes place under negligible depletion conditions described by Equation 1.7.  
3.3.2 Evaluation of coating thickness: effect on extraction time and inter-fibre 
reproducibility 
The effect of fibre thickness on coating performance was evaluated using C18 biocompatible coating 
prepared at four different thicknesses: 15, 30, 45 and 60 µm. The coatings of increasing thickness 
were prepared by Supelco by depositing additional layers of extraction phase until the desired 
thickness was achieved. The actual coating thickness of each fibre was determined experimentally 
using optical measurement and coating thickness variation was <3% RSD for all coating thicknesses. 
Increasing coating thickness increases Vf and results in higher amounts extracted by SPME as shown 
by the relationship in Equation 1.1. However, increasing coating thickness also adversely affects the 
time required to reach equilibrium, as the analytes need to diffuse through longer distances with 
thicker coatings as shown in Equation 1.5. 
The extraction time profiles were evaluated for all available coating thicknesses. They were 
constructed by extraction from 100 ng/mL carbamazepine standard solution and varying the 
extraction times from 1 min to 19 hr. During in vivo SPME sampling, agitation conditions are often 
unknown or changing, so two main approaches can be used during method development to find the 
time required to reach equilibrium for this type of application: (i) a flow-through system set at the 
expected flow rate in the system (for example, blood flow rate of the animal) or  (ii) using static (no 
agitation) conditions.
80, 136
 The latter case represents the worst-case scenario, as the only mass transfer 
occurs via diffusion. This time can then be selected as the in vivo sampling time and this approach 
ensures that equilibrium is reached regardless of whether agitation is present in the system under 
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study. The amount of analyte extracted at equilibrium is independent of agitation
136
, thus permitting 
quantitative analysis in conditions with unknown agitation rates. However, addition of any agitation 
increases mass transfer rates, so the resulting time needed to achieve equilibrium is shortened.  
The average extraction time profiles under static conditions for all coating thicknesses (n=3 fibres) 
are shown in Figure 3.7 (a).  From these results it can be concluded that the equilibrium was reached 
for 15 µm fibres after 60 min. For all other coatings the extraction time required to reach equilibrium 
was ≥300 min. For in vitro testing, agitation can be used in order to significantly decrease the 
equilibration times for these fibres as shown in Figure 3.7 (b). However, for in vivo testing, thin 
coatings with very short equilibrium times are preferred (<5 min) in order to obtain acceptable 
temporal resolution and enable equilibrium sampling for improved overall method precision. For 
instances when equilibrium sampling is not feasible, such as the case with these new coatings, short 
extraction times can still be employed in vivo as long as appropriate kinetic calibration method is 
used. An overview of all available kinetic methods and their main principles is provided in recent 
review article
80
, and the reader is also referred to relevant discussion for on-fibre standardization 
calibration method presented in Chapter 1.  
Table 3.3 shows the results of 2-min and 60-min static extractions for n=20 fibres, in order to 
investigate the impact of coating thickness on fibre variability. The results for both extractions show 
improved method precision as fibre thickness is increased. The result for 15 µm fibres is particularly 
informative as 2-min extraction represents pre-equilibrium sampling time, whereas 60-min extraction 
time represents equilibrium sampling. Method precision using equilibrium sampling is typically better 
than using 2-min short sampling times as the small errors in accuracy of timing are much more 
significant contributors to overall error as the sampling time is decreased. However, current results 
show deterioration of method precision with increase in RSD from 7 to 13%. On the timescale of 2-
min analytes typically only interact with the surface of the coating, as the time is too short for the 
analyte to diffuse within the entire thickness of the coating, and the variations in coating thickness 
would not be detected. However, as the extraction time is increased the analytes can diffuse further 
into the coating, and the variations in coating thickness can become more apparent. Small variation in 
coating thickness (for example ±1 µm) contributes more to the overall inter-fibre variability for thin 
fibres versus thicker fibres, and is the main factor for the observed deterioration in precision observed 







Figure 3.7 Example extraction time profiles for carbamazepine (a) using C18 coatings (n = 3 
fibres) of 15 µm, 30 µm, 45 µm and 60 µm thickness without agitation (b) using C18 and RPA 
coatings of 45 µm thickness (n=3 fibres) using 2400 rpm vortex agitation to enhance mass 
transfer rates of analyte. 
Table 3.3 Effect of increasing extraction time on the amount extracted and inter-fibre 
variability. 
Extraction time 2 min extraction (static) 60 min extraction (static) 
Coating thickness 15 µm 30 µm 45 µm 60 µm 15 µm 30 µm 45 µm 60 µm 
% extracted (mean, 
n=20) 
0.49 0.60 0.62 0.78 4.2 5.8 6.5 8.0 
% RSD (n=20) 7 8 4 5 13 12 6 7 
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3.3.3 Evaluation of carryover 
The carryover was evaluated using the thinnest (15 µm) and the thickest (60 µm) coatings  to provide 
the best and worst case carryover scenarios respectively. To facilitate rapid mass transfer, 2400 rpm 
vortex agitation was chosen for this study, because this is the highest agitation method currently 
available in our lab. The composition of the desorption solvent was not varied in this experiment in 
order to keep desorption solvent composition directly compatible with LC-MS/MS method. 
Therefore, the effect of two main parameters was investigated: desorption time and the volume of 
desorption solvent used. Figure 3.8 shows that the carryover was found to be negligible (≤ 0.2%) at 
all conditions tested for 15 µm fibres. For 60 µm fibres, carryover was found to be ~1% for all 
desorption times when 100 µL of desorption solvent was used, indicating that increasing the 
desorption time beyond 5 min was not beneficial. In contrast, increasing the desorption solvent 
volume to 1.5 mL reduced carryover to negligible levels (<0.1%).   Overall, the results show that 
efficient desorption was achievable for all fibre thicknesses in reasonable amount of time. The 
volume of desorption solvent can be selected based on analytical sensitivity required for a particular 
application. The method developed in this research was aimed for subsequent application for in vivo 
study, so maximum sensitivity is desirable and the smallest desorption volume was selected. For in 
vivo studies, the fibres are meant for single-use, so carryover is not problematic as long as it is 
sufficiently negligible to enable quantitative analysis. If coatings are re-used, the small amount of 
analyte remaining in the coating can be completely removed prior to next extraction during the 
solvent pre-conditioning step. High carryover (>10%) was cited as one of the most significant 
problems encountered with existing PDMS-DVB commercial coatings
130
, and the results show that 
these new coatings can offer significant improvement in this parameter. 
In a follow-up study, carryover was evaluated after equilibrium extraction using 45 µm C18 and 
RPA coatings and was found to be 0.9% and 1.4% respectively, which agrees with above results. A 
small amount of internal standard (CBZ d10) was also found in the carryover solution indicating that 
the coatings absorbed a small amount of internal standard during the desorption step (0.2 and 0.3% 
respectively for C18 and RPA coatings). This is negligible amount for current study. However, if 
lower proportion of organic solvent is used as the desorption solvent, the amount of internal standard 






Figure 3.8 Comparison of carryover results for carbamazepine using 15 µm and 60 µm C18 
coatings. Extraction conditions: 90 min extraction of 250 ng/mL carbamazepine standard in 
PBS buffer (n=3 fibres). Desorption conditions: two serial desorptions using conditions stated in 
figure. 
3.3.4 Selection of coating thickness  
Based on the results presented in previous section, several trends were observed.  Among the coating 
thicknesses evaluated in this study (15, 30, 45, 60 µm), none of the coatings were thin enough to 
permit in vivo applications with good temporal resolution using equilibrium sampling. For example, 
60-min extraction time was needed to reach equilibrium for 15 µm coating, whereas concentrations of 
drugs and metabolites can be expected to change rapidly within this time window in a typical 
pharmacokinetic study. Thinner coatings than tested in current study (<15 µm ) could not be reliably 
made by Supelco using semi-automated batch coating procedure as they exhibited unacceptable 
variation in coating thickness, which would in turn result in large variation in the amount extracted by 
individual fibres and overall poor inter-fibre reproducibility. Therefore, kinetic calibration methods 
need to be employed for in vivo studies requiring good temporal resolution. As expected according to 
theoretical consideration, the extraction efficiency increases with the increase in coating thickness, 
because of the corresponding increase in the volume of the fibre coating from Equation 1.1. 
Furthermore, slight improvement in inter-fibre reproducibility was observed for 45 and 60 µm 
coatings versus thinner 15 and 30 µm coatings especially as extraction times were increased. 
Carryover in the extraction phase was found to be acceptable regardless of the coating thickness 
Investigation of Carryover - PAN/C18 Fibres 
15 um and 60 um 















































employed (≤ 1%). Based on all of these results, 45 µm thickness was selected as the optimum choice 
balancing both extraction efficiency, good inter-fibre reproducibility and reasonable equilibrium 
extraction times when agitation is employed. All subsequent studies and subsequent prototype fibre 
production by Supelco focused on coatings of 45 µm thickness. 
3.3.5 Evaluation of inter-fibre reproducibility 
In the next step of the evaluation, the performance of coatings in biological matrices of increasing 
complexity was examined: PBS, urine and plasma. The results obtained are shown in Table 3.4.  As  a 
general trend the amount of analyte extracted in urine was approximately the same or slightly higher 
than the amount of analyte extracted in PBS. Ionic strength and pH of the urine used in this study 
were not adjusted prior to the experiment, so the slight differences in the amount extracted by the two 
matrices can likely be attributed to the variation in these parameters and its impact on the magnitude 
of Kfs for a given analyte-coating combination. As expected, the amount of analyte extracted from 
plasma was significantly lower than from PBS and urine for diazepam and propranolol. This is 
expected because these drugs are known to bind to a significant extent to proteins within this matrix, 
which lowers free analyte concentration available for the extraction. No increase in RSD was 
observed with increasing complexity of matrix for propranolol and diazepam with RSD values ≤13% 
for all coatings and all matrices. However, the results for carbamazepine were unexpected. For 
carbamazepine, extraction efficiency appeared to be the same as observed for urine matrix, even 
though about 85% binding is expected to occur for carbamazepine in plasma. Furthermore, method 
precision for carbamazepine in plasma was very poor, and significantly higher than in other matrices 
or for the other model compounds studied (28, 18, 29% RSD for cyano, RPA and C18 coatings 
respectively). One possible explanation for the observed results was that pre-incubation time of 60 
min used to establish binding between analyte and matrix of interest, was not sufficient for 
carbamazepine to establish binding equilibrium with plasma proteins. The variations in the free 
concentration of carbamazepine in plasma samples would subsequently lead to the variations in the 
amount extracted by SPME. Therefore, the plasma experiment was repeated for carbamazepine using 
C18 coating but pre-incubation time was increased to overnight incubation (12 hr) with refrigeration. 
The mean amount of carbamazepine extracted was found to be 0.18% with RSD of 11%. These 
results confirm the initial hypothesis. The amount extracted of carbamazepine decreased when pre-
incubation time was increased, which indicates that additional binding of carbamazepine to plasma 
proteins took place. Achieving equilibrium between drug and plasma proteins eliminated any 
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variability in free concentration, so overall method precision was improved and consistent with the 
results for other matrices. This result shows that during method development of bioanalytical methods 
using SPME, it is very important to use a sufficient pre-incubation time in order to establish binding 
equilibrium between drug spiked into the plasma (serum or whole blood) in order to obtain acceptable 
accuracy and precision. The length of pre-incubation time needed is analyte-dependent, so this 
parameter should be carefully examined during method development. Obviously, the length of 
incubation time can be reduced by employing agitation if overnight incubation is not feasible for 
given application. The need for incorporation of pre-incubation time is in contrast to traditional 
exhaustive sample preparation methods which usually incorporate a step to disrupt plasma protein 
binding with the drug, so the performance of such methods does not depend on whether binding 
equilibrium was established or not.  
The results in Table 3.4 show that good overall method precision was achieved with new coatings, 
and the results are in line with regulatory requirements for bioanalytical methods. The main 
contributing factor to the observed method precision is the slight variation in the amount of coating 
deposited on each fibre. Other contributions to overall experimental variance are variability of 
instrumental response (RSD for injections of quality control standard <5% RSD for all analytes in 
these sample sets), accuracy of sample and solvent dispensing step, accuracy of timing, and any 
evaporative and/or adsorptive losses of analyte during the entire procedure. Because the objective of 
the experiment was the evaluation of inter-fibre variability, internal standard was not added to the 
samples prior to extraction to remove this variation from the data, and was only added to the 
desorption solvent  to correct for any variation in injection volume. Furthermore, during in vivo 
experiments, the use of internal standard is not feasible, so this approach mimics the situation that 
would be encountered during in vivo use of these fibres (Chapter 4) and shows that the inter-fibre 
variability is sufficiently low to permit such applications. In fact, the inter-fibre variability of 
proposed coatings is significantly better than that reported for polypyrrole coatings (∼47–52% RSD 
for linezolid with single-use fibres), thus permitting single fibre use for the first time with suitable 
performance for quantitative analysis.
136
 Due to poor inter-fibre reproducibility, in vivo experiments 
with polypyrrole probes were carried out using three probes for each animal for each time point to 
allow for data averaging.
133
 Good inter-fibre reproducibility of new probes addresses this issue and 
permits the use of single probe for each sampling point. For routine in vitro use, method precision can 
be further improved by employing internal standard calibration to compensate for inter-fibre 
variability in the results, as previously shown in Section 2.3.1.15. However, considering that the 
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variability of instrumental response for bioanalytical LC-MS/MS methods is typically around 5-10% 
RSD, further correction of inter-fibre reproducibility may not be necessary. 
Table 3.4 Evaluation of inter-fibre reproducibility for three model drugs in three matrices of 
increasing complexity: PBS, urine and plasma. All extractions were performed using n=10 
fibres with 45 µm thickness coating. 
CYANO COATING 
 Carbamazepine Diazepam Propranolol 
 % Extracted % RSD % Extracted % RSD % Extracted % RSD 
PBS 0.28 5.6 0.34 7.6 0.44 6.6 
Urine 0.46 4.2 0.46 5.2 0.69 3.4 
Plasma 0.42* 28* 0.12 4.4 0.29 7.9 
RPA COATING 
 Carbamazepine Diazepam Propranolol 
 % Extracted % RSD % Extracted % RSD % Extracted % RSD 
PBS 0.48 10 0.34 13 0.69 10 
Urine 0.65 3.5 0.56 3.8 0.78 3.6 
Plasma 0.67* 18* 0.20 4.2 0.31 7.7 
C18 COATING 
 Carbamazepine Diazepam Propranolol 
 % Extracted % RSD % Extracted % RSD % Extracted % RSD 
PBS 0.64 11 0.61 9.0 0.59 9.3 
Urine 0.64 9.4 0.60 8.4 0.80 7.0 
Plasma 0.66* 29* 0.20 3.2 0.30 6.6 
* Pre-incubation time of 60-min was found insufficient for carbamazepine. Experiment was repeated 
as discussed in text. 
3.3.6 Evaluation of method linearity 
LOQ in urine using short 2-min extraction time was 1-5 ng/mL for all of the drugs tested. LOQ in 
plasma using 5-min extraction was 5-10 ng/mL for all of the drugs tested which is sufficient for 
therapeutic drug monitoring of these drugs. Furthermore, LOQ for diazepam of 5 ng/mL in plasma (5 
min pre-equilibrium sampling time) which was obtained in current study is significantly better than 
that obtained for polypyrrole probes (LOD of 7 ng/mL, 30 min sampling time) illustrating the 
potential of new coatings for in vivo sampling of drugs with good temporal resolution.
133
 The 
extraction time in plasma was increased versus 2-min time used for urine and PBS to ensure sufficient 
amount of analyte was extracted for accurate quantitation, because a significant portion of spiked 
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drugs was expected to bind to plasma proteins, thus lowering free drug concentration and  reducing 
the amount extracted. 
Linear range of proposed method was also evaluated and is summarized in Table 3.5. Only C18 and 
RPA coatings were considered in this test because extraction efficiency of cyano fibres was lower for 
all analytes tested, so their use was discontinued. Each point of each calibration curve in Table 
3.5.was obtained using a different fibre (n=1 determination per concentration level). Excellent results 
in terms of model fit and regression coefficient were observed in all cases. This gives further 
confirmation of the suitability of fibres for single use for in vivo applications, because no internal 
standard was spiked in the samples to eliminate inter-fibre reproducibility from the data set, thus 
mimicking situation that would be encountered in vivo. Internal standard was only spiked in 
desorption solvent to compensate for any variability in injection volume. An example calibration 
curve for carbamazepine in PBS buffer is shown in Figure 3.9. The method linear range is primarily 
limited by the linear dynamic range of ion trap instrument used in the study and ESI droplet surface 
saturation at high analyte concentrations. High concentration samples exceeding upper limit of linear 
dynamic range can be accurately analyzed after dilution to ensure their signal intensity does not 
saturate MS detector. This approach was successfully used during in vivo pharmacokinetic study 




Figure 3.9 Example calibration curve obtained for extraction of carbamazepine in PBS buffer  
pH 7.4 in concentration range 1-1000 ng/mL. LOQ of the method was 1 ng/mL. Extraction 
conditions: 2 min static, C18 coating. 
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Table 3.5 Summary of linearity results obtained for C18 and RPA coatings in human urine and 
plasma for diazepam and propranolol. Each point of each calibration set was obtained using 



















Urine C18 7 1-250 1.08E-03 3.5E-5 6.5E-3 1.2E-3 0.9981 
Plasma C18 7 5-700 8.4E-4 4.9E-5 3.4E-2 1.1E-2 0.9986 
Urine RPA 7 1-250 1.14E-3 3.1E-5 5.8E-3 1.6E-3 0.9995 
Plasma RPA 7 5-700 7.7E-4 8.9E-5 5.8E-2 2.0E-2 0.9949 
DIAZEPAM 
Urine C18 7 1-250 9.88E-04 3.0E-06 -2.9E-04 3.0E-04 1.0000 
Plasma C18 7 5-700 3.15E-04 3.1E-06 -1.7E-03 8.3E-04 0.9999 
Urine RPA 7 1-250 8.6E-04 3.0E-05 -2.7E-03 3.1E-03 0.9980 
Plasma RPA 7 5-700 2.64E-04 7.8E-06 1.5E-03 2.1E-03 0.9986 
PROPRANOLOL 
Urine C18 6 5-250 2.3E-4 1.9E-5 2.5E-3 1.2E-3 0.9948 
Plasma C18 6 10-700 6.5E-5 3.7E-6 4.0E-3 3.2E-4 0.9989 
Urine RPA 6 5-250 2.8E-4 1.2E-5 2.7E-3 6.7E-4 0.9990 
Plasma RPA 6 10-700 7.9E-5 4.9E-6 3.6E-3 6.5E-4 0.9960 
3.3.7 Evaluation of absolute matrix effects 
Absolute matrix effects were evaluated using human plasma matrix, as it is the most complex among 
the three matrices studies in this research and most likely to be susceptible to high degree of 
ionization effects. The experiment was performed according to procedures described in detail in 
2.3.2.1, and involves the comparison of signal intensity in plasma extract spiked post-extraction 
versus neat standard prepared at the same concentration directly in desorption solvent. The resulting 
solutions were evaluated both using direct infusion and full LC-MS/MS method. The direct infusion 
experiment provides true indication of all matrix components that are co-extracted by SPME and their 
overall influence on analyte ionization, whereas LC-MS/MS experiment evaluates the ability of 
chromatographic method to separate these species from analytes of interest. The results obtained are 
summarized in Table 3.6. According to direct infusion results, no ionization suppression or 
enhancement was observed for carbamazepine and diazepam, indicating any co-extracted 
interferences did not affect ionization for these model analytes. Ranitidine, propranolol and 
pseudoephedrine exhibited significant ionization enhancement when spiked in blank plasma extract. 
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However, once chromatographic step was added, ranitidine and pseudoephedrine no longer showed 
any signal enhancement, indicating they were sufficiently separated from co-extracted interferences 
that affected their ionization in direct infusion experiment. This result is quite interesting because, 
ranitidine and pseudoephedrine were not well-retained in reverse-phase method employed for the 
analysis, with retention times of 0.8 and 1.5 min respectively. The degree of matrix effects is usually 
the highest in this region with traditional sample preparation methods, so these results show that 
sample extracts obtained by SPME are much cleaner than usually observed for plasma protein 
precipitation and solid-phase extraction method. It can also be concluded that co-extracted species 
from plasma extract are likely to be hydrophobic in nature, as they did not impact the early-eluting 
species, implying they were well-retained on the chromatographic column employed in this analysis.  
Table 3.6 Evaluation of absolute matrix effects for the analysis of model drugs in human 
plasma. % signal represents the ratio of the signal of blank plasma extract spiked post-
extraction versus neat standard prepared directly in desorption solvent at the same 









LC-MS/MS (20 µL 
injection of 100 
ng/mL mixed drug 
standard) 
Conclusion 
Carbamazepine 94 No effect 94 No effect 
Ranitidine 274 Enhancement 107 No effect 
Pseudoephedrine 377 Enhancement 92 No effect 
Propranolol 154 Enhancement 76 Suppression 
Diazepam 114 No effect 100 No effect 
 
More surprisingly, significant degree of ionization suppression was observed for propranolol which 
is well-retained and chromatographically resolved from the other analytes in this method. To 
investigate the underlying cause for the observed ionization suppression, blank desorption solvent and  
blank plasma extracts were re-analyzed using full scan mode in m/z range of 100-500 (Figure 3.10). 
In comparison to desorption solvent, plasma extract showed additional peaks in the region of ~0.5 
min, 1-2 min, and 6-7 min but these did not interfere with the analysis of analytes, as shown by the 
results for ranitidine and pseudoephedrine which elute within 0.5-2.0 min window. However, the 
presence of two large contamination peaks (main contributing m/z of 453, 340 and 277 Da) was 
found at the retention time of propranolol. Considering these peaks were present in blank desorption 
solvent, the observed ionization suppression of propranolol did not originate from poor sample clean-
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up by SPME. Further experiments confirmed that the unknown contamination peaks originated from 
purified Nanopure water collected from in-house Barnstead purification system. Therefore, for 
accurate quantitative analysis of propranolol, another source of purified water or the use of deuterated 
internal standard for this compound is required. Alternatively, LC method could be re-developed in 
order to separate these impurity peaks from propranolol and eliminate the observed matrix 
suppression effect. These results also show that purity of chromatographic solvents is extremely 
important for successful LC-MS analysis. 
 
 
Figure 3.10 Overlaid TIC chromatograms obtained for 20 µL injection of desorption solvent 
and blank plasma extract in the region of m/z 100-500.  The main ions contributing to the peaks 
observed are marked directly on the chromatogram. Two large peaks with retention times 3-4 
min arose from purified water and interfered with the analysis of propranolol.  
3.3.8 Optimization of preconditioning procedure 
Preconditioning of reverse-phase sorbents such as C18 with an organic solvent such as methanol is 
important to wet hydrophobic chains and facilitate their interaction with the analytes. However, for 
kinetic calibration of SPME, standard pre-loading step must be incorporated prior to extraction step. 
To date, standard pre-loading step was primarily performed using purified water as diluent because 
the presence of organic solvent decreases significantly the amount of standard pre-loaded on fibre.
86
 
However, long exposure to purified water during standard pre-loading step could potentially cause the 
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collapse of C18 chains and poor extraction efficiency, although such effects were not reported 
previously
86
 nor observed in calibration comparison experiments performed in Chapter 2 (Section 
2.3.1.15). However, preliminary experiments with carbamazepine indicated poor extraction efficiency 
when standard pre-loading step was included, so this issue was further investigated in a systematic 
experiment. The extraction efficiency of C18 SPME coatings for diazepam and carbamazepine was 
compared when (i) no preconditioning (ii) 30 minute conditioning in  purified water or (iii) 30 minute 
conditioning in methanol/water (1/1, v/v) was performed. The results obtained are shown in Figure 
3.11. Preconditioning using methanol/water was found to be very important for the extraction of 
carbamazepine, and omission of preconditioning resulted in 12-fold decrease in extraction efficiency. 
The effect for diazepam was much less pronounced with less than 2-fold decrease. The difference in 
behaviour for the two analytes can be explained by poor aqueous solubility of carbamazepine in 
comparison to diazepam. However, these results also explain why standard pre-loading in purified 
water was acceptable for applications dealing with diazepam
86
, and found unacceptable in current 
work. To address this problem, the optimization of standard pre-loading procedure was investigated 
as the next step in this research. 
 
Figure 3.11 Investigation of the effect of fibre preconditioning on the amount of analyte 
extracted using carbamazepine and diazepam as model analytes. Effect of no preconditioning is 
compared versus 30 min preconditioning in purified water versus 30 min preconditioning in 
methanol/water mixture. Extraction conditions: C18 coating of 45 µm thickness, 2 min static 
extraction from 100 ng/mL standard in PBS buffer, n=6 fibres per each condition. 
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3.3.9 Optimization of standard loading procedure 
The loading of standard from purified water may have adverse effect on the extraction efficiency of 
the new coatings, so pre-loading from standard solutions containing organic solvent is required. For 
these applications it is advantageous to combine fibre conditioning and standard loading in one step, 
in order to streamline sample preparation procedure and decrease total sample preparation time 
required for each sample. Therefore, loading of carbamazepine d10 from methanol/water (1/1, v/v) 
solution was investigated as shown in Table 3.7. The data shows that it is possible to combine fibre 
pre-conditioning and standard loading into one step as long as relatively high concentrations of 
loading standard are used. For example, using 100 ng/mL concentration of loading standard, only 
0.17 ng of  standard was preloaded on the fibre even when equilibrium extraction was used (60 min 
with 2400 rpm vortex). This is not sufficient quantity because successful application of kinetic 
method requires differentiation between amount loaded and remaining on fibre, and the amount 
remaining on fibre after exposure in vivo may not be sufficient to be detected. However, the use of 
1000 ng/mL solution is able to load a sufficient quantity of standard, and was subsequently employed 
for in vivo study (Chapter 4). Furthermore, Table 3.7 shows that sample volume does not play a factor 
in the amount of standard loaded, because the amount of carbamazepine d10 loaded into C18 fibre was 
the same regardless of whether 0.25 mL or 1.7 mL standard volume was used for loading. This 
situation is expected to occur when Vs>>VfKfs according to Equation 1.1. The use of high amount of 
organic solvent in loading standard solution reduces the distribution constant between fibre and 
sample matrix (Kfs), so that the amount of standard loaded is independent of sample volume in the 
range of volumes tested.  This means that the smallest volume tested can be used to reduce overall 
consumption of deuterated standard. It is also interesting to note, without addition of organic 
modifier, the magnitude of Kfs is much higher as shown by higher % extracted of carbamazepine and 
its dependence on sample volume in Figure 3.6 (b). 
Table 3.7 Effect of sample volume and standard concentration on success of loading procedure. 
Concentration 
(ng/mL) 
Volume used for 
loading (mL) 
Amount loaded - 
CBZ d10 (ng) 
% loaded - CBZ d10 
100 0.25 0.17 0.67 
100 1.7 0.17 0.10 
1000 0.25 1.68 0.67 




3.3.10 Studies of coating performance: comparison between lots 
Once 45 µm biocompatible C18 coatings  were selected as the best prototype coating for further 
production, multiple batches of the fibres with this coating were prepared. A typical batch of coating 
can produce total of 100-200 fibres. Ten fibres were randomly selected from each batch for quality 
control testing. These ten fibres were analyzed using equilibrium extraction times for four model 
benzodiazepines, and two main parameters were considered: the dependence of the amount extracted 
on the lot of coating and inter-fibre variability within each lot. Good agreement between the amount 
extracted was observed for all lots and all analytes tested as shown in Figure 3.12. Excellent inter-
fibre reproducibility was found for all lots with all RSD values ranging from 2-7% for all analytes 
tested. 
However, if the results for extractions performed simultaneously on the same day for five different 
lots (lot 75, 90, 93, 94, 96) are evaluated using single-factor ANOVA, the lot of coating is found to be 
significant factor at 95% confidence level for all analytes except nordiazepam. Based on these results, 
it is recommended to use fibres from a single batch of coating in a given experiment (for both 
samples and calibration standards), rather than mixing fibres from different lots. 
 
Figure 3.12 Comparison of the extraction efficiency obtained for eight independent Supelco C18 
lots of coating (n=10 fibres per lot) prepared on different days in April-May 2009. The results 
for four model analytes: diazepam, lorazepam, nordiazepam and oxazepam are shown. 






























One other interesting aspect was encountered during experiments comparing different lots of 
coating. In initial studies, equilibrium extraction was performed using 60-min extraction time with 
2400 rpm vortex as shown in Figure 3.7 in the example of extraction of carbamazepine. However, in 
subsequent experiments with large number of fibres (n=10 or 20), poor method precision (20-30% 
RSD) was observed in some experiments. Further troubleshooting experiments showed that the 
agitation in all positions of multi-tube vortexer was not uniform, and that equilibrium was not reached 
within 60-min period for some fibres, while for others it would. Furthermore, replicate extractions 
using the same set of fibres and exactly the same extraction conditions (but only varying the position 
of fibres in the multi-tube vortexer) did not show good agreement in the amount extracted by 
individual fibres indicating agitation may not be uniform and reproducible even when the exact same 
rpm setting is used. This was further confirmed by performing equilibrium extraction with no 
agitation and by increasing extraction time when vortex agitation was employed to ensure all wells 
have sufficient time to reach equilibrium. In these experiments, excellent precision was observed for 
all lots and all compounds (<5% RSD), and the amount extracted further increased (over 60-min 
extraction) for some fibres indicating that equilibrium was not successfully achieved using 60-min 
extraction time. Based on the results of this study, the extraction time was increased from current 60-
min to 120-min to ensure equilibrium is achieved in all vials. This provided consistent results for all 
experiments, and poor precision results were not observed. The results show that even commercial 
agitation devices, may not provide sufficiently uniform agitation for use with SPME, and can be the 
cause of poor method precision. Uniformity of agitation  should be considered in any experiment 
where extraction is performed in parallel for multiple samples. These results further highlight the 
utility of Concept 96 system described in Chapter 2, where factors such as uniformity of agitation 
were fully evaluated and found satisfactory. During this research on the performance of in vivo SPME 
devices, Concept 96 could not be used due to different device geometry. However, efforts are 
currently under way in our laboratory to build attachment for Concept 96 in order to successfully 
house an array of 96 in vivo SPME probes for the automation of desorption step. 
3.4 Conclusions and future directions 
The research presented in this chapter investigated the performance of new prototype biocompatible 
SPME fibres from Supelco for bioanalysis. In the first stage of the work, 45 µm coating was to found 
to perform the best in terms of inter-fibre reproducibility and good extraction capacity, and was 
selected for further development and evaluation. Overall, the fibres were found to have good inter-
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fibre reproducibility permitting single fibre use, which is one of the important requirements necessary 
for successful in vivo studies where separate fibres are used at each sampling point. In fact, proposed 
coatings met all of the criteria presented in Figure 3.1 except for short extraction times. Previous 
studies have also highlighted difficulties in reproducible preparation of very thin coatings on very thin 
solid supports
136, 138
 and robustness of C18/polyethylene glycol thin coatings was not satisfactory
138
. 
Until this issue of coating preparation is resolved, thicker coatings with long equilibration times can 
still be successfully used for in vivo sampling applications by using kinetic calibration methods.
80
 For 
this purpose, the effect of conditioning and sample preloading was examined in the current study, and 
successfully combined in a single step. The recommended workflows for in vitro and in vivo SPME 
using these new biocompatible SPME coatings are summarized in Figure 3.13. The availability of 
commercial in vivo SPME device is particularly important outcome of this work, as it enables the use 
of in vivo SPME in laboratories without in-house capability of making reproducible coatings and 
devices. However, current study only evaluated probe performance in vitro, so the subject of a 
follow-up study was a detailed investigation of in vivo performance of the probes as discussed in 
Chapter 4. 
3.5 Addendum 
The text of this chapter was rewritten in comparison to published research article. The author 





Figure 3.13 Recommended workflow for (a) in vitro and (b) in vivo SPME procedure using 






In vivo SPME sampling of mice: application to pharmacokinetic 
studies of carbamazepine and its metabolite 
4.1 Preamble and introduction 
4.1.1 Preamble 
In vivo experiments described in this chapter are currently submitted for publication:  Vuckovic D., de 
Lannoy I., Gien B., Yang Y, Musteata F. M., Shirey B., Sidisky L, Pawliszyn J., In vivo solid-phase 
microextraction for single rodent pharmacokinetics studies of carbamazepine and carbamazepine-
10,11-epoxide in mice, (2010). 
In vivo experiments were performed in collaboration with Brad Gien and Ines de Lannoy from 
NoAB BioDiscoveries using their animal facility. The contributions of co-author, Brad Gien included 
the development of in vivo SPME sampling procedure for mice, the design and development of 
interface for sampling of mice as well as performing of entire in vivo sampling procedure including 
animal surgery to insert the interface and blood collection. Dr. Ines de Lannoy was involved in 
experimental planning and design of these in vivo experiments, performed data processing in order to 
estimate pharmacokinetic parameters using all three methods tested and co-wrote the manuscript. 
This data is summarized in Table 4.8 and Table 4.9, and is included with Ines’s permission in order to 
show that the proposed in vivo SPME sampling procedure yielded results equivalent to traditional 
methods, indicating the validity of proposed approach. Yingbo Yang from NoAB BioDiscoveries 
performed LC-MS analysis on plasma samples collected both using terminal and serial sampling 
approaches using NoAb’s in-house validated LC-MS/MS method. The detailed description of these 
methods is available in the manuscript. Only the final concentrations are shown here with permission 
of the authors in order to facilitate the comparison with in vivo SPME data. Florin Marcel Musteata 
was involved in experimental design and initial in vivo experiments performed on mice. Bob Shirey 
and Len Sidisky from Supelco Inc. prepared and further developed all in vivo SPME probes used in 
this study. 
Section 4.3.7 presented within this chapter has been incorporated in manuscript entitled: Vuckovic, 
D., de Lannoy, I., Gien, B., Shirey, R.E., Sidisky, L., Dutta, S., Pawliszyn, J. In vivo solid-phase 
microextraction: a new sample preparation tool in metabolomics, (2010) which is currently 
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submitted for publication. The contributions of the authors are the same as described above.  The 
contribution of S. Dutta is the LC-MS analysis of in vivo SPME samples using full hybrid Orbitrap 
system at Thermo facility in San Jose, while the relevant processing of this data set was performed by 
myself at the University of Waterloo. 
I, Brad Gien, authorize Dajana Vuckovic to use the material for her thesis. 
 
I, Ines de Lannoy, authorize Dajana Vuckovic to use the material for her thesis. 
 
I, Yingbo Yang, authorize Dajana Vuckovic to use the material for her thesis. 
 
I, Florin Marcel Musteata, authorize Dajana Vuckovic to use the material for her thesis. 
 
I, Bob Shirey, authorize Dajana Vuckovic to use the material for her thesis. 
 
I, Len Sidisky, authorize Dajana Vuckovic to use the material for her thesis. 
 




A typical pharmacokinetic study (PK) involves the dosing of multiple animals orally or intravenously 
with a drug compound, and monitoring the concentration of this compound (and possibly its 
metabolites) in plasma over time. Resulting drug concentrations are plotted against time, and this 
curve is used to estimate various PK parameters such as half life, clearance and availability. One 
recent trend in the analysis of biological samples, especially in the context of pharmacokinetic studies 
is a reduction in sample volume available for analysis, because increased number of samples are 
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collected from the same animal to ensure better data quality and greater number of sampling points.
50
 
There is also increased interest in single rodent pharmacokinetic studies, because collection of the 
data from single animal can result in improved estimation of PK parameters, and also considerable 
reduction in animal use and corresponding cost-savings.  
Mice are the most difficult species for serial sampling experiments due to small body size and 
corresponding total blood volume (~1.85 mL total blood volume/25 g mouse).  It is not recommended 
to exceed 20% of total blood volume during any 24-hr experiment, which poses strict limitations on 
the amount of blood that can be collected during each time point unless fluid replacement is 
performed. Traditional approach for performing PK studies on mice involves sacrifice of several mice 
per each time point. This results in significant overall animal use as typically 3-6 mice are employed 
per each time point and typical studies can have in excess of 10 time points.  Furthermore, dosing 
errors are likely to occur when dosing such large cohort of animals, and these errors are included in 
resulting PK data derived from such studies. Such datasets also reflect inter-animal variability in drug 
absorption, distribution, metabolism and elimination, and the differences in drug metabolism can be 
particularly significant. PK data is used for important decisions during drug discovery process about 
whether or not to continue with a particular drug entity, so data quality is extremely important to 
avoid reaching erroneous conclusions. For example, Ingelse et al. show significant differences in PK 
parameters obtained using terminal sampling of 21 mice versus serial data collected for 2 mice, 
indicating that single rodent studies are likely to provide truer representation of in vivo kinetics.
169
 In 
one crossover study in rats, the choice of sampling approach significantly influenced the results 
indicating that stress during sampling can exert an influence over the observed pharmacokinetic 
parameters.
170
 In particular, a significant difference in tMAX values was obtained by the two sampling 
approaches and attributed to physical stress which influenced blood flow and consequently drug 
absorption, distribution and metabolism. This comparison was facilitated by the ability to perform 
cross-over studies using the same animals, thus eliminating inter-animal variation from the results and 
clearly showing that sampling approach can have impact on the acquired pharmacokinetic data. In 
contrast, another study shows that PK data obtained from serial sampling was equivalent to the data 
obtained using multiple animals and terminal sampling.
171
 This indicates that the effect of sampling 
on PK data is still not fully understood, and merits further research. Other advantages of single rodent 
pharmacokinetic studies include reduction in animal use which is particularly important when using 
rare/expensive strains of mice, decrease in the amount of compound needed to perform the study 
which is particularly advantageous in early drug discovery stages where the amount of pure drug is 
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limited, elimination of the effects of anesthesia from pharmacokinetics data, the ability to study inter-
animal variation and the opportunity to perform multiple and/or simultaneous 
pharmacokinetic/pharmacodynamic investigations of mice.
171-174
  
There are currently few successful approaches for serial sampling of mice reported in literature. 
One approach involves manual withdrawal of small blood volume (4-10 µl) from tail vein followed 
by plasma protein precipitation.
172, 173
 Other approaches include withdrawal of 30 µL blood volume 
using external jugular vein cannulation followed by plasma protein precipitation
175
 or serial sampling 
of 30 µL of whole blood using lateral saphenous vein puncture in combination with plasma protein 
precipitation.
171
 The withdrawal of  50-70 µL blood volume using external jugular vein cannulation 
followed by turbulent flow chromatography on 2 µL aliquot has also been successfully employed.
176
 
To avoid difficulties in handling small blood volumes (steps such as filtration, centrifugation, protein 
precipitation) Ingelse et al. suggest the use of sorbent trapping for collection of small whole blood 
volumes of 5-10 µL, followed by protein precipitation, online SPE and LC-MS/MS analysis.
169
 
However, the proposed technique is considerably different from in vivo SPME sampling because (i) 
blood is withdrawn using established procedures of serial tail bleeding, (ii) sorbent device is designed 
not to interact with analytes of interest and is only used to physically hold the sample within the 
cartridge, (iii) exhaustive recovery is desired and (iv) sorbent trapping device does not provide  
sample clean up necessitating the subsequent use of SPE, which reduces overall sample throughput. 
Furthermore, problems with increased column back pressure were observed indicating insufficient 
sample clean-up even after application of SPE for sample clean-up. The main challenges with 
proposed serial sampling approaches were that the withdrawal of higher blood volumes limited the 
number of time points that could be collected and sometimes exceeded recommended blood volume 
sampling guideline. Furthermore, hemolysis was observed for tail vein bleeding during later time 
points, which caused overestimation of analyte concentrations.
175
 The use of in vivo SPME could 
address both of these shortcomings, as no blood is withdrawn. 
To date, in vivo SPME has been successfully applied for sampling of circulating blood in various 
animals such as dogs





. In addition to sampling of blood, in vivo SPME has 
also been successfully applied for sampling of tissue in freely moving animals within the past few 
years. For example, successful sampling of brain tissue of mice was reported for the estimation of 
toluene levels post-exposure to a single toluene dose.
178, 179
 In vivo SPME sampling of muscle and 





 Such studies are important for monitoring fate of various pollutants and its 
impact on aquatic wildlife, and the sensitivity of SPME was sufficient to detect diphenhydramine and 
diltiazem in wild fish without requiring lethal sampling.
180
 In comparison to the well-established in 
vivo sampling method of microdialysis, SPME was simpler to apply and did not require any pumps or 
other hardware, thus making it more amenable to field sampling.
182
 It was also found to provide better 
sensitivity and method precision, and eliminated adsorptive losses which are sometimes encountered 
with microdialysis. 
For sampling of circulating blood in larger animals such as dogs and pigs, an SPME fibre can be 
directly inserted into an appropriate peripheral vein using an in-dwelling catheter.
86, 87, 133, 138
 The 
catheter was then sealed using PRN adapter, and SPME probes were inserted with the aid of a 
hypodermic needle through the septum of PRN adapter. However for rodent sampling, the size of the 
blood vessels is too small to permit direct insertion of the current size of the probes without 
significant obstruction of the blood flow. To overcome this issue, the use of specially designed 
interface was proposed by Musteata et al.
88
 Two main approaches were considered after surgical 
implantation of carotid artery catheter: (i) recirculation of blood to the catheter through the out tube of 
interface using pumping action of the heart or (ii) connection of the out tube to a syringe for manual 
recirculation of blood using low push/pull rate. The first approach resulted in clotting problems and 
sufficient pressure for blood flow through the interface over extended time period could not be 
maintained, whereas the second approach was more amenable to repeated serial sampling. After 
evaluation of various interface designs for rat sampling, polyurethane interface was found to 
minimize issues with blood clotting within the interface and was successfully employed in PK study. 
However, the internal volume of this interface was still too large for successful use in mice, so one of 
the goals of the research reported in this study was to modify sampling procedure to enable its use for 
sampling of mice. Once successful sampling protocol was established, the in vivo SPME sampling 
approach was validated against the established techniques to study pharmacokinetics of 
carbamazepine (CBZ) and its main metabolite, carbamazepine-10,11-epoxide (CBZEP): (i) terminal 
sampling using cardiac puncture of 3 mice/time point and (ii) serial sampling of 3 mice using Culex® 
automated sampling unit. CBZ was selected for this study because of its widespread use as treatment 
for epilepsy, and because it is one of the drugs where therapeutic drug monitoring of unbound (free) 
concentration is recommended because of significant inter-individual variation of free drug fraction 
while total drug concentration remains within therapeutic range.
183, 184
  The latter feature makes CBZ 
a particularly interesting model drug for in vivo SPME studies because the amount of drug extracted 
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by SPME  is proportional to unbound fraction. CBZEP is obtained through hepatic oxidation of CBZ. 
It is clinically its most important metabolite because its pharmacological activity is similar to the 
parent drug and it possibly contributes to the appearance of side effects.
170, 185
 Finally, this research 
project was also used to evaluate the performance of commercial prototype in vivo SPME assemblies 
during in vivo studies, after satisfactory probe performance using biocompatible C18 probes with 45 
µm thickness was achieved during in vitro tests as previously described in Chapter 3. 
4.2 Experimental 
4.2.1 Chemicals and materials 
CBZEP was obtained from Sigma-Aldrich (Oakville, ON, Canada). The sources of all other 
chemicals and materials were the same as stated in Chapters 2 and 3. 
4.2.2 In vivo SPME procedure 
The day before in vivo SPME sampling, prototype in vivo SPME probes housed within 22-gauge 
hypodermic needle as described in Chapter 3 and consisting of biocompatible C18 coating (45 µm 
thickness, 5 µm particle size, Supelco, Bellefonte, PA, USA), were preconditioned and pre-loaded 
with deuterated carbamazepine internal standard. The conditioning and loading was performed at 
equilibrium from 300 µL of 1 µg/mL standard solution of carbamazepine-d10 (CBZ-d10, Alltech, 
Deerfield, IL, USA) dissolved in methanol/water (1/1, v/v) using vortex agitation of 1000 rpm. The 
development of this procedure was described in more detail in Chapter 3. The probes were kept in 
this conditioning/loading solution until each in vivo sampling time point in order to ensure that the 
coating does not dry out prior to sampling.  Five extra probes were pre-loaded and used to determine 
the amount of calibrant loaded as described in Section 4.2.3. 
In vivo SPME sampling was performed  in seven conscious male CD-1 mice (Charles River Labs, 
St. Constant, PQ, Canada) weighing 20 to 30 g. Prior to experiments, mice were acclimatized for a 
minimum of five days, and were provided with food and water ad libitum. One day prior to in vivo 
SPME experiments, a catheter was implanted surgically in the carotid artery and the mice were 
allowed to recover from surgery and anesthesia overnight. On the day of sampling, custom-made 
sampling interface, consisting of small volume tubing and a PRN adapter was connected by a 
stainless steel connector to the implanted catheter. The main difference between the interface used in 
current work and the interface used previously by Musteata et al. to sample rats was the reduction in 
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overall internal volume of the interface.
88
 The blood (~100 µL) was drawn in and out of the interface 
manually using a syringe. Conditioned in vivo SPME probes were inserted into the interface through 
PRN adapter and held within the interface for 2 min. Approximately 10 pull/push cycles using 
syringe were accomplished during each 2-min sampling period. This assisted agitation was used to 
increase the amount extracted by SPME, and thus improve overall method sensitivity. The photo of 
the entire sampling set-up is shown in Figure 4.1. 
 
Figure 4.1 Photograph of the mouse sampling interface shown with an SPME probe 
assembly inserted through the PRN adapter.  
The dosing of mice (2 mg/kg CBZ) was performed by injection into the lateral tail vein using CBZ 
dosing solution prepared in ethanol/propylene glycol/saline (1/1/3, v/v/v). In vivo SPME sampling 
was performed immediately prior to dosing and at 5, 15, 30, 60, 90, 120, 180 and 240 min post-dose. 
Between sampling points, catheter was periodically flushed with heparin-containing saline solution in 
order to prevent coagulation. For each sampling period, a new in vivo SPME probe was inserted into 
the blood-filled sampling interface 1 min before the stated time and held in the interface 1 min after 
the stated time (total sampling time of 2 min). Immediately after the probe removal from the 
interface, the SPME probe was rinsed for 30 sec using purified water to remove any cells or salts 
from the probe surface. The probes were stored in the freezer (–20°C) or on ice until analysis and LC-
MS/MS analysis was performed within 24 hr of sampling.  
The desorption of analytes from SPME probes was accomplished using 300 µL of desorption 
solvent (acetonitrile/water, 1/1, v/v) spiked with 50 ng/mL diazepam using 0.3 mL amber 
polypropylene HPLC vials (Labsphere, Brossard, PQ, Canada). Diazepam was used as internal 
standard in this study in order to correct for injection volume variability. The desorption was 
performed for 60 min on multi-tube vortexer at 1000 rpm. The resulting sample solutions were 
injected directly into LC-MS/MS. A second desorption using a fresh portion of desorption solvent 







4.2.3 In vivo SPME calibration procedure for determination of both free and total CBZ 
and CBZ-EP concentrations 
The concentration of CBZ and CBZEP was determined using kinetic on-fibre standardization method. 
The theoretical basis of this method is described in Section 1.4. As part of kinetic on-fibre 
standardization procedure it is necessary to determine the product of KfsVf by performing equilibrium 
extraction in a set of calibration standards of known analyte concentration prepared in appropriate 
matrix. The choice of appropriate matrix depends on whether free (unbound) or total (bound + 
unbound) concentration of analyte is of interest in a given study. In current study, both concentrations 
were of interest so two independent calibration curves were constructed. One matrix-free calibration 
curve was constructed in PBS pH 7.4 buffer and used to determine unbound CBZ and CBZEP 
concentrations. Second matrix-matched calibration curve was constructed in mouse whole blood and 
used to determine total concentrations of CBZ and CBZEP. The plot of the amount extracted versus 
standard concentration is then used to determine  Kfs•Vf  product using the slope of the linear 
regression line and known sample volume (using Equation 1.1). In cases of negligible depletion, the 
calculations are even simpler as the slope of the line is approximately equal to the Kfs•Vf  product as 
presented in Equation 1.7. 
4.2.3.1 Determination of q0 
In current study, the amount of standard pre-loaded on the fibre (q0) was determined by immediate 
desorption of five probes (without performing in vivo sampling), preconditioned and preloaded as 
described in Section 4.2.2 followed by LC-MS/MS analysis. The main considerations that were met 
when selecting the amount of standard to preload is that (i) sufficient quantity of calibrant should be 
preloaded to ensure some calibrant (sufficient for quantitative analysis) remains in the coating after in 
vivo sampling and (ii) there should be significant difference (within experimental error) between the 
amount of calibrant pre-loaded and remaining on the coating to facilitate the use of Equation 1.8. In 
current work, the amount of CBZ-d10 pre-loaded onto the fibres (q0) was ~1.6 ng and excellent 
precision was obtained as indicated by 7% RSD (n=5). The amount of calibrant remaining on the 
fibre (Q) was ~0.96 with 18% RSD (n=50). The alternative method for determination of q0 is to 
experimentally determine the amount of CBZ-d10 remaining in each loading solution. In this case, q0 
is then calculated as the difference in the amount initially present in each vial of loading solution 
minus the amount of calibrant remaining in the vial after loading procedure is finished. This approach 
is much more work-intensive as it requires the analysis of large number of loading solutions. 
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Furthermore, the concentration of loading standard employed in this study is very high (1 µg/mL) and 
exceeds linear dynamic range of LC-MS/MS method employed so serial dilution of these loading 
standard solutions is required prior to injection. This is the reason why the simpler approach 
described above was employed. The use of this simpler approach is further supported by extensive 
characterizations of various lots of Supelco biocompatible C18 fibres presented in Chapter 3 which 
show that at equilibrium intra-lot variability of the amount extracted by the probes is very low 
(typically <5% RSD). For other type of in vivo SPME fibres such as polypyrrole, where intra-lot 
variability is very high
136
, the simple approach employed here would not be adequate, and the 
alternative approach  should be used instead. 
4.2.3.2 Determination of n and Q 
The amount of analytes extracted during in vivo SPME sampling (n) and the amount of calibrant 
remaining on the fibre (Q) were calculated using CBZ, CBZEP and CBZ-d10 calibration curves (0.1 
ng/mL – 100 ng/mL, n=9 standards dissolved directly in desorption solvent and covering the entire 
linear dynamic range of the instrument). 
4.2.3.3 Matrix-free and matrix-matched calibration: determination of Kfs•Vf  product 
Blank mouse blood (~ 10 mL in total) was collected from a group of non-dosed animals by NoAB 
BioDiscoveries, pooled and mixed immediately with heparin as anticoagulant. Calibration standards 
were then prepared by spiking this pooled mouse blood with an appropriate volume of stock CBZ and 
CBZEP standard solutions (prepared in methanol) in such a way as to keep the organic concentration 
in final calibration standard solution at exactly 1% methanol (v/v). These spiked whole blood samples 
were incubated overnight with refrigeration to permit protein binding to take place, as 1 hr incubation 
was previously found to be insufficient for CBZ as described in Chapter 3. After incubation, 
calibration standards (0.3 mL sample volume in 0.3 mL capacity amber HPLC vial) were subjected to 
equilibrium SPME sampling procedure in parallel (16 hr extraction, 200 rpm orbital agitation) using 
individual in vivo SPME probes for each standard. Vortex agitation at 1000 rpm could not be used for 
whole blood samples due to possibility of disruption of red blood cells. Thus, more gentle orbital 
shaking was employed and extraction time was extended to ensure equilibrium was reached. Fibres 
were rinsed for 30 sec using purified water and desorbed as described in Section 4.2.2.  The 
calibration curve was obtained by 1/y weighted linear regression analysis using SigmaPlot 2004 for 
Windows (version 9.0) software. 
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For free concentration determination, calibration standards were prepared in PBS pH 7.4 buffer. 
Organic solvent concentration was kept at exactly 1% (v/v) for all standard concentrations, and 
overnight pre-incubation step was omitted for this calibration set as no binding matrix was present. 
The rest of the procedure was exactly the same as described for whole blood calibration standards. 
Example calibration curves obtained in different matrices for CBZ and CBZEP are shown in Table 
4.1. It should be noted that the slope of the calibration curve in PBS buffer cannot be used as the 
indication of the magnitude of KfsVf product because the extraction is not negligible. Therefore, 
sample volume used for calibration must be taken into account according to Equation 1.1. For whole 
blood and plasma calibration, the extraction is negligible as shown by good agreement between fibre 
constant and slope for 0.3 mL sample volume used during calibration. For best accuracy of results, 
the more exact KfsVf was used to calculate total concentrations. However, this data shows that despite 
small total blood volume in mice (1.8 mL), the main assumption for application of in vivo SPME 
holds and the amount extracted is independent of sample volume. 





















































The reason PBS buffer is often used to perform free concentration calibration is because it is easily 
available and it models well physiological conditions including pH and ionic strength. The suitability 
of PBS buffer to be used as artificial substitute for protein-free plasma was verified experimentally as 
follows: mouse protein-free plasma (n=2) was obtained by ultrafiltration of freshly collected mouse 
plasma using 3K MW cut-off Nanosep centrifugal devices (Pall, Port Washington, NY, USA) for 20 
min at 13000 rpm at 4°C as recommended by the manufacturer. These samples were then spiked with 
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known concentration of CBZ, allowed to incubate overnight, and then subjected to SPME extraction. 
The amount of CBZ extracted from protein-free plasma was compared versus the amount of CBZ 
extracted from PBS buffer pH 7.4 (n=2).  
4.2.3.4 Determination of blood to plasma concentration ratios 
Some compounds can preferentially partition into red blood cells, thus causing different drug 
concentrations to be measured in plasma versus whole blood samples. Drugs which do not exhibit 
preference for plasma versus red blood cells have blood to plasma concentration ratio of unity, and 
for such drugs direct comparison of the results for whole blood versus plasma analysis is possible. 
The ratios <1 show the exclusion of the drug from the red blood cells and the ratios >1 show the 
partitioning of the drug into red blood cells. For either of these types of drugs the knowledge of blood 
to plasma concentration ratio is crucial to accurately compare whole blood versus plasma analysis 
results. One of the goals of current study was the comparison of in vivo SPME results obtained in 
whole blood to the results obtained by traditional plasma analysis after terminal cardiac puncture, so 
it was necessary to experimentally determine blood to plasma concentration ratios for CBZ and 
CBZEP. This ratio can be determined using in vitro SPME by performing equilibrium SPME on two 
aliquots of same spiked whole blood sample: (i) whole blood aliquot as is and (ii) plasma aliquot 
obtained after centrifugation (4°C, 15000 rpm, 15 min) of the same spiked whole blood sample to 
isolate plasma sample.  These samples were prepared exactly as described in Section 4.2.3.3 
including overnight incubation period prior to SPME. Blood to plasma concentration ratio drug 
concentration dependent, so this experiment was performed over the entire range of CBZ 
concentrations observed in vivo. The total concentration of analyte in each matrix was determined 
using independent calibration curves prepared in whole blood and plasma at known analyte 
concentrations.  The results for this experiment are shown in Table 4.2. The first time the experiment 
was performed, one possible outlying value (2.73) was observed as highlighted in the table. This 
caused large uncertainty in the experimentally determined ratio, so the experiment was subsequently 
repeated and these results are also included in the same table. The second experiment confirmed that 
the value of 2.73 was an experimental outlier. The experimental blood to plasma concentration ratio 
for CBZ (1.10 ± 0.28) for the combined data sets excluding the outlying value is not statistically 
different from unity as determined by a paired t-test (t=0.80, tCRITICAL=2.16, p=0.44). In an 
independent experiment, blood to plasma concentration ratio of 1.32 ± 0.35 was determined for 
CBZEP (t=0.98, tCRITICAL=4.30, p=0.43). Based on these results, the concentrations measured by in 
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vivo SPME sampling of whole blood were compared directly to conventional plasma analysis without 
application of a correction factor. Mouse whole blood to plasma ratio for CBZ and CBZEP has not 
been reported in literature to date, but the results obtained in this study agree well with ratios of 1.06 
± 0.21 and 1.53 ± 0.45 obtained in humans
186
, and 1.37 ± 0.125 and 1.32 ± 0.134 obtained in rats
187
, 
for CBZ and CBZEP, respectively. 
Table 4.2 Determination of whole blood to plasma concentration ratio for CBZ using 
equilibrium in vitro SPME. 
Total CBZ Concentration (ng/mL) 
Whole Blood/Plasma 
Concentration Ratio 
Whole Blood Plasma 
Experiment 1 
25.0 15.5 1.61 
39.0 27.9 1.40 
131 48.0 2.73* 
188 145 1.30 
304 347 0.88 
499 835 0.60 
1921 2393 0.80 
4060 3386 1.20 
6767 5696 1.19 
 Mean (n=9) 1.30 
 S.D. (n=9) 0.62 
 % RSD (n=9) 48 
Experiment 2 
1.19 1.19 1.00 
11.7 14.8 0.79 
83.4 72.1 1.16 
439 323 1.36 
769 643 1.20 
1367 1436 0.95 
 Mean (n=6) 1.08 
 S.D. (n=6) 0.20 
 % RSD (n=6) 19 
*Potential outlier as described in text 
4.2.4 In vitro SPME validation 
Prior to in vivo experiments, the entire SPME-LC-MS/MS method was validated in order to evaluate 
its accuracy and precision.  The validation samples (n=4 at three concentration levels) were prepared 
as described above for preparation of mouse whole blood calibration standards and incubated 
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overnight with refrigeration to permit protein binding to take place (Section 4.2.3.3). These validation 
samples were allowed to equilibrate to room temperature. Then, the catheter end of the interface was 
placed directly into the vial containing spiked blood and the entire SPME procedure (2-min sampling, 
rinse and desorption) was carried out exactly as described for in vivo samples in section 4.2.3. SPME 
probes preloaded with calibrant were used for this experiment, and kinetic on fibre standardization 
was used to determine the total concentration of CBZ and CBZEP. Accuracy (% relative recovery) 
was calculated as the ratio of the experimentally determined amount of analyte to the true spiked 
amount x 100%.  
4.2.5 Terminal cardiac puncture sampling and automated serial sampling using 
Culex® 
The results of in vivo SPME were compared to two traditional sampling methods: (i) terminal cardiac 
puncture  (n=3 mice per time point) and (ii) serial blood sampling (n=3 mice) using an automated in 
vivo sampling system (Culex®, BASi, West Lafayette, IN, USA). Sample collection and analysis for 
these two methods were  performed entirely at NoAb BioDiscoveries, so only a brief overview of 
relevant procedures is given below. Additional details are included in the manuscript.
188
 
For automated sampling, 2 mg/kg CBZ dosing of mice was performed using the jugular vein 
catheter and for terminal cardiac puncture sampling the mice were dosed through the tail vein. Blood 
samples were collected prior to dosing and at 5, 15, 30, 60, 90, 120, 180, 240 and 270 min post-dose. 
For automated sampling method, 50 μL blood sample was automatically drawn via the carotid 
artery catheter from each of three mice at each time point, immediately diluted (1/1, v/v) with 
heparin-containing saline (20 IU/mL) and stored refrigerated until analysis. To enable serial sampling 
of the same animal for all of time points, it was necessary to replace the blood volume withdrawn at 
each time point using an equal volume of heparin-containing saline (20 IU/mL).  Prior to LC-MS/MS 
analysis, blood samples were centrifuged to isolate plasma (6500 rpm for 5 min at 4°C), followed by 
plasma protein precipitation with acetonitrile (1/3, v/v) and evaporation/reconstitution in mobile 
phase as described in detail elsewhere. For terminal sampling method, 600 to 800 µL of blood was 
collected into heparinized tubes by direct cardiac puncture while mice were under CO2/O2 anesthesia. 
Plasma was immediately isolated by centrifugation at 6800 rpm for 5 min at 4°C and stored frozen 
until analysis.  Immediately, prior to LC-MS/MS analysis, thawed plasma samples were subjected to 
plasma protein precipitation using acetonitrile (1/4, v/v) followed by evaporation/reconstitution in 
mobile phase and dilution (1/10, v/v) as described in detail elsewhere.  
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4.2.6 LC-MS/MS analysis 
For terminal puncture and automated sampling experiments, LC-MS/MS analyses were performed at 
NoAB using appropriate validated methods described elsewhere. For all LC-MS/MS methods (both at 
the University of Waterloo and NoAB BioDiscoveries), samples were diluted if necessary to ensure 
they fall within linear dynamic range of the instrument employed. Full calibration curves were run 
before and after samples, and injections of quality control sample of known CBZ and CBZEP 
concentrations were performed periodically to ensure good signal stability throughout the entire run. 
For SPME experiments, LC-MS/MS analyses were performed using a LC-MS system consisting of 
Accela autosampler with cooled sample tray, Accela LC pumps and TSQ Vantage triple-quadrupole 
mass spectrometer equipped with heated electrospray (HESI) source (Thermo Fisher Scientific, San 
Jose, CA, US). Xcalibur software (version 2.0.7. SP1) was used for all data acquisition and 
processing. Reverse-phase LC method using Symmetry Shield RP18 column (2.1 x 50 mm, 5 µm, 
Waters, MA, US) was used to separate the analytes using gradient elution with mobile phases (A) 
acetonitrile/water/acetic acid (10/90/0.1, v/v/v) and (B) acetonitrile/water/acetic acid (90/10/0.1, 
v/v/v). The gradient included  hold at 100% A for 0.5 min, linear increase to 90% B in 2.5 min, hold 
at 90% B for 0.5 min and re-equilibration of the column to initial conditions for 1.5 min for a total run 
time of 5 min. Flow rate was 0.5 mL/min and eluent was diverted to waste for initial 1.5 min of the 
run time. 
MS conditions were set using direct infusion of standard solution containing all analytes using 
syringe pump and systematic optimization of all parameters. Optimized ESI conditions included: 
sheath gas = 50 arbitrary units, auxiliary gas = 10 arbitrary units, spray voltage = 4000 V, and 
capillary temperature =  275 °C. All of the compounds were analyzed in positive ion SRM mode 
using the following transitions 237.1→194.1 (CBZ), 247.1→204.2 (CBZ-d10), 253.1→180.1 
(CBZEP) and 285.1→193.1 (diazepam). Capillary and S-lens voltages were set to 20 and 87 V for 
CBZ, 22 and 89 V for CBZ-d10,  31 and 167 V for CBZEP, 32 and 122 V for diazepam. Example 
chromatogram is shown in Figure 4.2 and demonstrates that baseline chromatographic separation of 
CBZ and CBZEP was achieved by this method. This was very important for accurate analysis of 
CBZEP because approximately 0.3% of in-source oxidative conversion of CBZ to CBZEP was 
detected. This conversion was detected in high concentration CBZ standards, where a distinct peak 
with the retention time of CBZEP was observed. In the absence of chromatographic separation of the 
two analytes, this could cause systematic bias when trying to simultaneously analyze low 




Figure 4.2 Example selected reaction monitoring chromatogram of  5 ng/mL CBZ and CBZEP 
validation sample prepared in mouse whole blood with heparin as anticoagulant using SPME-
LC-MS/MS method as described in Experimental. 
4.3 Results and discussion 
4.3.1 Summary of SPME method development 
SPME method for CBZ was developed as described in Chapter 3 simultaneously with the methods for 
other drugs. The desorption conditions were changed slightly from those presented in Chapter 3 to 
increase the volume of desorption solvent from 100 µL to 300 µL as this was found to decrease 
carryover to ≤0.7% even at the highest in vivo concentrations observed during early time points. The 
optimized CBZ method was then applied to CBZEP, and it was found that sufficient analytical 
sensitivity was achievable to observe this important metabolite directly in vivo without any further 
optimization necessary.  
Initial in vivo studies used sampling approach proposed by Musteata et al. where blood is 
recirculated back to the animal using slow manual push and pull action using syringe.
88
 These initial 
studies were performed using 4 push/pull cycles of 100 µL of blood within 2-min sampling period, 
and the speed was selected on the basis of Musteata et al. study where 3 push/ pull cycles were 
completed within each 2-min sampling interval. However, this initial data showed poor agreement 
between SPME and traditional sampling based on blood withdrawal at the early time points where 
concentrations are expected to change rapidly after intravenous dosing. One possible cause of this 
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observation was averaging of analyte concentrations during the sampling period or slow response of 
SPME coating to rapidly changing concentrations. Using a simple in vitro test, the effect of increasing 
the sampling speed on the amount extracted by SPME was investigated. As a control, fibre was 
placed in a 50 ng/mL CBZ standard solution in PBS buffer for 2 min with 10 push/pull cycles 
completed over the sampling period (10 push and pull cycles, no delay). The sampling was then 
repeated using the same fibre, but this time the fibre was first placed in blank PBS for 30 sec, then in 
50 ng/mL CBZ standard solution in PBS for the remaining 90 sec sampling time (10 push and pull 
cycles with delay). The overall sampling speed was kept constant at 10 pull/push cycles over 2-min 
sampling period. A third experiment was performed with the same 30-s delay, but the agitation speed 
was lowered to 4 push/pull cycles.  Agitation speeds above 10 push/pull cycles were not suitable for 
use in vivo, as they could cause animal shock and/or premature death. All determinations were 
performed in triplicate using the same fibre, and the results obtained are shown in Figure 4.3. The 
results show that using slower speed of 4 push/pull cycles, the amount of analyte extracted by SPME 
fibre was significantly lower versus 10 push/pull cycles and did not properly reflect the final 
concentration of 50 ng/mL. Instead, it represented time-weighted average concentration over the 
sampling time. However, when 10 push and pull cycles were employed, no significant difference in 
the amount extracted was observed whether sampling was performed in 50 ng/mL standard solution 
for the entire 2-min period or only for 1.5- min period with 0.5-min initial sampling period in blank 
solution. Based on these results, sampling speed of 10 push and pull cycles was employed for all 
subsequent in vivo experiments. 
 
Figure 4.3 Results of in vitro evaluation of assisted agitation speed. The dependence of the 
response (chromatographic peak area of CBZ, n=3 determinations) of SPME sampling 
to a rapid change in CBZ concentration (0 to 50 ng/mL as described in text) and 
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4.3.2 Investigation of suitability of PBS buffer for free concentration determination 
During in vivo studies, it was desirable to monitor both free and total analyte concentrations. The 
determination of free concentration can be performed by preparing SPME calibration curve in matrix 
which does not contain any binding species. For this purpose, PBS buffer at pH 7.4 is often used 
because it is easier to obtain than protein-free plasma, especially for studies in mice where such 
limited blood volume is available. To investigate whether PBS buffer can serve as adequate surrogate 
matrix for current application, the amount of analyte extracted from PBS was compared to the amount 
extracted from protein-free plasma. Protein-free plasma was obtained using ultrafiltration through 3K 
ultrafiltration device. The mean absolute recovery of CBZ from protein-free plasma was 29.3 ± 7.8% 
and in PBS was 44.9 ± 1.5% using 0.22 mL sample volume. Using Student’s t test at 95% confidence 
interval, there was no statistically significant difference between two matrices (t=-2.78, tcritical =4.30, 
p=0.11) indicating PBS buffer can serve as good substitute for protein-free plasma. It should be noted 
that very small n was used for this test due to very limited availability of mouse plasma. For example, 
total blood volume that can be extracted during terminal sampling of mice is about 50% of total blood 
volume, or approximately 800-900 µL. After centrifugation, only about 400 µL of plasma is obtained 
from such sample. The amount of filtrate obtained after ultrafilitration further reduces the volume to 
about 200 µL. 
4.3.3 Summary of method validation results 
The entire in vivo SPME procedure was validated by performing sampling from a vial of whole blood 
spiked with known CBZ concentration. Sampling was performed using interface and assisted 
agitation of 10 push/pull cycles in order to mimic in vivo situation as much as possible. The 
experiments were performed at three concentration levels using n=4 independent determinations per 
level and on-fibre standardization method was used. A summary of the results is shown in Table 4.3 
and shows acceptable accuracy and precision of the entire method including the on-fibre 
standardization approach. 
Furthermore, extraction efficiency (or absolute recovery) was evaluated at equilibrium across the 
entire range of concentrations of interest using calibration standards prepared in different matrices as 
summarized in Table 4.4.  Absolute recoveries of CBZEP were lower than for CBZ due to the slightly 
more polar nature of the compound. As noted in Section 3.3.10, extraction efficiency was dependent 
on the lot of the probes used, so for in vivo studies it was ensured that all in vivo samples and all 
calibration samples were extracted using probes from the same lot. The absolute recovery in plasma 
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Mean % relative 
recovery (n=4) 
Precision 
% RSD (n=4) 
5 96.8 17 
200 109 14 
2000 93.1 8 
 
and whole blood was very low due to high degree of binding to plasma proteins. However, low 
absolute recoveries are permitted according to regulatory guidelines as long as it is shown that the 
absolute recovery is consistent across all concentration levels of the entire linear dynamic range of the 
method.
142
 This is the case for the developed SPME methods as indicated by good precision of 
absolute recovery determination obtained using different concentration levels spanning the entire 
range of expected in vivo concentrations. 
A 30-second washing step with purified water was incorporated between extraction and desorption 
steps in order to eliminate any salts from the surface of the fibre and/or any small blood droplets from 
in vivo assembly. These washing solutions were subsequently analyzed for the presence of CBZ, but 
no CBZ was detected in any of the chromatograms indicating no detectable loss of CBZ occurs 
during wash step. 
Table 4.4 Absolute recovery of CBZ and CBZEP at equilibrium in PBS, plasma and whole 
blood (n=10 concentration levels for CBZ, n=6  concentration levels for CBZEP). 
Analyte 
Absolute recovery  
in PBS (%) 
Absolute recovery 
in plasma (%) 
Absolute recovery in 
whole blood (%) 
CBZ 68±4 2.4±0.3 2.1±0.4 
CBZEP 39±6 1.5±0.1 1.0±0.2 
 
The lower limit-of-quantitation (LOQ) of proposed in vivo SPME procedure was 1 ng/ml for CBZ 
and CBZEP in whole blood, and was determined using 10x signal-to-noise ratio and exhibited 
acceptable precision (<20% RSD). The linear range evaluated in current study was 1-2000 ng/mL for 
CBZ and 1-150 ng/mL for CBZEP in whole blood because the expected concentrations of the drug 
and metabolite were not expected to exceed this range. The reported linear range is not limited by the 
probe capacity, and can be further extended depending on application requirements, as long as 
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samples are sufficiently diluted so that the signal falls within the linear range of the MS instrument 
employed. Example calibration curves in all matrices are shown in Table 4.1. 
The effect of 1% methanol in plasma calibration standards was also examined by comparing the 
amount extracted from CBZ calibration standard with no methanol versus calibration standard 
prepared with 1% methanol. Due to poor solubility of CBZ in water, CBZ calibration standard 
without methanol was prepared by pipetting 10 µL of appropriate CBZ stock standard prepared in 
methanol, allowing the solvent to evaporate completely to dryness and then reconstituting the residue 
using mouse plasma.  The determination was performed in triplicate, and % extracted of CBZ was 
2.35 ± 0.3 and 1.93 ± 0.07 for extraction of standard solution without and with 1% methanol, 
respectively. The results were compared using t test and no significant differences were found at 95% 
confidence interval (tEXPTL= 2.34, tCRITICAL = 2.78, p = 0.08). Therefore, all subsequent whole blood 
and plasma calibration curves were prepared by keeping the proportion of methanol constant at 1% in 
all standard solutions. 
Finally, the degree of overall plasma protein binding of CBZ in mouse plasma was also evaluated 
using equilibrium SPME and found to be 97.1±0.1% (n=3 determinations). This is significantly 
higher than 76% binding typically reported for carbamazepine according to DrugBank data.
189, 190
 
This unexpected result was further investigated to verify if the presence of 1% methanol in spiked 
plasma samples affected the degree of binding. However, >90% binding was observed even when 
methanol was completely omitted from the preparation of spiked plasma samples. The binding of 
CBZ was then investigated in independent experiments using fluorescence spectroscopy and NMR by 
Dr. Barbara Bojko, and high degree of binding (>90%) was found using these methods for low CBZ 
concentrations such as the ones used in current SPME study, thus confirming the validity of SPME 
results. 
4.3.4 Evaluation of in vivo performance of prototype SPME assemblies 
Two main issues were encountered during early in vivo SPME experiments on mice and initial testing 
of in vivo SPME probes. First, it was necessary to completely eliminate any blood leaks during the 
entire sampling procedure as even minor leaks could result in premature animal death, and/or 
subsequent sample contamination during desorption step.  In early studies, it was found that large 
number of in vivo SPME prototype probes (~20-50% depending on the study) leaked in the hub of the 
hypodermic needle due to inefficient sealing between the needle and SPME fibre using silicone glue 
used to prepare the probes. To address this issue, prototype in vivo SPME probes were modified by 
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the manufacturer as necessary until they were able to withstand expected blood pressure in mice.  
This was accomplished by reducing the gauge of needle from original 21-gauge to 22-gauge, 
changing the type of silicone glue used in the needle hub, and ensuring glue was properly filled 
within the hub and cured for sufficient amount of time during probe production.  This resulted in the 
successful elimination of leaking problem and permitted in vivo SPME sampling on mice without 
adverse effects due to blood loss. 
The second observed problem was that few probes during each in vivo experiment would exhibit 
outlying results (very low amount extracted as compared to adjacent time points). This problem was 
subsequently correlated to red appearance (by visual examination) of some of the probes which could 
not be eliminated using 30-second water rinse. The probes with good performance remained white in 
appearance after sampling and rinse steps, as long as rinse step was performed immediately after 
sampling without letting the probe dry out. The probes with poor performance, on the other hand, 
remained red after sampling and rinsing steps indicating hemolysis (1-2% of all the probes tested).  
Example results obtained during an example study on three mice are shown in Table 4.5. The fibres 
originally used for the time points shown in the table (mouse 3 time = 60 min, mouse 3 t = 120 min, 
mouse 2 time = 120 min and mouse 1 time = 30 min) remained red in appearance after rinsing step 
with purified water immediately post-extraction. The sampling was repeated using a new probe and 
these results are shown with label “repeat” in the table. The results show that three out of four red 
probes exhibited poor extraction efficiency. The use of such points would result in erroneous data 
points within PK curve with 5-10-fold underestimation of true CBZ amount.  The red probe observed  
Table 4.5 Results obtained for repeated sampling: probes with red appearance versus new 
probes used for re-sampling.  











mouse 3 time 60 0.1916* 0.72 0.87 2.84 48.8 
mouse 3 time 62repeat 0.6097 3.02 6.69 21.87 376 
mouse 2 time 120 0.8593 0.28 1.24 4.04 69.5 
mouse 2 time 122repeat 0.9065 0.24 1.30 4.25 73.0 
mouse 3 time 120 0.3059* 0.27 0.37 1.22 20.9 
mouse 3 time 122repeat 0.7561 0.87 2.72 8.90 153 
mouse 1 time 30 0.3318* 2.25 3.21 10.51 181 
mouse 1 time 32 repeat 0.7378 4.17 12.43 40.63 698 




after sampling of mouse 2 at 120-min time point showed good extraction efficiency despite its red 
appearance. In this case, the results for the second sampling show excellent agreement. Based on the 
results of in Table 4.5, it is clear that it is valuable to repeat any samplings where coating remains red 
after rinsing. This means that few extra probes should be preloaded and preconditioned prior to in 
vivo study in case re-sampling needs to be performed. However, if re-sampling is not performed 
during the study for any reason, any poor quality data points can be found in raw data by checking for 
very low amount of CBZ d10 remaining in the coating (as marked with asterisk  in Table 4.5). 
This problem of occasional probe failure is currently under further investigation and is attributed to 
possible incomplete coverage of biocompatible binder on the surface of some probes. This hypothesis 
was confirmed by comparison of the surfaces of white versus red probes using scanning electron 
microscopy. The probes that were red showed cracked and jagged surface, in contrast to the relatively 
smooth surface observed for normal probes. The manufacturer is currently examining possible causes 
of poor probe surface properties and/or developing an appropriate quality control procedure to 
eliminate any such probes before shipping. Until this is accomplished, any probes that remained red 
after rinsing were discarded and the sampling was immediately repeated using a new probe (one 
incidence during entire in vivo experiment on n=7 mice described in section below). 
4.3.5 Results of in vivo study: pharmacokinetics of CBZ and CBZEP using in vivo 
SPME 
Single-dose full pharmacokinetic profiles for individual mice (n=7) were obtained using in vivo 
SPME after intravenous dosing of CBZ at 2 mg/kg. The results obtained for total concentration of 
CBZ and CBZEP are shown in Figure 4.4 and clearly demonstrate that in vivo SPME can be used 
effectively to study inter-animal variability as significant differences were observed in the amount of 
conversion of CBZ to CBZEP between individual mice. This is in agreement with previous studies in 
rats  where inherent variability in clearance was estimated as 20-40%.
187
 The total concentrations 
reported in Figure 4.4 were based upon calibration curve obtained in pooled mouse whole blood. 
Within-animal calibration is not feasible with mice due to limited blood volume – total extractable 
blood volume is insufficient to construct a full SPME calibration curve even if the mouse is sacrificed 
post-study. The exact amount of binding proteins varies from individual-to-individual, and any such 
variation can cause a small systematic error in the reported in vivo SPME results because the amount 
extracted by SPME is proportional to free fraction and free fraction is correlated to the amount of 
binding proteins present, especially for highly-bound drugs. However, this does not really represent a 
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major disadvantage of SPME, because it is the unbound drug concentration which is 
pharmacologically active. Considering that the amount of the drug extracted by SPME is directly 
proportional to unbound drug concentration, unbound drug concentration profiles obtained by in vivo 
SPME are much more accurate, regardless of the calibration strategy employed as they are 
independent of the amount of binding proteins present in particular individual. Unbound drug 
concentration also provides much more meaningful clinical information than total drug concentration. 
Table 4.6 and Table 4.7 show the results of free concentration determination for CBZ and CBZEP in 
current in vivo study. One assumption made in current study is that CBZ-d10 could be used as  
Table 4.6 Free concentration (ng/mL) of CBZ in circulating blood of n=7 mice obtained by in 












0 ND ND ND ND ND ND ND ND ND ND 
5 151 166 200 110 91 111 115 135 39 29 
15 140 202 177 78 112 62 77 121 54 44 
30 170 72 109 71 39 57 55 82 45 54 
60 61 32 49 47 16 38 18 37 17 44 
90 10 11 27 36 2 16 42 21 15 72 
120 8 6 23 11 1 5 2 8 7 93 
180 2 3 ND ND ND ND ND 3 1 28 
 
Table 4.7 Free concentration (ng/mL) of CBZEP in circulating blood of n=7 mice obtained by in 












0 ND ND ND ND ND ND ND ND ND ND 
5 0.48 0.33 0.56 0.25 0.86 1.7 0.79 0.71 0.49 69 
15 0.71 0.63 0.86 0.4 2.08 1.7 1.24 1.09 0.61 56 
30 1.02 0.33 0.79 0.48 1.17 2.85 1.4 1.15 0.84 73 
60 0.48 0.25 0.4 0.33 0.71 2.24 0.56 0.71 0.69 97 
90 0.25 0.21 0.33 0.33 0.25 1.17 1.55 0.58 0.54 93 
120 0.25 0.19 0.25 0.25 0.25 0.48 0.25 0.27 0.09 34 




calibrant for kinetic calibration for CBZEP or in other words that the time constants a for the two 
compounds were similar. This is reasonable assumption considering the two structures are very 




4.3.6 Results of in vivo study: comparison of in vivo SPME to automated serial and 
discrete terminal sampling of mice 
The results obtained for automated serial sampling of n=3 mice in combination with traditional 
plasma analysis are shown in Figure 4.5 for individual mice. SPME results follow the same general 
profile as obtained for traditional analysis, showing rapid decrease in carbamazepine concentrations 
over the course of study as expected after i.v. dosing. Average concentration-time profiles obtained 
for CBZ and CBZEP using all three sampling methods are overlaid in Figure 4.6. No correction 
factors to account for red blood cell portioning were applied to either analyte according to the results 
reported in Section 4.2.3.4. The total drug concentrations for CBZ and CBZEP obtained by three 
methods were also used to calculate PK parameters such as peak blood concentration (C0), terminal 
half-life, clearance (CL) and area under the curve (AUC).  This calculation of PK parameters was 
performed by Dr. de Lannoy and Table 4.8 and Table 4.9 are included with her permission for 
method comparison purposes. It is clearly shown that the results obtained by in vivo SPME agree with 
the results obtained by both serial and terminal sampling approaches for both CBZ and CBZEP. The 
comparison of the data using t test also showed  no significant differences in determined PK 





Figure 4.4 Whole blood concentration versus time profiles obtained by in vivo SPME 
sampling for CBZ (A) and its formed metabolite, CBZEP (B), in seven individual mice 
(M01 to M07) following the administration of a single i.v. dose of 2 mg/kg CBZ. Samples 
were collected up to 240 min, but CBZ and CBZEP were not detected in some of the 
late time point samples as shown in the figure. Y-scale is shown on logarithmic scale. 
 




















































































Figure 4.5 Whole blood concentration versus time profiles obtained by automated serial 
sampling for CBZ and its formed metabolite, CBZEP, in three individual mice (M01 to 
M03) following administration of a single i.v. dose of 2 mg/kg of CBZ. This data was 
collected by NoAB BioDiscoveries and is included for comparison purposes only with 
permission of authors. 





































Figure 4.6 Mean (±SD) concentration versus time profiles of CBZ (A) and CBZEP 
metabolite (B), following 2 mg/kg i.v. administration of CBZ to mice. Samples were 
taken by serial SPME sampling (n=7 mice), by serial automated blood draws (n=3 mice) 
or by terminal blood draws (3 mice/time point). SPME and serial blood sampling 
measured whole blood concentrations whereas terminal sampling measured plasma 
concentrations. SPME analysis was performed at the University of Waterloo, while 
serial and terminal analysis were performed by NoAB BioDiscoveries and are included 
only for comparison purposes with permission of authors.  































































Table 4.8 Mean (± SD) estimated PK parameters for CBZ following 2 mg/kg i.v. 
administration of CBZ to mice. Blood was sampled by SPME sampling (n=7 mice) and 
by serial automated blood draws (n=3 mice) and plasma was sampled by terminal blood 
draws (n=3 mice/time point). SPME analysis was performed at the University of 
Waterloo, while serial and terminal blood draw analyses were performed by NoAB 















C0 ng/mL 600 ± 100 800 ± 300 680 
Terminal t1/2 min 32 ± 12 50 ± 23 45 
AUC0-inf min*ng/mL 26600 ± 10000 42700 ± 8000 36500 
CL mL/min/kg 87 ± 35 48 ± 9 55 
MRT0-inf min 40 ± 11 50 ± 7 47 
Vss mL/kg 3200 ± 800 2400 ± 800 2600 
a 
Parameters are estimated from individual whole blood concentration versus time profiles for 
each animal. 
b 
Parameters are estimated from the mean plasma concentration versus time 
profiles. 
Table 4.9 Mean (± SD) estimated PK parameters in blood for the formed metabolite, 
CBZEP, following 2 mg/kg i.v. bolus administration of CBZ to mice.  Blood was 
sampled by SPME sampling (n=7 mice) and by serial automated blood draws (n=3 
mice). SPME analysis was performed at the University of Waterloo, while serial blood 
draw analysis was performed by NoAB BioDiscoveries and is included only for 









tmax min 34 ± 26 30 ± 0 
Cmax ng/mL 57 ± 37 33 ± 17 
Apparent t1/2 min 36 ± 17 23 ± 5 
AUC0-inf min*ng/mL 3400 ± 2600 2200 ± 1000 
MRT0-inf min 62 ± 20 52 ± 9 
a
Parameters are estimated from individual whole blood concentration versus time profiles for 
each animal. 
The precision of SPME results obtained in current study is about 60% for CBZ (mean RSD for all 
time points of 60%, RSD range of 39-109%, n= 7 mice). This is higher than that for serial sampling 
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(mean RSD 29%, RSD range 11-47%, n=3 mice) and terminal sampling (mean RSD 50%, RSD range 
4-173%, n=3 mice/sampling point) approaches. The data for traditional approaches obtained in 
current study is in good agreement with literature report of precision of <35% for serial sampling in 
mice and <50% for discrete terminal sampling in mice.
171
   
The overall method precision reported for SPME includes inter-probe variability, the experimental 
error inherent in the determination of the amount of on-probe calibrant as well as the analytes of 
interest, the variability in dosing and probably, the most significant factor, which is inter-animal 
variability in both the extent of metabolism as well as plasma protein binding. The magnitude of the 
contribution of the first two factors was estimated during method validation by repeated sampling of 
known CBZ concentrations via interface and was found to be <20% RSD for all concentrations tested 
(Section 4.3.3). Therefore, it appears that inter-animal variability is significant factor contributing to 
overall method precision. This variability in plasma-protein binding, which can result in significant 
differences in unbound fraction, is not included  in plasma analysis data, because the traditional 
analysis is based on the total concentration determination (unbound + bound), which would not be 
affected by the differences in binding. In humans, the variability of unbound fractions was reported as 
0.15 to 0.3 for CBZ and from 0.33 to 0.67 for CBZEP, and no significant relationship was established 
between unbound and total CBZ concentrations indicating that degree of binding can vary 
significantly in vivo.
191
 Furthermore, a recent report based on serial miniscule bleeding in mice and 
traditional sample preparation found inter-animal variation as high as 200% at any given time point 
indicating that inter-animal variability can be very significant.
192
 The extent of inter-animal variability 
can be verified in follow-up experiments using inbred strains of mice and larger cohorts of animals, as 
both the study by Watanabe et al. and current study used small number of animals. Both in vivo 
SPME and automated sampling experiments were performed over three days, so the results also 
reflect inter-day variability. For example, slight variations in preparation of dosing solution are 
reflected in the data. If only the data for n=3 mice collected on the same day and dosed with the same 
dosing solution is considered, SPME method precision shows improvement (mean RSD of 49%, RSD 
range of 12-104%). This method precision is in agreement with the findings of an earlier independent 
study on three mice performed on the same day by in vivo SPME (mean RSD for all time points of 
42%, RSD range of 2-77%, n=3 mice). Regardless of the sampling method employed, all the method 
precision data shows a general trend towards higher RSD values for later time points versus early 
time points. This can be attributed to the differences in the rate of metabolism and elimination of 
CBZ. Based on the data of this study, it appears that the analytical variability of SPME is less than 
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inter-animal variability, thus permitting the use of SPME to study factors such as differences in 
binding and metabolism. 
4.3.7 Preliminary investigation of suitability of in vivo SPME for global metabolomics  
As a proof of concept study, the potential of in vivo SPME sampling for global metabolomic studies 
was investigated using the same experimental procedure described in Section 4.2.2, but the mice were 
dosed with 4 mg/kg of carbamazepine. The profiles obtained at 5 and 30-min post-dose were 
compared after analysis using a HILIC method in positive ESI mode as described elsewhere
193
 (LC-
MS analysis performed by S. Dutta at Thermo Fisher facility, data processing performed by D. 
Vuckovic at the University of Waterloo according to procedures described in detail in Chapter 7). The 
results obtained after principal component analysis with Pareto scaling are depicted in Figure 4.7 and 
show clear clustering of the two sets of samples. First principal component was found to describe 
93.7% of variance, and second principal component described an additional 5.9% of variance. The 
data was further examined to select the peaks most responsible for the observed clustering, and the 
pairwise comparisons of the intensity observed for these metabolites are also shown in Figure 4.7. 
Among the metabolites shown to contribute to clustering (Figure 4.7c), peak 56 was identified as 
carbamazepine with an exact mass of 237.1030 and confirmed against the authentic standard. CBZ 
was expected to contribute to the observed differences in the 5 min versus 30 min post-dose samples 
according to PK study results presented earlier. 
These results gave preliminary indication of the utility of in vivo SPME in global metabolomic 
studies. However, they were not further processed for several reasons: very small sample size was 
used so any conclusions drawn from the data would be of limited utility. Furthermore, biocompatible 
C18 coating was used for the extraction while HILIC LC-MS was employed for global analysis. This 
resulted in <500 observed metabolites peaks, and most of the peaks observed were not well-retained 
using HILIC method indicating their hydrophobic nature. Therefore, further research efforts focused 
on the development of SPME coatings suitable for metabolomics (Chapter 5) and LC-MS method 




































Figure 4.7 Representative results from a proof of concept in vivo SPME metabolomics study. (a) 
Scores scatter plot indicating good clustering of two sample types  5 min post-dose samples 
(labelled as 5B and C) and 30 min post-dose samples (labelled as 30 B and C). (b) Loadings 
scatter plot of PC1 versus PC2 illustrating the peaks contributing most to the observed 
clustering. (c) Example of a score contribution plot showing 30 representative metabolites. In 
this metabolite subset, metabolites with IDs of 56, 60, 432 and 1980 contribute the most to the 
observed clustering. (d) pair-wise comparison of selected differentiating peaks based on PCA 
analysis including observed signal intensity and RSD. 
4.4 Conclusions 
In vivo SPME sampling in mice provides advantages over established sampling methods. The use of 
SPME permits simultaneous determination of both total and unbound analyte concentrations as 
described in this chapter, whereas traditional methods require two separate sample analyses to obtain 
both parameters, increasing both time and cost of analysis and requiring additional volume of 
biofluids. This determination of unbound fraction of analytes is an important factor in bioavailability 
and intrinsic clearance calculations.
194
 In comparison to terminal sampling approaches, in vivo SPME 
significantly reduces animal use by 5-10-fold or more depending on the number of animals used per 
sampling point and the total number of sampling points. For example, in study described herein 33 
mice were used (11 time points x 3 mice/time point) versus 7 mice sampled using in vivo SPME 
method. In comparison to serial sampling approaches, in vivo SPME enables the sampling of 
unlimited number of points as no blood is withdrawn and the total circulating blood volume remains 




sampling requires expensive robotic equipment with the cost of $20,000 per machine, while in vivo 
SPME can be carried out with much simpler apparatus (in vivo SPME probes and interface), for 
overall reduction in the cost of analysis. In vivo SPME can also be used for simultaneous sampling of 
different compartments, for example blood and brain, and such studies are currently underway within 
our laboratory, while Culex® sampling unit is limited to sampling of blood. The ability for multi-
compartment studies and reduced animal use can be particularly important for precious expensive 
animals such as genetically modified mice for human cancer research.
22
 Furthermore, serial sampling 
approaches (whether by SPME or Culex®) provide opportunity for longitudinal studies, for example 
in metabolomic studies of aging, recovery from an illness or systems biology. For example, a recent 
global metabolomics study measuring internal body time using diurnal variability of selected 
metabolites, relied on terminal sampling procedures  and resulted in the sacrifice of numerous mice 
and introduction of inter-animal variation into collected data.
17
 The availability of in vivo SPME for 
mice for the first time can provide a useful tool for similar studies in future and extend such studies 
from urine analysis
125
 to plasma analysis. 
4.5 Addendum 





Systematic evaluation of SPME extraction phases for 
metabolomics 
5.1 Preamble and introduction 
5.1.1 Preamble 
This work has not yet been published. HiSep and polyethylene glycol (PEG) coatings were prepared 
by Francois Breton and submitted for inclusion in the evaluation. Biocompatible prototype coatings 
described in Chapter 3 (cyano, C18 and RPA) were obtained as research samples from Supelco to be 
included in the evaluation. I am the sole author of all other experimental work reported herein.  
5.1.2 Introduction 
The focus of this chapter is to describe the development of suitable SPME coatings for the 
simultaneous extraction of polar and non-polar metabolites suitable for use in metabolomic studies. 
This coating development was necessary because the existing commercial coatings do not perform 
well for the direct extraction of polar compounds as previously discussed in Chapter 3. The choice of 
sorbent is very important in SPME methods because it determines the magnitude of distribution 
constants for a given analyte and/or interferences and therefore impacts both extraction efficiency and 
selectivity.  
For global metabolomics, it is desirable to find the least selective coating in order to enable 
simultaneous extraction of as many metabolites as possible, both hydrophilic and hydrophobic. The 
experimental approach first focused on the development of suitable LC-MS methods for 
metabolomics using a standard mixture of known metabolites. This metabolite test mixture consisted 
of a diverse range of compounds including amino acids, amines, organic acids, hormones, sugars, 
nucleosides and small peptides. The metabolites were selected based on (i) their amenability to 
electrospray ionization, (ii) commercial availability of authentic standards, (iii) wide molecular 
weight range (80-777 Da) and (iv) wide polarity range (log P range of -5 to 7.4). This standard 
mixture and LC-MS methods were subsequently used to perform systematic evaluation of 40 types of 
commercially-available sorbents for their usefulness in metabolomic studies.  It was desirable to test 
as wide range of sorbents as possible, so silica-based, carbon-based and polymer-based sorbents were 
included in this systematic evaluation. Polymeric sorbents typically have several advantages over 
 
 130 
silica-based sorbents including higher surface area, improved pH working range, and minimal 
requirements in terms of preconditioning prior to use.
195, 196
 These polymeric sorbents were also 
developed to improve extraction efficiency towards polar compounds, which was achieved through 
introduction of polar functional groups within the polymer and/or increasing surface area in order to 
increase the number of interactions between analyte and sorbent. The primary mechanism of 
interaction using chemically bonded silica-based sorbents are van der Waals forces, although some 
sorbents also incorporate other mechanisms such as ion-exchange due to the addition of appropriate 
functional groups. The primary mechanism of carbon-based sorbents is adsorption, but one of the 
problems that can be encountered using this type of sorbent is excessive or even irreversible retention. 
In SPME methods, this translates into poor desorption efficiency. Polymeric sorbents interact with 
analytes primarily through pi-pi interactions, although additional interactions are possible depending 
on the nature of functional groups introduced during polymer modification (for example, hydrogen 
bonding or ion-exchange). A variety of mixed-mode sorbents, both silica-based and polymer-based 
was included in the study because of the potential to extract a wide range of analytes, including both 
ionizable and neutral species. For mixed-mode anion-exchange sorbents, positively charged groups 
on the sorbent interact with negatively charged functional groups on the analytes, while hydrophobic 
interactions between hydrophobic portions of the molecule and hydrophobic portions of the sorbent 
can also occur. For mixed-mode cation-exchange sorbents, negatively charged groups of the sorbent 
interact with positively charged groups of the analytes. In the final stage of the study, the influence of 
pH on extraction capability was also evaluated to verify if it can further improve metabolite coverage. 
pH range selected for use in this study was 3.0, 5.0, 7.4 and 9.5. Higher and lower pH values were not 
examined as silica-based sorbents are not stable beyond this range.
197
  
5.1.2.1 Overview of LC-MS methods for metabolomics 
The majority of global metabolomics methods described in literature rely on a reverse-phase LC 
separation using C18 stationary phase.
12, 17, 26, 33, 38, 51, 54, 67, 124, 198-210
 Most of these reverse-phase 
methods with C18 columns rely on simple linear gradient of acetonitrile/water or methanol/water with 
formic or acetic acid used as the additive to help the ionization process. However, this is somewhat 
surprising as many metabolites are polar species which are not sufficiently retained on C18 columns. 
Thus, the observed trend may be indicative that insufficient attention is paid in some studies to the 
analytical method employed in the analysis. Despite the prevalence of C18 methods in literature, 
inadequate evidence exists that they are the best platform for global metabolomics. For example, 
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Bruce et al. compared the performance of C18, C8 and phenyl column for UHPLC-MS method for 
global metabolomics analysis of human plasma.
211
 They found that C18 and C8 columns performed 
better for separation of lipophilic components of plasma than phenyl column. However, C18 column 
exhibited carryover effects of lipophilic species and baseline drifts which could not be eliminated 
even with the use of extended gradient times, so C8 stationary phase was recommended as the best 
choice for metabolomic studies. In another study, Evans et al. proposed the use of two 
complementary mobile phase conditions (pH 3 for acidic analytes using positive ESI and pH 8 for 
basic analytes using negative ESI) in order to improve the coverage of acidic and basic analytes.
205
   
The use of ion-paring strategies in combination with LC-MS is usually avoided because these 
additives are often not sufficiently volatile and can cause significant ionization suppression and 
adduct formation. As such relatively few ion-paring methods have been reported for global 
metabolomic studies. For instance, Coulier et al. proposed the use of hexylamine as ion-pair agent for 
the analysis of nucleotides, coenzyme A esters, sugar nucleotides and sugar biphosphates.
70
 The 
optimized elution conditions using C18 column included both a pH gradient (pH 6.3 to pH 8.5) and ion 
pair reagent gradient (5 to 0 mM). The method was documented to have good inter- and intra-day 
precision. However, the use of ion pair gradient is unusual as the variation in the amount of ion pair 
reagent can cause differences in retention and poor reproducibility of retention times. Closer 
examination of the paper does in fact reveal that authors observed retention time variation of ~0.5 min 
over long run times (>1 day) and <0.1 min over 12-hr run time. Most global metabolomic studies 
require analysis times in excess of 24 hr, so this retention time drift makes the proposed method very 
problematic in terms of chromatographic alignment necessary during data processing stage. In a 
similar approach, Büscher et al. used tributylamine for the global metabolomics analysis of yeast cell 
extracts.
45
 However, considering the potential for ionization suppression and drifting retention times, 
ion pairing strategy was not explored in current research. This strategy seems to be more suitable for 
the analysis of well-defined targeted set of analytes with a particular objective. For example, Gu et al. 
proposed an ion pair strategy with perfluoroheptanoic acid for the analysis of twenty amino acids for 
large-scale screening of metabolic phenotypes and one of the advantages of this method was 
chromatographic resolution between isobaric species such as leucine and isoleucine.
212
  
A more promising method to increase metabolite coverage appears to be the use of hydrophilic 
interaction chromatography (HILIC). The main advantages reported in literature of HILIC versus 
reverse-phase methods include better retention of polar compounds such as sugars and phosphates 
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and improved analytical sensitivity when using MS detection due to the use of mobiles phases with 
high organic content. The main disadvantages include the need for long re-equilibration times when 
gradient elution is employed 
213
 which decreases overall sample throughput and poor retention of 
acidic compounds. The mechanism of HILIC separation mainly relies on the partitioning of analytes 
into hydrated layer existing on the surface of the stationary phase. Gradient elution in HILIC method 
begins with a mobile phase with low polarity and high organic content (such as acetonitrile), and 
analyte elution is achieved by increasing aqueous content of the mobile phase. Volatile buffer salts 
are used as additives to reduce any electrostatic interactions between analytes and stationary phase.
64
 
Several recent studies document the usefulness of HILIC in order to improve metabolite coverage in 
global metabolomic studies, similar to what is proposed in this chapter.
31, 213-215
  For example, 
Mohamed et al. used the combination of (i) reversed-phase method with C16 column embedded with 
sulfonamide group and (ii) HILIC methods to enhance the metabolite coverage.
215
 Kamleh et al. used 
Zic-HILIC column with formic acid/acetonitrile mobile phase and 32 min analysis time.
216
Jankevics 
et al. proposed the use of HILIC method with ammonium acetate 10 mM buffer/acetonitrile mobile 
phases
217
, while Cubbon et al. proposed the use of 5 mM ammonium acetate buffer/acetonitrile 
phases, with typical analysis times of 30 min.
64
 Chen et al. used the combination of C18 reversed-
phase method and HILIC method using unmodified silica.
214
 Their HILIC method using ultra-high 
pressure liquid chromatography (UHPLC) relied on a very slow gradient of 95 to 80% acetonitrile 
with run time of 35 min, whereas typical UHPLC analysis times are 10-15 min and rely on much 
steeper gradients.  The use of these two complementary LC-MS methods increased the information 
content of the acquired data. Using reversed-phase method, oxidation of fatty acids was detected as 
the important contribution for the differentiation between healthy and liver cancer patients. Using 
HILIC methods, improved separation of the groups was achieved and compounds related to arginine 
and proline metabolism, alanine and aspartate metabolism, lysine degradation, and nicotinamide 
metabolism were found to be significantly changed in the two populations. Two acylcarnitines were 
found as differentiating metabolites using both methods.  
In addition to reversed-phase and HILIC methods, the use of silica hydride stationary phases using 
aqueous normal phase chromatography has also been proposed for the analysis of polar metabolites.
53, 
218




5.2.1 Materials and coatings preparation 
For this evaluation, all SPME coatings suitable for direct extraction and commercially available from 
Supelco Inc. (Bellefonte, PA, USA) were included. These were polyacrylate coating (PA, 85 µm) , 
polydimethylsiloxane (PDMS, 100 µm) coating, polydimethylsiloxane/divinylbenzene coating 
(PDMS/DVB, 60 µm ) and Carbowax/template resin coating (CW/TPR, 50 µm). New prototype 
Supelco biocompatible coatings whose development and evaluation was discussed in Chapter 3 were 
also obtained as research samples and included in this evaluation: C18, RPA and cyano coatings (1.5 
cm coating length, 45 µm coating thickness, prepared using porous coated silica particles of 5 µm 
size). The remaining coatings were prepared by immobilization of commercially available SPE 
sorbents using Loctite adhesive on stainless steel wire of 1.55 mm diameter (0.061 inch, Small Parts 
Inc., Florida, USA) using optimized procedure described in Chapter 2 (coating length 1.5 cm). All 
sorbents utilized in this work were obtained as research samples in the format of SPE cartridges from 
their respective manufacturers as outlined in Table 5.1. Additional carbon tape coating, previously 
found to perform well for extraction of polar Ochratoxin A, was also prepared by the immobilization 
of one adhesive side of the tape on the stainless steel wire (coating length 12 mm).
152
  Self-adhesive 
carbon tape was obtained from TAAB Laboratories Equipment (Calleva Park, Reading, UK) with 
dimensions of 12 mm wide x 20 m long. 
All coatings were prepared in triplicate. Prior to each extraction, coatings were evaluated visually 
for uniformity of particle coverage. If any particle loss was noted, coatings were discarded and new 
coatings were prepared. The problem of particle loss occurred primarily for coatings with very large 
sorbent particles (>80 µm), and these coatings could be used only for 2-3 times prior to requiring 
replacement. The coating reusability and robustness were not the main concerns in current study, 
because the coating procedure would be changed to use biocompatible binder, smaller particle size 
and smaller solid support diameter after the most promising sorbents were isolated in current study.  
5.2.2 Materials and metabolite standard mixture preparation 
All metabolites and buffer reagents were obtained from Sigma-Aldrich (Oakville, Canada). All 
metabolites and their properties are listed in Table 5.2 and their structures are shown in Figure 5.1. 
Stock standard solutions were prepared in water/methanol/ethanol and diluted as appropriate. 
Protoporphyrin and β-carotene had poor solubility, so the stock solutions of these analytes were 
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prepared separately in acetonitrile and chloroform, respectively and spiked (100 µL) into combined 
stock standard solution. Stock standard solutions were kept frozen (-20°C), protected from light and 
were prepared fresh weekly. 
 Buffer solutions at pH 3.0, 5.0, 7.4 and 9.5 were prepared using formate, acetate, phosphate and 
carbonate salts and pH was verified to be within ±0.05 pH units experimentally. Sodium chloride (8 
g) was added to all buffers to keep ionic strength constant and close to physiological levels. For 
extraction, metabolite standard solutions were prepared at 1 µg/mL concentration level by dilution of 
stock standard in such a way to keep the organic content of all extraction standards at 1% organic 
solvent (v/v).  
For instrument calibration, working standard solutions with known concentration of metabolites were 
prepared by dilution of stock standard with desorption solvent. This calibration set was analyzed 
before and after each sample set and mid-level standard was also periodically analyzed as QC sample 
every 12 injections to ensure method and instrument stability. Sample batches could be run for 3-4 
days without interruption with QC standard showing RSD <20% over this time period for most 
analytes.  
5.2.3 SPME procedure 
All coatings were preconditioned in solution of methanol/water (1/1, v/v) for a minimum of 1 hr prior 
to extraction. All extractions were performed for 16 hr at room temperature with no agitation using 
1.5 mL sample volume contained in amber 2-mL HPLC glass vials. The desorption procedures 
differed depending on whether metabolites were analyzed using reverse phase or HILIC LC-MS 




Table 5.1 Summary of SPE sorbents and their properties.  









Clean Screen DAU UCT silica reverse phase+ SCX 
proprietary and benzenesulfonic 
acid 
40-63 NA NA 
Clean Screen GHB UCT silica proprietary mixed-mode NA NA NA 
SSBCX UCT silica SCX benzenesulfonic acid 40-63 NA NA 
C18+B UCT silica reverse phase+ SCX C18 and benzenesulfonic acid 40-63 NA NA 
C8+B UCT silica reverse phase+ SCX C8 and benzenesulfonic acid 40-63 NA NA 
RPA  Supelco silica reverse phase C16 with embedded amide  3 450 100 
HiSEP Supelco silica reverse phase 
surface modified with hydrophilic 
polymer 
5 NA 120 
PEG Supelco silica reverse phase polyethylene glycol 5 NA 120 
Discovery MCAX Supelco silica reverse phase+ SCX C8 and benzenesulfonic acid 50 480 70 
DPA 6S Supelco polymer 
adsorption of 
compounds containing -
OH and -COOH groups 
polyamide resin 50-120 NA NA 
Oasis MCX Waters polymer reverse phase + SCX 
N-vinylpyrrolidone divinyl 
benzene copolymer + sulfonic 
acid  
30 810 80 
Oasis WAX Waters polymer reverse phase + WAX 
N-vinylpyrrolidone divinyl 
benzene copolymer + piperazine 
30 810 80 
Oasis WCX Waters polymer reverse phase + WCX 
N-vinylpyrrolidone divinyl 
benzene copolymer + carboxylic 
acid 
30 810 80 
Oasis MAX Waters polymer reverse phase + SAX 
N-vinylpyrrolidone divinyl 
benzene copolymer + 
quartenary amine 




polymer reverse phase 
highly porous styrene 
divinylbenzene polymer 




polymer reverse phase 
hydrophobic styrene 
divinylbenzene polymer 
85 1000 55-60 
Carboxen-1016 Supelco carbon adsorption graphitized carbon, 60/80 mesh 177-250 NA NA 
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polymer reverse phase + WAX 
polar-modified styrene 
divinylbenzene polymer + 
unknown WAX  group 
80 650-700 50 
AccuCAT Varian silica SAX + SCX 
sulfonic acid and quartenary 
amine 




polymer reverse phase + WCX 
polar-modified styrene 
divinylbenzene polymer 
(carboxylic acid modification) 
NA NA NA 
Certify Varian silica reverse phase + SCX C8 and benzenesulfonic acid 40 NA 60 




silica reverse phase cyclohexyl 40 NA 60 
Focus Varian polymer normal + reverse phase 
polar-modified styrene 
divinylbenzene polymer 
NA NA NA 
Screen A Phenomenex silica reverse phase + SAX C8 55 500 70 
Screen C Phenomenex silica reverse phase + SCX C8 and benzenesulfonic acid 55 500 70 
Strata X Phenomenex polymer reverse phase 
surface modified styrene 
divinylbenzene polymer with 
pyrrolidone group 
33 800 85 
Strata XAW Phenomenex polymer reverse phase + WAX 
surface modified styrene 
divinylbenzene polymer + 
diamine group 
33 800 85 
Strata XCW Phenomenex polymer reverse phase + WCX 
surface modified styrene 
divinylbenzene polymer + 
carboxylic acid 
33 800 85 




silica reverse phase phenyl 40 NA 60 
Plexa Varian polymer reverse phase proprietary highly polar 
hydroxylated polymer 
NA NA NA 




Table 5.2 Physicochemical properties of metabolites included in standard metabolite mixture. 





3-hydroxybutyric acid (HBA) C4H8O3 104.1 4.41 -0.47 
Adenine C5H5N5 135.1 4.15 -0.09 
Adenosine C10H13N5O4 267.2 NA -1.05 
Adenosine diphosphate (ADP) C10H15N5O10P2 427.2 NA -2.64 
Adenosine monophosphate (AMP) C10H14N5O7P 347.2 NA -1.68 
Ascorbic acid C6H8O6 176.1 4.7 -1.85 
Adenosine triphosphate (ATP) C10H16N5O13P3 507.2 NA -3.61 
β-carotene C40H56 536.9 NA 17.62 
β-Estradiol C18H24O2 272.4 NA 4.01 
β-NAD C21H27N7O14P2 663.4 NA -3.68 
Cholic acid C24H40O5 408.6 4.98 2.02 
Choline C5H14NO
+
 104.1 NA -5.16 
Citric acid C6H8O7 192.1 2.79 -1.64 
Folic acid C19H19N7O6 441.4 NA -2.81 
Fructose C6H12O6 180.2 12.1 -1.55 
Fructose-6-phosphate C6H13O9P 262.2 NA -2.14 
Fumaric acid C4H4O4 116.1 3.03 0.46 
Glucose C6H12O6 180.2 12.9 -3.24 
Glucose 6-phosphate C6H13O9P 260.1 1.11 -3.79 
Glutamic acid C5H9NO4 147.1 2.23 -3.69 
Glutathione (oxidized) C20H32N6O12S2 612.6 NA -7.89 
Glutathione (reduced) C10H17N3O6S 307.3 NA -5.41 
Histamine C5H9N3 111.1 9.8 -0.7 
Histidine C6H9N3O2 155.2 2.76 -3.32 
Hydrocortisone (cortisol) C21H30O5 362.5 NA 1.61 
Linoleic acid C18H32O2 280.4 4.77 7.05 
Lysine C6H14N2O2 146.2 3.12 -3.05 
Maleic acid C4H4O4 116.1 1.83 -0.48 
Nicotinamide C6H6N2O 122.1 3.35 -0.37 
Phenylalanine C9H11NO2 165.2 1.24 -1.38 
Progesterone C21H30O2 314.5 NA 3.87 
Protoporphyrin IX C34H34N4O4 562.7 NA 7.43 
Pyruvic acid C3H4O3 88.1 2.45 -1.24 
Retinal C20H30O 286.5 NA 7.6 
Riboflavin C17H20N4O6 376.4 10.2 -1.46 
Ribose-5-phosphate C5H11O8P 230.1 NA -2.65 
Sucrose C12H22O11 342.3 12.6 -3.7 
Taurocholic acid C26H45NO7S 515.7 NA 0.01 
Thyroxine C15H11I4NO4 776.8 NA 4.12 
Tryptophan C11H12N2O2 204.2 7.38 -1.06 
Uridine diphosphate (UDP) C9H14N2O12P2 404.2 NA -3.12 







Figure 5.1 Structures of metabolites included in metabolite standard test mixture.  
 
 140 
Due to long LC-MS analysis times, coatings were sub-divided into several batches, and 
independent extractions were performed for metabolites amenable to reverse phase chromatography 
versus metabolites amenable to HILIC chromatography. This ensured that all samples would be 
analyzed within 48 hr of preparation to eliminate potential issues with analyte degradation while 
waiting for analysis. 
5.2.3.1 SPME desorption prior to reverse phase LC-MS (used for analytes of low to 
intermediate polarity) 
Fibres were desorbed immediately after extraction using 250 µL of desorption solvent (acetonitrile/ 
water, 1/9, v/v) for 120 min. Three additional desorptions (120 min each) were then performed using 
fresh 250 µL aliquots of acetonitrile/water (1/1, v/v) as the desorption solvent to ensure complete 
removal of all analytes for the comparison. All desorption steps were performed in 0.3 mL capacity 
amber polypropylene HPLC microvials. After desorption, vials were manually vortexed for a 
minimum of 1 min. Samples (20 µL) were injected directly using reverse phase LC-MS method 
described in Section 5.2.5.  
5.2.3.2 SPME desorption prior to HILIC LC-MS (used for polar analytes) 
Fibres were desorbed immediately after extraction using 250 µL of desorption solvent (acetonitrile/ 
water, 9/1, v/v) for 120 min. Three additional desorptions (120 min each) were then performed using 
fresh 300 µL aliquots of acetonitrile/water (3/2, v/v) as the desorption solvent to ensure complete 
removal of all analytes for the comparison. All desorption steps were performed in 0.3 mL capacity 
amber polypropylene HPLC microvials. Vials were manually vortexed for a minimum of 1 min. 
Samples (20 µL) were injected directly using reverse phase LC-MS method described in Section 
5.2.5.  
5.2.4 Calculation of correction factors to account for different coating dimensions 
To prepare coatings with commercial sorbents, particles of different size were immobilized because 
of limited commercial availability. Coating length and solid support core were kept constant at 15 
mm and 1.55 mm, respectively. However, to facilitate the comparison of different sorbent types, 
particle size needed to be taken into account. Furthermore, the coatings obtained from Supelco (both 
commercial and prototype) had different dimensions than lab-made coatings, so appropriate 
correction factors were needed to account for different dimensions of all fibres used in this 
comparison. Coating volume was estimated by simply treating all types of coatings as cylinders and 
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assuming the entire volume of immobilized phase could act as sorbent. Based on SEM results, it was 
determined that a single layer of sorbent particles was immobilized using the described procedure for 
lab-made coatings for all particle sizes ≥ 5 µm. Therefore, particle size was used as an approximation 
of coating thickness. However, particle size of 3 µm resulted in multiple layer coverage with 
estimated coating thickness of 10 µm, so this was used as coating thickness for this particular type of 
coating. In the next step, the volume of two cylinders was calculated: (i) the volume of fibre core 
cylinder only (radius = core diameter/2) and (ii) the volume of entire fibre (radius = fibre core 
diameter/2 + coating thickness). The volume of the coating is then determined by the subtraction of 
fibre core volume (i) from the total volume of entire fibre (ii). Full calculations for all types of 
coatings used in current study are shown in Table 5.3. For sorbents where a range of particle sizes 
was given, the mean size was used as coating thickness for volume estimation. For example, for HR-P 
sorbent where size was reported as 50-100 µm, the value of 75 µm was used to estimate the coating 
volume. Clearly, the correction factors shown in Table 5.3. are only approximate because  they 
assume (i) tight packing of spherical particles within the coating (ii) uniform size of all particles (iii) 
same extraction efficiency for sorbent and binder and (iv) do not take into account different surface 
areas and porosity of particles. Despite of this, the approximation is useful to give an estimate of how 
the performance of new coatings compares to existing coatings and to ensure coatings are not 
accidentally rejected simply based on different dimensions. Particle size information for Plexa, Plexa 
PCX and Focus sorbents from Varian and for Speed Advanta sorbent from Applied Separations could 
not be obtained as shown in Table 5.1 so no correction factor was applied to these coatings. This is in 
agreement with visual examination (< 50 µm), so 40 µm particle size appears to be a reasonable 
assumption for these coatings. Finally, no correction factor was applied for carbon tape coatings as 
the proportion of carbon was unknown. Therefore, the results for this coating are reported “as is”, 
whereas the results for all other coatings are reported with respect to performance of 40 µm particle 





































lab-made 213.5 1.5 1550 1977 988.5 775 4.60E+07 2.83E+07 1.77E+07 0.17 
lab-made 85 1.5 1550 1720 860 775 3.49E+07 2.83E+07 6.55E+06 0.46 
lab-made 80 1.5 1550 1710 855 775 3.44E+07 2.83E+07 6.14E+06 0.49 
lab-made 51 1.5 1550 1652 826 775 3.22E+07 2.83E+07 3.85E+06 0.78 
lab-made 55 1.5 1550 1660 830 775 3.25E+07 2.83E+07 4.16E+06 0.72 
lab-made 75 1.5 1550 1700 850 775 3.40E+07 2.83E+07 5.74E+06 0.52 
lab-made 40 1.5 1550 1630 815 775 3.13E+07 2.83E+07 3.00E+06 1.00 
lab-made 45 1.5 1550 1640 820 775 3.17E+07 2.83E+07 3.38E+06 0.89 
RPA 3 µm 10 1.5 1550 1570 785 775 2.90E+07 2.83E+07 7.35E+05 4.08 
lab-made 5 1.5 1550 1560 780 775 2.87E+07 2.83E+07 3.66E+05 8.18 
lab-made 33 1.5 1550 1616 808 775 3.08E+07 2.83E+07 2.46E+06 1.22 
lab-made 30 1.5 1550 1610 805 775 3.05E+07 2.83E+07 2.23E+06 1.34 
lab-made 50 1.5 1550 1650 825 775 3.21E+07 2.83E+07 3.77E+06 0.80 
CW TPR 50 1.0 160 260 130 80 5.31E+05 2.01E+05 3.30E+05 9.09 
biocompatible 
prototypes 
45 1.5 200 290 145 100 9.91E+05 4.71E+05 5.20E+05 5.77 
PA 85 1.0 160 330 165 80 8.55E+05 2.01E+05 6.54E+05 4.58 
PDMS 100 1.0 160 360 180 80 1.02E+06 2.01E+05 8.17E+05 3.67 




5.2.5 LC-MS analysis 
All samples were analyzed according to one of the two optimized LC methods described in Table 5.4 
using LC-MS system consisting of Varian pumps (212-LC), Prostar 430 Autosampler and 500-MS 
ion trap mass spectrometer using positive electrospray ionization (ESI) mode unless otherwise 
specified. While waiting for analysis, samples were stored refrigerated at 4°C in the lab refrigerator in 
order not to exceed 12 hr storage on autosampler tray at room temperature (no cooling option 
available on autosampler).  The analysis of metabolite standard mixture of known concentrations was 
performed at the beginning, end and throughout each sample batch, and was used for quality control 
and calibration purposes. An example chromatogram of metabolite standard analyzed using reverse 
phase PFP method is shown in Figure 5.2. 
Table 5.4 Summary of optimized LC-MS parameters 
LC parameter Reverse phase LC method  HILIC LC method 
Analytical column HS F5 Pentafluorophenyl (Supelco) Ascentis Si (Supelco) 
Column dimensions 2.1 x 10 mm 2.1 x 10 mm 
Particle size 3 µm 3 µm 
Mobile phase A 
Water/acetic acid (99.9/0.1, v/v) ammonium formate/acetonitrile 
(5/95, 2 mM total) 




(40/60, 2 mM total) 
Flow rate 200 µL/min 200 µL/min 
Injection volume 20 µL 20 µL 
Run time 35 min 30 min 
Gradient program 
0-3 min 100% A, 3-20 min linear 
gradient to 10%A, 20-30 min hold at 
10% A, 5 min re-equilibration at 
100% A 
0-2 min 100% A, 2-14 min linear 
gradient to 65%A, 14-18 min hold at 
65% A, 12 min re-equilibration at 
100% A 
Nebulizer pressure 60 psi 60 psi 
Drying gas pressure 22 psi 22 psi 




Figure 5.2 Example chromatogram using reverse phase pentafluorophenyl LC-MS method.   
Optimum MS parameters for each analyte were initially determined using direct introduction of 1 
µg/mL single component standard solution into mass spectrometer. These optimum parameters are 
summarized in Table 5.5,Table 5.6 and Table 5.7. Using this data, general parameters for full scan 
methods were set by selecting the parameters that will provide the best performance across the range 
of analytes. The following settings were used based on the data presented in tables. Using positive 
ESI for analytes with MW<500, needle, capillary and RF voltage were set to 6000 V, 45V and 60V 
respectively in full scan mode. Using positive ESI for analytes with MW>500, needle, capillary and 
RF voltage were set to 6000 V, 80V and 80V respectively in full scan mode. Using negative ESI for 
analytes with MW<500, needle, capillary and RF voltage were set to 5000 V, 45V and 60V 
respectively in full scan mode. Furthermore, it was decided to run the methods using two scan ranges: 
m/z 100-500 and m/z 500-1000 because the optimum parameters differed greatly for low MW species 
versus high MW species and good sensitivity could not be achieved simultaneously for all 
compounds regardless of MW. However, despite the extensive optimization, analytical sensitivity for 
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some analytes was very poor (analytes for which optimum voltages deviated from set voltages had 
extremely poor sensitivity indicating ion transmission was very sensitive to selected parameters) as 
determined during preliminary column evaluation experiments, so MS/MS mode with optimized 
capillary and RF voltage parameters for each analyte was used during coating evaluation experiments. 
This minimized the number of analytes that could be successfully monitored during each analysis 
because of slow acquisition rates in MS/MS mode which permitted monitoring of 4-5 analytes per 
each retention time window with adequate number of data points across peak.  
Table 5.5 Optimization of MS parameters (a) needle voltage, (b) capillary voltage and (c) RF 






RF voltage range 
(V) 
3-hydroxybutyric acid 4800 85 100 40 55 
Cholic acid 6000 50 110 55 65 
Glucose-1-phosphate 5250 100 120 65 72 
Folic acid 5200 75 160 63 70 
Glucose 5230 30 60 50 60 
Hydrocortisone 5577 30 60 85 100 
Estradiol (β) 6000 30 80 70 85 
Histidine 4300 30 50 50 65 
Progesterone 6000 60 72 80 90 
Adenine 6000 55 65 50 60 
Riboflavin 6000 40 90 85 100 
Phenylalanine 6000 20 50 55 65 
Glutamic acid 6000 20 45 50 60 
Histamine 6000 30 50 45 55 
Tryptophan 6000 30 50 60 75 
Lysine 6000 20 45 50 60 
Nicotinamide 6000 40 70 48 55 
Choline 6000 30 60 45 55 
β-NAD 5200 75 90 77 85 
Retinol 6000 65 75 77 85 
Adenosine 2800 40 60 70 80 
Sucrose 6000 50 90 85 95 
Maleic acid 5500 20 60 50 85 
Pyruvate 6000 20 60 48 65 
ADP 6000 25 80 60 70 
AMP 6000 30 70 85 95 
Fumarate 6000 50 150 60 70 
Glutathione reduced 4300 40 60 80 95 
Ribose 5-phosphate 6000 40 100 75 85 
Fructose 6-phosphate 4500 40 80 80 92 
Glucose-6-phosphate 6000 30 75 75 90 
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Table 5.6 Optimization of MS parameters (a) needle voltage, (b) capillary voltage and (c) RF 






RF voltage range 
(V) 
Citric acid 5000 40 60 40 60 
Ascorbic acid 4700 20 40 40 60 
3-hydroxybutyric acid 6000 20 35 35 60 
Cholic acid 6000 140 200 45 55 
Folic acid 6000 40 60 50 60 
Glucose-1-phosphate 5250 30 60 60 100 
Linoleic acid 6000 75 100 120 140 
UDP 6000 20 70 45 55 
Folic acid 5500 70 90 68 75 
Glucose 6000 20 40 50 60 
Estradiol (β) 6000 80 150 140 160 
Adenine 6000 40 60 90 110 
Riboflavin 4000 40 80 70 80 
D-phenylalanine 6000 30 60 45 100 
Glutamic acid 5000 25 55 40 75 
Tryptophan 4000 40 70 40 70 
Lysine 5000 40 60 75 85 
Pyruvate 6000 20 40 115 128 
ADP 4500 40 90 65 80 
AMP 4000 40 80 95 110 
Maleic acid 6000 20 40 55 65 
Fumarate 6000 15 35 60 75 
Glutathione reduced 3800 45 55 90 100 
Ribose 5-phosphate 5000 30 50 80 90 
Fructose 6-phosphate 5000 25 50 80 95 
Glucose-6-phosphate 4500 20 70 82 95 
 
Table 5.7 Optimization of MS parameters (a) needle voltage, (b) capillary voltage and (c) RF 






RF voltage range 
(V) 
ATP 6000 60 80 60 75 
Taurocholic acid 4600 100 220 70 78 
Beta-NAD 5200 75 90 77 85 
Protoporphyrin IX 6000 80 180 70 80 
UDPG 3900 75 110 70 90 
Beta-CAROTENE 6000 70 110 70 80 
Glutathione oxidized 6000 80 120 75 90 




5.3  Results and discussion 
5.3.1 Development of pentafluorophenyl (PFP) reverse-phase method 
In initial work, the performance of reverse phase methods with C18, C16 amide (RPA) and 
pentafluorophenyl (PFP) stationary phases was evaluated for their ability to retain metabolites within 
standard metabolite mixture.  Alkyl stationary phases with embedded polar groups such as C16 amide 
used in this evaluation, tend to improve retention of some poorly retained compounds on C18 column 
and have improved wettability which allows their use in 100% aqueous mobile phases without alkyl 
chain collapse which is observed with traditional C18 columns.
218
 PFP column was incorporated in 
this evaluation because it relies on different retention mechanism versus those employed for alkyl 
stationary phases. Among the columns tested, PFP column provided the best retention for the largest 
number of metabolites tested. PFP column was able to adequately retain 22 analytes with one analyte 
exhibiting unacceptable peak shape. In comparison, C18 column was able to retain 13 analytes among 
which three had unacceptable peak shape. Overall, RPA column had very similar performance to C18 
column and did not sufficiently retain more polar analytes. Examples of retained analytes on PFP 
column which were not well-retained on C18 column included adenine, adenosine, lysine, histidine, 
nicotinamide, phenylalanine and histamine (Figure 5.2). Excellent performance of PFP column versus 
typical C18 column is attributed to the ability to use 100% aqueous phase and to the different retention 
mechanism of PFP column that is more likely to incorporate some aromatic interactions. These results 
are in agreement with recent report in literature, where a comparison of C18 versus PFP columns for 
LC-MS metabolomics of food also showed superior performance of PFP column to retain more polar 
metabolites.
219
  This improved metabolite coverage subsequently resulted in better class separation of 
fermentation samples during statistical analysis, and is therefore highly important for global 
metabolomic studies.  
5.3.2 Evaluation of extraction reproducibility 
To ensure the comparison of coatings was meaningful, the reproducibility of extractions using n=3 
fibres of all types for all metabolites was regularly documented. Example results for pH 7.4 extraction 
followed by reverse-phase LC analysis are shown in Figure 5.3 (a) with average RSD of 8% for all 
coatings and metabolites tested within this set.  The RSD for glutamic acid is higher than for other 
compounds because the extraction capacity is poor so the signal intensity is close to LOQ of this 
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compound. Figure 5.3 (b) shows the results for pH 9.5 extraction followed by HILIC analysis with 




Figure 5.3 Example of extraction reproducibility (a) at extraction pH of 7.4 and analysis using 
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Figure 5.4 Comparison of the extraction efficiency of all sorbents for the extraction of 12 
selected metabolites at pH 7.4 analyzed using PFP reverse phase method. 



























































Figure 5.5 Comparison of the extraction efficiency of all sorbents for the extraction of seven 
selected metabolites at pH 7.4 analyzed using HILIC method. 






















































5.3.3 Comparison of extraction efficiency of various sorbents at pH 7.4 
The performance of various sorbents was compared for the extraction from PBS buffer at 
physiological pH. The results of these studies are summarized in Figure 5.4 for the metabolites 
analyzed using reverse-phase method and in Figure 5.5 for the analytes analyzed using HILIC 
method. Several trends are easily apparent. Commercial coatings performed extremely poorly for the 
extraction of polar metabolites, and the data clearly demonstrates why coating development was 
necessary. Mixed-mode coatings significantly improve the extraction of polar species, while 
polymeric polystyrene divinylbenzene sorbents with and without modification (for example, Easy and 
HRP from Macherey Nagel and Advanta from Applied Separations) perform even better than mixed-
mode coatings of any type. A third type of coating that performed very well is phenylboronic acid 
(PBA) coating. PBA forms reversible covalent interaction with compounds containing 1,2- or 1,3-
diols. Many compounds of biological interest contain this functionality, so it is not surprising PBA 
coating performed so well for the analysis of these type of metabolites. Most stable binding is 
observed at alkaline pH, but in our study good results were observed at physiological pH as well. To 
disrupt the binding, it is necessary to include acid in the desorption solvent and in current study 1% 
formic acid was added to the desorption solvent for this purpose. 
Figure 5.6 shows in more detail the performance of six selected coatings including commercial 
CW-TPR and prototype RPA coating discussed in Chapter 3. The results clearly illustrate that mixed-
mode, PS-DVB and PBA coatings show better and more balanced performance across the wide 
polarity range which makes them more suitable for global metabolomic studies. Figure 5.7 shows the 
extraction performance of all sorbents for several selected metabolites of varying MW and polarity to 
further illustrate the described trends. The examination of all data for all analytes showed that the 
extraction of very polar species (log P< -2) is typically very poor for all coatings. The only exception 
to this trend is if the said polar analyte can be extracted by PBA coating (for example, β-NAD in  
Figure 5.7). 
5.3.4 Dependence of extraction efficiency on pH 
The results of extraction performed at pH 9.5 for all sorbents are included in Figure 5.8 and show 
very similar trends to what was observed at pH 7.4. Similar trends were observed for pH 3.0 and 5.0. 
The dependence of extraction efficiency on pH is shown for selected metabolites for three most 
promising coating types in Figure 5.9. The results show that generally physiological pH works well 








































































































































Figure 5.6 Comparison of extraction efficiency of CW-TPR, HRP, FOCUS, PBA,C8+B and 

































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.7 Extraction efficiency of selected individual metabolites (histidine, phenylalanine, 


























































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.8 Comparison of the extraction efficiency of all sorbents for the extraction of 12 
selected metabolites at pH 9.5 analyzed using PFP reverse phase method. 




















































































































Figure 5.9 Dependence of the extraction efficiency of selected metabolites on pH using (a) PBA 
coating (b) mixed-mode C8+B coating and (c) HRP coating. 
Table 5.8 Dependence of the extraction efficiency of Waters Oasis MAX, MCX, WAX and 
WCX coatings on sample pH. 
pH Coating type ADP AMP ATP Beta NAD HBA Sucrose 
pH 3.0 
 
WAT MAX ND 0.01 ND 0.13 23 0.54 
WAT MCX ND 0.04 ND 0.38 32 0.55 
WAT WAX ND 0.01 ND 0.15 24 0.48 
WAT WCX ND 0.01 ND 0.15 30 0.53 
pH 5.0 
 
WAT MAX ND 0.19 ND ND 39 0.22 
WAT MCX 0.03 0.16 ND ND 35 0.30 
WAT WAX ND 0.19 ND ND 48 0.28 
WAT WCX ND 0.15 ND ND 49 0.29 
pH 7.4 
 
WAT MAX ND 0.15 ND 1.1 27 0.31 
WAT MCX 0.05 0.12 ND 0.72 29 0.26 
WAT WAX ND 0.21 ND 0.86 39 0.29 
WAT WCX 0.02 0.13 ND 0.64 33 0.32 
pH 9.5 
 
WAT MAX 0.05 0.32 ND 8.7 2.2 0.78 
WAT MCX 0.09 0.27 0.05 2.8 2.5 0.41 
WAT WAX 0.17 0.74 ND 7.5 0.78 0.91 
WAT WCX 0.31 0.62 0.15 5.8 1.4 0.87 
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adjustment step within the global metabolomics workflow. Interestingly, the results of different types 
of mixed-mode coatings (SCX, SAX, WCX, WAX) also do not show strong dependence on pH 
(Table 5.8).  
5.3.5 Summary of coating selection and performance 
Figure 5.10 compares the performance of three best types of coatings identified in this study: (i) 
mixed-mode coating (C18 or C8 with benzenesulfonic acid from any manufacturer), (ii) polystyrene-
divinylbenzene polymeric coatings (HR-P, EASY or Advanta) and (iii) PBA coating. The ability to 
extract basic, neutral and acidic compound simultaneously at physiological pH without pH adjustment 
using modified and non-modified polystyrene-divinylbenzene was also shown in other studies for the 
extraction of pharmaceuticals from aqueous samples using solid-phase extraction.
220
 In this 
comparison, Chromabond EASY showed better performance for majority of analytes (log P range  
 
Figure 5.10 Comparison of three most promising types of coatings for global metabolomic 
studies for the extraction of representative metabolites at pH 7.4: mixed mode coating, 
polystyrene divinylbenzene polymer and PBA coating. For mixed mode coating, experimental 
results for C8 with benzenesulfonic acid coating from UCT is shown as example. For 
polystyrene divinylbenzene polymer coating, the results for HRP coating from Macherey Nagel 
are shown. Correction factor to account for differences in particle size was applied as discussed 
in text to facilitate the comparison between various coatings. The metabolites are arranged in 
the order of decreasing polarity (increasing log P value) from left to right to illustrate any 
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tested -1.3 to 4.1) versus HR-P sorbent, but Oasis HLB sorbent showed the best overall performance 
and was selected for further use. This sorbent is similar to Oasis sorbents included in current 
comparison, but without addition of an ion-exchange group. Low recoveries were observed for acidic 
compounds using EASY and HR-P sorbents but this was attributed to poor desorption efficiency due 
to the use of unoptimized elution protocol, and recoveries were improved with subsequent elution 
steps. Recoveries for acidic compounds have been reported to be lower using Easy sorbent than 
hydrophobic sorbents such as Chromabond HR-P.
195
 For EASY sorbent, the effect of preconditioning 
was previously evaluated. Addition of preconditioning step was important for acidic species, while 




Phenylboronate resins and phenylboronic acid sorbents were previously successfully used for 
targeted metabolomics analysis of urinary nucleosides due to selective binding of cis-diol groups 
available on ribose sugar group under basic conditions.
221
 However, for the latter sorbent type, 
selectivity for cis-diol groups can be modified by using aprotic conditions which enables the 
extraction of Lewis base containing compounds, especially amino species. Their data indicates 
suitability of phenylboronic sorbents for more generic screens, similar to results obtained in our 
study. However, our results were not obtained under aprotic conditions so a further study of the 
mechanism involved would be interesting for the compounds not expected to bind to phenylboronic 
acid. 
In another study focused on developing SPE method for metabolomics analysis of urine by NMR, 
the authors propose the use of two SPE cartridge system C18 and Hysphere strong hydrophobic 
polystyrene divinylbenzene resin.
56
 In this method, hydrophobic species are trapped on C18 cartridge, 
while non-retained polar species are subsequently trapped on Hysphere polystyrene-divinylbenzene 
sorbent, results which are in good agreement with our findings.  In contrast to our study, these authors 
recommend extraction at pH 3. Among 72 observed metabolites, 28 were retained on C18, 23 on PS-
DVB, and 21 metabolites were retained by both types of sorbent. Overall the use of SPE methodology 
was found to work well and allowed identification of various amino acids, organic acids, osmolytes, 
polyols, methylamines, saturated and unsaturated fatty acids and their derivatives, aromatic 




In this study, the coatings suitable for the simultaneous extraction of polar and hydrophobic species at 
physiological pH were identified. The results indicate that good metabolite coverage can be achieved 
using these new coatings, and this was explored further for the extraction of human plasma reported 
in Chapter 6. In preparation for in vivo global metabolomic studies it is important to produce the 
identified best coatings in biocompatible format. On the basis of this research, Supelco produced 
biocompatible prototype mixed-mode coatings using the same procedure they developed for C18 and 
RPA coatings as described in Chapter 3. The production of polar-modified PS-DVB and PBA 
coatings in biocompatible format is currently under development. Some of the preliminary results of 
this study indicate the coating coverage with the biocompatible layer can have some impact on the 
extraction efficiency of polar species in particular (for example, comparing the results of RPA 3 µm 
versus RPA Supelco). This could be a potential further area of study to select a biocompatible 




Development and evaluation of global SPME-LC-MS metabolomics 
methods on benchtop Orbitrap instrument 
6.1 Preamble and introduction 
6.1.1 Preamble 
This work has not yet been published. Biocompatible mixed-mode prototype coatings were obtained 
as research samples from Supelco on the basis of the findings reported in Chapter 5. These new 
coatings were prepared using the same semi-automated batch coating procedures previously described 
in Chapter 3. I am the sole author of all other experimental work reported herein.  
6.1.2 Introduction: metabolomics and high-resolution mass spectrometry 









17, 51, 208, 214, 215, 223
, Orbitrap
36, 216, 224
 and Fourier transform ion cyclotron resonance 
(FTICR)
38, 39, 205
 instrument. Instruments with low mass resolution (quadrupole and ion trap) are not 
ideally suited for this type of analysis, as many metabolites can have exactly the same nominal mass. 
Considering the complexity of LC chromatograms it is not feasible to assume that chromatographic 
resolution is sufficient to separate all possible metabolites with the same nominal mass.  As such the 
use of higher mass resolution instrument such as TOF, Orbitrap and ICR is preferred as it can resolve 
peaks with the same nominal mass in mass dimension, and provide very accurate metabolite mass and 
isotope ratio information which can aid in tentative identification by assigning or narrowing down the 
possible chemical formulas that could give rise to this mass. Among these instruments, TOF and 
QTOF type of instruments have the advantage of very fast data acquisition times, while the resolution 
achievable is approximately 10,000-20,000 depending on the exact instrument design.  Orbitrap 
instruments can have resolution up to 100,000, but data acquisition speeds are lower than for TOF 
instruments. ICR instruments offer the highest mass resolution (up to 1,000,000), but data acquisition 
speeds are lower and they can be difficult to couple with LC methods and often require use of nano-
LC.
38
 With the improvement of the duty cycles of triple quadrupole instruments, they can also be used 
for targeted monitoring of selected metabolites with high sensitivity and specificity, but the main 
disadvantages of this approach are that only a finite number of transitions can be monitored. This 
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means that the data on only selected metabolites are collected, thus losing the advantage of global 
metabolomics methods. 
In current work, new type of bencthop Orbitrap instrument (Exactive, Thermo Fisher, San Jose, 
CA, USA) was employed and the metabolomics methods previously reported in Chapter 5 using ion 
trap instrument, were transferred onto this high resolution instrument. The main reason for the change 
in platforms was an increased mass resolution (100,000), improved mass accuracy (<5 ppm for most 
compounds with external calibration), improved sensitivity and ability to use higher LC flow rates 
versus ion trap instrument due to better design of ESI source. In addition to the collection of full scan 
high-resolution data, the use of this instrument was also reported to enable simultaneous quantitative 
analysis of selected analytes by isolation of narrow mass windows around monoisotopic m/z of 
interest.
225
 The isolation of such narrow mass windows eliminates significant amount of noise and 
permits quantitation with similar figures of merit to what has traditionally been obtained on triple-
quadrupole instruments.  
In Exactive, which is the benchtop single stage MS used in current study,  the ions are transferred 
from ion source to heated capillary to tube lens to skimmer to RF lens to lens L0 through analyzer ion 
optics in order to reach the C-trap. The ions are then accumulated in C-trap, their energy is dampened 
using nitrogen gas and they are then injected in a short burst into Orbitrap. The main operating 
principle of Orbitrap detector involves trapping of ions in an electric field around a central spindle-
shaped electrode.
226
 The movement of ions induces an image current on the outer barrel-like 
electrode, and m/z of ions is determined based on their oscillation frequency after performing Fourier 
transformation. The resolution of the analysis is determined by the length of oscillating time, and 
maximum resolution achievable is 100,000 at full width half-maximum of reference m/z of 200. This 
means that higher resolution is typically achievable for masses lower than m/z<200 and lower 
resolution is achievable for m/z>200.
227
 
6.1.3 Strategies for improving metabolite coverage in LC-MS metabolomics 
The main strategies reported to date in order to improve metabolite coverage in global 
metabolomics methods by LC-MS include: using both positive and negative electrospray ionization 
modes, use of complementary LC methods relying on different separation mechanisms (see Chapter 
5), use of different ionization sources (atmospheric pressure chemical ionization, atmospheric 
pressure photoionization) and the use of ultra-high performance liquid chromatography  (UHPLC) or 
capillary liquid-chromatography with nanospray ionization.
30, 31, 55, 205, 228
  Capillary methods are 
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ideally suited for coupling with ESI because of slow flow rates, and have been demonstrated to 
improve metabolite coverage. However, run times for these methods can be very long, for example 
60-min run time was used in a recent study with 25-min wash step between each injection, for a total 
run time of 85 min/sample using only a single ionization mode
67
, although run times as long as 2000 
min/sample have also been reported
31
. This low throughput is a major disadvantage for large-scale 
metabolomic studies, so the use of capillary methods is currently not widespread.  Previous studies 
comparing the performance of HPLC (LC performed on columns with particles with 3-10 µm size) 
versus ultra-high performance liquid chromatography UHPLC (LC performed on columns with sub 2 
µm particle size) showed improved performance of UHPLC methods in terms of sample throughput, 
analytical sensitivity and metabolite coverage.
30, 205
 For example, Evans et al. were able to reduce run 
time form 32 min to 12 min per sample by switching from HPLC to UHPLC, while obtaining 
narrower chromatographic peaks (increased peak height translates into increased analytical 
sensitivity) and improved chromatographic resolution due to the decrease in particle size.
 197
 
However, these studies were performed on TOF MS instrument or linear ion trap instruments capable 
of high acquisition rates. In our study, although Accela U-HPLC system is capable of operating under 
both HPLC and UHPLC conditions, HPLC mode was selected in order to ensure sufficient number of 
data points can be obtained across chromatographic peak using Exactive scan rates of 1 Hz at 
maximum 100,000 resolution. Bateman et al. previously demonstrated that at 1 Hz data acquisition 
rate, too few data points are collected when coupling UHPLC with Exactive Orbitrap instrument.
199, 
225
 The selection of HPLC versus UHPLC in current study means that longer analysis times were 
required and that some analytical sensitivity and metabolite coverage may have been lost in 
comparison to UHPLC methods. However, this choice was made to ensure good method precision 
and sufficient number of points across the peak to permit semi-quantitative differential analysis of the 
obtained profiles.  
Finally, fast polarity switching is available on Exactive instrument (1 second switch between 
positive and negative ionization modes) and although successful use of this type of feature was 
reported
26, 44
, this feature was not utilized in current work because it is impossible to find ion 
transmission conditions which will simultaneously give stable electrospray in both positive and 
negative mode. Also, polarity switching would further reduce the number of points across the peak, 
which could worsen overall method precision even further for some peaks.    Data quality was 
deemed more important than sample throughput, so all samples were analyzed separately in positive 
and negative ionization modes using each of proposed LC-MS methods. The importance of 
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performing analysis in both positive and negative ESI modes was demonstrated using recent 
metabolomics study on human serum, where the use of negative ESI was found to increase metabolite 
coverage by >90%.
124, 228
 The use of APCI in positive mode, MALDI and desorption ionization on 
silicon (DIOS) mass spectrometry further enhanced metabolite coverage but the gains in metabolite 
coverage over electrospray methods were more modest (~20%).  However, the cited study was 
performed using low resolution MS, giving rise to possibility of incorrect ion assignments, so the 
number of unique ions may be somewhat underestimated for each method. 
The main objectives of the research presented in this chapter were to set-up and evaluate the 
performance of reverse-phase and HILIC LC-MS methods on Exactive with the goal of developing 
very robust methods with optimum analytical sensitivity. Furthermore, mixed-mode coating identified 
in Chapter 5 and subsequently produced by Supelco in the biocompatible format and housed within 
an in vivo device such as described in Chapter 3 was evaluated for the extraction of selected 
metabolites in human plasma, with particular focus being paid to parameters such as ionization 
suppression, extraction time and analyte carryover. Prior to their use in metabolomic studies as 
described below, the extraction efficiency of these new Supelco biocompatible coatings was 
evaluated using targeted extraction of benzodiazepines according to the procedures described in 
Section 3.3.10. The inter-fibre reproducibility was found to be <5% RSD before proceeding with the 
metabolomics applications. 
6.2 Experimental 
6.2.1 Materials and reagents 
All reagents used for mobile phase preparation were of LC-MS grade. LC-MS grade solvents and LC-
MS grade formic acid (1 mL glass ampoules) were obtained from Fisher Scientific. LC-MS grade 
salts were obtained from Sigma-Aldrich (Oakville, Canada).  
6.2.2 LC-MS analysis 
LC analysis was performed using Accela U-HPLC system and Accela autosampler (Thermo 
Scientific, San Jose, CA, USA). Injection volume for all analyses was 10 µL. Autosampler trays were 
cooled to 4°C.  
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6.2.2.1 Reverse-phase LC method using pentafluorophenyl stationary phase 
Chromatographic separation was performed using Discovery HS F5 column, 2.1 x 100 mm, 3 µm 
particle size (Supelco, Bellefonte, PA, USA) using method previously described in Chapter 5. Guard 
column with same stationary phase and dimensions of 2.1 mm x 20 mm was used to extend column 
lifetime. Flow rate was 300 µL/min. Mobile phase A consisted of water/formic acid (99.9/0.1, v/v) 
and mobile phase B consisted of acetonitrile/formic acid (99.9/0.1, v/v). The gradient conditions 
employed for the analysis were 100% A from 0 to 3.0 min, linear gradient to 10% A from 3.0 to 25.0 
min and isocratic hold at 10% A until 34.0 min. The column was re-equilibrated to starting mobile 
phase conditions for 6 min, for a total run time of 40 min per sample.  
6.2.2.2 HILIC LC method using aminopropyl stationary phase 
Bajad et al. compared the performance of different reverse-phase and HILIC methods for their ability 
to retain water-soluble cellular metabolites.
222
 Based on the results of this study, amino column, pH 9 
and 50 min total analysis time were identified as the best chromatographic conditions to analyze 
highly polar water-soluble species. In current work, similar conditions were found to work the best 
after comparison of mobile phases pH 3, 7 and 9.  In comparison to literature method, the run time in 
current work was shortened to 30 min, and salt concentration decreased to 2 mM to avoid ionization 
suppression and improve analytical sensitivity. The LC column used for this separation was 
Nucleodur 100-5 NH2 RP, 2 mm x 250 mm column from Macherey Nagel (Duren, Germany). 
Gradient elution was used with total flow rate of 500 µL/min. The composition of mobile phases A 
and B was ammonium formate-hydroxide buffer, pH 9.0/acetonitrile with proportions of 9/1 (v/v) and 
1/9 (v/v), respectively. The total concentration of buffer was kept at 2 mM. The gradient program 
used was 100% B from 0 to 3.0 min, linear change to 100% A from 3.0 to 8.0 min and hold at 100% 
A until 22.9 min. The column was re-equilibrated to starting conditions for 7.0 min prior to next 
injection, thus making the total run time of 30 min per sample. 
6.2.2.3 HILIC LC method using underivatized silica stationary phase 
The LC column used for this separation was Luna HILIC Si, 2 mm x 100 mm column with 3 µm 
particle size obtained from Phenomenex (Torrance, CA, USA). Analytical column was protected 
using a guard column with same stationary phase and dimensions of 4 mm x 2 mm obtained from the 
same manufacturer. Total flow rate was 400 µL/min. Mobile phase A consisted of 
acetonitrile/ammonium acetate buffer (9/1, v/v, effective salt concentration 20 mM) and mobile phase 
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B consisted of acetonitrile/ammonium acetate buffer  (1/1, v/v, effective salt concentration 20 mM). 
Starting mobile phase composition was 100% A held for 3.0 min, with linear ramp to 100% B in 5 
min, followed by a 4-min hold at 100% B. The column was re-equilibrated for 8 min prior to next 
injection, thus making the total run time of 20 min per sample. 
6.2.2.4 Summary of optimized MS conditions for all LC methods 
MS analysis was performed on Exactive benchtop Orbitrap instrument (Thermo Scientific, San Jose, 
CA, USA). Only one literature report to date utilized this second-generation Orbitrap instrument for 
metabolomics/lipidomics studies and the authors do not adequately describe how they selected MS 
parameters for analysis (capillary voltage 51 V, spray voltage 4.2 kV).
199
 Thus, in current study, 
various parameters were systematically investigated as discussed in Sections 6.3.3 to 6.3.5 in order to 
ensure suitable full scan parameters were used for the analysis. Based on these results, optimized MS 
parameters for each method employed are summarized in Table 6.1. The stability of proposed ESI 
conditions was verified by monitoring spray current and ensuring it was stable at all mobile phase 
conditions and  <1 µA for reverse-phase methods and <5 µA for all HILIC methods. All experiments 
were performed at maximum resolution (100,000 resolution, 1 Hz data acquisition) with AGC target 
set to Balanced (1,000,000 ions). In positive mode, scan range was m/z 100 -1000 for both reverse-
phase and HILIC methods. In negative mode, m/z scan range was 80-1000 for reverse-phase and 
HILIC method using amino column. For HILIC method using  underivatized Si column, the scan 
range was reduced to m/z of 125-1000 in order to eliminate the influence of  large intensity m/z 117 
background  ion.  




























PFP Positive 40 25 4.0 27.5 275 100 100 
PFP Negative 50 25 -2.7 -67.5 325 -85 100 
Amino Negative 50 25 -2.5 -55 275 -110 100 
Si Positive 60 30 2.8 90 325 155 250 
Si Negative 50 25 -2.5 -55 275 -110 250 
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6.2.3 Data processing 
Known metabolites were processed using Xcalibur software version 2.1 (Thermo Fisher) by 
extraction of theoretical monoisotopic mass with 5 ppm (for positive ESI) and 10 ppm (for negative 
ESI) window tolerance and subsequent integration of the resulting extracted ion chromatograms. 
Mass accuracy of the measurement is defined as the ratio of mass error (difference between 
experimentally measured mass and true mass of given analyte) and the theoretical mass, and can be 
calculated using Equation 6.1. 
𝒎𝒂𝒔𝒔 𝒂𝒄𝒄𝒖𝒓𝒂𝒄𝒚  𝒑𝒑𝒎 =
𝒎𝒆𝒙𝒑𝒕𝒍−𝒎𝒕𝒉𝒆𝒐𝒓𝒆𝒕𝒊𝒄𝒂𝒍
𝒎𝒕𝒉𝒆𝒐𝒓𝒆𝒕𝒊𝒄𝒂𝒍
× 𝟏𝟎𝟎𝟎𝟎𝟎𝟎   Equation 6.1 
6.2.4 Evaluation of absolute matrix effects 
For this test, human plasma samples were extracted using C18 or mixed mode (C18 + benzenesulfonic 
acid) SPME fibres (n=2 of each type, 45 µm thickness, housed in in vivo SPME assembly). The 
resulting extract was divided into two aliquots: one aliquot was analyzed as is to determine the 
amount of known endogenous metabolites present. The second aliquot was spiked with known 
concentration of the metabolites. The signal obtained for this post-extraction spike was compared 
versus neat standard prepared at the same concentration directly in the desorption solvent after taking 
into account any endogenous level of each metabolite using the simple formula of Equation 6.2. 
Relative signal intensity of 80-120% were deemed to be free from absolute matrix effects. 
% 𝒔𝒊𝒈𝒏𝒂𝒍 = 𝟏𝟎𝟎% ×
 𝒔𝒊𝒈𝒏𝒂𝒍𝒑𝒐𝒔𝒕𝒆𝒙𝒕𝒓𝒂𝒄𝒕𝒊𝒐𝒏 𝒔𝒑𝒊𝒌𝒆−𝒔𝒊𝒈𝒏𝒂𝒍𝒃𝒍𝒂𝒏𝒌 𝒆𝒙𝒕𝒓𝒂𝒄𝒕  
𝒔𝒊𝒈𝒏𝒂𝒍 𝒏𝒆𝒂𝒕 𝒔𝒕𝒂𝒏𝒅𝒂𝒓𝒅
  Equation 6.2 
6.3 Results and discussion  
6.3.1 Comparison of instrumental sensitivity: ion trap versus triple quadrupole versus 
benchtop Orbitrap 
Prior to setting up metabolomics methods on Exactive, a preliminary evaluation of its performance in 
comparison to existing ion trap and triple quadrupole instruments was carried out using 
benzodiazepine standard solutions. The benzodiazepine method for each instrument was optimized 
using direct infusion of individual standard and the parameters were systematically varied to select 
the optimum value for each. LOQ on each instrument was first estimated using 10x signal-to noise 
ratio by injecting progressively more dilute standard solutions. LOQ was then further verified 
according to Food and Drug Administration method validation guidance to ensure RSD observed at 
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LOQ level does not exceed 20%.
142
 A summary of the results for four benzodiazepines is shown in 
Table 6.2. It is shown that for these analytes the sensitivity of Exactive in full scan mode is 
approximately equal to that of API 3000 triple quadrupole instrument in MS/MS mode and even 
better than sensitivity of Varian 500 ion trap instrument in MS/MS mode. This was very promising 
result for in vivo metabolomics as we were previously able to successfully use API 3000 for analysis 
of benzodiazepines and carbamazepine after in vivo sampling. Full scan mode on either ion trap or 
triple quadrupole instrument is typically 50-100x fold less sensitive than MS/MS mode (and also less 
selective), so the overall results show excellent performance of Exactive in full scan mode even when 
large full scan range is utilized (100-1000 m/z). In another study, the authors compared performance 
of TOF instrument in MS mode with QTOF instrument in MS/MS mode and found 10-1000-fold 
improvement in analytical limits of detection.
45
  
Table 6.2 Comparison of instrumental sensitivity for benzodiazepines based on injections of 
neat standards using reverse phase C18 method and positive ESI mode.  
Compound 
Varian 500 LOQ in 
MS/MS mode* 
(pg) 
API 3000 LOQ in 
MS/MS mode 
(pg) 
Exactive LOQ in 
full scan mode 
100-1000 m/z 
(pg) 
Exactive LOQ in 
full scan mode 
250-350 m/z 
(pg) 
Oxazepam 30 1.2 4.2 4.2 
Lorazepam 30 1.8 4.7 4.7 
Diazepam 12 6 4.3 0.9 
Nordiazepam 15 3.6 4.7 0.9 
*full scan mode about 100x less sensitive 
6.3.2 Development of MS methods on Exactive 
In the first step of MS method development, individual standard mixtures of all metabolites described 
in Chapter 5 were infused directly into Exactive MS using a syringe pump at 5 µL/min. The ions 
observed for each compound in both negative and positive ESI were documented and MS parameters 
individually optimized for each compound and recorded. All compounds in positive ESI exhibited 
mass accuracy < 5 ppm except for β-carotene, with poor mass accuracy of 9 ppm (Table 6.3), similar 
to what was documented elsewhere
229
. A possible explanation for this observation is that fragile or 









H resulting in M
+•
 ion. When this reaction occurs in Orbitrap, it decreases 






ions, thus resulting in less accurate mass assignment. As a 
general trend in Tables 6.3 and 6.4, the largest errors are observed for relatively fragile ions which  
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Table 6.3 Summary of ions observed and mass accuracy in positive ESI mode during direct 
infusion of metabolite standard mixture using 5 µL/min flow rate.  
 Theoretical Observed positive mode 
Analyte MW Pos H 
MW Pos 
Na 







Lysine 147.1128 169.0947 147.1127 -0.68 169.0946 -0.59 
Histidine 156.0768 178.0587 156.0767 -0.34 178.0586 -0.55 
Maleic acid 117.0182 139.0002 no no no no 
Fumaric acid 117.0182 139.0002 no no no no 
Citric acid 193.0343 215.0162 no no 215.0161 -0.58 
Hydrocortisone 363.2166 385.1985 363.216 -1.65 no no 
Progesterone 315.2319 337.2138 315.2314 -1.45 no no 
Phenylalanine 166.0863 188.0682 166.0862 -0.33 188.0706 no 
Glutamic acid 148.0604 170.0424 148.0604 -0.23 no no 
Tryptophan 205.0972 227.0791 205.0971 -0.26 227.0789 -0.88 
Nicotinamide 123.0553 145.0372 123.0554 0.90 no no 
β-estradiol 273.1849 295.1669 273.1843 -2.22 no no 
Taurocholic acid 516.2989 538.2809 no no 538.2803 -1.10 
Folic acid 442.1470 464.1289 442.1458 -2.62 464.1277 -2.59 
Cholic acid 409.2949 431.2768 no no 431.2756 -2.77 
Ascorbic acid 177.0400 199.0219 no no no no 
Glucose 181.0707 203.0526 no no 203.0522 -2.02 
Sucrose 343.1235 365.1054 343.1225 -2.88 365.1043 -3.10 
Fructose 181.0707 203.0526 no no 203.0522 -2.02 
Glutathione ox 613.1592 635.1412 613.1587 -0.88 635.1404 -1.23 
Adenine 136.0618 158.0437 136.0617 -0.53 none no 
Adenosine 268.1040 290.0860 268.1037 -1.23 290.0854 -1.98 
HBA 105.0546 127.0366 no no 127.0366 0.27 
Pyruvic acid 89.0233 111.0053 no no no no 
Glutathione red 308.0911 330.0730 308.0902 -2.86 330.0719 -3.41 
Protoporphyrin 563.2653 585.2472 563.2651 -0.32 no no 
Retinol 287.2369 309.2189 287.2361 -2.93 no no 
β-carotene 537.4455 559.4274 537.4406 -9.08 no no 
Histamine 112.0869 134.0689 112.0872 2.46 no no 
Choline 104.1070 127.0968 104.1073 2.97 no no 
Linoleic acid 281.2475 303.2295 no no no no 
AMP 348.0704 370.0523 348.0703 -0.17 370.0523 -0.01 
Riboflavin 377.1456 399.1275 377.1453 -0.69 399.1272 -0.77 
ADP 428.0367 450.0186 428.0366 -0.21 450.0179 -1.63 
Fructose 6-phosphate 
261.0370 283.0189 no no 283.0188 -0.49 Glucose 6-phosphate 
Glucose 1-phosphate 
Ribose 5-phosphate 231.0264 253.0084 no no 253.0083 -0.30 
ATP 508.0030 529.9850 no no 529.9847 -0.50 
UDP 405.0095 426.9914 no no no no 
β-NAD 665.1242 687.1061 665.1246 0.60 687.1071 1.46 




Table 6.4 Summary of ions observed and mass accuracy in negative ESI mode during direct 
infusion of metabolite standard mixture using 5 µL/min flow rate.  
 Theoretical Observed in negative mode 




 Mass accuracy 
Lysine 145.0983 145.0968 -9.99 
Histidine 154.0622 154.0607 -9.76 
Maleic acid 115.0037 115.0022 -12.9 
Fumaric acid 115.0037 115.0022 -12.9 
Citric acid 191.0197 191.0182 -8.00 
Hydrocortisone 361.2021 no no 
Progesterone 313.2173 no no 
Phenylalanine 164.0717 164.0704 -7.95 
Glutamic acid 146.0459 146.0445 -9.48 
Tryptophan 203.0826 203.0814 -5.93 
Nicotinamide 121.0407 no no 
β-estradiol 271.1704 271.1702 -0.58 
Taurocholic acid 514.2844 514.2842 -0.39 
Folic acid 440.1324 440.1338 3.16 
Cholic acid 407.2803 407.2811 1.96 
Ascorbic acid 191.0197 175.0233 no 
Glucose 179.0561 179.0547 -7.90 
Sucrose 341.1089 341.1092 0.77 
Fructose 179.0561 179.0547 no 
Glutathione oxidized 611.1447 611.1443 -0.64 
Adenine 134.0472 134.0458 -10.61 
Adenosine 266.0895 no no 
Hydroxybutyric acid 103.0401 103.0387 -13.30 
Pyruvic acid 87.0088 87.0075 -14.60 
Glutathione reduced 306.0765 306.0766 0.22 
Protoporphyrin 561.2507 no no 
Retinol 285.2224 no no 
β-carotene 535.4309 no no 
Histamine 110.0724 no no 
Choline no no no 
Linoleic acid 279.2330 279.2332 0.87 
Riboflavin 375.1310 no no 
Fructose 6-phosphate 259.0224 259.0225 0.21 
Glucose 6-phosphate See above see above no 
Glucose 1-phosphate See above see above no 
Ribose 5-phosphate 229.0119 229.0114 -2.10 
AMP 346.0558 346.0567 2.57 
ADP 426.0221 426.0237 3.66 
ATP 505.9885 505.9888 0.65 
UDP 402.9949 402.9963 3.42 
β-NAD 662.1018 662.1030 1.74 




can dissociate early. This can occur in Orbitrap as a result of ion energy deposition during the 
injection of ions from C-trap into the Orbitrap detector.  All compounds in negative ESI mode 
exhibited mass accuracy <15 ppm (Table 6.4). Mass accuracy was particularly poor (10-15 ppm) for 
compounds with m/z<200 indicating that Orbitrap mass calibration procedure in this region may use 
further improvement by inclusion of an ion with m/z<100 during the mass calibration process. A 
useful approach for further increasing mass accuracy using Orbitrap instrument is to use background 
ions to perform internal calibration during each sample run, and resulting mass accuracy was 
improved from 1-2 ppm to 0.2 ppm.
230
 
Therefore, among the compounds tested 25 were observed in positive mode and 31 in negative 
mode. Total of 21 compounds were observed in both modes, but the method sensitivity is not the 
same in both modes. These results show significant overlap in the metabolite coverage by both modes 
using the selected metabolite test mixture, but the best coverage and analytical sensitivity is obtained 
when the data from two modes is combined. According to literature, the complementary nature of the 
two modes has also been documented with Giavalisco reporting only 10% overlap between the two 
modes in plant metabolomics study
38
 and 14% overlap reported in the analysis of human plasma
205
. In 
contrast Xie et al. used only positive ESI mode on the basis of greater number of total metabolites 
observed during their metabolomics study on urine to study acute toxicity of melamine.
204
 
Table 6.5 shows that the combination of chromatographic and ionization conditions can have 
significant impact on the analytical sensitivity of a given metabolite. For example, the LOQ of 
taurocholic acid can be improved 275-fold by performing analysis in negative ESI mode (using 
reverse phase LC-MS method). On the other hand, analytical sensitivity for folic acid is improved by 
50-fold by the use of HILIC method and negative ESI. These differences can be important as a 
metabolite may not be detected by one method, but successfully detected by another. The use of 
complementary methods provides improved metabolite coverage.  
6.3.3 Evaluation of reverse-phase LC-MS method using pentafluorophenyl column 
The effect of capillary and tube lens voltages was evaluated, while spray voltage and capillary 
temperature were kept constant at 4000V and 275°C respectively. Example results are shown for 
positive ionization mode in Figure 6.1. No significant differences between methods 1 (capillary 
voltage 27.5 and tube lens voltage 100 V) and 2 (capillary voltage 57.5 and tube lens voltage 110 V) 
were observed. Positive method 3 (capillary voltage 90 V, tube lens voltage 170 V) showed 2-fold 
decrease in sensitivity for analytes with lower MW, but no significant improvement for higher MW   
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Table 6.5 Summary of LOQs obtained for various metabolites using proposed LC-MS methods 
on Exactive instrument. 
 LOQ - Amount injected on-column (pg) 
Analyte 
Positive ESI – 
reverse phase 
Positive ESI – 
HILIC 
Negative ESI – 
reverse phase 
Negative 
ESI – HILIC 
Phenylalanine 1.3 700 26 5.0 
Histidine 1.9 85 76 85 
Lysine 2.1 105 NA 11 
Tryptophan 2.1 117 41 12 
Progesterone 2.9 119 NA NA 
Hydrocortisone 3.5 2430 NA 7.3 
Riboflavin 4.0 37 NA NA 
Adenosine 8.2 11 NA 109 
Glutamic acid 9.0 840 5.4 9.2 
Adenine 9.3 5.5 9.3 5.5 
Nicotinamide 28 12 NA NA 
Protoporphyrin 28 NA NA NA 
Thyroxine 39 286 NA 286 
AMP 55 110 NA 110 
Histamine 155 NA NA NA 
Glutathione reduced 203 97 20 97 
Taurocholic acid 550 89 2.0 8.9 
Cholic acid 673 827 6.7 9.1 
Glutathione oxidized 1800 418 540 418 
Folic acid 2100 42 NA 42 
Ascorbic acid 9900 NA 990 130 
Sucrose 13550 (Na) 19 (Na) NA 189 
Glucose+fructose 24200 4260 24 35-116 
Citric acid 25850 (Na) NA 860 2350 
Choline 0.03 NA NA NA 
Ribose phosphate NA 3610 24 107 
β-NAD NA 124 693 124 
Glucose-or-fructose phosphate NA 2610 30 19 
Pyruvic acid NA NA 269 5650 
Maleic and fumaric acid NA NA 285 NA 
Hydroxybutyric acid NA NA 19 NA 
β-estradiol NA NA NA 1610 
Linoleic acid NA NA 2390 NA 
ATP NA 540 NA 540 
UDP NA 630 NA 630 




Figure 6.1 Effect of capillary and tube lens voltage on signal intensity of selected analytes using 
positive ESI PFP LC-MS method. The capillary and tube lens settings for methods positive 1, 2 
and 3 were 27.5 and 100 V, 57.5 and 110 V and 90 and170 V, respectively.  
analytes versus methods 1 and 2. Based on this data, capillary and tube lens voltages of 27.5 V and 
100 V, respectively, were selected for future studies. Similar evaluation was performed in negative 
ESI mode and capillary and tube lens voltages of -67.5 V and -85 V were selected as optimum for the 
chosen metabolite mixture. These results are in agreement with Brown et al. who investigated the 
effect of tube lens voltage in negative ESI mode on the number of metabolites detected and the 
propensity of ions to fragment or form adducts under different electrospray conditions.
33
 It was found 
that higher voltages (100 V versus 20 V) showed increased number of peaks without significant 
amounts of fragmentation. However, no evaluation of sensitivity similar to that performed in current 
study was carried out.  
One of the problems that is commonly observed in LC-MS analysis is ionization suppression or 
enhancement caused by co-eluting matrix components. For targeted analysis, the goal of sample 
preparation is to remove as many of these matrix components as possible. Isotopically labeled 
standards are also used in order to compensate for any remaining matrix effects due to incomplete 
removal of possible interferences.
50
 In metabolomics, the situation is much more complicated as the 
analysis of all compounds is desired, so the goal of sample preparation is to be as unselective as 
possible. In this case, great issues with matrix effects can be expected. To evaluate SPME 
performance in terms of this parameter, the absolute matrix effects were evaluated. The results 
obtained in this experiment are shown in Figure 6.2. In positive ESI, significant absolute matrix 
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effects were observed only for citric acid using both coatings tested (C18 and mixed mode).  In 
negative ESI, the majority of metabolites showed no ionization suppression or enhancement, 
indicating satisfactory performance of SPME method. However, significant ionization suppression 





































Figure 6.2 Evaluation of absolute matrix effects using (a) positive and (b) negative ESI reverse-
phase LC-MS method with PFP column. Percent signal was calculated as the area obtained in 
human plasma extract spiked post-extraction versus neat standard at the same concentration 
level prepared directly in desorption solvent. Percent signal >120% represents ionization 
enhancement for a given metabolite and % signal <80% represents ionization suppression for a 
given metabolite. The results are shown for two types of Supelco biocompatible coatings: mixed 
mode and C18 coatings. 
ionization enhancement (% signal >120%) was observed for citric and pyruvic acid (both coatings). 
The result for citric acid was not surprising in this particular test as this analyte was present in large 
concentrations since it was used as anti-coagulant in human plasma sample used for the study. Citric 
acid peak was the most intense peak in the entire chromatogram in either ionization modes (taking 
into account both known and unknown metabolites). Ascorbic acid and maleic acid were not 
chromatographically resolved from large citric acid peak, which affected their ionization properties. 
Interestingly, hydroxybutyric acid, β-NAD and reduced glutathione also eluted within the same 
retention time window and exhibited no significant suppression or enhancement, indicating the effect 
was analyte dependent, not only retention time dependent. In positive ESI mode, no metabolites 
which co-eluted with citric acid showed any significant ionization suppression or enhancement. 
Finally, it should be noted for the cases where an apparent ionization enhancement was observed, this 
is not likely to be true enhancement of the signal. This unexpected increase in signal can most likely 
be attributed to fragmentation of other species within the complex matrix which contain the particular 
group (for example, citrate or pyruvate in current example).  
6.3.4 Evaluation of LC-MS method using amino column for improved separation of 
sugar compounds 
Using HILIC method employed in Chapter 5, it was not possible to achieve chromatographic 
separation of sugars such as glucose and fructose, or various sugar phosphates. Considering these 
species are also isobaric, they cannot be distinguished by mass spectrometric detector, which makes 
chromatographic resolution of these species highly desirable. To address this issue, the use of LC 
column with aminopropyl phase was investigated, as this column packing was reported to enable 
separation of various sugars under reverse phase conditions. The successful use of this column 
packing under HILIC conditions was also reported by Bajad et al. for separation of various polar 
metabolites of interest in current work. 
222
  In fact, in this study Bajad et al. tested  nine different LC-
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MS methods (both reverse phase and HILIC) and found that aminopropyl column in HILIC mode at 
pH 9 performed the best for separation of large number of polar metabolites.  
Thus, in current study, the performance of aminopropyl column using both reverse phase and 
HILIC modes was tested. The particular focus was paid to polar metabolites containing sugar and/or 
phosphate moieties which were not well retained on pentafluorophenyl column. Using reverse phase 
mode, the retention of some sugar compounds was still not satisfactory while other compounds were 
too broad or suffered from excessive tailing. HILIC mode at pH 9 was found to provide best retention 
for the compounds of interest and an example chromatogram of selected metabolites is shown in 
Figure 6.4. Furthermore, this amino column based method was not as sensitive to high aqueous 
content of injection solvent as HILIC method based on underivatized silica making it more suitable 
for metabolomics. Based on these results, it was investigated whether this amino method can 
completely replace HILIC method proposed in Chapter 5 and the performance of the method using 
human plasma samples was evaluated. 
As a first step, the absolute matrix effects were evaluated to ensure that a significant degree of 
ionization suppression or enhancement was not observed. The results obtained in this experiment are 
shown in Figure 6.3. Significant suppression was observed for taurocholic acid using both coatings, 
and for glucose, fructose and histamine using mixed-mode coating.  
However, when it was attempted to use the method for a full sample set, two important problems 
were encountered. First, a significant loss of signal intensity over time was observed for all 
metabolites due to build-up of salt deposits in the ion source even though volatile salts were 
employed. This is illustrated in using the results of two QC samples. After ~ 10 hr of run time, 
significant loss of intensity was observed as shown by drop in intensity for most compounds (QC2) 
and after ~20 hr of run time the loss of signal intensity was so severe that 13 out of 21 compounds 
could no longer be observed. Based on these results, the method was not deemed suitable for further 
use. This lack of robustness is surprising considering that similar method was employed by Bajad et 
al. for the analysis of Escherichia coli extracts using similar design ion source as employed in our 
analysis.
222
 The same method was also successfully employed in cross-platform comparison for 
quantitative metabolomics study of primary metabolism.
45
 One possible explanation for this 
discrepancy is that Bajad et al. analyzed very small sample sets at a time with full source cleaning 
between sets, but this was not discussed in manuscript. For example, in our work, analysis of 15-20 
samples at a time would yield acceptable results such as reported by Bajad et al. (intra- and inter-day 
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RSD <35% for 141 out of 144 compounds analyzed). However, such small sample sets are not 
feasible for metabolomic studies which typically require analysis of large number of samples as well 
as quality control samples to ensure data integrity. Another possible explanation is poor stability of 
stationary phase under high pH conditions resulting in phase bleed contaminating MS, as the columns 
used in our study and in literature studies were obtained from different manufacturers. This could be 




Figure 6.3 Evaluation of absolute matrix effects using negative ESI HILIC LC-MS method with 
amino column. Percent signal was calculated as the area obtained in human plasma extract 
spiked post-extraction versus neat standard at the same concentration level prepared directly in 
desorption solvent. Percent signal >120% represents ionization enhancement for a given 
metabolite and % signal <80% represents ionization suppression for a given metabolite.  
6.3.5  Evaluation of HILIC LC-MS method on Exactive using underivatized Si column 
HILIC method developed in Chapter 5 was transferred to Exactive instrument and its performance for 
metabolomics analysis of plasma was investigated. The minimum recommended buffer salt 
concentration for this column was 5 mM, so this was used as starting mobile phase versus 2 mM used 
in method developed in Chapter 5. However, the use of this mobile phase resulted in very broad peaks 


















shown in Figure 6.4 (b). Using these conditions, ATP and UDP were not detected at all. This finding 
agrees with the results reported by Kamleh et al. who did not detect ATP when only formic acid was 
used as additive in their proposed HILIC method.
216
 Increasing pH to improve peak shape of 
phosphates while retaining chromatographic resolution was not possible due to working pH range of 
the column (up to pH 8). Chromatographic peak shape was improved by increasing salt concentration 
to 20 mM and modifying gradient conditions as shown in Figure 6.4 (a). Increasing buffer 
concentration helped the peak shape by reducing electrostatic interactions 
Table 6.6 Results of QC sample analysis for known metabolites using negative ESI mode HILIC 
LC-MS method with aminopropyl column. % signal intensity of QC2 and QC3 is shown with 
respect to signal intensity observed for QC1 with approximately 10 hr elapsed between each QC 






Hydrocortisone ND ND 
Adenine ND ND 
Taurocholic acid 135 ND 
Glucose+fructose 17 ND 
Thyroxine 124 20 
Tryptophan 34 8 
Phenylalanine 41 4 
Cholic acid 27 ND 
Sucrose 100 8 
HBA 18 2 
Glutamic acid 30 8 
Maleic+fumaric cad 2 ND 
Histidine 57 4 
Histamine 113 ND 
AMP 37 6 
Fructose+glucose phosphate 6 ND 
Ribose phosphate ND ND 
Lysine 30 ND 
UDP ND ND 
ADP ND ND 
ATP ND ND 
 
between charged analytes and stationary phase. Further increases in salt concentration were not 
investigated because of possible ionization suppression effects as salt concentration is further 
increased. The results of this development indicate that the exact properties of HILIC columns can 
vary to a large extent between manufacturers and demand thorough method re-optimization even 
when a stationary phase of the same type is employed. Therefore, the proposed method resulted in 
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acceptable peak shapes and chromatographic resolution between metabolites, except for sugar 
phosphates which co-eluted. Lack of chromatographic resolution between eluting components can 
result in ionization suppression or enhancement, so matrix effects were investigated in detail. 
 
Figure 6.4 Example XIC of metabolite standard solution prepared at 1 µg/mL in 60% 
acetonitrile and analyzed using HILIC method with unmodified Si column in negative ESI 
mode (a) final method using 20 mM effective concentration of buffer and (b) initial method 














Figure 6.5 Evaluation of absolute matrix effects using (a) positive and (b) negative ESI HILIC 
LC-MS method with underivatized Si column. Percent signal was calculated as the area 
obtained in human plasma extract spiked post-extraction versus neat standard at the same 
concentration level prepared directly in desorption solvent. Percent signal >120% represents 
ionization enhancement for a given metabolite and % signal <80% represents ionization 

































The results obtained in positive and negative ESI modes with proposed method are shown in Figure 
6.5. Overall the results were satisfactory, except in the region of 3-4 min where significant ionization 
suppression was observed as indicated by the results for ascorbic acid, glutamic acid, pyruvic acid, 
folic acid and reduced glutathione in negative ESI mode. However, these species were well-retained 
on PFP column and most of these species (except ascorbic acid) did not show adverse ionization 
effects using reverse-phase LC-MS method. Thus, they should be analyzed using reverse-phase 
method. Furthermore, ionization suppression was observed for phenylalanine (mixed mode fibre) as 
well as histidine and lysine (both coatings). These species were also well-retained on reverse-phase 
method and could be suitably analyzed using that method with no adverse matrix effects. Citric acid 
also showed significant ionization suppression, due to its use as anti-coagulant in the batch of human 
plasma used for this analysis. The analytes of interest for HILIC separation such as phosphates did 
not show any ionization suppression or enhancement indicating suitability of the method for the 
metabolomics analysis of plasma as a complementary method to reverse-phase method. 
In a targeted metabolomics study employing mixed-mode extraction using Strata-XCAW 
significant absolute matrix effects for estrogens were encountered (all target estrogen species not 
detected when spiked in biological matrix) even though analysis was performed using reverse-phase 
method where estradiols have good retention and chromatographic resolution between different 
species can be achieved.
231
 In our study we did not detect estradiol using reverse-phase method 
(below method LOD, presumably due to presence of acid in mobile phase as documented 
previously
231
). Using HILIC method estradiol peak was detected and was not subject to ionization 
suppression, even though it eluted with solvent front using HILIC column (retention time of 0.9 min), 
where matrix effects are expected to be the most predominant. The predominance of matrix effects 
using traditional exhaustive techniques has been well-documented in various targeted analysis, 
although it has been largely unreported in global metabolomic studies. For example, in a study 
examining levels of amino acids in plant seeds, ionization suppression of 31-65% was reported for all 
amino acids tested with worst performance for glutamic acid, aspartic acid and serine.
212
 
Injection solvent with relatively high aqueous content is proposed for this method (60-75% 
acetonitrile) to ensure adequate solubility of polar species, nucleosides in particular. Poor solubility of 
nucleosides in acetonitrile versus water was demonstrated in other studies.
221
 Cubbon et al. also 
successfully used 50% acetonitrile as injection solvent in their HILIC method for the analysis of 
urine.
64
 This choice of desorption solvent comes with some deterioration in peak shape for early 
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eluting compounds. However, these species can be reliably analyzed on reverse-phase method, 
whereas the more polar species are the focus of current study and can be successfully analyzed with 
60-75% acetonitrile with good peak shape. In contrast, Gika et al. injected 100% aqueous urine 
sample with no solvent strength adjustment prior to analysis.
213
 Such high aqueous content usually 
results in very poor chromatographic peaks shape, and it is not clear how this was overcome in their 
method.  
The results for optimization of MS parameters for this method are shown in Figure 6.6. Part (a) of 
this figure shows the results for the most polar analytes which are not well-retained using reverse-
phase method. These analytes are the focus of HILIC method so optimum analytical sensitivity was 
desirable for these species. Capillary voltage and tube lens voltage of 90V and 155V respectively 
were found to perform the best for the analysis of these species. Similar performance was achieved 
whether 275 or 325 °C capillary temperature was observed, so the lower temperature of 275 °C was 
selected. The particular settings selected for inclusion in this evaluation were chosen on the basis of 
direct infusion experiments. It is interesting to note the optimum settings for the polar analytes of 
interest resulted in considerable reduction in signal intensities of other metabolites such as 
phenylalanine, glutamic acid and tryptophan as shown in Figure 6.6 (b). This shows that simple 
optimization using total ion intensity of metabolite standard mixture may not be the best MS 
































Figure 6.6 Optimization of MS parameters (capillary temperature, capillary voltage and tube 
lens voltage) for metabolites using negative ESI HILIC LC-MS method (a) results for very 
polar metabolites (b) results for metabolites with sufficient retention using reverse phase 
method – full scale (c) same as in (b) but y-scale zoomed in to show trends for metabolites not 
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Finally, the robustness of the proposed method was evaluated, and the method was found to be very 
stable over long analysis times. Example results for repeated injection of QC sample are shown in 
Table 6.7. 
Table 6.7 Results of QC sample analysis for known metabolites using negative ESI mode HILIC 
LC-MS method with unmodified Si column. % signal intensity of QC2 and QC3 is shown with 
respect to signal intensity observed for QC1 with approximately 10 hr elapsed between each QC 






Estradiol 107 83 
Hydrocortisone 105 102 
Maleic + fumaric acid (FA adduct) 111 65 
Adenosine 109 112 
Adenine 115 113 
Glucose 95 83 
Fructose 111 88 
HBA (FA adduct) 106 105 
Taurocholic acid 98 108 
Cholic acid 99 101 
Thyroxine 101 107 
Phenylalanine 118 107 
Tryptophan 100 97 
Sucrose 107 124 
Ascorbic acid 86 79 
Glutamic acid 86 86 
Glutathione reduced 94 96 
Pyruvic acid (FA adduct) 87 79 
Folic acid 91 89 
ADP 117 103 
AMP 91 95 
ATP 127 88 
β-NAD 103 103 
Citric acid 106 84 
Fructose+glucose phosphate 98 96 
Glutathione oxidized 118 102 
Ribose phosphate 99 97 
UDP 130 116 
Histidine 103 109 




6.3.6 Summary of proposed LC-MS methods on Exactive 
The combination of reverse phase pentafluorophenyl and Si HILIC LC-MS method was found to 
provide good coverage of many metabolites of interest. In comparison to other complementary 
methods reported in literature, the reverse-phase and HILIC methods proposed by Mohamed et al. 
were unable to retain some of very  important metabolites, for example ATP and glutathione.
215
 These 
metabolites are very important as ATP is involved in energy metabolism, and glutathione ratio can be 
used as a measure of cellular toxicity. Thus, it was important to ensure in our methods that these 
important metabolites can be analyzed. It is suspected that Mohamed et al. did not observe ATP due 
to poor solubility in their chosen injection solvent for HILIC method (acetonitrile/methanol, 75/25).  
This highlights the importance of compromise when selecting an appropriate injection solvent for a 
global metabolomics method. For optimum chromatographic peak shape, final sample extract should 
be dissolved in solvent of weaker or equal strength to starting conditions. For HILIC chromatography, 
this means using acetonitrile/water (9/1) as injection solvent. However, many polar metabolites are 
not sufficiently soluble under these conditions as encountered in our work. The use of injection 
solvents with higher aqueous portion (75/25, or 3/2) improves solubility of such species so that they 
can be detected but sacrifices good peak shape for some of the early eluting analytes. In our work, the 
main reason for the use of HILIC method was to retain and separate very polar species such as AMP, 
ADP, UDP, and ATP, so injection solvent with higher aqueous proportions was selected. This did 
result in poor peak shape of some early eluting analytes such as taurocholic acid.  However, these 
analytes could be analyzed with good peak shape and sensitivity on proposed reverse phase method, 
so this was not problematic.  
The observed ionization suppression results show that when using SPME and proposed LC-MS 
methods, ionization suppression was mostly observed for high-intensity citric acid peak used as an 
additive in human plasma, and particularly in negative mode some acidic compounds eluting within 
the same retention time window were susceptible to ionization effects (about 2-fold suppression or 
enhancement). For in vivo SPME samples, this issue will be completely eliminated as no additives are 
added, and the extraction is performed directly in animal blood stream. In contrast to traditional 
methods, no significant matrix effects were observed in early parts of chromatogram either in HILIC 
or reverse-phase mode when SPME is used as sample preparation method. This is not the case for 
traditional methods, where 10-fold dilution of urine was shown to result in significant ionization 
suppression for 162 components, while acceptable results were achieved for 283 components using 





 Using capillary LC-MS method which is less prone to matrix effects due to the use of low 
flow rates, significant absolute and relative matrix effects were observed for 3 out of 7 compounds 
tested in plant metabolomics study.
232
 The observation of relative matrix effects, which could affect 
relative quantification in metabolomics study, is particularly problematic and was found to depend on 
the exact nature of matrix under study. For example, A. Thaliana leaf and root extracts were not 
susceptible to relative matrix effects while A. Halleri leafs exhibited significant relative matrix 
effects. The authors explain this observation by explaining that A. Thaliana plants were less diverse 
(grown under strict and identical conditions), while A. Halleri plants were independently grown in a 
greenhouse under less-controlled conditions, thus exhibiting more inter-individual variability.  
Another study on yeast extracts evaluated matrix effects using an ion-par reverse-phase method and 
HILIC method, and significant matrix effects were observed for 75% of about 60 metabolites tested.
45
 
In another study on yeast cell extracts using direct introduction mass spectrometry which is the most 
susceptible to matrix effects, severe matrix effects were observed for 4 out of 10 studied metabolites 
with 5-fold loss in signal intensity observed even at lowest extract concentration.
36
 No similar matrix 
effects evaluation for global metabolomic studies on human plasma have been reported to date using 
LC-MS methods, but based on the studies cited for other matrices it appears that significant absolute 
matrix effects can be expected for a minimum of 30-40% of analytes, whereas SPME appears to be 
less susceptible due to lower extraction efficiency (non-exhaustive nature of extraction) and the 
absence of highly intense ions that are likely to cause ionization suppression/enhancement. This can 
be an important finding as presence of ionization suppression can obscure weak signals, so their 
intensity is below limit of detection.
232
  
In other studies, detector saturation was also observed for some species in urine including hippuric 
acid, betaine, creatine and creatinine,
215
 but this effect was not observed for our SPME-LC-MS 
method for any metabolites as the extraction efficiency for polar compounds was relatively low. 
Finally, it should be mentioned that the proposed combination of methods was not able to separate 
isobaric sugar phosphates (for example, glucose 1-phosphate and glucose 6-phosphate or fructose 1-
phosphate and fructose 6-phosphate), so if these metabolites are of interest alternative methods need 
to employed. For example, these species were successfully separated in recent targeted metabolomic 
studies using anion exchange chromatography
48
 or using porous graphitic carbon column
28
, but are 
not applicable for more global metabolomics analyses. Alternatively, the reasons for poor robustness 
of HILIC method with aminopropyl column can be further examined. 
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6.3.7 Evaluation of global SPME-LC-MS method using pentafluorophenyl LC-MS 
method 
6.3.7.1 Evaluation of extraction time 
An in-depth investigation of the influence of extraction time on the richness of the metabolite profile 
was carried out using pentafluorophenyl LC-MS method using both positive and negative ionization 
mode. The extractions were performed from human plasma using Supelco mixed-mode fibres and the 
extraction times were varied from 5 min to 24 hr. The dependence of the amount extracted was first 
evaluated for the known metabolites which were identified against the injection of authentic standard. 
It was found that for the more polar species equilibrium was reached by 5 min extraction time, and no 
further increases in the amount extracted were observed with subsequent increases in extraction time. 
These results are shown in Figure 6.7 (a) and (b). For example, the examination of Figure 6.7 (a) 
shows that glutamic acid, histidine, lysine, choline, phenylalanine, tryptophan and nicotinamide 
reached equilibrium using 5 min extraction time. Similar trend was observed for citric acid, but was 
not included in Figure 6.7 (a) since very large amounts of citric acid were extracted (3000 ng) so it 
could not be easily presented on the same scale as the other compounds. The main reason for the 
extraction of large amounts of citric acid is the fact that sodium citrate was used as anti-coagulant for 
the human plasma employed in this study. Taurocholic acid, hydrocortisone, cholic acid and 
progesterone, on the other hand, showed significant increases in the amount extracted with increasing 
extraction time, and in fact equilibrium was not reached even after 2 hr extraction time. Among the 
compounds showing improved extraction at the longer extraction times, some of the compounds were 
observed at all extraction times, indicating analytical sensitivity was sufficient for these compounds 
to detect small amounts extracted even at the shortest time. This was the case for hydrocortisone and 
progesterone in Figure 6.7 (a), for example. Other compounds in Figure 6.7 (a), such as cholic and 
taurocholic acid required longer time to ensure sufficient amount was extracted to be detectable by 
the instrumental method employed. For example, in positive ionization mode, cholic acid became 
detectable only using extraction time of 68 min or longer.  
These results agree with expectations and show that richer metabolic profiles can be obtained using 
larger extraction times. In the example of Figure 6.7 (a), 9 out of 11 compounds could be detected 
using 5-min extraction time, whereas by increasing extraction time to 68 min, all 11 compounds could 
be analyzed.  An interesting general trend was also observed. The more polar compounds, which have 
shorter retention times in reverse phase method, reached equilibrium very fast with Supelco mixed-
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mode extraction phase employed in this study, as no further increases in the amount extracted was 
detected  beyond 5-min extraction time. This finding is important from calibration perspective, as it 
means that equilibrium calibration can be used to determine the metabolite concentration in the 
system under study for any polar metabolites identified during data processing that are of interest, 
provided authentic standard of the identified compound is available (post-processing calibration of 
metabolites of interest identified in global study). This trend was further verified by processing the 
data of all unknown metabolites observed in human plasma as discussed in Section 7.3.5. 
For the compounds which were detected using both positive and negative ESI mode, the results 
obtained using two modes at different extraction times show good agreement for all compounds with 
typical differences within ± 30 %. Furthermore, this data was compared using paired t-test, and no 
significant differences were found  in the amount extracted determined using each of two methods at 
99% confidence interval (t = -2.25, tCRITICAL = 2.73, p = 0.03). This is an excellent result especially 
considering a very simple one-point calibration standard curve was used to estimate the total amount 
extracted of each known metabolite and the sample analysis occurred over relatively long-time 
period(4 days). This data indicates reliable quantitative analysis of selected metabolites can be 
performed using large metabolomics data sets such as collected in this study. 
The extraction time trends were also evaluated using HILIC method after independent extractions 
of same pooled human plasma samples (Figure 6.8). The results show very good agreement between 
the two sets of data both in terms of extraction time trends and with regards to the amount of analyte 
extracted. The two data sets for overnight extraction (1440 min) for metabolites observed in both 
reverse and HILIC modes (negative ESI, total of 8 analytes observed in both modes) were further 
compared  using paired t-test and no significant differences were found at 99% confidence (t = -1.03, 
tCRITICAL = 3.50, p = 0.34) indicating good data quality achievable by both methods. No additional 






Figure 6.7 The dependence of the amount extracted of known metabolites on extraction time 
using Supelco mixed-mode fibres (n=3 at each time point).  Samples were analyzed using 
pentafluorophenyl LC-MS method. (a) The results for analytes observed in positive ESI mode. 
The inset graph shows expanded region to facilitate the comparison of analytes with sub-ng 
amounts extracted (b) the results for analytes observed in negative ESI. The inset graph shows 




Figure 6.8 The dependence of the amount extracted of known metabolites on extraction time. 
All extractions were performed from human plasma using Supelco mixed-mode fibres (n=3 at 
each time point).  Samples were analyzed using HILIC LC-MS method. The results for analytes 
observed in negative ionization mode. The inset graph shows full scale for glucose and fructose. 
6.3.7.2 Evaluation of carryover of SPME method for metabolomics 
The data shown in Chapter 5 demonstrated significant carryover of many metabolites when static 
desorption conditions were used and multiple desorption steps were necessary in order to ensure 
complete desorption of analytes for the comparison of different sorbents. During the evaluation of 
coatings it was not desirable to employ agitation to facilitate faster mass transfer during desorption 
step in order to avoid possible loss of particles from the coating (the coating procedure was not 
optimized for each particle type). Based on the results of that study, Supelco prepared research 
prototype mixed-mode (C18+benzenesulfonic acid, 45 µm thickness) biocompatible coatings using 
proprietary biocompatible polymer. The robustness of these coatings is very good, so it was possible 
to employ vortex agitation to speed up the desorption step. Desorption time of 60 min with 1000 rpm 
agitation was found sufficient to effectively desorb both polar and hydrophobic metabolites from the 
coatings. To ensure, the desorption was efficient and that no additional desorption steps were 
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necessary, carryover was evaluated after SPME extraction from plasma. Example results obtained 
using reverse-phase method are shown in Figure 6.9 and the dependence of % carryover on the length 
of extraction time is also illustrated. No significant carryover (≤2%) was detected for the majority of 
compounds. Only histidine, lysine and choline exhibited significant carryover. Possible explanation 
for the higher carryover of amines could be that at pH values above pKa of silanol groups (4.5-4.7), 
silanol groups can become ionized, which can lead to ionic interactions with positively charged 
species such as protonated amines, thus resulting in poor elution or desorption of these species.
197
 
The carryover experiment was repeated for the known metabolites detected using HILIC LC-MS 
method. No carryover was found for the majority metabolites with the exception of glucose, 
phenylalanine and glutamic acid where carryover was found to be ≤2% in all cases. These results 
indicate that single desorption step is sufficient when using proposed mixed-mode coating for 
metabolomics. However, considering that it is impossible to evaluate the potential for carryover of all 
metabolites present in a biofluids sample and extracted by the coating, it cannot be verified with 
absolute confidence that the coating is absolutely clean prior to any subsequent extraction with 
absolutely no metabolites remaining within the coating. For this reason, it is recommended to use 
these coatings as single-use fibres to ensure no accidental contamination peaks are observed during 
subsequent sample analysis. This is not problematic, as these coatings are produced at low-cost and 
are already aimed as single-use devices during in vivo sampling as discussed in Chapter 4 due to 





Figure 6.9 The amount of carryover observed for known metabolites and its dependence on 
extraction time. All extractions were performed from human plasma using Supelco mixed-mode 
fibres (n=3 at each time point).  Samples were analyzed using pentafluorophenyl LC-MS 
method. The carryover was evaluated by performing a second desorption using fresh 300 µL 
portion of desorption solvent. The results for analytes observed in (a) positive and (b) negative 
ionization mode.  
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6.3.7.3 Evaluation of analyte stability in SPME coating 
In the next experiment, the stability of selected metabolites in coating after 7-day storage in freezer (-
20°C) was performed. The extraction was performed using a set of fibres on one day ( time 0). Half 
of the fibres were analyzed immediately and the amount of analytes extracted was determined using a 
freshly-prepared standard. The remaining fibres were retracted in the hypodermic needle, wrapped in 
aluminum foil and stored frozen for exactly 1-week. They were analyzed on day 7 against a freshly-
prepared standard. Two consecutive desorptions were performed on both days to evaluate the 
carryover as well. The results obtained are summarized in Figure 6.10.  Overall, the stability on fibre 
was found to be acceptable as indicated by no statistically significant difference in the amount 
extracted for the analytes tested. However, it appears that during storage, the coating dries out as the 
amount desorbed during first desorption was significantly lower than for the freshly extracted fibres. 
Once the results for the first and second desorptions are taken into account, there are no significant 
differences in the amount extracted. These results imply that the initial desorption time for fibres 
stored in freezer should be extended or sufficient number of desorptions performed to ensure effective 
removal of all analytes. 
 
Figure 6.10 The results of the evaluation of metabolite stability (1-week, -20°C storage) within 
SPME coating for selected metabolites using n=3 mixed-mode Supelco fibres. 
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6.3.7.4 Comparison of coating performance for the extraction of human plasma for known 
metabolites 
Using HILIC LC-MS method, the performance of mixed mode coating was compared to that of C18 
coating. The comparison was done using HILIC method  to check the extraction efficiency of polar 
analytes. Example results for a set of known metabolites are depicted in Figure 6.11. Small 
improvement in the extraction efficiency of these compounds was consistently observed. Further 
processing of unknown metabolites was performed and gave consistent results. Metabolite coverage 
could be further enhanced by the use of other complementary coatings identified in Chapter 5.  
 
Figure 6.11 Comparison of the performance of biocompatible C18 versus biocompatible mixed-
mode (C18 + Benzenesulfonic acid) coating for extraction of human plasma. Extraction was 
performed using n=3 fibres of each type, for 1440 min and the analysis was performed using 
negative ESI HILIC LC-MS method. Coating dimensions and thickness were the same so no 
correction factor was applied. Error bars show one standard deviation from the mean. 
6.4 Conclusions 
This chapter illustrates some of the difficulties in developing truly global LC-MS  methods with 
adequate performance for metabolomic studies. No single LC method can sufficiently retain all 
compounds of interest, thus necessitating the use of complementary methods. Although proposed 
HILIC method with aminopropyl column was able to retain the vast majority of compounds not well 




















metabolomic studies with 10-fold loss of signal intensity observed over 30-hr run time. Considering 
metabolomic studies typically require the analysis of large number of samples, methods with such 
poor robustness are not acceptable. Thus, the original HILIC method using underivatized silica was 
employed in all subsequent studies due to its demonstrated robustness over long run times.  
In terms of the development of SPME method suitable for global metabolomic studies, the results 
presented herein show excellent performance of SPME in terms of matrix effects with <5% and 
<20% of metabolites exhibiting suppression and/or enhancement effects, and in most cases these 
effects were correlated to elution within the time window of highly intense sodium citrate peak which 
was used as anticoagulant. These results show another important advantage of in vivo SPME methods 
where the effect of anticoagulant can be completely eliminated from the data because no additives are 
required for direct in-vein extraction approaches. Furthermore, the use of short extraction times (5 
min with no agitation) was sufficient to extract measurable quantities of various metabolites from a 
human plasma sample (non-spiked). Interestingly and surprisingly, it was possible to detect some 
very polar metabolites such as lysine and glutamic acid which exhibited very poor extraction 
efficiency during method development experiments in Chapter 5. Clearly, the concentrations of these 
metabolites in human plasma are sufficiently high so that low extraction efficiency (<0.5%) was still 
sufficient to detect these metabolites in plasma. Analyte carryover was also evaluated for the set of 
known metabolites and found to be ≤2% for majority of analytes except for selected amines. The use 
of desorption conditions of acetonitrile/water (1/1, v/v) presented a compromise between good 
solubility of metabolites of varying polarity, good desorption efficiency and reasonable 
chromatographic shapes upon direct injection into reverse-phase method. The same extract was also 
compatible with direct injection into HILIC method after slight adjustment of injection solvent 
strength by dilution with acetonitrile (1/1, v/v). Increasing the proportion of organic solvent in HILIC 
method even further was found to cause poor solubility of very polar species such as ADP and ATP, 
thus preventing analysis of these species, which was not desirable as the aim of this HILIC method 





Metabolomics of human plasma: comparison of in vitro SPME to 
traditional methods 
7.1 Preamble and introduction 
7.1.1 Preamble 
Some of the data presented within this chapter has been incorporated in manuscript entitled. 
Vuckovic, D., de Lannoy, I., Gien, B., Shirey, R.E., Sidisky, L., Dutta, S., Pawliszyn, J. In vivo solid-
phase microextraction: a new sample preparation tool in metabolomics, (2010) which is currently 
submitted for publication. However, all of the work reported within this chapter has been performed 
solely by myself at the University of Waterloo, so permissions of other co-authors cited on the 
manuscript are not deemed necessary. The contributions of the authors as cited on manuscript are as 
follows:  I. de Lannoy and B. Gien developed in vivo SPME procedure for mice which was previously 
described in Chapter 4 with appropriate permissions. The contributions of R.E. Shirey and L. Sidisky 
are the development of biocompatible prototype probes suitable for in vivo SPME sampling as 
described in Chapters 3 and 4 with appropriate permissions. The contribution of S. Dutta is the LC-
MS analysis of in vivo SPME samples using full hybrid Orbitrap system at Thermo facility in San 
Jose as described in Chapter 4 with appropriate permission. 
7.1.2 Introduction: current sample preparation trends for global metabolomics of 
human plasma 
The objective of the research presented in this chapter was to compare the optimized SPME method 
presented in Chapter 6 to some of traditional methods employed to in global metabolomic studies of 
human plasma. It was not feasible to compare SPME to all possible plasma protein precipitation 
methods reported in literature, so the two best candidate methods were selected from literature based 
on their performance in comparison studies which examined factors such as efficiency of protein 
removal and number of observed metabolites. For instance, Polson et al. compared the effectiveness 
of various protein precipitation methods (organic solvent, acid, salt and metal) for use with LC-MS.
233
 
Among the tested methods, acetonitrile, trichloroacetic acid and zinc sulfate were found to provide 
best protein removal efficiencies as determined using spectrophotometric method, but precipitation 
with acetonitrile was most compatible with subsequent LC-MS analysis. Protein removal efficiency 
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of acetonitrile was found to be slightly higher for acetonitrile (93.2±0.7%) versus ethanol 
(88.6±0.5%) and methanol (88.7±1.1) for all plasma species tested including human, mouse, rat and 
dog. Minimum plasma to precipitant ratio of 1 to 2.5 was recommended, and further increases in the 
amount of precipitant (for example 1 to 4 ratio) did not yield any further improvements in terms of 
protein removal efficiency. In contrast, a more recent study using Bradford assay for estimation of 
protein concentration, found that acetonitrile had poorest protein removal efficiency (94%) versus 
pure ethanol (96%) and pure methanol (98%).
234
 The authors do not provide an explanation for this 
apparent discrepancy, but this could be caused by different errors inherent in two assays for the 
estimation of protein concentration. The examination of protein removal efficiency by gel 
electrophoresis indicated better performance of acetonitrile versus methanol supporting results by 
Polson et al.
12
 Heat and acid treatment were also found to be efficient for protein removal (98%), but 
resulted in much fewer number of metabolite features versus organic solvent extraction.
234
  Among 
the fourteen extraction methods tested, the precipitation with methanol was found to perform the best 
in term of metabolite coverage and method reproducibility.  Pereira et al. compared the performance 
of three different plasma protein precipitation methods: methanol precipitation (1/2, v/v), methanol 
precipitation (1/4, v/v) and slow precipitation with acetonitrile (1/1.35, v/v) over 3 days.
58
 In this 
study, best results were obtained using plasma protein precipitation with methanol in 1 to 2 ratio. 
However, this finding is in apparent disagreement with other reports claiming minimum ratio of 1 to 
2.5 plasma-to-solvent ratio is needed for effective protein removal
233
, and shows there is no consensus 
in literature regarding the best plasma to precipitant ratio. In an early study, Bruce et al. compared the 
performance of plasma protein precipitation using various aqueous solutions of methanol or 
acetonitrile using 1 to 4 plasma to precipitant ratio for the analysis of human plasma.
211
  Precipitation 
with pure methanol was found to be optimum method with the best metabolite coverage. However, 
the overall sample procedure was very long and demanding and incorporated 2-hr standing period, 
ultrafiltration step as well as evaporation/reconstitution step. Such long multi-step sample preparation 
procedure can be expected to result in significant loss of metabolites, and in fact only 516-735 
features were observed which is quite low in comparison to other reported methods. The same group 
further refined their methodology in a more comprehensive study where performance of four different 
solvents (methanol, ethanol, acetonitrile and acetone) and combinations of solvents was tested.
12
 The 
best method performance for the solvent precipitation of human plasma samples was obtained using 
methanol/ethanol (1/1, v/v) and methanol/acetonitrile/acetone (1/1/1, v/v/v) using 1 to 4 plasma to 
precipitant ratio. Protein removal efficiency was examined using gel electrophoresis and the best 
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performance was found for acetonitrile, acetone, acetonitrile/acetone and ethanol/acetonitrile/acetone 
precipitants. However, the number of metabolites observed for these solvents was the lowest. The 
reproducibility of precipitation methods with pure acetone and acetonitrile was also worse than for 
remaining methods. Thus, the authors propose precipitation with methanol/ethanol and  
methanol/acetonitrile/acetone as the two best options taking into account all three criteria.
12
  
Michopoulos et al. evaluated the performance of precipitation with methanol, precipitation with 
acetonitrile and SPE in combination with reverse-phase UHPLC-MS method for global metabolomic 
studies on human plasma.
51
 Precipitation with methanol was found to provide better results than 
acetonitrile, while SPE with C18 cartridge was found to improve method precision over solvent protein 
precipitation methods, presumably due to improved sample clean-up. Tiziani et al. examined various 
deproteinization methods for human serum before NMR analysis.
235
 After comparison of 
ultrafiltration versus plasma protein precipitation with perchloric acid, acetone, methanol/chloroform 
or acetonitrile, the authors found that ultrafiltration and acetone precipitation methods provided the 
best protein removal on the basis of NMR data. However, ultrafiltration provided better results for 
some of the polar species, due to better solubilization than acetone precipitation so it was 
recommended as the best method of sample preparation prior to NMR.  
The above discussion shows that there is an increased interest in recent years in researching the 
effect of different sample preparation methods on global metabolomics LC-MS data, but there is still 
no consensus regarding the optimum method(s) to employ. However, certain trends are apparent from 
different studies comparing the performance of various plasma protein precipitation methods. The 
precipitation with acetonitrile appears to perform better in terms of protein removal
12, 233
, while the 
precipitation with methanol, ethanol or methanol/ethanol mixture results in better metabolite coverage 
and method precision
12, 234
. Based on these results, we selected (i) precipitation with pure acetonitrile 
and (ii) precipitation with methanol/ethanol (1/1, v/v) as two plasma protein precipitation methods to 
incorporate in our study. We selected plasma to precipitant ratio of 1 to 4 for the comparison which is 
in line with the recommendations in literature to use minimum ratios of 1 to 2 or 1 to 3. Not 
surprisingly, all of the above literature results show that none of the precipitation methods provides 
complete protein removal, with estimates of 2-10% of proteins remaining in final extract indicating 
incomplete sample clean-up.
12
 This explains the observation of short column lifetimes for 
metabolomic studies
51, 52
 as this protein portion can build up over time in the analytical column. The 
presence of proteins is very problematic because it can drastically affect properties of 
chromatographic column employed for analysis and reduce column lifetime. For example, 
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metabolomics analysis of urine resulted in an unusable data set because clear run order pattern was 
observed during principal component analysis.
31
 This was subsequently attributed to an increase in 
column back-pressure over an analytical run, which can be caused by poor sample clean-up.  In 
another study, Zelena et al. estimated column lifetime at approximately 400 samples in combination 
with plasma protein precipitation methods.
52
 However, the inability to use a single column to collect 
an entire large metabolomics data set, can be very problematic from data processing perspective as it 
can be difficult/impossible to successfully align data from different columns due to small variations in 
column performance.  Thus, one possible advantage of SPME over these methods is the extension of 
column lifetime. A second useful feature of SPME for metabolomic studies is that the amount 
extracted is proportional to the biologically-active free (unbound) concentration. Therefore, 
ultrafiltration was selected for inclusion in current study, as it is one of the most commonly used 
methods for the determinations of unbound concentration. 
Table 7.1 gives an overview of the sample preparation methods employed for global metabolomics 
analysis of human serum or plasma, and shows large variations in methods employed. Among these 
applications, the most successful study to date is the identification of sarcosine as putative biomarker 
for prostate cancer.
20, 44
 It is informative to note that the sample preparation workflow for this 
application is the most demanding among all reported methods and includes a four-step solvent 
extraction.
44
 Further research and investigation is needed to directly compare this method versus more 




Table 7.1 Overview of global LC-MS metabolomic studies using human plasma or serum.  
Sample 
type 
Purpose of study Sample preparation method Ref. 
Serum 
Recommended 
method for Human 
serum metabolome 
(HUSERMET) project 
Thawing on ice, precipitation with methanol (1/3, v/v), 
15 min centrifugation, lyophilization at 45°C for 16 hr, 








Precipitation with acetonitrile (1/4, v/v), 10 min 







hepatotoxicity in mice 







Precipitation with methanol (ratio and centrifugation 
conditions not stated), evaporation to dryness, 





colorectal cancer and 
disease 
understanding 
Dilution with water (1/1, v/v), precipitation with 62.5% 
methanol/ 37.5% acetonitrile (1/2 v/v), 10 min standing 
at room temperature, 20 min centrifugation, filtration of 








normal variability in 
metabolomics with 
respect to age, sex 
and race 
Four-step solvent extraction at 4°C: extraction with 
50% ethyl acetate/50 % ethyl alcohol (1/4, v/v), 
extraction with methanol (1/2, v/v), extraction with 75% 
methanol/ 25% water (1/2,v/v) and extraction with 50% 
dichloromethane/ 50% methanol (1/2, v/v), pooling of 
all extracts, solvent evaporation, lyophilization, 













analysis of anionic 
metabolome 








Precipitation with cold methanol (1/2, v/v), 20 min 
incubation at -20°C, 10 min centrifugation, 








precipitation with acetonitrile (1/3, v/v), 10 min standing 
at 4°C, 10 min centrifugation, lyophilization at -50°C, 





Diagnosis of intestinal 
fistulas 
Precipitation with acetonitrile (1/4, v/v), 10 min 
standing at room temperature, 10 min centrifugation at 








Precipitation with cold methanol (1/4, v/v), 45 s vortex, 
1 hr precipitation at -20°C, 2x15 min centrifugation, 






7.1.3 Challenges with existing sample preparation methods 
For the preparation of plasma or serum samples, metabolism quenching step is often not employed or 
it is not clear how soon after sample collection it was performed.
198
 This can be expected to have a 
significant impact on the composition of metabolome, but no global metabolomic studies currently 
discuss how well the analyzed metabolome represents the true metabolome at the time of sampling. A 
recent more targeted study using red blood cell lysate focused on the extraction of thiols and 
determination of reduced/oxidized glutathione ratio which can be used as an indicator of oxidative 
stress.
238
 In this study, ultrafiltration was found to perform better than plasma protein precipitation 
because of significantly smaller amount of conversion of reduced glutathione to oxidized form during 
the sample preparation procedure (3.5±0.2% conversion for ultrafiltration versus 21±1% conversion 
for plasma protein precipitation with acetonitrile).  
Several studies incorporate evaporation/reconstitution step as part of sample preparation strategy, 
but this can result in poor solubilization of some metabolites.
17, 51, 205, 223
 The composition of utilized 
reconstitution solvents varied greatly: for example, Michopoulos et al. used 5% acetonitrile as 
reconstitution solvent, Yin et al. 75% acetonitrile and Minami et al. used 100% acetonitrile.  Evans et 
al. tested two reconstitution solvents (100% aqueous and 10% methanol).
205
 Using 10% methanol 
poor peak shape was observed for early eluting compounds, but using either method relatively 
hydrophobic species such as diacylglycerols, triacylglycerols or diacylphospholipids could not be 
observed indicating ineffective solubilization of these species using sample preparation conditions 
employed. Bruce et al. on the other hand advocate the use of 80% methanol as reconstitution solvent, 
but no discussion of resulting chromatographic peak shapes is provided. 
12, 211
 Zelena et al. 
recommend lyophilization, followed by reconstitution in purified water, but this method appears 
likely to fail to solubilize more hydrophobic species, although this is not discussed in manuscript.
52
  
Current initiatives aim to further define normal human metabolome through large-scale studies, 
such as human serum metabolome project which aims to analyze 7000 samples of healthy subjects, 
subjects with ovarian cancer and Alzheimer’s disease.
52
 Recent global metabolomics analysis of 
human plasma samples for effects of age, sex and race found that the most significant changes in the 
metabolome occurred as consequence of the aging process, but even in this case the majority of 
metabolites showed < 2-fold change with the exception of some xenobiotics such as caffeine and 
iminodiacetate.
44
 This is in agreement with recent study examining normal biological variability of 
human plasma and cerebrospinal fluid which recommends ≥2-fold as a statistically relevant threshold 
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with respect to inherent variability of healthy control group.
67
 More efforts are also needed to 
accurately define normal concentration levels of various metabolites, as such information is currently 
not available for numerous known metabolites. Clearly, establishing a normal baseline of various 
metabolomes can aid in biological interpretation and is an important step in moving metabolomics 
forward. Studies, such as current study, which clearly document the performance of different methods 
are also crucial to aid in the appropriate method selection depending on the problem being studied. 
The main goals of this study were to evaluate the performance of SPME versus existing methods 
commonly employed for global metabolomic studies of human plasma: (i) plasma protein 
precipitation with acetonitrile, (ii) plasma protein precipitation with methanol/ethanol and (iii) 
ultrafiltration. A particular focus within the study was paid to parameters such as metabolite coverage 
and method precision. 
7.2 Experimental 
7.2.1 Materials 
Human plasma with sodium citrate as anticoagulant was obtained from Cedarlane Laboratories 
Limited (Burlington, ON, Canada). 3K Nanosep centrifugal device (molecular weight cutoff of 3000 
Da) were obtained from Pall, Port Washington, NY, USA. The main component of the device is 
ultrafiltration membrane consisting of modified polyethersulfone on polyethylene substrate, while the 
remaining components were made of polypropylene. Ethanol (HPLC grade) was obtained from Fisher 
Scientific. Other materials and reagents are the same as described in Chapters 5-6. 
7.2.2 SPME sample preparation 
SPME samples (n=7) were prepared according to the method developed and described in detail in 
Chapter 6. Briefly, 300 µL of human plasma was extracted using Supelco prototype biocompatible 
mixed-mode fibre (C18 and benzenesulfonic acid, 45 µm thickness, 5 µm particle size) for 5 min 
under static conditions. The fibres were then desorbed in 300 µL of desorption solvent for 60 min in 
acetonitrile/water (1/1, v/v) using vortex agitation at 1000 rpm. This extract was directly analyzed 
using pentafluorophenyl reverse-phase and amino HILIC methods in both negative and positive ESI 
modes using conditions described in Chapter 6. 
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7.2.3 Ultrafiltration (UF) sample preparation 
Aliquots of human plasma (500 µL, n=7) were placed in 3K Nanosep centrifugal device and 
centrifuged at 10000 rpm for 30 min at 4 °C. The resulting filtrate was diluted 30-fold in purified 
water prior to LC-MS analysis. 
7.2.4 Plasma protein precipitation with acetonitrile (PP) 
This procedure was adapted from study by Bruce et al.
12
Aliquots of human plasma (100 µL, n=7) 
were precipitated by addition of 400 µL of acetonitrile (LC-MS grade). The samples were then 
manually vortexed for minimum of 60 seconds, followed by centrifugation at 12000 rpm for 15 min 
at 4 °C. The resulting supernatant (150 µL) was transferred to amber polypropylene HPLC vials (0.3 
mL capacity) and diluted with 150 µL of purified water prior to LC-MS analysis.  
7.2.5 Plasma protein precipitation with methanol/ethanol (PM) 
This procedure was adapted from study by Bruce et al.
12
 Aliquots of human plasma (100 µL, n=7) 
were precipitated by addition of 400 µL of methanol/ethanol (1/1, v/v). The samples were then 
manually vortexed for minimum of 60 seconds, followed by centrifugation at 12000 rpm for 15 min 
at 4 °C. The resulting supernatant (150 µL) was transferred to amber polypropylene HPLC vials (0.3 
mL capacity) and diluted with 150 µL of purified water prior to LC-MS analysis. 
7.2.6 LC-MS analysis 
All of the samples (SPME, PP, PM, and UF) were directly analyzed using pentafluorophenyl reverse-
phase and unmodified silica HILIC methods in both negative and positive ESI modes using 
conditions described in Chapter 6. Prior to start of each sample set, mass calibration of Exactive 
instrument was performed using standard test mixture of caffeine, MRFA and Ultramark as 
recommended by manufacturer. Mass accuracy was within 1 ppm for all calibration peaks on all days. 
Negative calibration was found stable for a minimum of 48 hr, while positive calibration was found 
stable for minimum of 96 hr, so mass calibration was performed at 48-hr intervals and sample sets 
were arranged in batches not to exceed 48-hr analysis time. Sample sets for reverse-phase and HILIC 
methods were prepared as independent sets on different days to ensure sample degradation does not 
occur while waiting for analysis. For HILIC analysis, samples were diluted with acetonitrile to adjust 
the injection solvent strength. After preparation, samples were stored refrigerated on the autosampler 
while waiting for injection.  
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Samples were run in randomized order. Randomization of run order is extremely important in 
metabolomic studies in order to eliminate the factors such as small changes in sample concentration 
due to storage in autosampler while waiting for injection, solubility and adsorption issues with time, 
as well as change in instrument signal over time. If randomization is not performed, then the analysis 
of data sets can result in erroneous identification of potential biomarkers which are not relevant to 
treatment itself but rather stem from the inability to perfectly control all variables during an analysis.  
QC sample was run at the beginning, the end and periodically throughout the sample batch (every 
10-12 injections) to verify instrument performance. This QC sample was prepared by combining 10 
µL aliquots of each sample within entire sample set according to procedure proposed by Wilson et al. 
and is the leading approach adopted in metabolomic studies.
239
 The reason for the preparation of this 
pooled sample is to ensure that this sample contains most of the potential metabolites within a given 
data set, whereas a prepared standard mixture of known metabolites would not sufficiently represent 
the sample complexity and could not adequately ensure good quality control for all metabolites. 
These repeated injections of the same QC sample can be checked during principal component 
analysis, and should cluster tightly together if instrument performance was acceptable for the run. 
Furthermore, the mass accuracy and  precision obtained for selected metabolites of interest (for 
example, once differentiating metabolites are found during PCA analysis) can be further examined to 
provide further verification whether differences in given metabolite arise from samples or from 
analytical variability improving overall confidence in the results.  Other quality control approaches 
reported in literature include reinjection of random study samples
200
 and single point calibration using 
QC samples
240
. Former approach does not appear sufficient for quality control purposes as it does not 
provide sufficient number of replicates of any single sample, while the latter approach is very time 
and processing-intensive and assumes significant amount of instrumental drift and correlation of this 
drift with run-order. However, if the employed LC-MS method is sufficiently robust, this extent of 
instrumental drift should not be observed. Appropriate blank solutions and a known metabolite 
standard mixture were also analyzed throughout each sample set and subsequently used to identify 
relevant metabolites or to eliminate peaks originating from blank solution and not the plasma samples 
themselves. For each data set, the performance of QC sample was examined using both known 
metabolites and principal component analysis. Figure 7.1 shows example results for one QC set 
processed for known metabolites. The results were in line with reported results in literature of <20% 
RSD over 48-hour period for known metabolites and good clustering of QC samples was observed in 
PCA.
215
 Sucrose consistently showed poor performance using PFP method with typical RSD >50% so 
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it was preferentially analyzed using HILIC method. RSDs for retinol and β-NAD were higher than for 
other compounds due to very low signal intensities observed for these compounds (Figure 7.2). 
 
Figure 7.1 Example results for QC sample analyzed using positive ESI PFP LC-MS method 
over 48-hr period. 
7.2.7 Data processing 
Known metabolites in plasma samples were analyzed using Xcalibur software Version 2.1 (Thermo 
Fisher) by isolating extracted ion chromatograms (XIC) using 5 ppm (positive ESI mode) and 10 ppm 
(negative ESI mode) windows around the accurate mass of a given compound. These metabolites 
were identified in human plasma samples by comparison of retention time and accurate mass with 
that of the authentic metabolite standard mixture.  
Global metabolomics analysis was performed using SIEVE software version 1.2.0 (Thermo 
Fisher). The main steps of SIEVE workflow include (i) alignment (ii) identification of frames meeting 
given criteria (also called peak picking or feature detection) (iii) comparison of signal abundances in 
control versus treatment groups for each peak to yield univariate statistical probability that the levels 
are different or not and (iv) tentative identification of features using ChemSpider database. 
Chromatographic alignment is performed during data processing, because small differences in 

























Figure 7.2 Dependence of % RSD on signal intensity for n=7 injections of QC sample prepared 
by mixing aliquots of each sample within the sample set. The sample set was SPME extraction 
from human plasma using different extraction times. The QC injections were made randomly 
throughout the sample run over 48-hour period using pentafluorophenyl LC-MS method. Each 
point represents known metabolite detected in human plasma. (a) results for positive ionization 
mode (b) results for positive ionization mode: expanded scale to enable comparison of RSD for 
low signal intensities. (c) results for negative ionization mode (d) results for negative ionization 
mode: expanded scale to enable comparison of RSD for low signal intensities. 
and these differences can affect subsequent comparison across samples unless they are properly 
corrected.
241
 The success of alignment was evaluated using likeness score provided by the software 
and values greater than 0.8 were found acceptable. Following parameters were used for framing: 
0.005 mass window, 1.0 min retention time window, maximum number of frames =20000, minimum 
signal intensity of 10000. Initial 1.0-2.0 min and final 2.0 min of chromatographic run time were 
excluded from processing, as they represent column void and column re-equilibration time, 
respectively. The results obtained after framing were evaluated manually to eliminate any frames 
containing only background noise and no real chromatographic peaks (typically 50-70% of frames 
were rejected using this criterion as current version of SIEVE software was not able to distinguish 
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between chromatographic peak shape and random background noise if the noise exceeded the 
intensity threshold level. If the signal intensity threshold was increased, this resulted in omission of 
significant number of real peaks without resolving the problem of background noise, so manual 
verification of all SIEVE data sets was absolutely necessary. At this stage, any peaks which were also 
present in the corresponding blank injections were removed from the data set (~ 20% of peaks). 
According to this procedure, a typical SIEVE data set of 20000 frames would be reduced to a final 
data set of 1000-3000 real chromatographic peaks (and not present in blanks) depending on the 
sample preparation and LC-MS method employed. This data set also contained probability 
calculations that each frame is different in each set of samples, as well as integrated signal intensities 
for each sample and each frame, facilitating inter-sample comparison.  
Relevant three-dimensional data sets (m/z, retention time and signal intensity) were also further 
subjected to PCA using SIMCA P+ Version 12.0.1 software (Umetrics, Sweden) using Pareto scaling 
as recommended for LC-MS data sets.
214, 215, 223, 231
 Pareto scaling is a scaling method which uses 
square root of standard deviation as the scaling factor, and is used to ensure small-fold changes can be 
detected even in presence of large-fold changes (for example, to ensure several very high intensity 
peaks do not dominate PCA results).
242
 In other words, this method reduces the importance of large 
values within a data set, while still keeping the underlying structure of data. PCA reduces the 
dimensionality of data, and isolates orthogonal components which contribute the most to observed 
variation in inputted data sets. It is blinded or unsupervised type of analysis, and it attempts to find 
natural clusters within the data set, which can be examined using a scores plot. In a properly-designed 
and executed metabolomics study, analytical variation should be smaller than biological variation due 
to specific treatment, so samples are expected to cluster according to the group they belong (for 
example, control versus disease). The variables contributing the most to a given principal component 
then can be further examined for their potential as biomarkers using a loadings plot. The overall 
processing workflow is illustrated in Figure 7.3. PCA is used extensively in metabolomic studies to 
help isolate potential variables of interest because univariate approaches would yield a high false 
discovery late when dealing with data sets containing thousands of peaks. The main disadvantages of 
the technique are that it looks for global patterns in the data, so some fine underlying structure in the 
data may be lost and the interpretation of loading plots can be difficult if dealing with large number of 
variables.
2
 Another problem is the input of large number of variables versus usually relatively limited 
number of samples, which reduces the power of statistical approaches employed. This means that a 
high false positive discovery rate can result unless high significance thresholds are used.
19




Figure 7.3 Data processing procedures for LC-MS-based metabolomics. Chromatographic and 
spectral data are acquired by high-resolution LC-MS. Subsequent data processing, such as 
centroiding, deisotoping, filtering, peak recognition, yields a data matrix containing 
information on sample identity, ion identity (RT and m/z) and ion abundance. With appropriate 
data transformation and scaling, a multivariate model can be established through unsupervised 
or supervised multivariate data analysis (MDA). The scores plot illustrates the principal or 
latent components of the model and sample classification, while the loadings plot presents the 
contribution of each ion to each principal component of the MDA model. Figure reprinted with 
permission from Taylor & Francis from review by Chen et al.
27
 
data sets may benefit from PLS-DA approaches, but the main disadvantage of these supervised 
methods is potential for overfitting of data resulting in overall poor model performance.
2
 This is 
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particularly likely when using small sample numbers such as used in current study so PLS approaches 
were not explored. 
7.3 Results and discussion 
7.3.1 Comparison of sample preparation methods for known identified metabolites 
The authentic standards for the metabolites which were used for coating development (Chapter 5) 
were used to identify these metabolites in human plasma samples. Both accurate mass and retention 
time were used to assign the identity of these species in unspiked plasma samples. Method precision 
for each sample preparation procedure was determined on the basis of seven independent extractions 
of the same pooled human plasma sample and example results are shown in Figure 7.4. Overall the 
performance of SPME was similar to that of traditional methods with RSDs for most compounds 
≤30%. 
For ultrafiltration, an interesting trend was observed where more hydrophobic species such as 
cholic acid, taurocholic acid, linoleic acid and hydrocortisone were not detected at all as illustrated by 
missing bars in Figure 7.4. This is further illustrated in Figure 7.5 using taurocholic acid as an 
example. The same figure also shows another important trend. In general, the signal intensities for 
plasma protein precipitation methods shown in (b) and (c) for taurocholic acid example were much 
higher than observed for SPME as depicted in (d) for taurocholic acid. This was a general trend 
observed across the entire chromatographic space and is attributed to non-exhaustive nature of SPME 
whereby only a small portion of analyte is extracted depending on the magnitude of its Kfs value and 
the length of extraction time. However, despite lower signal intensities, the signal intensities were still 
sufficiently high for reliable detection and sufficient number of points across peaks could be acquired 







Figure 7.4 Comparison of method precision (expressed as % RSD for n=7 replicates) obtained 
for plasma protein precipitation with methanol/ethanol (PM), plasma protein precipitation with 
acetonitrile (PP), ultrafiltration (UF) and SPME. The samples were prepared using single 
pooled lot of human plasma with sodium citrate as anti-coagulant using procedures described 
in Experimental section. Missing bars denote peak not detected by a particular method. (a) 
Results for the analysis using pentafluorophenyl LC-MS method in positive ESI mode. (b)  
Results for the analysis using pentafluorophenyl LC-MS method in negative ESI mode. The 

























































Figure 7.5 Taurocholic acid example. Taurocholic acid peak detected using negative ESI 
pentafluorophenyl LC-MS method in  (a) standard mixture (b) human plasma sample prepared 
using PM (c) human plasma sample prepared using PP (d) human plasma sample prepared 
using SPME shown on same scale as PM and PP methods (e) human plasma sample prepared 
using SPME but y-scale zoomed in to better see peak shape (f) number of points obtained across 
SPME peak (g) human plasma sample prepared using UF shown using y-scale zoomed to the 
same scale as shown in (e). 
For ultrafiltration, very high signal intensities were observed for early eluting metabolites (typically 
with retention times <5 min), while most late-eluting metabolites were completely missing. This is 
depicted in total ion chromatograms of Figure 7.6 for reverse phase method. Due to complementary 
nature of HILIC method, this trend was reversed when samples were analyzed using HILIC LC-MS 
as shown in Figure 7.7. In this case, ultrafiltration showed the highest signal intensity for mid-to-late 
eluting peaks, while precipitation methods had much higher signal intensities for more hydrophobic 
early eluting species. Figure 7.7 also shows example extracted ion chromatograms for tryptophan to 
illustrate that the trend of generally higher signal intensities for precipitation methods versus SPME is 
consistent for both reverse-phase and HILIC methods. 
7.3.2 Global metabolomics - plasma protein precipitation with acetonitrile (PP) results 
The analysis of two data sets of the results obtained on human plasma after plasma protein 
precipitation with acetonitrile resulted in total of 2975 peaks (positive ESI) and 2082 peaks (negative 
ESI) mode with reverse-phase LC-MS method performed using pentafluorophenyl column. The 
results of these analyses are summarized in Figure 7.8 and Figure 7.9.  A single metabolite can give 
rise to more than one ion observed in MS. These ions include protonated ions, sodium adducts, 
potassium adducts, ammonium adducts, multiply-charged ions, isotope peaks and ions corresponding 
to loss of neutral species such as carbon monoxide, carbon dioxide, water, ammonia or formic acid, 
although other more unusual species have also been documented.
33
 Therefore, the observation of 
2082 peaks in negative mode does not mean 2082 unique metabolites were observed. For example, a 
recent study on human serum using hybrid Orbitrap instrument investigated the occurrence of various 
ions originating from same species using both positive and negative ESI modes.
33
 In negative ESI, 
among total of 4513 peaks observed, 18% of peaks detected were attributed to isotopes, 1.6% were 











Figure 7.6 Total ion count (TIC) chromatograms obtained using negative ESI 
pentafluorophenyl LC-MS method in  (a) human plasma sample prepared using UF (b) human 
plasma sample prepared using SPME (c) human plasma sample prepared using PP (d) human 
plasma sample prepared using PM. All TICs are shown on the same scale (1x10
8
) to facilitate 
comparison. 
In positive ESI, among total of 2079 detected peaks, 14% were attributed to isotope peaks, 3.4% to 
Na and K adducts, 8.1% to doubly charged species and 1.9% to neutral loss fragments. In other 
words, based on these results unique metabolite coverage can be estimated to be approximately 30% 
less than the total number of peaks reported. In a second study, the authors estimated approximately 
three m/z ions were observed for each compound in each ESI mode using UHPLC-nanospray FTICR, 
so the overall number of metabolites was approximately one third of the total number of peaks 
reported.
38
A third study by Evans et al. reported average of seven m/z ions observed for each unique 
metabolite during the building of their metabolite library.
205
 However, a manual examination of our 
data for the known metabolites indicates the presence of isotope peaks, but very few adduct peaks. 
Sodium adducts were particularly observed for acids and phosphorylated species, but not often 
observed for other metabolites. Few metabolites showed very small intensities for formic acid adduct 
peaks. This is in line with the estimate of three ions per metabolite.
38
 However, the examination of 
SIEVE data indicates that usually only the most abundant ion is entered in the feature table, although 
additional minor ions with small signal intensities may be present in the collected spectra. Therefore, 





Figure 7.7 Total ion count (TIC) and extracted ion chromatogram (XIC) for tryptophan 
obtained using negative ESI HILIC LC-MS method in (a) human plasma sample prepared 
using PM (b) human plasma sample prepared using PP (c) human plasma sample prepared 
 
 219 





, respectively) to facilitate comparison across methods. 
ions per single metabolite appears to be an overestimate for the data collected/processed in current 
study. The likely number of unique metabolites appears to fall in line with estimates of Brown et al.
33
 
especially for SPME data where may peaks had very low signal intensity, and adducts and fragments, 
even if formed, may be below instrumental limit of detection. As can be seen from this discussion, the 
discrepancy in the reported percentage of unique metabolites may in fact arise from the data 
processing stage of the workflow where different software may treat minor ions differently in terms 
of inclusion in the feature table. The formation of multiple ions as observed in ESI also further 
complicates putative identification of metabolites because during global metabolomics analysis it is 
not known a priori what type of ion is formed. The development of software that can correlate the 
ions belonging to the same species is currently an active area of research in order to help address this 
issue. Standardization of data processing procedures and software can also help to reach consensus 
regarding the number of unique features reported in various studies. 
Figure 7.8 and Figure 7.9 also show the histograms of the distribution of method precision 
observed for all unknown peaks when seven replicate independent extractions are considered. This 
type of representation is indicative of overall data quality. High metabolite coverage with poor 
method precision is not useful from the data interpretation perspective as biological variability cannot 
be confidently distinguished from analytical variability. Although currently there are no set 
requirements regarding acceptable precision of peaks in global LC-MS metabolomics analysis, RSD 
values of up to 20-30% should be acceptable
29, 52
 considering that RSD values of 15% are allowed for 
targeted analysis by LC-MS/MS, and 20% RSD is allowed at LOQ level
142
. For plasma protein 
precipitation with acetonitrile, the distribution of % RSD for all peaks shows that 67% of all peaks 
had RSD of ≤ 20%, and 82% of the peaks had RSD of ≤30% in negative ESI mode. In positive ESI 
mode, 54% and  71% of peaks had RSD of ≤ 20% and ≤ 30% respectively. This is significantly better 
than recently reported for similar plasma protein precipitation method with acetonitrile in 




The metabolite coverage achieved in current study is typically better than reported in literature 
using other LC-MS platforms. For instance, in one study on mouse blood relying on the precipitation 
with acetonitrile and reverse-phase LC-MS analysis on QTOF system, the authors detected 938 and 
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695 peaks using positive and negative ESI.
17
  This is significantly less than observed in our study and 
indicates that the selection and optimization of analytical platform plays an important role in 
metabolite coverage. It is interesting to note that among these peaks, 142 and 176 peaks respectively 
exhibited significant circadian oscillations, indicating significant influence of  the time of day on 
observed metabolite profile.  Among the identified metabolites, certain lysophosphatidylcholines and 
amino acids showed significant circadian rhythms. This study clearly shows that the sampling time is 
another important factor to standardize during the development of blood collection protocols. 
 Another study on human serum utilizing precipitation with acetonitrile followed by UHPLC-MS 
analysis with QTOF instrument reported detection of 4900 and 3600 peaks in positive and negative 
ESI modes, respectively.
223
 However, this number is most likely an overestimation of true number 
found in human serum because the authors did not eliminate blank peaks from their data sets prior to 
reporting of overall number in this particular study.  In our study, significant number of blank peaks 
(~20%) were observed even when the reagents of highest available purity were used for solvent and 
mobile phase preparation. Therefore, the studies which do not exclude these peaks from their reports 
tend to considerably overestimate true number of features detected. 
7.3.3 Global metabolomics - plasma protein precipitation with methanol/ethanol (PM) 
results 
In positive ESI reverse-phase LC method, plasma protein precipitation using methanol/ethanol 
resulted in total of 3245 peaks observed. The results of this analysis are summarized in Figure 7.10. 
The analysis of two data sets of the results obtained on human plasma after plasma protein 
precipitation with methanol/ethanol resulted in total of 2252 peaks observed in negative ESI mode 
with pentafluorophenyl column. The results of this analysis are summarized in Figure 7.11 Overall, 
the results show that plasma protein precipitation method with methanol/ethanol performed better 
than precipitation with acetonitrile for the metabolomics analysis of human plasma, as it resulted in 
better metabolite coverage. Furthermore, method precision was better for PM method as shown by the 
results for distribution of % RSD shown in Figure 7.11 (b). In fact, 69% and 81% of peaks observed 
with PM method had % RSD ≤20%, while 80% and 89% had % RSD ≤30% in positive and negative 
ESI mode, respectively. Finally, the sensitivity of PM method was higher than for PP method as 
shown in Figure 7.12. 973 peaks exhibited higher signal intensity in PM method than in PP method as 
shown by area ratio of 1.2 and above.  In contrast, only 274 peaks exhibited higher signal intensity in 
PP method than in PM method as shown by area ratio of 0.8 and below. Only 30 peaks were observed 
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in PP method and not present in PM method versus 176 peaks observed in PM method only (negative 
ESI). In positive ESI mode, only 6 unique peaks were observed for PP method versus 270 unique 
peaks observed for PM method.  
 
 
Figure 7.8 (a) Ion map (m/z versus retention time) for human plasma sample prepared using 
plasma protein precipitation with acetonitrile (PP) and analyzed using positive ESI 
pentafluorophenyl LC-MS method. (b) Number of peaks with given % RSD obtained in two 
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Figure 7.9 (a) Ion map (m/z versus retention time) for human plasma sample prepared using 
plasma protein precipitation with acetonitrile (PP) and analyzed using negative ESI 
pentafluorophenyl LC-MS method. (b) Number of peaks with given % RSD obtained in two 





































Method precision (expressed as % RSD)





Figure 7.10 (a) Ion map (m/z versus retention time) for human plasma sample prepared using 
plasma protein precipitation with ethanol/methanol (PM) and analyzed using positive ESI 
pentafluorophenyl LC-MS method. (b) Number of peaks with given % RSD obtained in two 
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Figure 7.11 (a) Ion map (m/z versus retention time) for human plasma sample prepared using 
plasma protein precipitation with ethanol/methanol (PM) and analyzed using negative ESI 
pentafluorophenyl LC-MS method. (b) Number of peaks with given % RSD obtained in two 
independent data sets. 
The improved results for plasma protein precipitation with methanol/ethanol are attributed to better 
solubility of some polar metabolites in methanol/ethanol versus acetonitrile mixture, while improved 
method precision is attributed to typically higher signal intensities observed in PM method versus PP 
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differences between the two methods can arise from factors such as difference in the amount and type 
of protein remaining after precipitation, degree of metabolite binding to proteins and degree of protein 
denaturation which causes disruption of metabolite binding.
234
  Our results show significant overlap 
in metabolite coverage between the two plasma protein precipitation methods and higher overlap than 
reported previously (overlap of 1354 peaks for acetonitrile versus total of 2056 observed peaks in 
methanol in Want et al. study), but the reasons for this remain unclear at this time.
234
 
The results obtained using PM method and pentafluorophenyl LC-MS method developed on 
Exactive compare favourably with UHPLC-MS method on C18 column in combination with plasma 
protein precipitation using methanol proposed by Pereira et al 
58
 In their approach, 1108 and 814 ions 
were observed  in negative and positive ESI mode respectively.  In another study on human serum 
after precipitation with methanol/acetonitrile (5/3, v/v) followed by analysis with UHPLC-MS 
method on C18 column, 1570 peaks were observed in positive ESI and 450 peaks in negative ESI 
mode.
206
  Want et al. reported detection of 2056 features using methanol precipitation versus 1606 
features detected for acetonitrile precipitation using LC-MS method with ion trap.
234
  Excellent results 
observed in our study (~2-fold increase in peaks observed) are attributed to good analytical sensitivity 
of Exactive instrument as well as the use of pentafluorophenyl reverse phase method rather than a 
simple C18 reverse method. Increased separation/retention of polar analytes such as achieved by   
pentafluorophenyl column improves metabolite coverage. In another UHPLC-MS study with hybrid 
Orbitrap instrument by Brown et al., the observed metabolite coverage was 2079 peaks in positive 
and 4513 peaks in negative mode. These results agree well with our findings, although better 
coverage in negative mode was observed using their method.
33
 In contrast, 5300 peaks were reported 
in metabolomics study of human plasma using capillary LC-TOF MS method in positive ESI mode 
after precipitation with methanol.
67
 However, this number includes any background contamination 
ions, as these features were not removed from the data by the authors so it represents a significant 
overestimation of metabolite coverage. The number of reliably identified features was further reduced 
to 3641 features upon examination of plasma from different individuals, which agree very well with 
our results using PM method. Therefore, based on the plasma protein precipitation results with both 
methanol/ethanol and acetonitrile, it can be concluded that Exactive provides an excellent LC-MS 
platform for metabolomics and achieved metabolite coverage is better or equivalent to what is 
reported in literature for other LC-MS platforms including TOF both in combination with 
conventional LC and UHPLC, as well as full hybrid Orbitrap instruments. Of course, the main 





Figure 7.12 Comparison of plasma protein precipitation methods using data collected with (a) 
positive and (b) negative ESI pentafluorophenyl LC-MS method. Two independent data sets are 
shown (T0 and T7) acquired a week apart on the same human plasma sample using n=7 
independently prepared replicates. The graph shows number of peaks with given area ratio. 
For peaks with area ratios of 0.8-1.2, two methods can be considered to be equivalent. For 
peaks with area ratios <0.8 plasma protein precipitation with acetonitrile (PP) yielded better 
results. For peaks with area ratios >1.2 plasma protein precipitation with methanol/ethanol 









































on instruments such as QTOF or hybrid Orbitrap which can be used to aid in identification of 
metabolites. However, for comparative global metabolomic studies, where identification is not 
routinely performed, Exactive provides an excellent choice in terms of high mass resolution, excellent 
analytical sensitivity and excellent signal stability and mass accuracy over long analysis times. 
7.3.4 Global metabolomics - ultrafiltration (UF) results 
The analysis of two independent data sets obtained on human plasma after ultrafiltration resulted in 
2686 peaks in positive ESI mode using pentafluorophenyl LC-MS method. The ion map and the 
histogram of the distribution of RSD values are shown in Figure 7.13. The analysis of same samples 
using negative ESI resulted in total of 2093 peaks observed. The results of this analysis are 
summarized in Figure 7.14. Both ion maps show relatively poor metabolite coverage in the region of 
5-30 min, indicating poor performance of UF method for more hydrophobic species. This is in line 
with the trends reported for the analysis of identified metabolites in Section 7.3.1. The observed poor 
coverage is attributed to poor solubility of some hydrophobic species in aqueous solution, possible 
high degree of protein-binding which would result in low analyte concentrations (below LOD) and 
possible adsorptive losses to ultrafiltration device. Poor performance of ultrafiltration for hydrophobic 
species was also previously shown in combination with NMR metabolomic studies.
235
 To overcome 
this difficulty, the authors proposed an additional method for the extraction of hydrophobic species 
from the ultrafiltration membrane. However, the proposed method relied on multi-step time-
consuming procedure, thus significantly reducing sample throughput. As shown in Figure 7.15 and 
Figure 7.16, SPME is able to successfully overcome this issue and provides balanced coverage of 
both hydrophilic and hydrophobic species.  
Both Figure 7.13 and Figure 7.14  show that method precision for UF method was worse than the 
results obtained for either of plasma protein precipitation methods. In fact, only 52% of peaks 
observed in positive ESI mode had %RSD ≤20% and only 69% had % RSD ≤30%. In negative ESI 
mode, 48% of peaks observed with UF method had % RSD ≤20%, and 64% had % RSD ≤30%. This 
is attributed to the fact that large degree of co-elution was observed in 1-5 min retention time 
window, so there is likely to be large degree of competition for ionization which can result in large 






Figure 7.13 (a) Ion map (m/z versus retention time) for human plasma sample prepared using 
ultrafiltration (UF) and analyzed using positive ESI pentafluorophenyl LC-MS method. (b) 













































Figure 7.14 (a) Ion map (m/z versus retention time) for human plasma sample prepared using 
ultrafiltration (UF) and analyzed using negative ESI pentafluorophenyl LC-MS method. (b) 
Number of peaks with given % RSD obtained in two independent data sets. 
7.3.5 Global metabolomics - SPME results using mixed-mode coating 
The metabolite coverage and method precision observed for the extraction of human plasma using 
SPME is summarized in Figure 7.15 and Figure 7.16. The number of metabolites observed depended 









































figures show all metabolites subdivided into three groups as illustrated with examples in Figure 7.17. 
The first group labelled as equilibrium reached, showed no further increase in the amount detected 
when the extraction time was incrementally increased from 5 min to 24-hr overnight extraction. 
Approximately 40-50% of all metabolites exhibited this trend. The second group, consisting of 
approximately 40-50% of all metabolites, showed an increasing trend in the amount extracted with 
the extraction time, indicating that the equilibrium was only reached using longer extraction times. 
Depending on the analytical sensitivity and extraction efficiency for a given individual analyte, 
majority of the metabolites from this group could be detected even using the shortest time tested of 5 
min. For these metabolites, increasing extraction time only resulted in increasing of signal intensity. 
Some metabolites, however, only became detectable at longer extraction times. However, some care 
should be taken in the interpretation of the metabolites which were only observed when very long 
extraction times were used as these may be due to degradation or conversion of some metabolites 
during long extraction at room temperature in human plasma. Short extraction times are preferable for 
metabolomics to reduce the possibility of such conversion/degradation when using in vitro SPME and 
also from the perspective of sample throughput. The results clearly illustrate that although some gain 
in metabolite coverage can be observed using long extraction times, the metabolite coverage with 
very short times of 5 min already provides 84% and 60% of coverage achievable at equilibrium for 
positive and negative ESI reverse-phase method, respectively. Therefore, the best approach when 
using SPME for global metabolomic studies is to use very short extraction times and improve 
metabolite coverage by using complementary coatings such as recommended in Chapter 5 






Figure 7.15 (a) Ion map (m/z versus retention time) for human plasma sample prepared using 
SPME and analyzed using positive ESI pentafluorophenyl LC-MS method. (b) Number of 
peaks with given % RSD obtained in two SPME data sets where extraction time was varied 















































Figure 7.16 (a) Ion map (m/z versus retention time) for human plasma sample prepared using 
SPME and analyzed using negative ESI pentafluorophenyl LC-MS method. (b) Number of 
peaks with given % RSD obtained in two SPME data sets where extraction time was varied 
from 5 min to overnight. 
The third group of metabolites was labelled as decreasing trend, where the amount extracted 
decreased with extraction time. Such trend can be observed for adsorptive coatings in case of 
competitive displacement effects when the number of binding sites becomes limited. In current study, 


































































Figure 7.17 Example of three metabolites processed using SIEVE software (a,b) peak showing 
equilibrium reached trend with no further increases in the amount extracted with increasing 
extraction time (c,d) peak showing decreasing trend where the amount extracted decreases with 
increasing extraction time (e,f) peak showing increasing trend where the amount extracted 
increases with increasing extraction time. The panels a, c, e show XIC for this metabolite and 
demonstrate good chromatographic alignment of the peaks. The panels b, d, f show the 
magnitude of integrated intensity for each extraction time (n=3 extractions per each time point), 
while label 0 shows the results for blank injection of desorption solvent. 
observed for very few metabolites (2 in negative ESI mode and <35 in positive ESI mode) as 
summarized in Table 7.2. 
Both Figure 7.15 and Figure 7.16 show that method precision for SPME method was similar to the 
results obtained for plasma protein precipitation methods. In positive ESI mode, 66% and 80% of 
peaks had  RSD ≤20% and ≤30% respectively using 5-min extraction time. Using overnight 
extraction times (equilibrium), method precision was even better with 81% having RSD≤20% and 
92% of peaks having RSD ≤30%. In negative ESI mode, 68% and 88% of peaks had  RSD ≤20% and 
≤30% respectively using overnight extraction time versus 58% and 74% for 5-min extraction time. It   
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negative 1.42 289.9239 no hits N/A N/A 
negative 17.35 243.1707 no hits N/A N/A 
positive 17.29 245.1860 no hits N/A N/A 
positive 17.83 387.1925 C21H32O4 -1.7 M+K[1+] 
positive 20.96 672.4352 no hits N/A N/A 
positive 21.06 650.4218 no hits N/A N/A 
positive 21.11 628.4086 C28H52NO7P 0.1 M+2ACN+H [1+] 
positive 21.11 628.9105 no hits N/A N/A 
positive 21.11 625.9312 no hits N/A N/A 
positive 21.15 606.3958 no hits N/A N/A 
positive 21.15 606.8975 no hits N/A N/A 
positive 21.17 584.4138 no hits N/A N/A 
positive 21.17 603.9180 no hits N/A N/A 
positive 21.23 562.4007 C24H50NO6P 5.0 M+2ACN+H [1+] 
positive 21.23 584.3824 no hits N/A N/A 
positive 21.28 562.3692 no hits N/A N/A 
positive 21.30 562.8708 no hits N/A N/A 
positive 21.64 287.2216 C16H30O4 -0.2 M+H [1+] 
positive 21.64 224.6278 no hits N/A N/A 
positive 21.64 111.1171 no hits N/A N/A 
positive 21.64 225.1294 no hits N/A N/A 
positive 22.24 573.9073 no hits N/A N/A 
positive 22.25 328.3207 C20H38O2 -0.8 M+NH4 [1+] 
positive 22.40 529.8813 no hits N/A N/A 
positive 22.70 865.6229 C50H90O7P2 -0.6 M+H [1+] 
positive 22.88 291.1954 no hits N/A N/A 
positive 23.79 338.2278 C52H99NO13 4.1 M+3Na [3+] 
positive 23.84 339.3963 C63H118O6 -2.7 M+H+2Na [3+] 
positive 24.02 639.3123 no hits N/A N/A 
positive 24.02 638.3095 no hits N/A N/A 
positive 24.02 678.3326 no hits N/A N/A 
positive 24.02 659.2878 no hits N/A N/A 




is important to mention that all steps of extraction and desorption in current study were performed 
manually, which makes small errors in accurate timing likely for short 5-min extraction times. 
However, as previously shown in Chapter 2, precision of pre-equilibrium SPME methods can be 
improved to be in line with that of equilibrium methods when automated system such as Concept 96 
is used. Therefore, future work for in vitro metabolomics using SPME can make use of this 
automated 96-well plate format for further improvement of method precision. 
Another contributing factor to poor method precision observed for some peaks can be low signal 
intensity, where a peak is inconsistently detected either by detector or by data processing software. 
The effect of signal intensity on method precision is shown for SPME and PP methods in Figure 7.18. 
The figure clearly shows that signal intensity plays a major role in the number of peaks meeting 
acceptable RSD criteria. For example using SPME, only approximately 40% of peaks with integrated 





>90% of peaks showed acceptable precision. This is in agreement with other studies where similar 
trend was reported.
208
 Interestingly, the number of peaks of given intensity that meet acceptable RSD 
criteria appears to be higher when SPME is used as sample preparation method versus plasma protein 
precipitation. One possible explanation for this observation could be ionization suppression which has 





Figure 7.18 Dependence of % RSD on signal intensity. Comparison of plasma protein 
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7.3.6 Results for semi-quantitative analysis of identified metabolites using traditional 
methods 
The current goal of the global LC-MS metabolomic studies is not full identification and absolute 
quantitation of all metabolites because current analytical capability is not sufficiently advanced to 
permit this because of the difficulties such as lack of authentic standards and databases, inadequate 
resolution, matrix effects, issues with degradation and conversion, etc.
15
 However, an acceptable 
global metabolomics method must be sufficiently quantitative to at least enable differential 
quantification of metabolites. Ionization suppression/enhancement effects are particularly problematic 
for any type of quantitative work as the observed changes in signal intensity for a particular 
metabolite may simply due to different composition of given sample which resulted in different 
ionization behaviour of that analyte, even if it is present at the same concentration in both samples. 
 The completeness of metabolite extraction for traditional methods and susceptibility to matrix 
effects can be verified by comparing the ability of each of three methods to extract metabolites from 
identical biological samples. This comparison was performed for a set of known metabolites and the 
results are reported in Table 7.3. The concentration in human plasma sample of each metabolite was 
determined using semi-quantitative approach where 100% recovery of metabolite was assumed for 
each method, and the concentration in human plasma was estimated in comparison to neat metabolite 
standard. Theoretically, if the quality of metabolomics data collected by each method was good with 
no matrix effects, the two plasma protein precipitation methods should give identical results. 
Ultrafiltration should give identical results to plasma protein precipitation methods for compounds 
that are not highly bound, and lower results for highly protein-bound compounds. Such results were 
observed for some of metabolites tested, for example maleic acid, fumaric acid, tryptophan and 
phenylalanine and are summarized by indicator good in the Data quality column of Table 7.3. 
However, the results shown in this table also illustrate problems with the analysis of some of 
metabolites. For example, for some of the polar analytes there was a large discrepancy observed 
between PM and PP results, for example citric acid and pyruvic acid. Not surprisingly, these results 
indicate that exhaustive extraction is not achieved for all metabolites. This can be caused by poor 
metabolite solubility in precipitant used and/or co-precipitation of metabolite. Precipitation with 
methanol/ethanol was found to perform better for these polar species, while more hydrophobic 
species performed well using either of the two precipitation approaches. For some metabolites, such 
as glucose, fructose, histidine, lysine, citric acid and hydroxybutyric acid (HBA), the results for UF 
method were significantly higher than for plasma protein-precipitation methods. In addition to poor 
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metabolite solubility and/or accidental co-precipitation, the observed results can be caused by very 
significant ionization suppression effects, as these compounds were eluting with relatively short 
retention times (<5 min) where many other co-eluting species were also present as shown in ion maps 
in Figure 7.9 and Figure 7.11. Although, large number of co-eluting species were also present in UF 
method, this extract was diluted 30-fold prior to injection (compared to 2-fold dilution for 
precipitation methods), so it would be expected to have  less significant ionization suppression 
effects. It is important to mention that all methods and all compounds reported in Table 7.3 exhibited 
good method precision for n=7 replicates as discussed in Section 7.3.1. Signal-to-noise ratio and 
signal intensity precision are typically the only criteria used to include or exclude peaks from global 
metabolomics data sets prior to further processing. However, our results clearly show that this is not 
adequate approach. Issues with ionization suppression can lead to erroneous results and conclusions 
when comparing samples from different individuals due to inter-sample variation in composition and 
lead to false discovery of possible biomarkers. Furthermore, plasma protein precipitation data cannot 
be reliably used to estimate concentrations of metabolites in given biofluids for more polar species.  
In addition to inter-method comparison, the results obtained  for the three methods were also 
compared to known expected concentrations of each metabolite in normal human plasma as reported 
in Human Metabolome Database (HMDB).
243-245
 For this comparison, only normal adult plasma 
concentrations were considered. The range shown in Table 7.3 presents minimum and maximum 
concentration of all ranges reported within HMDB. The results show reasonable agreement for 
majority of metabolites. The concentrations experimentally estimated for few metabolites are lower 
than expected (for example, ascorbic acid, cholic acid, glucose/fructose) but this can be attributed to 
the fact that no metabolism quenching for this plasma sample was not performed upon collection, as 
this was commercially purchased pooled human plasma sample. Also, this plasma sample was stored 
for approximately 6 months at -20°C prior to analysis, which could have resulted in the observed 
changes of unstable metabolites. This is especially likely for metabolite such as ascorbic acid which is 





Table 7.3 Summary of metabolite concentrations in human plasma determined using traditional 
sample preparation methods and comparison to normal concentrations expected in plasma 
according to the ranges reported in Human Metabolome Database.
243-245
  
Metabolite Plasma concentration estimated in 
current study 
Normal concentration 










Glucose+fructose 73 88 667 3300-6100 glucose, 
32-64 fructose 
Poor 
Ascorbic acid 0.84 ND 0.71 11-114 Good 
Glutamic acid 47 33 44 21-151 Good 
Pyruvic acid 921 61 1593 22-258 Poor 
Histidine 7.4 6.7 38 55-120 Poor 
Lysine 8.7 3.5 342 130-467 Poor 
Citric acid 9193 10 342103 Anticoagulant in current 
study 
Poor 
Maleic+fumaric acids 3.3 1.8 4.2 0-4 fumaric, N/A maleic Good 
HBA 321 255 604 0-700 Poor 
Phenylalanine 34 30 40 38-169 Good 
Tryptophan 36 33 4.4 36-130 Good 
Taurocholic acid 0.09 0.10 ND 0.2-0.6 Good 
Cholic acid 0.02 0.02 ND 0.5-2.0 Good 
Linoleic acid 51 36 ND 10-370 Good 
 
Above example shows that the reliance on good method precision (as indicated by acceptable RSD 
for a given peak in QC sample) cannot be used as the only criteria for ensuring good data quality in 
comparative metabolomics experiments. New approaches to address such problems are currently 
under development to ensure only signals with adequate performance are included in data 
interpretation. For example, Croixmarie et al. recently proposed injection of series of pooled samples 
rather than single QC pooled sample (for example 3/1, 1/1, 1/3). During data processing, the signal 
for each metabolite was then examined for linearity and any signals not meeting criteria were 
eliminated.
71
 This included the elimination of blank peaks, peaks with erratic profiles, peaks that 
exceed linear dynamic range of the instrument and so on. Using this method, 5296 initial peaks in 
negative ESI mode and 8937 peaks in positive ESI mode were reduced to 1286 and 2095 peaks using 
correlation cutoff value of 0.8.  Using this reduced data set improved the clustering during PCA 
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analysis as well as separation between treatment and controls, thus leading to more reliable 
interpretation.  These examples illustrate that there is still significant amount of research needed to 
improve data processing workflows for metabolomic studies and ensure only god quality data is used 
in the search for biomarkers. This example also illustrates that high metabolite coverage (for example 
>5000 peaks in the cited study) is not the only parameter to consider during the development of 
global metabolomic studies, as high number of peaks of poor quality contribute nothing to the 
improved understanding of living systems. 
7.3.7 Comparison of methods: summary 
The main results obtained for each of four methods discussed in previous sections are summarized in 
Table 7.4. Median RSD is included in Table 7.4 rather than mean RSD, because median is more 
robust estimator and less significantly influenced by presence of outliers.
72
 In general, the precision of 
SPME method was similar to that observed for plasma protein precipitation methods, and better than 
precision observed for ultrafiltration. However, this result is somewhat surprising as signal intensities 
using traditional methods were significantly higher than for SPME method, so improved method 
precision would be expected. In fact, equilibrium SPME using overnight extraction time exhibited the 
best method precision among all methods tested in positive ESI mode, whereas in negative ESI mode 
it provided the highest metabolite coverage. These results indicate that SPME is a useful sample 
preparation method for global metabolomic studies. In terms of metabolite coverage in positive ESI 
mode, SPME performed more poorly than other methods tested, so alternative coatings to further 
improve metabolite coverage should be explored in future.  Another interesting aspect for future 
studies is to begin the characterization of metabolites observed by SPME and not by other methods, to 
see if any previously unknown or unreported metabolites can be discovered. One such example is 
shown in Figure 7.19. This metabolite was detected by SPME using mixed mode coating and 5-min 
short extraction time, as well as by ultrafiltration and SPME using different coatings such as 
phenylboronic acid coating. The accurate mass of this unknown metabolite was submitted to database 
search using HMDB for tentative identification of possible chemical formula. Five possible 






Table 7.4 Summary of results (metabolite coverage and median RSD) observed for the analysis 
of technical replicates (n=7) of the same human plasma sample prepared using different sample 
preparation methods as discussed in experimental and analyzed using reverse-phase PFP LC-
MS method. 
 
Number of peaks or features Median RSD of signal intensity 
  Positive ESI Negative ESI Positive ESI Negative ESI 
PP 2975 2082 19 12 
PM 3245 2252 12 8 
UF 2686 2093 20 22 
SPME (5 min) 1592 2005 16 18 
SPME (overnight) 1821 3320 11 17 
 
In terms of method precision, our results show good agreement with literature reports. For example 
median RSD of 16% was observed for the analysis of technical replicates of human plasma sample, 
and similar method precision distribution as obtained in Figure 7.11.
67
 SPE using C18 sorbent was 
found to result in 1500 features using UHPLC-MS platform
51
, which is in line with the results we 
observed for SPME using positive ESI reverse-phase method. However, using SPE only 48% of 
detected peaks had acceptable RSD of ≤30% indicating better performance of SPME method 
developed in current study. In HUSERMET project study which uses plasma protein precipitation 
with methanol followed by lyophilization, method precision was similar to what was observed in our 
methods, but metabolite coverage was significantly less (1600 and 1100 in positive and negative ESI , 
respectively).
52
 The results shown in Table 7.4 are better than results reported in other studies in 
human plasma or serum. For example, Want et al. reported mean RSD values of 36% for acetonitrile 






Figure 7.19 Example metabolite detected (m/z of 411.0783) by SPME and UF methods, but not 
by plasma protein precipitation methods. All XICs are shown on the scale of 5x10
4
 to facilitate 
comparison between methods. The analysis was performed using negative ESI HILIC LC-MS 
method. Search of HMDB resulted in four possible hits with mass accuracy of 0.8 ppm (HMDB 
00379, 06471, 06355 and 03518)  and one hit with mass accuracy of -3.6 ppm (HMDB ID 01451). 
This may be attributed to use of low resolution instrument (ion trap), so species with same nominal 
mass could not be distinguished. Another possible explanation is that their method used lower plasma 
to precipitant ratio of 1 to 2 while our study employed 1 to 4 ratio, possibly resulting in lower extent 
of ionization suppression. The number of features observed by precipitation with acetonitrile (2200) 
reported by UHPLC-MS analysis using QTOF system in positive ESI mode
51
 is less than found in 
current study using conventional LC and single-stage Orbitrap system, indicating that a powerful LC-
MS platform for metabolomics was developed in current study. Similar to what was observed in 
current study, HILIC LC-MS methods resulted in fewer features than reverse-phase methods.
64, 213
 For 
example, Gika et al. observed 3284 features after analysis of rat urine using reverse-phase method 
versus 2098 of features observed using HILIC method.
213
 However, due to complementary nature of 
HILIC and reverse-phase mechanism, the metabolites identified by each of two methods are likely to 
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Furthermore, the results obtained in our study compare well to the results obtained in the study 
which compared various plasma protein precipitation methods with ultrafiltration.
235
 Ultrafiltration 
with 3K membrane similar to the one used in our study was found to provide efficient protein 
removal and good solubilization of highly abundant polar metabolites (for example, citrate, lactate, 
alanine and succinate) observed by NMR. The loss of hydrophobic species, similar to what was 
observed in our study, was also documented. To overcome this disadvantage of ultrafiltration, the 
authors propose the extraction of membrane material with methanol/water mixture followed by 
liquid-liquid extraction with chloroform, followed by evaporation and reconstitution step. This was 
found to efficiently recover hydrophobic species. However, this adds extra steps to the sample 
preparation method, so the use of SPME as proposed in current work provides a simpler and faster 
alternative with fewer steps and less potential for accidental contamination/analyte loss. Furthermore, 
the same study also shows that precipitation with acetonitrile leaves a considerable amount of 
lipoprotein. This can have adverse effect on the lifetime of chromatographic columns used in LC-MS 
studies, and the methods with more efficient protein removal should preferably be used.  
From ion maps shown for all methods it can seen that the region of 3-10 min has relatively fewer 
peaks, and any peaks that are present are of low molecular weight. The raw data files were 
subsequently manually examined to verify whether this was an artifact of data processing, but no 
additional metabolite peaks were found beyond those reported in figures.  The bias towards low 
molecular weight species in this region of chromatogram can be attributed to the fact that larger 
molecular weight species are expected to have more hydrophobic character in at least some portions 
of the molecule, which would result in their increased retention under reverse-phase conditions and 
elution in later portions of chromatogram. 
Brown et al. recently reported an instrument-specific artifact for Orbitrap mass analyzer which 
causes reporting of Fourier artifact peaks within 0.3 Da window of  true peak, situation which occurs 
if there is overabundance of ions of certain m/z which causes the detector to overload and clipping of 
associated oscillation signal.
33
 For study of serum, 0.8% of peaks and 1.6% of total peaks detected 
using positive and negative ESI  were assigned to be Fourier artifact peaks after examination of 
Fourier data. Considering the intensities of some abundant peaks using traditional methods were very 
high in current study, plasma protein precipitation and ultrafiltration methods can be considered to be 
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more susceptible to this type of artifact than SPME. For example, intensity distribution plot shown 
previously in Figure 7.18 shows that signal intensity using PP method exceeded 1x10
6
 for some 
peaks, while no peaks in SPME exceeded this intensity.    
Some of the factors that must be taken into account during the design of metabolomics study 
include number of samples to be collected, proper selection of controls and quality/robustness of the 
overall analytical method employed for the analysis. Other experimental factors impact the quality of 
the data collected and include: autosampler carryover, sample degradation while awaiting analysis, 
background ions originating from solvents, columns and glassware/plasticware used during sample 
preparation, contamination buildup that can elute and change intensity, sensitivity changes in MS 
during the run, saturation of the detector by exceeding linear dynamic range of instrument, and of 
course ionization suppression/enhancement due to co-eluting components.
203
 Croixmarie et al. found 
that the main source of variation in their data set was the origin of liver hepatocytes (46% of 
variance), while the treatment with drug only accounted for 13% of variation and run order accounted 
for 11% of variation.
71
 The biological variability was found to be 35% and 46% RSD for 
cerebrospinal fluid and human plasma respectively, versus analytical variability of 15-16% RSD for 
both matrices.
67
 In animal, plant and cell studies it can be easier to control biological variation as the 
study can be designed in such a way to minimize variability due to genetic makeup, environmental 
factors, diet or growth conditions, etc. When dealing with human samples, biological variability is 
much greater as it is impossible to control many of these factors. However, the results of current study 
on human plasma show that analytical reproducibility of proposed SPME-LC-MS methods is 
sufficient to be able to detect biological variability with 2-fold changes in signal intensity of 




7.3.8 Global metabolomics: data processing and identification challenges 
Current versions of SIEVE software do not employ any normalization strategy, and other 
metabolomics software such as XCMS also does not employ any normalization. Few LC-MS 
metabolomic studies do employ normalization strategies, but there is currently no consensus  in 
literature regarding the optimum (and if any) normalization strategy to use. Burton et al. report that 
normalization is not necessary for relatively small batches of data acquired on the same instrument at 
the same time.
203
 This was the situation in current work, so no normalization was employed. One 
potential drawback of this is that large intensity peaks could obscure some important low intensity 
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peaks. However, in samples prepared by SPME there were no peaks observed with very high 
intensity, so this approach should be adequate. 
Among the studies that do employ normalization, there is no consensus regarding the most 
appropriate normalization process to use during data processing, and both statistical (for example, 
normalization by median intensity) and internal standard normalization methods are employed.
241
 Van 
der Kloet et al. advocate the use of normalization to single internal standard selected from cocktail of  
internal standards.
240
 The selection is based on which internal standard results in the lowest RSD for 
the unknown metabolite. However, the assumption these authors make prior to application of their 
proposed method, is that no ionization suppression or enhancement is observed for any analyte. This 
assumption is clearly not realistic for a practical data set. Also, it is not practical to include internal 
standards for each of hundreds or thousands of potential metabolites present in a given sample, while 
the use of few, selected internal standards does not cover the entire expected chemical diversity and 
would not be expected to perform equally well for all metabolites. Several reports use normalization 
by dividing each peak with sample median on particular run-day, with each run-day containing 
exactly balanced number of samples from each treatment group.
20, 44, 205
 Other reports used 
normalization by total peak intensity observed for each sample
64, 206, 214, 218
, or  normalization to 
constant total signal intensity arbitrarily set to a single value as the most effective normalization for 
LC-MS data.
214, 217
 Such total area normalization, also often employed in NMR studies, assumes that 
decreases in certain metabolites are balanced by increases in other metabolites, thus keeping the total 
number of metabolites nearly constant. However, in LC-MS analysis, this is not a feasible assumption 
as the intensity of signal observed is dependent on the identity of analyte. Furthermore, exogenous 
species ingested through diet or originating from environmental exposure are also present in 
untargeted LC-MS chromatograms. These species are expected to vary from individual-to-individual, 
for example signal intensity for caffeine peak will depend on the individual’s consumption of 
beverages containing caffeine. This means that the total signal intensity would not be expected to be 
constant, so this type of normalization may not be suitable for LC-MS data.
241
 
Burton et al. advocate the use of artifact detection prior to using multivariate statistical approaches 
on data and that the data should be checked for background ions (constant across all runs), 
suppression/enhancement that occurs at specific retention times and trends dependent on acquisition 
order.
203
 Typically, if the exact same sample preparation procedure is used for all samples within the 
batch, the background ions do not need to be removed prior to statistical analysis, because they are 
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present at the same levels in all samples and will not cause differentiation of samples during principal 
component analysis. However, depending on what type of normalization is used on data, it may 
change the apparent levels of background ions leading to statistically relevant differences, so for 
improved data quality the removal of these peaks is recommended although it is not often performed 
in studies reported in literature.
203
 In our case, it was desired to compare the performance of several 
sample preparation methods and the exact sample treatment and solvent composition varied between 
these different techniques. In this case, to enable any meaningful comparison, it was absolutely 
necessary to remove any blank peaks from all data sets using appropriate blank controls for that 
method, in order to facilitate the accurate comparison across methods.  
Another area in need of further research is an improvement in the identification of metabolites. 
Current version of HMDB database contains about 6500 entries, but often does not contain 
compounds after phase I and II metabolism (such as glucuronides, sulfates, amino acid conjugates, 
etc.) For example, the search for unknown metabolites presented in Table 7.2 resulted in many 
metabolites with no known matches within the database. Other approaches reported in literature to 
improve the identification part of metabolomics workflow include the use of in-house library of a 
large number of authentic compounds collected using particular methods employed in metabolomics 
study and the use of retention time indices such as routinely employed in GC-MS.
205
 However, the 
use of retention indices in LC is complicated by the variation in retention index caused by the factors 
such as column aging and/or slight changes in mobile phase pH with time. This means that if the 
chromatographic behaviour of retention marker differs from that of  the analyte of interest, a drift can 
be observed in metabolite retention index. The authors addressed this issue by using larger retention 
index windows for compounds that showed such drift experimentally. Finally, existing public 
databases currently do not provide any retention time information, so the addition of such information 
could aid in tentative identification of metabolites. 
7.4 Conclusions 
The data presented within this chapter support the use of SPME in global metabolomic studies of 
human plasma. In comparison to ultrafiltration, SPME provided more comprehensive simultaneous 
coverage of both hydrophilic and hydrophobic species, while ultrafiltration performed very poorly for 
hydrophobic species.  Plasma protein precipitation methods performed poorly for many polar 
metabolites, indicating that the results for such species may not be reliable and method precision 
cannot be the only measure of ensuring good data quality in metabolomic studies. SPME also reduced 
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potential for ionization effects and provided unbound concentration information which is not 
achievable by plasma precipitation methods.  The developed LC-MS methods on Exactive were 
found to perform as well or better than most methods reported in literature and provided excellent 
metabolite coverage and method precision. 
7.5 Addendum 






In vivo SPME sampling for global metabolomic studies in mice 
8.1 Preamble and introduction 
8.1.1 Preamble  
This work has not yet been published.  Animal experiments were performed in collaboration with 
Brad Gien and Ines de Lannoy from NoAB BioDiscoveries using their animal facility. The 
contributions of Brad Gien included the development of in vivo SPME sampling procedure for mice, 
the design and development of interface for sampling of mice as well as performing of entire in vivo 
sampling procedure including animal surgery to insert the interface and blood collection. Dr. Ines de 
Lannoy was involved in experimental planning and design of these in vivo experiments. 
I, Brad Gien, authorize Dajana Vuckovic to use the material for her thesis. 
 
I, Ines de Lannoy, authorize Dajana Vuckovic to use the material for her thesis. 
 
8.1.2 Introduction 
In pharmaceutical industry, global LC-MS metabolomic studies can be used to investigate drug 
mechanism, distribution, metabolism and toxicity of existing drugs as well as drugs under 
development.
27
  Experimental designs for such clinical and/or pharmaceutical metabolomic studies 
vary depending on the main objective of the study. One common design includes the investigation of 
the effect of xenobiotic on the whole animal by studying changes in metabolism over time via 
monitoring of single or multiple biofluids.
209
 The main approaches for identifying xenobiotic 
metabolism include the comparison of animals dosed with drug (or other xenobiotic) versus animals 
dosed only with vehicle, and this type of experimental design would permit investigation of both 
endogenous and exogenous metabolism.
210
 If the objective of the study is primarily xenobiotic 
metabolism, then a better experimental design involves the dosing of one group of animals with 
xenobiotic versus second group which is treated with stable isotopically-labelled form of the same 
xenobiotic. In this case, the main difference between data sets should stem from xenobiotic 
metabolites as they would show mass shift between two groups due to isotopic labelling, and would 
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largely eliminate effect of endogenous metabolism from the data. A third type of study can be 
employed to reveal inter-species differences in metabolism, for example by comparing response of 
normal strains of mice versus genetically modified strains of mice (for example, humanized mouse 
lines or mouse lines with particular genes knocked-out).
27
  For example, Liu et al. used this 
methodology to discover four new metabolites of fenofibrate indicating new Phase II taurine 
conjugation pathway of this drug.
202
. In another study, the mechanism of hepatoxicity of existing 
drugs was successfully classified using UHPLC-MS metabolomics approach, and can in future enable 
classification of drug candidates during discovery stage.
71
  
The main objectives of current experiment were (i) to perform full metabolomic study on mice 
after i.v. dosing with 2 mg/kg carbamazepine and (ii) to investigate any advantages of in vivo SPME 
sampling versus ex vivo approaches based on blood withdrawal. This study was selected to expand on 
the preliminary data shown in 4.3.7 using larger number of mice (n=4 control and n=4 dosed) and 
using optimized coatings (Chapter 5) and LC-MS methods on Exactive (Chapter 6). Furthermore, the 
advantages of in vivo mode of sampling were investigated whereby the results obtained using in vivo 
SPME were compared versus ex vivo SPME, ultrafiltration  and plasma protein precipitation using 
methanol/ethanol. As such, this chapter complements data presented in Chapter 7 using human 
plasma but further expands the discussion in order to include the role and benefits of  in vivo 
sampling within the context of animal global metabolomic studies. 
8.2 Experimental 
8.2.1 Materials 
Same materials and reagents as described in Chapters 3-7 were utilized for this study. L-
phenylalanine-d5 (99.3 % purity ) was obtained from CDN Isotopes (Pointe-Claire, PQ, Canada) and 
D-glucose 1,2,3,4,5,6,6-d7 (98% purity) was obtained from Cambridge Isotope Laboratories 
(Andover, MA, USA). 
8.2.2 Summary of overall experiment design 
Animal experiments were performed on eight male CD-1 mice (Charles River Labs, St. Constant, PQ, 
Canada) weighing 20 to 30 g. All procedures followed were reviewed by the NoAb BioDiscoveries’ 
animal care committee and were performed in accordance with the principles of the Canadian Council 
on Animal Care. Prior to experiments, mice were acclimatized for a minimum of five days, and were 
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provided with food and water ad libitum. One day prior to in vivo SPME exepriments, a catheter was 
implanted surgically in the carotid artery and the mice were allowed to recover from surgery and 
anesthesia overnight. On the day of sampling, custom-made sampling interface, consisting of small 
volume tubing and a PRN adapter was connected by a stainless steel connector to the implanted 
catheter using the procedure and devices described in detail in 4.2.2. In vivo SPME sampling was 
performed on all eight conscious mice without any dosing of carbamazepine (n=1 sampling per 
mouse). One mouse (M3) was selected randomly in order to estimate intra-animal variability and the 
reproducibility of in vivo SPME sampling. For this mouse, five independent consecutive in vivo 
SPME samplings were performed using five individual SPME probes. 
For traditional analysis based on blood withdrawal, four of the above mice were designated as 
control mice (M1, M2, M3, M4) and no CBZ dosing was performed for these mice. Immediately 
following the completion of in vivo SPME sampling, these mice underwent direct cardiac puncture 
while under CO2/O2 anesthesia in order to collect the blood. The collected blood for each individual 
mouse was centrifuged immediately upon collection at 4°C to obtain plasma. Resulting plasma was 
stored on dry ice for transportation and to minimize metabolism.  The processing of plasma was 
completed within 6 hr post-collection according to the procedures described below. 
The remaining four mice (M5, M6, M7, M8) were dosed (2 mg/kg CBZ) by injection into the 
lateral tail vein using CBZ dosing solution prepared in ethanol/propylene glycol/saline (1/1/3, v/v/v). 
In vivo SPME sampling was performed 30-min post-dose using the procedures described below. 
Immediately following the completion of in vivo SPME sampling, each mouse underwent direct 
cardiac puncture while under CO2/O2 anesthesia in order to collect its blood for traditional analysis. 
The collected blood for each individual mouse was centrifuged immediately upon collection at 4°C to 
obtain plasma. Resulting plasma was stored on dry ice for transportation and to minimize metabolism.  
The processing of plasma was completed within 6 hr post-collection according to the procedures 
described below. 
The overview of the entire animal study employed in this research is provided in Figure 8.1. To 
summarize, using in vivo sampling it was possible to evaluate the effects of CBZ dosing using the 
same mice as samples before and after dosing were collected (t0 and t30 samples for M5, M6, M7, 
M8). Using traditional methods requiring relatively large blood volumes, the comparison could not be 
performed on the same mice so n=4 mice were used as controls (M1, M2, M3, M4) and compared 
against does mice (M5, M6, M7, M8).  During 30-min sampling of M6, a significant blood clot was 
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found, which prevented proper sample collection. Therefore, the only data point available for this 
mouse is in vivo SPME sampling at t=0. For traditional experiment based on plasma, sufficient 
amount of plasma (300 µL) could not be collected for M1 and M7, so ex vivo SPME was performed 
using 150 µL aliquot. These samples were used only for confirmation of the presence and absence of 
certain metabolites of interest and were not included in general data processing due to the dependence 
of the amount extracted by SPME on sample volume. 
 
Figure 8.1 Overview of animal study employed for comparison of in vivo SPME to traditional 
methods based on blood withdrawal. 
8.2.2.1 In vivo SPME sampling 
The day before in vivo SPME sampling, prototype in vivo SPME probes housed within 22-gauge 
hypodermic needle as described in Chapter 3 and consisting of biocompatible mixed-mode coating 
(C18 with benzenesulfonic acid, 45 µm thickness, 3 µm particle size, Supelco, Bellefonte, PA, USA), 
were preconditioned and pre-loaded with deuterated carbamazepine internal standard. The 
conditioning and loading was performed at equilibrium from 300 µL of 1 µg/mL standard solution of 
carbamazepine-d10 (CBZ-d10, Alltech, Deerfield, IL, USA) dissolved in methanol/water (1/1, v/v) 
using vortex agitation of 1000 rpm. The development of this procedure was described in more detail 
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in Chapter 3. The probes were kept in this conditioning/loading solution until each in vivo sampling 
time point in order to ensure that the coating does not dry out prior to sampling.  Three extra probes 
were pre-loaded and used to determine the amount of calibrant loaded according to similar procedures 
as described in Section 4.2.3. 
For each sampling period, a new conditioned in vivo SPME probe was inserted into the blood-filled 
sampling interface 1 min before the stated time and held in the interface 1 min after the stated time 
(total sampling time of 2 min). Immediately after the probe removal from the interface, the SPME 
probe was rinsed for 30 sec using purified water to remove any cells or salts from the probe surface. 
The probes were stored on dry ice until desorption which was carried out within 6-hr post-collection. 
The desorption of analytes from SPME probes was accomplished using 300 µL of desorption solvent 
(acetonitrile/water, 1/1, v/v) spiked with two internal standards  1450 ng/mL glucose-d7 and  300 
ng/mL phenylalanine-d5 using 0.3 mL amber polypropylene HPLC vials (Labsphere, Brossard, PQ, 
Canada). The desorption was performed for 60 min on multi-tube vortexer at 1000 rpm.  
8.2.2.2 Ex vivo SPME 
Ex vivo SPME was performed on 300 µL of mouse plasma obtained after cardiac puncture as 
described above, except for M1 and M7 where 150 µL plasma aliquot was used due to limited sample 
availability. SPME was performed according to the method developed and described in detail in 
Chapter 6. Briefly, SPME was performed using Supelco prototype biocompatible mixed-mode fibre 
(C18 and benzenesulfonic acid, 45 µm thickness, 3 µm particle size) for 5 min with 1000 rpm vortex 
agitation. The fibres were then desorbed using 300 µL of desorption solvent (acetonitrile/water, 1/1, 
v/v, containing glucose-d7 and phenylalanine-d5 internal standards) for 60 min in using vortex 
agitation at 1000 rpm.  
8.2.2.3 Ultrafiltration (UF) sample preparation 
After completion of ex vivo SPME experiment, 200 µL aliquot of mouse plasma used in 8.2.2.2 was 
placed in 3K Nanosep centrifugal device and centrifuged at 10000 rpm for 30 min at 4 °C. The 
resulting filtrate was diluted 10-fold in purified water prior to LC-MS analysis. 
8.2.2.4 Plasma protein precipitation with methanol/ethanol (PM) 
This procedure was adapted from study by Bruce et al.
12
. Experiments performed in Chapter 7 
confirmed better performance of solvent precipitation with methanol/ethanol versus solvent 
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precipitation with acetonitrile, so in this study only solvent precipitation with methanol/ethanol was 
used. Aliquots (100 µL) of mouse plasma from Section 8.2.2.2 were precipitated by addition of 400 
µL of methanol/ethanol (1/1, v/v). The samples were then manually vortexed for minimum of 60 
seconds, followed by centrifugation at 12000 rpm for 15 min at 4 °C. The resulting supernatant (150 
µL) was transferred to amber polypropylene HPLC vials (0.3 mL capacity) and diluted with 150 µL 
of purified water prior to LC-MS analysis. 
8.2.3 LC-MS analysis 
Aliquots (100 µL) of in vivo SPME, ex vivo SPME, UF and PM sample solutions were analyzed 
directly using pentafluorophenyl positive ESI LC-MS method (Section 6.2.2.1 and 6.2.2.4 for 
conditions) according to same general procedures described in Section 7.2.6. The remaining sample 
solutions were stored frozen (-30°C) for subsequent analysis to be described in follow-up studies. 
8.2.4 Data processing 
Same data processing scheme as described in Section 7.2.7 was used in current study. For framing 
using SIEVE, the following parameters were used: 0.005 mass window, 1.0 min retention time 
window width, maximum number of frames =20000, minimum signal intensity of 5000, retention 
time 1.0-33.0 min. 
8.3 Results and discussion 
8.3.1 Blank controls 
One important aspect to consider during the design of global metabolomic studies using SPME is to 
collect the appropriate blank controls to ensure peaks detected by SPME are real and belong to the 
biological sample under study. With this goal in mind, it is not sufficient to only run injections of 
blank desorption solvent, but it is necessary to analyze blank fibres which have undergone the same 
preconditioning and desorption procedures as the probes used in the study. Figure 8.2 shows TIC 
traces obtained for blank fibre and for direct injection of blank desorption solvent. Although, the 
chromatograms generally have the same appearance and TIC intensity, the blank fibre does show 





Figure 8.2 TIC of (a) blank SPME fibre (absolute intensity 9.3x10
7 
counts, run order 66) and (b) 
blank desorption solvent (absolute intensity 1.1x10
8
 counts, run order 81) collected using 
positive ESI LC-MS method with pentafluorophenyl column.  
processing (n=3 of each blank type) shows that 430 features have higher intensities than observed in 
direct injection of blank desorption solvent. These peaks can occur due to  preconcentration of the 
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contaminant species present in conditioning solvent  by the fibre (for example, any contaminants 
present in purified water or methanol). Additional sources of these species can be fibre production 
process itself or possibly vessels (such as vials or well-plates) used during the conditioning procedure. 
For traditional methods, appropriate blank controls were prepared by taking an aliquot of purified 
water through the entire sample preparation procedure and injecting the resulting sample. As one of 
the goals of current study was comparison of different methods, samples obtained using each method 
were processed in SIEVE together with the corresponding blank controls in order to ensure all peaks 
used for subsequent PCA were real peaks originating from the biological system rather than artifacts 
of the sample preparation procedure. 
8.3.2 Quality control (QC) results 
In current study, quality control sample was prepared by combining aliquots of all samples (in vivo 
SPME, ex vivo SPME, UF and PM) within the sample set. This QC was run at the beginning of the 
sample set to ensure system is properly conditioned, throughout the sample set after every 12 sample 
injections and at the end of the sample set. The results for this QC are used to ensure no systematic 
drift occurred throughout the entire run time. Plots of signal intensity versus run order for several 
identified metabolites are shown in Figure 8.3. The metabolites were selected to cover a wide range 
of signal intensities and the entire chromatographic space in terms of retention time. Injections 005 to 
008 were considered part of  the preconditioning procedure and are included to show that the system 
was adequately pre-conditioned. Figure 8.4 shows RSD results for all QC injections for all known 
metabolites observed using in vivo SPME. The results indicate good performance of the entire LC-
MS system with mean RSD of 16% for all known metabolites in QC sample. Two internal standards 
glucose-d7 and phenylalanine-d5 had RSD of 7 and 12% for all QC injections and RSD of  23% and 
2% for in vivo SPME injections (n=8 animals). Carbamazepine d10 which was used as on-fibre 
calibrant for CBZ had RSD of 12% in all QC injections and 17% for in vivo SPME injections (n=8 
animals) indicating no problems with any of the probes used during the study.  
Furthermore, in addition to targeted processing of selected metabolites confirmed using authentic 
standards, QC samples can also be used to evaluate the quality of global metabolomics data. This is 
performed by subjecting these QC samples to SIEVE processing followed by PCA together with the 
actual samples. The results of PCA analysis for current study including QC samples are shown in 
Figure 8.6 (a, b and d). All QC injections (shown in red) cluster tightly together with no evident 
outliers indicating good quality of the data set indicating that further processing and interpretation of 
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the dataset is worthwhile as analytical variability was properly kept in check during the run. This is 






































































































































































































Figure 8.3 Signal intensity versus QC run order for selected compounds (a) glucose (b) reduced 
glutathione (c) progesterone (d) nicotinamide and (e) carbamazepine. 
8.3.3 Evaluation of intra-animal variability and reproducibility of in vivo SPME 
sampling 
One of the goals of current study was to evaluate the reproducibility of in vivo SPME sampling for 
global metabolomics on one mouse (n=5 consecutive samplings prior to dosing). Although some 
temporal variability in metabolite concentrations can be expected over the time scale of the 
experiment, some of the metabolites should remain effectively unchanged permitting an approximate 
evaluation of in vivo SPME procedure. The results of this experiment are shown in Figure 8.4 for the 
set of known metabolites and compared against the inter-animal variability (n=8 mice) for the same 
set of metabolites. The reproducibility of QC injections is also included in the figure as a reference 
point. For the majority of the metabolites inter-animal variation is significantly higher than within-
animal variation, with some of the metabolites such as reduced and oxidized glutathione exhibiting 




































































































































reported biological variability of 35% and 46% RSD for cerebrospinal fluid and human plasma 
respectively, versus analytical variability of 15-16% RSD for both matrices.
67
 One exception to this 
general trend was adenosine where inter-animal variation was similar to within-animal variation. This 
can perhaps be attributed to extremely short half life of this species which may contribute to rapidly 
changing concentrations on the timescale of the experiment.   
 
Figure 8.4 Comparison of inter-animal versus intra-animal variability (expressed as %RSD) for 
the set of known metabolites detected using in vivo SPME sampling. 
8.3.4 Principal component analysis: effect of CBZ dosing 
Using in vivo SPME, it was possible to sample the same n=4 mice before and after dosing with 
carbamazepine. The data set consisted of 1845 features detected using short 2-min sampling time 
which is in agreement with our previous studies on human plasma (see Table 7.4). The results of PCA 
for this data set are shown in Figure 8.5. First three components described 87.9% of variance and the 
differentiation of mice according to dosing was immediately apparent as shown in Figure 8.5 (a). The 
main source of variation was biochemical individuality of animals as shown in 2D scores plot of 
principal components 1 and 2 (Figure 8.5 (b)), with the two components contributing to 60.2 and 
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the differentiation of this data set according to CBZ dosing. These results are in agreement with the 
study performed by Croixmarie et al. who found that the main source of variation in their data set was 
the origin of liver hepatocytes (46% of variance), while the treatment with drug only accounted for 
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Figure 8.5 (a) 3D scores plot obtained for in vivo SPME sampling of n=4 mice (M5, M6, M7, 
M8) prior to (T0) and 30-min (T30) post dose. (b) 2D scores plot of the same dataset showing 
PC1 versus PC2  (c) Loadings scatter plot of PC1 versus PC2 illustrating the peaks contributing 
most to the observed clustering (d) 2D scores plot of the same dataset showing PC1 versus PC3 
(e) Loadings scatter plot of PC1 versus PC3 illustrating the peaks contributing most to the 
observed clustering. Blank injections are shown, while QC injections are omitted for clarity in 
all plots.  
Figure 8.6 shows the results of PCA for samples obtained using ultrafiltration (UF) and solvent 
precipitation with methanol/ethanol (PM). The results indicate large influence of the sample 
preparation method on the data collected. This is the result of vastly different metabolite coverage 
achievable by the two methods as discussed in detail in Chapter 7 using human plasma example. 
Differentiation according to dosing is observed only for UF samples, and no such differentiation is 
observed for PM samples using three principal components which contribute 66.2, 14.5 and 5.6% of 
variance respectively. Clearly one disadvantage of the traditional analysis employed here was the fact 
that different mice were sampled as control versus treatment groups. This was necessary in order to 
collect sufficient blood volume to perform the analysis using all methods. The results show that the 
use of small sample set (n=4 mice/group) may or may not permit acceptable differentiation of 
samples according to dosing as inter-animal variability is included within the data set. Inter-animal 
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to obscure the effect of dosing as was found for PM method in current study. Thus, if the only 
objective of the study was a classical metabolomics study to the effects of xenobiotic dosing, PM data 
set would be virtually unusable and would require a new study with much larger number of animals. 
In contrast, both SPME and UF were able to clearly differentiate the samples based on dosing even 
when such small data set was used. Both of these methods provide a response which is proportional to 
biologically active free concentration. The fact that both methods were able to differentiate the 
samples indicates that free concentration information can be extremely valuable in the context of 
metabolomic studies.  
Furthermore, the data was examined for known CBZ metabolites which include 10,11-









Figure 8.6(a) 3D scores plot obtained using ultrafiltration (UF, black spheres) and solvent 
precipitation (PM, blue spheres) for n=4 mice prior to CBZ dosing (PM and UF) and n=4 mice 
30-min  post dose(PM CBZ and UF CBZ). (b) 2D scores plot of the same dataset showing PC1 
versus PC2  (c) Loadings scatter plot of PC1 versus PC2 illustrating the peaks contributing most 
to the observed clustering (d) 2D scores plot of the same dataset showing PC1 versus PC3 (e) 
Loadings scatter plot of PC1 versus PC3 illustrating the peaks contributing most to the 
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for protonated ion), 3-hydroxycarbamazepine (m/z 253.0972 for protonated ion), 10,11-
dihydrocarbamazepine (m/z 239.1179 for protonated ion), 10,11-dihydro-10-hydroxycarbamazepine 
(m/z 255.1128 for protonated ion) and 10,11-dihydro-10,11-dihydroxycarbamazepine (m/z 271.1077 
for protonated ion).
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 The main CBZ metabolite, 10,11-carbamazepine epoxide was detected using 
all sample preparation methods employed in current study,  while other metabolites were only 
detected in samples prepared using solvent precipitation (PM) and had relatively low signal intensity. 
In other words, the detection of these species by SPME and UF failed due to very low concentrations 
in blood at the time point of analysis. The low concentration of these metabolites may be due to the 
fact that samples were analyzed only 30-min post-dose, and perhaps monitoring of longer times 
would be useful in this situation. Thus, from the perspective of monitoring very low level exogenous 
drug metabolites PM data was invaluable even though it failed to differentiate mice according to 
dosing using the global metabolomics approach. Therefore, this study clearly shows the advantages of 
using set of complementary methods during an animal study to further enhance the understanding of 
the biological processes and shows that each method can contribute an important piece of the puzzle. 
Figure 8.6 depicts another interesting finding. Mouse 2 (labelled as M2) is shown as an outlier 
using both UF and PM methods as shown by this point falling outside Hotelling’s 95% confidence 
interval. This result is not simply an analytical outlier as shown in Figure 8.7, as QC standards, blanks 
and other samples do not exhibit significant trends with respect to run order. Furthermore, ex vivo 
SPME results also indicate M2 as an outlier, whereas in vivo SPME results show reasonable 
clustering of M2 with other mice (Figure 8.9). This data seems to indicate that important metabolic 
changes occurred for blood collected from M2 during sampling or sample storage procedures, which 
resulted in a significantly changed composition of this sample. From experimental viewpoint, blood 
from M2 was treated in exactly the same way as for the rest of the mice, so it is not clear what 
additional precautions could be taken to ensure sample integrity for this particular blood sample. This 
data therefore indirectly indicates an advantage of in vivo SPME sampling – the ability to properly 
capture the metabolome composition at the time of sampling without inadvertent changes in 



































































































































































Colored according to Obs ID (Primary)
-3 SD = -632.366  -2 SD = -421.577  2 SD = 421.577    3 SD = 632.366    



































































































































































Colored according to Obs ID (Primary)
-3 SD = -296.236  -2 SD = -197.49   2 SD = 197.49     3 SD = 296.236    









Figure 8.7 Plot of principal component 1 (a), 2 (b) and 3 (c) versus observation ID for data set 
shown in Figure 8.6.  
No global metabolomic studies on the dosing of carbamazepine have been reported in literature, so 
the current study also presented an interesting model to examine CBZ effects on endogenous 
metabolites, whereas CBZ exogenous metabolites are well-characterized in literature. The most 
relevant metabolites detected after PCA analysis were subjected to database search using HMDB for 
tentative identification of possible chemical formula. Current version of HMDB database contains 
about 6500 entries, but often does not contain compounds after phase I and II metabolism (such as 
glucuronides, sulfates, amino acid conjugates, etc.) . In current study, the tentative identification was 
performed by comparing the accurate mass obtained for unknown peak with database entries within 5 
ppm accuracy. Furthermore, possible matches were examined according to the compound polarity 
and ion type. For example, compounds with higher log P values would be expected to have longer 

































































































































































Colored according to Obs ID (Primary)
-3 SD = -183.249   -2 SD = -122.166   2 SD = 122.166     3 SD = 183.249     









Figure 8.8 Individual 3D scores plot obtained using (a) ultrafiltration (UF) and  (b) solvent 
precipitation (PM) for n=4 mice prior to CBZ dosing (PM and UF) and n=4 mice 30-min  post 
dose(PM CBZ and UF CBZ). 
 
Figure 8.9 Results of PCA comparing in vivo versus ex vivo SPME sampling (no CBZ dosing) 





would not represent a likely match and would be omitted from the table. Likely matches were also 
examined according to ion type, with protonated and sodiated ions being more likely than other 
adducts. Finally, expected concentration in blood of tentative matches was also considered with more 
abundant species being more likely to be observed using this global metabolomics workflow. For 
unknown peaks, where no suitable ions were identified using database according to the described 
criteria, the entry was marked as no hits. For unknown species with many possible chemical formulas, 
the entry was marked accordingly as it was not possible to further narrow down chemical identity of 
the compounds.  
Table 8.1 summarizes the tentative identification of top 20 metabolites observed using 
ultrafiltration which contributed to the differentiation of samples according to the dosing. The 
majority of these species are very polar metabolites with retention times ≤ 3.5 min, and one of the 
entries likely corresponds to propylene glycol which was used as dosing vehicle and only present in 
mice receiving CBZ treatment. Interestingly, both carbamazepine and carbamazepine 10,11-epoxide 
were observed in UF samples, but were not identified as the main contributors according to PCA so 
they are not listed within this table. Table 8.1 also shows whether each particular metabolite was 
observed by other methods employed in current study (SPME and PM). The results show that one of 
differentiating metabolites is unique to UF only, while others were observed by other methods as 
well. As mentioned previously, differentiation of samples after solvent precipitation could not be 
performed successfully, so no such list of features could be collected based on PM data. 
Table 8.2 lists top 20 features obtained using in vivo SPME after PCA. It is immediately apparent 
that the differentiating metabolites observed by in vivo SPME are completely different than those 
observed for UF (Table 8.1) indicating the techniques are complementary in nature due to the 
differences in metabolite coverage achievable by the two techniques. In contrast to UF data, 
carbamazepine (both protonated and sodiated forms) were detected by PCA as important 
differentiating metabolites. One potentially interesting finding is tentative identification of oleamide. 
According to HMDB, oleamide interacts with multiple neurotransmitter systems, although its mode 
of action is not fully understood. An indication of seizure-limiting properties of this compound was 
previously reported in literature, although exogenous dosing of this compound did not result in 
statistically significant attenuation of full epileptic episodes when compared to dosing of known anti-
epileptics such as CBZ due possibly to potency and/or dosage selection.
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1.65 158.9612 no hits N/A N/A no yes 
1.25 203.0527 C6H12O6 0.53 M+Na[1+] yes yes 
1.28 153.0869 no hits N/A N/A no yes 
1.34 115.0366 multiple formulas  0.33 M+Na[1+] yes yes 
1.36 169.0582 C5H10N2O3 -0.91 M+Na[1+] no yes 








0.39-0.45 M+H [1+] yes yes 
1.41 120.0657 C4H9NO3 1.5 M+H [1+] yes yes 
1.45 148.0603 Glutamic acid* -0.93 M+H[1+] yes yes 
1.47 176.1030 C6H13N3O3 0.18 M+H[1+] yes yes 





0.39-0.45 M+H[1+] yes yes 
1.93 147.0757 C5H10N2O3 -4.8 M+H[1+] yes yes 
2.16 148.0426 no hits N/A N/A no yes 




-0.92 M+H[1+] yes yes 
7.65 182.0809 C19H11NO3 -1.5 M+H[1+] yes yes 
9.51 166.0863 Phenylalanine* 0.28 M+H[1+] yes yes 
12.26 205.0966 Tryptophan* -2.7 M+H[1+] yes yes 
17.58 207.1490 no hits N/A N/A yes yes 
*confirmed with authentic standard 
first report to tentatively link oleamide to the in vivo action of carbamazepine, and clearly merits 
further exploration. Another interesting compound tentatively identified in Table 8.2 is thromboxane. 
Thromboxane is one of the products of arachidonic acid cascade, and this cascade within brain is 
under discussion as putative drug target of common mood stabilizers such as carbamazepine 
according to current literature.
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 It is interesting to note that this simple study resulted in two possible 
links to known or putative endogenous metabolites involved in carbamazepine mechanism. In future 
studies, it would be interesting to further characterize and interpret the unknown metabolites reported 
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in Table 8.2, as it could provide additional information regarding biological processes affected by 
CBZ administration. 
















1.90 158.9640 no hits N/A N/A no no 
1.90 226.9513 no hits N/A N/A no no 
2.88 102.0340 no hits N/A N/A yes no 
10.47 156.1380 C14H28O2 -1.8 M+2ACN+2H[2+] yes yes 
14.31 259.0836 Carbamazepine* -1.9 M+Na[1+] yes yes 
14.32 237.1017 Carbamazepine* -2.1 M+H[1+] yes yes 
















0.46 M+H[1+] yes yes 
21.64 256.2733 no hits N/A N/A yes no 
21.96 282.2786 C18H35NO oleamide -1.9 M+H[1+] yes yes 
21.96 283.2719 no hits N/A N/A yes no 
21.96 282.3002 no hits N/A N/A yes no 
22.05 282.2584 no hits N/A N/A yes no 
24.02 338.3409 C20H40O thromboxane -2.4 M+ACN+H[1+] yes yes 
19.94 303.2313 C20H30O2 -1.8 M+H[1+] yes no 




2.7 2M+K[1+] yes yes 
*confirmed with authentic standard 
8.3.5 Principal component analysis: biochemical individuality 
As shown in 2D scores plot presented in Figure 8.5(b) principal component 1 and 2 corresponded to 
biochemical individuality: individual mice clustered closely together regardless of CBZ dosing. Table 
8.3 lists 20 most important features contributing to this differentiation as extracted from the loadings  
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1.63 308.0905 Glutathione* -1.8 M+H [1+] yes no 
1.90 294.9385 no hits N/A N/A no no 
1.90 362.9258 no hits N/A N/A no no 





-2.0 M+ACN+2H[2+] no no 

















3.0 M+ACN+2H[2+] no no 
6.45, 7.28 132.1019 
C6H13NO2 leucine 
isomers 
-0.10 M+H[1+] yes yes 
9.36 166.0862 Phenylalanine* -0.37 M+H[1+] yes yes 
10.47 156.1383 C14H28O2 0.20 M+2ACN+2H[2+] yes yes 
11.70 116.1435 no hits N/A N/A yes yes 
17.55 207.1491 no hits N/A N/A yes yes 




-0.12 M+H[1+] yes yes 
21.64 256.2733 no hits N/A N/A yes no 
21.96 282.2786 C18H35NO oleamide -1.9 M+H[1+] yes yes 




-0.16 M+H[1+] yes no 
*confirmed with authentic standard 
plot shown in Figure 8.5(c). The list includes glutathione and several amino acids, tentative 
identification of hydroxylated base and several lipids and seven unknown features. Some of these 
features are detected only using in vivo SPME and not by any other method (PM or UF) further 
indicating complementary nature of the tested methodologies. 
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Compound identification remains a bottleneck of metabolomics analysis, and the tentative 
identification performed in current study represents at best only an educated guess – further work is 
absolutely necessary to confirm the identity of discussed species. As shown in Tables 8.1 to 8.3, 
numerous features could not even be tentatively identified with a likely chemical formula, showing 
concerted global effort is needed to further characterize and catalogue mammalian metabolites in 
various specimens.  
8.3.6 Advantages of in vivo sampling versus blood withdrawal approaches 
Table 8.4 shows 83 features which were detected using in vivo SPME sampling, and not detected 
using ex vivo SPME after blood withdrawal. The majority of these peaks (all except 9) were also not 
detected using solvent precipitation and ultrafiltration methods. This data was compiled by comparing 
in vivo SPME  results versus ex vivo SPME results for the mice which were not dosed (n=8 mice for 
in vivo SPME, n=4 mice for ex vivo SPME), so it represents endogenous metabolites, rather than CBZ 
metabolites. The fact that in vivo SPME is capable to capture this many unique features not observed 
by any other methods  presents a unique advantage of in vivo sampling approaches as the metabolome 
at the time of analysis is better representative of the true metabolome at the time of sampling. Efforts 
are currently underway in our laboratory to further characterize these species, but preliminary data 
indicates that many of the species are energy metabolites with fast turnover rates. For example, in 
vivo SPME was able to capture β-NAD which was not observed using the in vitro methodology post-
blood withdrawal (SPME, UF or PM) as shown in Figure 8.10 and Figure 8.11. These results are 
shown in Figures 8.10 and 8.11 for one mouse but are consistent for the entire cohort of eight mice 
sampled within the study. The figure shows the detection of β-NAD using reversed-phase negative 
ESI method, but the same finding was also confirmed in reversed-phase positive ESI method. 
Tentative database identification of few additional species seem to indicate the presence of 
hydroxylated bases as well as some phosphorylated species such as phosphohydroxypyruvic and 
imidazole acetol-phosphate, but this requires further confirmation against authentic standards or using 
fragmentation patterns on a full Orbitrap. For the nine species in Table 8.4 which were also found 
using solvent precipitation method, the fact they were not observed using ex vivo SPME on the same 
plasma sample seems to indicate that the free (unbound) concentration of these species decreased in 
the collected blood samples in comparison with the true in vivo concentration. This is supported by 
the fact that these species have relatively long retention times, indicative of relatively hydrophobic 
species which generally exhibit higher degree of binding. The time delay between blood collection 
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and sample preparation could indicate slow-binding kinetics. Alternatively, it is possible that the total 
concentrations of these species decreased after blood withdrawal due to other processes occurring 
such as degradation or enzymatic conversion, but the total concentration remained sufficiently high to 
still be detectable by PM method. 








Observed by in 
vivo SPME 
Observed by 
ex vivo SPME 
1.60 232.0913 no no yes no 
1.62 349.0733 no no yes no 
1.63 359.5208 no no yes no 
1.63 665.1195 no no yes (β-NAD) no 
1.63 380.0340 no no yes no 
1.63 310.0972 no no yes no 
1.63 309.0939 no no yes no 
1.63 332.5612 no no yes no 
1.90 498.8875 no no yes no 
1.91 704.3677 no no yes no 
1.92 881.8183 no no yes no 
1.95 658.8367 no no yes no 
1.97 472.8165 no no yes no 
2.86 174.9391 no no yes no 
2.86 338.9091 no no yes no 
2.87 334.9113 no no yes no 
10.33 216.0663 no no yes no 
10.46 132.0808 no no yes no 
11.44 455.1882 no no yes no 
11.64 290.1706 no no yes no 
12.21 329.2295 no no yes no 
12.21 307.2476 no no yes no 
12.26 383.1205 no no yes no 
12.65 213.1597 no no yes no 
13.47 379.3050 no no yes no 
13.48 401.2866 no no yes no 
13.79 585.2098 no no yes no 
13.80 753.3840 no no yes no 
14.73 263.1725 no no yes no 










Observed by in 
vivo SPME 
Observed by 
ex vivo SPME 
15.56 837.4057 no no yes no 
15.64 247.0880 yes no yes no 
17.43 226.1225 no no yes no 
17.50 269.1280 no no yes no 
17.55 279.1814 no no yes no 
17.56 300.1600 no no yes no 
17.91 302.1207 no no yes no 
18.11 476.2348 no no yes no 
18.22 346.1468 no no yes no 
18.62 266.1536 no no yes no 
18.86 252.1250 no no yes no 
18.86 250.1292 no no yes no 
19.11 263.2116 no no yes no 
21.27 590.4322 no no yes no 
21.40 757.3939 no no yes no 
21.51 730.5676 no no yes no 
21.60 686.5406 no no yes no 
21.69 642.5152 no no yes no 
21.72 657.3538 no no yes no 
21.79 643.8542 no no yes no 
21.79 581.4620 no no yes no 
21.80 599.4922 no no yes no 
21.91 537.4360 no no yes no 
21.91 555.4663 no no yes no 
21.91 560.4216 no no yes no 
22.00 516.3995 no no yes no 
22.01 511.4394 no no yes no 
22.02 493.4092 no no yes no 
22.12 449.3831 no no yes no 
22.12 472.3685 no no yes no 
22.26 428.3424 no no yes no 
22.46 791.4290 no no yes no 
22.46 781.9151 no no yes no 
22.50 339.2866 no no yes no 
22.67 727.8665 no no yes no 
22.78 693.8612 no no yes no 










Observed by in 
vivo SPME 
Observed by 
ex vivo SPME 
23.16 896.4543 no no yes no 
23.88 717.8722 no no yes no 
24.15 911.4509 no no yes no 
24.18 480.1591 no no yes no 
24.33 866.9233 no no yes no 
24.58 738.5066 yes no yes no 
24.60 813.5258 yes no yes no 
24.62 385.2452 no no yes no 
24.72 788.5220 yes no yes no 
24.80 388.3417 no no yes no 
24.81 764.6094 yes no yes no 
24.81 763.6062 no no yes no 
25.43 788.5201 yes no yes no 
25.45 744.5446 yes no yes no 
25.81 762.5433 yes no yes no 
26.69 796.5851 no no yes no 
 
Table 8.5 shows 24 compounds which were found in ex vivo SPME samples and not found in in 
vivo samples, indicating these species were likely formed during or after blood collection. In majority 
of cases (18 out of 24), the presence of these species was also confirmed in samples obtained after 
PM method, and two of these species were also found using ultrafiltration. For six species which were 
not confirmed in solvent precipitation samples, it is possible that significant ionization suppression 







(b) in vivo SPME 





Figure 8.10 XIC of m/z 662.1019 corresponding to β-NAD for the same mouse sample analyzed 
using negative ESI reverse phase PFP LC-MS method by (a) PM (b) in vivo SPME (c) ex vivo 
SPME (d) UF and (e) injection of authentic metabolite standard containing β-NAD. 
 
(d) UF 




Figure 8.11 Mass spectrum of (a) authentic β-NAD standard solution dissolved directly in 
desorption solvent (mass accuracy -2.1 ppm) (b) unknown peak identified for in vivo SPME 
sample shown in Figure 8.10 (mass accuracy 0 ppm). Mass accuracy is calculated using 
expected accurate mass of β-NAD of 662.1019 for [M-H]
-
 in negative ESI mode. m/z of 685.0916 
corresponds to [M+Na-2H]
- 
ion of NAD while 664.1174 ion corresponds to [M-H]
- 






(a) authentic std 
(b) in vivo SPME 
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Observed by in 
vivo 
SPME 
Observed by ex 
vivo SPME 
1.63 192.9099 no no no yes 
1.90 835.8282 no no no yes 
10.23 427.2228 yes yes no yes 
13.29 381.1538 yes yes no yes 
13.42 347.2210 yes no no yes 
14.73 345.2052 yes no no yes 
18.27 480.2990 yes no no yes 
18.65 282.6229 yes no no yes 
18.71 520.2381 yes no no yes 
18.71 520.2143 yes no no yes 
18.71 547.2985 yes no no yes 
18.71 520.4332 yes no no yes 
18.71 520.4213 yes no no yes 
18.71 520.4647 yes no no yes 
18.71 551.3123 yes no no yes 
18.73 591.3254 yes no no yes 
18.73 544.2952 yes no no yes 
18.73 539.8147 yes no no yes 
19.08 880.8452 no no no yes 
19.99 539.2618 no no no yes 
20.23 759.3737 no no no yes 
21.17 337.2733 yes no no yes 
21.20 439.2361 yes no no yes 
29.32 925.2700 no no no yes 
 
In conclusion, both Table 8.4 and Table 8.5 present convincing evidence that observable changes 
occur in metabolome during and/or after blood collection. Additional studies to further elucidate the 
nature of compounds captured by in vivo SPME can help further establish this technique as an 
important tool in metabolomics. 
8.4 Conclusions 
This chapter presents an important addition to global metabolomics data of human plasma presented 
in Chapter 7. Primarily, it shows distinct advantages of in vivo SPME sampling approach over 
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traditional methods based on blood withdrawal. Firstly, in vivo SPME is capable of capturing 
numerous metabolites not observed by other techniques including some important energy metabolites. 
This means that the true metabolome at the time of sampling is captured more accurately and can help 
lead to more accurate biological data interpretation in future. Secondly, the ability to repeatedly 
sample the same animals permits the use of small cohort of animals while still obtaining highly 
relevant data, which may not be the case when animal sacrifice per each experiment data point is 
utilized as the underlying data structure may be obscured by inherent inter-animal variability in 
metabolic processes. Thirdly, in vivo SPME can be a very promising tool to study inter-animal 
variation with the information on unbound concentration providing an important dimension for 
biological data interpretation.  Finally, the results for mouse 2 in current study indicate significant 
changes in sample composition versus in vivo SPME sample collected for the same mouse, indicating 
sample composition can unpredictably change after biofluid collection despite the precautions taken. 
From the perspective of CBZ metabolism, two seemingly important links to oleamide and 
thromboxane have emerged from SPME data, but further characterization of all potentially 






Summary and future directions 
9.1 Summary 
Increasing the number of steps involved in sample preparation for metabolomics applications results 
in the narrowing of chemical diversity of captured metabolome, as each step can contribute some 
degree of selectivity and/or inadvertent metabolite losses can occur during sample handling due to 
adsorption, degradation, etc.
34
 The use of solid-phase microextraction, in particular in vivo SPME, 
completely streamlines the process and reduces the overall number of steps as well as eliminates the 
need for metabolism quenching while ensuring captured metabolome is a good representation of true 
metabolome at the time of sampling. In comparison to the traditional methods, SPME  is 
characterized by lower amounts extracted due to its non-exhaustive nature, which translates into 
lower MS signal intensities and overall lower analytical sensitivity. However, despite this apparent 
shortcoming, method precision of SPME was found equivalent or better than traditional methods, 
indicating that the small amounts of metabolites extracted are still sufficient for reliable quantitative 
analysis. In fact, non-exhaustive nature of SPME resulting in small amounts extracted is of utmost 
importance for in vivo sampling using SPME as it minimizes the disturbance to the system under 
study and permits the use of small probe dimensions making the technique less invasive than other 
more traditional approaches. Furthermore, lower overall signal intensities encountered in SPME 
methods resulted in additional two significant benefits: (i) reduced ionization suppression which 
improves quantitation and data quality and (ii) improved metabolite coverage as low intensity peaks 
are not obstructed by the presence of highly intense peaks. In fact, highest metabolite coverage among 
all methods tested was achieved by SPME in combination with negative ESI LC-MS method, 
indicating that SPME can be a powerful tool for metabolomics analysis. One important aspect of 
SPME is that the amount extracted is proportional to unbound concentration which is biologically 
active, so it is possible that SPME metabolomics data may be more easily correlated to the observed 
biological effect, but this aspect demands further investigation. The current study does clearly show 
that SPME performs better than ultrafiltration in terms of improving the coverage of hydrophobic 
species. These species tend to be more highly protein-bound, so information on the unbound 
concentration of these analytes becomes extremely valuable for biological interpretation. In fact, for 
some xenobiotics such as carbamazepine, significant inter-individual variability of unbound 
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concentrations has been documented even when total concentration is effectively the same, and 
similar situation can be envisioned for some of endogenous metabolites. 
The success of current study also relied heavily on detailed optimization of LC-MS methods in 
order to achieve optimum analytical sensitivity. Interestingly, when a generic method on a full hybrid 
instrument was used <500 features were observed in positive ESI mode, which is significantly less 
than minimum of 1500 features observed in current study using a single-stage Orbitrap MS. The use 
of complementary HILIC and reverse phase methods, as well as positive and negative ionization 
modes also significantly increased metabolite coverage. The obtained SPME extract was compatible 
for direct injection using both methods after appropriate dilution with acetonitrile prior to HILIC 
method. The step of evaporation/reconstitution was completely avoided in current workflow in order 
to avoid possible issues with metabolite solubility in a given reconstitution solvent.  
The results of this thesis clearly show that SPME can be a very useful sample preparation method 
for global metabolomic studies in order to improve/complement metabolite coverage, to provide 
information on biologically active free concentration and to improve quantitative information of the 
collected metabolomics data. However, the true promise of SPME for metabolomic studies lies in its 
potential for use during in vivo sampling. The in vivo mouse study described in Chapter 8 clearly 
demonstrates the utility of in vivo SPME sampling and shows improved metabolism quenching of in 
vivo SPME versus traditional approaches based on blood withdrawal. Clearly, in vivo SPME presents 
an important step towards the development of sampling methodology that can properly capture the 
true metabolome at the time of sampling. Further investigation of all metabolites that are 
preferentially extracted using in vivo SPME and not observed using other methods is currently 
underway using the preliminary data reported in Section 8.3.6. At this point in time, it appears that 
SPME is very useful for capture of short-lived and unstable metabolites such as energy metabolites 
and anti-oxidants such as glutathione species. In addition to the capture of unique metabolites not 
accessible by common metabolomic methods, another advantage of in vivo SPME is the ability to 
repeatedly sample the same animal to further increase reliability of analytical results. This permits the 
use of smaller animal data sets while still collecting appropriate data. As shown in the example of 
Chapter 8, in vivo SPME was able to differentiate mice based on carbamazepine dosing using only 
n=4 mice, whereas same size cohort (n=4 control and treatment animals) was insufficient for solvent 
precipitation method presumably due to the confounding influence of underlying inter-animal 
variability when sampling different mice in control versus treatment groups. This seriously limited 
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the usability of such dataset. Of course, further opportunities for improvement of in vivo SPME 
methodology in the context of metabolomics do exist, and one limitation encountered in the study 
described in Chapter 8 is the fact that some known CBZ metabolites could not be detected using 
SPME samples, while they were detected in solvent precipitation samples. This is likely due to low 
concentration of these species, and can be addressed in future with further improvements in 
sensitivity of LC-MS instrumentation. With currently available technology, this can be addressed by 
performing animal studies with higher doses of drug (relatively low 2 mg/kg dose) or increasing the 
sampling time further from the short 2-min time used in the study reported herein. In terms of 
understanding the effects of carbamazepine dosing, current study provided interesting links between 
carbamazepine and endogenous metabolites such as (i) oleamide which was previously reported to 
have seizure-reducing effects and (ii) thromboxane which is one of the species in cascade regarded as 
putative drug target of carbamazepine and similar medicines. Both of these links merit further and 
more detailed exploration.  
Some of the research outcomes presented within this thesis are relevant not only for the use of 
SPME in metabolomics, but for the analysis of any non-volatile and/or polar species, such as drugs or 
pesticides in biological fluids. Firstly, the issue of low sample throughput for SPME-LC methods was 
successfully addressed through the development and evaluation of 96-well plate SPME system 
described in Chapter 2. Although, the current study only evaluated the system in terms of targeted 
analysis and found its performance satisfactory, efforts are already underway in our laboratory to 
extend its use to metabolomic studies. Secondly, the feasibility of in vivo SPME sampling in mice 
was demonstrated for the first time, and is valuable to permit longitudinal or multiple studies on the 
same mice, thus reducing animal use which is especially important when genetically-modified or 
other rare strains of mice are used. Finally, this work addressed several limitations of existing 
commercial SPME coatings and devices. In collaboration with Supelco, new line of biocompatible 
SPME coatings housed inside a hypodermic needle was evaluated. The availability of such single-use 
devices with good-inter fibre reproducibility is extremely important to make in vivo SPME 
technology available to any user rather than confined to specialized laboratories capable of producing 
their own coatings.   Furthermore, new types of coatings including mixed-mode, polar-modified 
polystyrene-divinyl benzene and phenylboronic acid were found to drastically improve extraction of 
polar compounds using SPME. Mixed-mode coating was already successfully incorporated into 
biocompatible in vivo SPME assemblies by Supelco, and efforts are currently under way to produce 
the other two types of coatings (phenylboronic acid and polar-enhanced polystyrene-divinylbenzene 
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polymers) in biocompatible format. However, it is important to mention that some challenges in terms 
of SPME coating do remain. In particular, there is a lack of suitable coating procedures to produce 
very thin coatings on very thin solid supports. Another opportunity in improvement of coatings and 
SPME devices lies in further miniaturization of the device dimensions. Such research is particularly 
important from miniaturization perspective in order to further decrease invasiveness of SPME 
procedures and increase spatial resolution when studying heterogeneous systems, such as tumor and 
surrounding tissue, for example. For some applications such as high-throughput bioanalysis, coating 
reusability plays an important role in overall cost of analysis, so further evaluation and improvement 
of long-term coating robustness is beneficial.  
9.2 Future directions 
The field of metabolomics provides interesting opportunities for in-depth study of living systems. 
Some of the driving forces for the interest in metabolomics is that (i) the complexity of metabolome 
of a given organism is expected to be lower than that of proteome/genome in terms of number of 
components, (ii) changes in metabolites can be amplified and easier to detect versus correlated 
changes in transcriptome/proteome, and (iii) metabolomics experiments are more cost-effective than 
their genomic/proteomic counterparts.
14
 The research presented herein supports the use of solid-phase 
microextraction as an effective sample preparation method for global metabolomic studies of 
biofluids. In future, this metabolomics workflow can also be extended to in vivo SPME sampling of 
tissues. For example, Zhou et al. and Zhang et al. have successfully sampled adipose and muscle 
tissue of fish.
180, 181, 249
 The methodology was validated for targeted analysis of pharmaceuticals, but 
global metabolomic studies can be envisioned as a next logical step. Tissue metabolomics is 
particularly interesting for the study of damaged tissues such as tumors in search of novel biomarkers 
because the concentration of such biomarkers is expected to be higher in such tissue than in 
surrounding areas.
22
 For this type of studies, in vivo SPME presents a less-invasive sampling method 
over traditional methods that typically rely on invasive biopsy followed by solvent extraction. SPME 
also provides improved spatial resolution sampling which is important when dealing with such 
heterogeneous specimens, and coatings with 1 mm and 2 mm dimensions have already been 
successfully employed by our research group. Other interesting areas for exploration include single 
cell studies pending further miniaturization of SPME devices or the use of special coatings to trap 
known reactive metabolites and intermediates (for example, using glutathione or methoxylamine 
trapping agents).
194, 250
 From SPME perspective, it is also important to further characterize additional 
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unknown metabolites observed by SPME in current study and not detected by other methods in the 
hope of identifying new or previously undetected components of human and/or mouse plasma. This 
will further enhance understanding of advantages and disadvantages of this new methodology for 
global metabolomic studies. 
From technical perspective, LC-MS-based metabolomic studies would greatly benefit from 
improved data processing workflows, especially in terms of peak detection and identification. The 
former aspect was found particularly problematic in current study when using commercial SIEVE 
software, as large number of noise features was reported as peaks. This demanded manual verification 
of all reported peaks in order to exclude the noise peaks and retain only the true analyte peaks. This 
step presented the bottleneck of the entire workflow, with a typical dataset of  20,000 peaks requiring 
5-10 hr unattended computer processing time and > 20 hr of manual verification. The issue of rapid 
peak identification can be addressed in part by building of comprehensive databases, and such efforts 
are currently underway worldwide as exemplified by HMDB database used extensively in current 
work. However, the metabolite coverage of such databases is still inadequate as large proportion of 
peaks cannot be even tentatively matched with a chemical formula using this approach. Furthermore, 
more efforts into standardization of LC methods and inclusion of LC retention times within such 
databases are needed. From MS instrument perspective, Orbitrap instruments present a great advance 
to improve mass resolution and are easily compatible with conventional LC analysis. In future, 
further increases in acquisition speeds can help couple these instruments with UHPLC for increased 
chromatographic resolution, sensitivity and sample throughput. Further increases in instrumental 
sensitivity are also greatly beneficial in order to detect metabolites present at very low concentrations, 
which may remain undetected using current workflows. It is also important to remember that 
electrospray LC-MS is simply one suitable platform for global metabolomics, and introduces 
systematic bias towards metabolites that are amenable to electrospray ionization. Other platforms and 
ionization methods play important role to achieve the goal of comprehensive metabolite coverage. 
The study of inter-animal variability is a fascinating topic and the availability of in vivo SPME to 
sample various compartments of freely moving animals (for example, blood, bile and tissue such as 
liver, muscle and adipose tissue) opens up new possibilities to investigate fate of xenobiotics and 
metabolites in living system. Such integrative multi-compartmental studies are particularly important 
when studying fate and distribution of xenobiotics
198
, and the availability of in vivo SPME would 
provide more opportunity to longitudinal studies over time, as no sacrifice of animals is required. 
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Numerous studies to establish the variability of endogenous metabolites and their normal 
concentrations are currently ongoing, and some of the discrepancies in literature can be attributed to 
inadequate performance of analytical approach selected for the study. For well-designed studies, great 
degree of inter-animal variability can provide fascinating insight in biology of various processes. For 
example, in a recent study Coen et al. used metabolomics of various compartments (using both NMR 
and LC-MS approach) to understand toxic response of rats to the administration of galactosamine.
198
 
Even within the same strain, age and sex of rats, about 25% of rats were found to be non-responders 
(no liver toxicity was observed due to differences in distribution and metabolism of this compound) 
versus 75% of rats which suffered from various degrees of hepatotoxicity. This study provided 
interesting insight into mechanism of galactosamine toxicity and inter-individual variation in response 
to xenobiotics.  It effectively illustrates the power of metabolomic studies to study the differences in 
individual response rather than overall population response and opens up many new areas of 
investigation. 
In contrast to hypothesis-driven approaches, global metabolomics data is collected without  prior 
assumptions or hypotheses, so it allows testing of multiple hypotheses as well as a posteriori 
hypothesis generation. Furthermore, the holistic approach for simultaneous analysis of large number 
of metabolites has promise in the area of personalized health and nutrition, where metabolic profiles 
are expected to provide a snapshot of homeostasis within giving individual, and any departures from 
such homeostasis when monitored over time can be addressed by nutritional or medical intervention 





(1) Ceglarek, U.; Leichtle, A.; Brügel, M.; Kortz, L.; Brauer, R.; Bresler, K.; Thiery, J.; 
Fiedler, G. M. Mol. Cell. Endocrinol. 2009, 301, 266-271.  
(2) van der Greef, J.; Smilde, A. K. J. Chemom. 2006, 19, 376-386.  
(3) Fiehn, O. Comp. Funct. Genomics 2001, 2, 155-168.  
(4) Ryan, D.; Robards, K. Anal. Chem. 2006, 78, 7954-7958.  
(5) Novotny, M. V.; Soini, H. A.; Mechref, Y. J. Chromatogr. B 2008, 866, 26-47.  
(6) Williams, R. J. In Biochemical Individuality; Wiley and Sons: New York, 1956.  
(7) Horning, E. C.; Horning, M. G. J. Chromatogr. Sci. 1971, 9, 129-140.  
(8) Horning, E. C.; Horning, M. G. Methods Med. Res. 1970, 12, 369-371.  
(9) Jellum, E. J. Chromatogr. 1977, 143, 427-462.  
(10) Pauling, L.; Robinson, A. B.; Teranishi, P.; Cary, P. Proc. Natl. Acad. Sci. U. S. A. 1971, 
68, 2374-2376.  
(11) Villas-Bôas, S. G.; Mas, S.; Åkesson, M.; Smedsgaard, J.; Nielsen, J. Mass Spectrom. 
Rev. 2005, 24, 613-646.  
(12) Bruce, S. J.; Tavazzi, I.; Parisod, V.; Rezzi, S.; Kochhar, S.; Guy, P. A. Anal. Chem. 
2009, 81, 3285-3296.  
(13) Nielsen, J.; Oliver, S. Trends Biotechnol. 2005, 23, 544-546.  
(14) Dunn, W. B.; Ellis, D. I. TrAC, Trends Anal. Chem. 2005, 24, 285-294.  
(15) Orešič, M. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 816-824.  
(16) Bernini, P.; Bertini, I.; Luchinat, C.; Nepi, S.; Saccenti, E.; Schäfer, H.; Schütz, B.; 
Spraul, M.; Tenori, L. J. Proteome Res. 2009, 8, 4264-4271.  
(17) Minami, Y.; Kasukawa, T.; Kakazu, Y.; Iigo, M.; Sugimoto, M.; Ikeda, S.; Yasui, A.; 




(18) Ackermann, B. L.; Hale, J. E.; Duffin, K. L. Curr. Drug. Metab. 2006, 7, 525-539.  
(19) Koulman, A.; Lane, G. A.; Harrison, S. J.; Volmer, D. A. Anal. Bioanal Chem. 2009, 
394, 663-670.  
(20) Sreekumar, A.; Poisson, L. M.; Rajendiran, T. M.; Khan, A. P.; Cao, Q.; Yu, J.; 
Laxman, B.; Mehra, R.; Lonigro, R. J.; Li, Y.; Nyati, M. K.; Ahsan, A.; Kalyana-
Sundaram, S.; Han, B.; Cao, X.; Byun, J.; Omenn, G. S.; Ghosh, D.; Pennathur, S.; 
Alexander, D. C.; Berger, A.; Shuster, J. R.; Wei, J. T.; Varambally, S.; Beecher, C.; 
Chinnaiyan, A. M. Nature 2009, 457, 910-914.  
(21) Griffin, J. L. Curr. Opin. Chem. Biol. 2006, 10, 309-315.  
(22) Griffin, J. L.; Kauppinen, R. A. J. Proteome Res. 2007, 6, 498-505.  
(23) Robertson, D. G.; Reily, M. D.; Baker, J. D. J. Proteome Res. 2007, 6, 526-539.  
(24) Lee, S. H.; Woo, H. M.; Jung, B. H.; Lee, J.; Kwon, O. S.; Pyo, H. S.; Choi, M. H.; 
Chung, B. C. Anal. Chem. 2007, 79, 6102-6110.  
(25) Rezzi, S.; Ramadan, Z.; Fay, L. B.; Kochhar, S. J. Proteome Res. 2007, 6, 513-525.  
(26) Idborg-Bjorkman, H.; Edlund, P. -.; Kvalheim, O. M.; Schuppe-Koistinen, I.; Jacobsson, 
S. P. Anal. Chem. 2003, 75, 4784-4792.  
(27) Chen, C.; Gonzalez, F. J.; Idle, J. R. Drug Metab. Rev. 2007, 39, 581-597.  
(28) Buchholz, A.; Takors, R.; Wandrey, C. Anal. Biochem. 2001, 295, 129-137.  
(29) Koulman, A.; Cao, M.; Faville, M.; Lane, G.; Mace, W.; Rasmussen, S. Rapid Commun. 
Mass Spectrom. 2009, 23, 2253-2263.  
(30) Griffiths, W. J.; Wang, Y. Chem. Soc. Rev. 2009, 38, 1882-1896.  
(31) Theodoridis, G.; Gika, H. G.; Wilson, I. D. TrAC Trends. Anal. Chem. 2008, 27, 251-
260.  
(32) Graca, G.; Duarte, I. F.; Goodfellow, B. J.; Carreira, I. M.; Couceiro, A. B.; Domingues, 
M. D. R.; Spraul, M.; Tseng, L. -.; Gil, A. M. Anal. Chem. 2008, 80, 6085-6092.  
(33) Brown, M.; Dunn, W. B.; Dobson, P.; Patel, Y.; Winder, C. L.; Francis-Mcintyre, S.; 
Begley, P.; Carroll, K.; Broadhurst, D.; Tseng, A.; Swainston, N.; Spasic, I.; Goodacre, 
R.; Kell, D. B. Analyst 2009, 134, 1322-1332.  
 
 288 
(34) Moco, S.; Vervoort, J.; Moco, S.; Bino, R. J.; De Vos, R. C. H.; Bino, R. TrAC Trends 
Anal. Chem. 2007, 26, 855-866.  
(35) Blow, N. Nature 2008, 455, 697-700.  
(36) Madalinski, G.; Godat, E.; Alves, S.; Lesage, D.; Genin, E.; Levi, P.; Labarre, J.; Tabet, 
J. -.; Ezan, E.; Junot, C. Anal. Chem. 2008, 80, 3291-3303.  
(37) Bedair, M.; Sumner, L. W. TrAC Trends Anal. Chem. 2008, 27, 238-250.  
(38) Giavalisco, P.; Köhl, K.; Hummel, J.; Seiwert, B.; Willmitzer, L. Anal. Chem. 2009, 81, 
6546-6551.  
(39) Giavalisco, P.; Hummel, J.; Lisec, J.; Inostroza, A. C.; Catchpole, G.; Willmitzer, L. 
Anal. Chem. 2008, 80, 9417-9425.  
(40) Miura, D.; Fujimura, Y.; Tachibana, H.; Wariishi, H. Anal. Chem. 2009.  
(41) Sun, G.; Yang, K.; Zhao, Z.; Guan, S.; Han, X.; Gross, R. W. Anal. Chem. 2007, 79, 
6629-6640.  
(42) Kaplan, K.; Dwivedi, P.; Davidson, S.; Yang, Q.; Tso, P.; Siems, W.; Hill Jr., H. H. 
Anal. Chem. 2009, 81, 7944-7953.  
(43) Boudonck, K. J.; Mitchell, M. W.; Német, L.; Keresztes, L.; Nyska, A.; Shinar, D.; 
Rosenstock, M. Toxicol. Pathol. 2009, 37, 280-292.  
(44) Lawton, K. A.; Berger, A.; Mitchell, M.; Milgram, K. E.; Evans, A. M.; Guo, L.; 
Hanson, R. W.; Kalhan, S. C.; Ryals, J. A.; Milburn, M. V. Pharmacogenomics 2008, 9, 
383-397.  
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